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Drug discovery and therapeutic targets for pharmacological  
modulators of aquaporin channels 
 
AIM: To review the association between aquaporins (AQPs) and various diseases 
and to review the potential of AQPs as therapeutic targets.  
 
Hypothesis: Modulators of AQP channels are promising pharmaceutical targets for 
drug development treating brain edema, cancer and other disorders.  
 
Conclusions: 
1. AQP4 channels subserve water movement during cerebral edema formation; 
AQP4 pharmacological agents will be advantageous for interventions in brain 
fluid disorders particularly if administered with an understanding of the dynamic 
mechanisms of aquaporin channel regulation. 
2. Various types of AQPs are upregulated in cancer cells suggesting AQPs are 
ideal candidates as pharmaceutical targets.  
3. AQP1 contributes to cell migration and angiogenesis and facilitates tumour 
growth and metastasis through mechanisms that remain to be defined. 
Pharmacological modulation of AQP1 could be a pivotal adjunct to existing 
cancer therapies, improving the prognosis for cancer patients by slowing 
cancer angiogenesis and metastases. 
4. In addition to the heavy metals (mercury, silver and gold) previously 
characterized as AQP1 water channel blockers, the first small molecule 
modulators discovered for both AQP1 and AQP4 were AqB013 which is an 
antagonist of water channel activity, AqF026 which is a water channel agonist.  
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Other new antagonists have since been described by research groups around 
the world.  
5. Both AQP1 and AQP4 are highly functional water channels, but only the 
expression of AQP1 enables rapid cell movement in certain classes of cells. 
One important difference is that AQP1 but not AQP4 can function as a gated 
monovalent cation channel. The loop D region in AQP1 is essential for AQP1 
function as an ion channel. 
6. The small molecule agent AqB011 and Cd+ ions selectively block the AQP1 
ionic conductance, but not water channel activity.  
7. New avenues for aquaporin drug discovery can be found from traditional and 
alternative medicines. Few candidate species have been selected after meta-
analysis of literature. The species are: Polyporus umbellatus, Poria cocos, and 
Bacopa monnieri.   
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Fluid homeostasis in the body is well known to be regulated by ion channels and 
transporters, but equally important are the co-expressed classes of aquaporin water 
channels that facilitate transmembrane water movement. The field of aquaporin 
pharmacology is expanding rapidly with the new identification of small molecule drug-
like agents with distinctive properties in aquaporin modulation, allowing exploration of 
potential therapeutic applications in brain edema, cancer and other disorders. 
Pharmacological agents could modulate AQPs by direct occlusion of the water pore 
itself, by acting at distinct sites that confer other channel properties, or by altering 
levels of protein expression or membrane targeting. Expanding the pharmacological 
portfolio will benefit basic research and promote new therapeutic strategies in many 
conditions involving aquaporins in the symptoms or disease processes. Exploring 
herbal alternative medicines as sources of pharmacological agents for aquaporins is 
likely to have a substantial impact on the field of aquaporin research, which has keenly 
awaited the development of chemical interventions as a platform for therapeutic 
approaches. Recent work is providing an enhanced understanding of the molecular 





Aquaporins (AQPs) found throughout the kingdoms of life (Zardoya, 2005) are channel 
proteins which facilitate water and small solute movement across plasma membranes 
based on chemical, osmotic and hydrostatic gradients (Hachez and Chaumont, 2010; 
Ishibashi et al., 2011; Madeira et al., 2014). The existence of water channels in red 
blood cells and barrier membranes and their hallmark sensitivity to block by mercury 
(Benga et al., 1986; Macey, 1984; Macey et al., 1972; Naccache and Sha'afi, 1974) 
were deduced before AQP1 cDNA was cloned and characterized in the early 1990s 
(Preston and Agre, 1991; Preston et al., 1992). Progress since has defined thirteen 
mammalian subtypes of AQPs, their relative protein abundance, tissue-specific 
distributions, and expression levels under various conditions. AQP crystal structures 
have provided insights into the homotetrameric channel structure, and the location of 
the water pores within each of the four subunits (Ishibashi et al., 2009; Jensen et al., 
2003; Sui et al., 2001). AQP1 is a tetrameric channel with water pores located within 
each of the four individual subunits (Fu et al., 2000; Sui et al., 2001). Review articles 
have emphasized the compelling need for development of AQP modulators as 
candidate treatments for a variety of disorders (Castle, 2005; Frigeri et al., 2007; Huber 
et al., 2012; Jeyaseelan et al., 2006). However, prior to 2009, the discovery of AQP 
pharmacological agents had not progressed substantially beyond mercuric 
compounds, which lacked translational potential due to toxicity, and agents that 
affected multiple targets and lacked potency. Recent advances have shown that drug-
like lead compounds are emerging, complementing work that has investigated the 




1  Overview of aquaporin channel functions in brain fluid homeostasis and cell 
migration 
Fluid homeostasis in the body is regulated by partnerships of ion channels and 
transporters with co-expressed classes of aquaporin channels (Conde et al., 2010; 
Fischbarg, 2010). The thirteen classes of mammalian aquaporin water channels 
(AQPs 0 to 12) are expressed in tissue-specific patterns in the body, and are essential 
in regulating the movement of fluid across barrier membranes, and contributing to 
control of cell volume, production of cerebral spinal fluid, edema formation and 
recovery, mediating renal function, and more (Ishibashi, 2009; Nielsen et al., 2007). 
Under pathological conditions, dysfunctions in the control of fluid movement create 
serious problems. The physiological importance of AQP channels and their compelling 
potential value as therapeutic targets have motivated researchers to work toward 
defining a pharmacological panel of chemical modulators for AQPs. A comprehensive 
pharmacological portfolio for all classes of aquaporins will provide an array of new 
therapeutic opportunities that will continue to expand as new roles for aquaporin 
channels are uncovered.  Two major areas of current interest in aquaporin-based 
mechanisms of disease are brain swelling after injury or stroke, and the migration of 
cancer cells in the process of metastasis.  
 
1.1   AQP4 in cerebral edema  
An area of intense interest for new therapies directed at AQPs is aimed at reducing 
brain swelling after acute traumatic injury or stroke (Mack and Wolburg, 2013; Yool et 
al., 2009). Cerebral edema and increased intracranial pressure are life-threatening 
sequelae of severe brain injuries, associated with a poor prognosis as evidenced by a 
mortality rate near 60 to 80% (Feickert et al., 1999; Hacke et al., 1996). Traumatic 
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brain injury affects an estimated 10 million people annually; according to the World 
Health Organization, it will be the major cause of death and disability by the year 2020 
(Hyder et al., 2007). Nearly one-third of hospitalized traumatic brain injury patients die 
from injuries that are secondary to the initial trauma, including neuroinflammation, 
excitotoxicity, brain edema, and intracranial hypertension (Miller et al., 1992). 
Traumatic brain injury reduces life expectancy and compromises quality of life 
(Schiehser et al., 2014) with increased incidences of seizures, sleep disorders, 
neurodegenerative disease, neuroendocrine dysregulation, psychiatric problems, and 
non-neurological disorders that can persist years after the injury event (Masel and 
DeWitt, 2010). The burden of mortality and morbidity makes traumatic brain injury a 
pressing public health and medical concern, but there is currently no targeted 
pharmacological treatment for reducing the secondary damage (Park et al., 2008).  
Cerebral ischemia following severe traumatic brain injury involves a combination of 
cytotoxic and vasogenic events (Hossmann, 1994; Papadopoulos et al., 2004; Shi et 
al., 2012; Tourdias et al., 2011). Brain edema commonly occurs when cerebral blood 
flow drops beneath 10ml/100g/min, and essential ionic pump activity is impaired. 
During the first 5 h of ischemia, blood brain barrier integrity can be maintained without 
substantial brain swelling (Betz et al., 1989), but upon reperfusion, a rise in brain water 
content can occur in conjunction with an elevation in intracranial pressure depending 
on the extent of ischemia, and the delay until cerebral blood flow is restored (Avery et 
al., 1984). Conventional treatments focus on reducing edema and intracranial 
pressure using hyperventilation, mannitol, diuretics, corticosteroids or barbiturates 
(Manno et al., 1999; Winter et al., 2005). Decompressive craniectomy involves the 
surgical removal of part of the skull, creating a space for the swollen brain tissue to 
expand. This surgical method improves survival, but doesn't fully address pathological 
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outcomes as many patients are left moderately or severely disabled (Fischer et al., 
2011; Vahedi et al., 2007).  
Work in animal models relies on optimizing the reliability and reproducibility of the 
injury event. The middle cerebral artery occlusion model in rodents has been a 
standard method for testing experimental therapeutic agents, but is difficult in part 
because of unexplained variability in infarct volumes. When analyzed with computed 
tomography cerebral blood volume maps, variability was found to result from 
unintended occlusion of a second artery (the anterior choroidal artery) in a subset of 
animals, causing expanded infarct areas (McLeod et al., 2013). Brain computed 
tomography perfusion imaging provides a powerful tool for improving the experimental 
method by fully defining the arteries affected by occlusion, and accurately identifying 
the infarct core and penumbra domains (McLeod et al., 2011). 
The concept of edema as being the primary cause of increased intracranial pressure 
has been challenged; small ischemic strokes in rats resulted in minimal amounts of 
edema but were associated with a substantial elevation in intracranial pressure at 24 
h, which was effectively countered by application of hypothermia soon after the stroke 
event. Mechanisms in addition to cerebral edema alone must be considered as 
important drivers of intracranial pressure elevation (Murtha et al., 2014a; Murtha et al., 
2014b). Assessing the regulated contributions of transporters and channels including 
AQP1 and AQP4 might offer insight into possible molecular mechanisms generating 
the distinct outcomes. 
AQP4 is the predominant water channel in the brain, localized to the blood-brain 
barrier, ependymal cells lining the ventricles, subependymal astrocytes and the glia 
limitans (Amiry-Moghaddam and Ottersen, 2003; Nagelhus and Ottersen, 2013; Xiao 
and Hu, 2014) for their involvement in water movement both in and out of the brain 
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(Mack and Wolburg, 2013). Studies in AQP4-deficient mouse models showing partial 
protection from water intoxication and edema after stroke (Manley et al., 2000; 
Papadopoulos and Verkman, 2008) support the idea that ligand modulators of AQP4 
could revolutionize clinical treatment of brain edema. To date, progress in the field has 
been limited by the lack of availability of pharmacologic modulators of the AQP 
channels. Identification of agonists and antagonists of AQP4 remains an important 
goal in the field of cerebral edema research. AQP4 channels subserve water 
movement during cerebral edema formation (Jullienne and Badaut, 2013; Manley et 
al., 2000), highlighting them as an attractive therapeutic target for non-surgical 
management of cerebral edema (Yool, 2007a; Yool et al., 2009).  
Alterations in levels of AQP expression in response to cerebral fluid imbalance can 
offer clues for understanding the functional roles of water channels, assuming the goal 
is to restore homeostasis. In experimental models of cerebral ischemia, expression 
levels of AQP4 were reduced in the initial period post-injury, and significantly 
increased thereafter (Taniguchi et al., 2000; Yamamoto et al., 2001). Regulation of 
AQP4 expression appears to correlate with levels of the transcription factor HIF-1α 
(hypoxia-inducible factor 1-alpha) (Kaur et al., 2006). Early after traumatic brain injury 
(5h), levels of HIF-1α were low and increased to peak at 24-48 h post-injury (Ding et 
al., 2009; Higashida et al., 2011). Inhibition of HIF-1α correlated with decreased AQP4 
and attenuated swelling post-injury (Shenaq et al., 2012). The temporal pattern of 
AQP4 regulation suggests that downregulation of channels early after injury could be 
a protective response to limit the influx of fluid into the brain, whereas delayed 
upregulation might serve to enable fluid export and the restore fluid homeostasis. 
However, altered gene expression responses are not spatially uniform. A reduction in 
AQP4 expression occurred in astrocytes within the ischemic core while an elevation 
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in AQP4 expression was seen in glial endfeet in the surrounding penumbra, in a middle 
cerebral artery occlusion model (Frydenlund et al., 2006). Spatially selective regulation 
of AQP4 might limit water influx into the ischemic core without preventing the 
amelioration of vasogenic edema in the penumbra. The loss of AQP4 was not linked 
to a decrease in the astrocyte marker, glial fibrillary acidic protein, GFAP (Friedman et 
al., 2009), indicating that decreased AQP4 expression was not an indirect effect of 
glial cell loss in the injured domain.  
AQP4 water channels are dynamically regulated components of brain fluid 
homeostasis, being mobilized or deactivated as needed to reduce damage arising 
from shifts or disturbances in cerebral fluid homeostasis. The temporal and spatial 
patterns of AQP4 regulation are contingent upon the extent and duration of injury and 
stage of pathology. AQP pharmacological agents will be advantageous for intervention 
brain fluid disorders particularly if administered with an understanding of the dynamic 
mechanisms of aquaporin channel regulation. 
 
1.2  AQP1 in cell migration   
Cell migration is essential in development, repair, regeneration, and immune 
protection in multicellular organisms. In 1937, the neuroanatomist Ramon y Cajal 
pondered: "What mysterious forces stimulate the migrations of cells...?" (Kater and 
Letourneau, 1985). Currently it is thought that branched assemblies of actin filaments, 
actively polymerising at the leading edge, generate the primary force which pushes 
out thin ruffled membrane extensions known as lamellipodia (Le Clainche and Carlier, 
2008). Parallel arrays of actin are stalled by small loads on the order of 1 pN (Footer 
et al., 2007), but branched actin networks with many points of contact can generate 
nN of force per μm2, on the scale needed for movement through viscous extracellular 
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environments (Marcy et al., 2004; Parekh et al., 2005). Cell adhesions at the leading 
edge hold the new position while the trailing edge detaches, and the cell resets for the 
next push forward.  
Aquaporins found in all the kingdoms of life facilitate fluxes of water and small solutes 
across membranes (King et al., 2004). In diverse motile cells from amoeba to human, 
specific AQPs are localized in lamellipodial leading edges. When these cells are made 
AQP-deficient (for example by genetic knock-out or RNA-interference techniques), cell 
migration is greatly impaired. Reintroduction of AQP restores rates of movement, but 
interestingly, the effects of different AQPs are not interchangeable (McCoy and 
Sontheimer, 2007).  
Of the 13 known mammalian classes of AQPs, the three often associated with 
migration thus far are AQPs 1, 3 and 5. In the "World Cell Race" event held at the 
American Society for Cell Biology meeting in 2011, cell lines were submitted by teams 
around the world; the winner was a bone marrow stem cell which covered the 400 μm 
track at a speed of at 5.2 μm/min. Bone marrow stem cells express lamellipodial AQP1 
that is required for migration (Meng et al., 2014). The need for AQPs in migration 
extends to life forms other than mammals. The amoeba Dictyostelium discoideium 
migrates in a chemotactic response to external cAMP signals, and expresses an AQP 
orthologous to human AQP1 (48% amino acid sequence similarity) which is localized 
in lamellipodia (von Bulow et al., 2012). If D. discoideium had been in the competition, 
it might have taken the honors, moving at up to 11 μm/min in response to cAMP 
chemotactic stimuli (Van Duijn and Inouye, 1991). Other contenders could have 
included activated T-cells moving at >10 μm/min (Katakai et al., 2013) which express 
AQPs 1, 3, and 5 (Moon et al., 2004); and fibroblasts moving at up to 9 μm/min (Ware 
et al., 1998) which express AQP1 (Minami et al., 2001). 
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Even though AQP1 and AQP4 are both highly functional water channels, the 
expression of AQP1 enables rapid cell movement, whereas expression of AQP4 does 
not. One important difference is that AQP1 but not AQP4 can function as a gated 
monovalent cation channel (Anthony et al., 2000; Yool and Campbell, 2012). AQP1 
ion channel activity has been replicated in other laboratories (Saparov et al., 2001; 
Zhang et al., 2007), but its physiological significance remains unknown. During 
migration, changes in cytoplasmic volume are required. Fluid flux is commonly thought 
of as a passive process in which water follows salt. Yet the observation that water 
channels cannot simply be swapped between cells suggests that other properties in 
addition to water channel function are needed. The pro-migratory effect of AQP1 and 
its orthologs appears to be a convergent target of evolution across phyla. 
 
2  Small molecule drug discovery for aquaporin channels  
Inhibitors of AQPs have long been heralded as important goal in the field. A database 
of structurally diverse compounds will be of substantial value in expanding our 
understanding of drug structure-activity relationships and molecular sites of action for 
aquaporin pharmacological modulators. Pharmacological agents could modulate 
AQPs by direct occlusion of the water pore itself, by acting at distinct sites that confer 
other channel properties, or by altering levels of protein expression or membrane 
targeting.  
 
2.1    Modulators of water channel activity 
Regulatory domains in aquaporins can control membrane localization, interaction with 
proteins to create signaling complexes and scaffolds, and gated permeation of small 
solutes other than water through AQPs (Cowan et al., 2000; Yool, 2007a; Yool, 
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2007b).  Much of the work to date has focused on agents that act to occlude the water 
pore. The existence of water channels in cell membranes and their hallmark sensitivity 
to block by mercury were deduced before the first AQP1 cDNA was cloned (Preston 
and Agre, 1991; Preston et al., 1992). Finding non-mercurial AQP blockers has been 
essential for aquaporin drug discovery (Table 1). Silver and gold compounds were 
reported to block water channel activity of both plant and human aquaporins (Niemietz 
and Tyerman, 2002; Tyerman et al., 2002). Membrane-permeable derivatives of the 
loop diuretic drugs bumetanide and furosemide have proven useful as 
pharmacological antagonist AqB013 (Migliati et al., 2009) and agonist AqF026 (Yool 
et al., 2013) agents for AQP1 and AQP4 water channel activities. Characterized in 
vitro and in rodent models in vivo, these candidate AQP drugs appear to be effective 
and well tolerated. In a mouse model of peritoneal dialysis, the lack of effect of the 
agonist AqF026 in AQP1 knockout animals indicated specificity of action without 
appreciable off-target effects (Yool et al., 2013). Other groups also have investigated 
arylsulfonamides as AQP blockers (Gao et al., 2006; Huber et al., 2007; Ma et al., 
2004; Seeliger et al., 2013). Acetazolamide (AZA) has been reported to inhibit AQP4 
water permeability with an IC50 value of 0.9 μM. In silico docking suggested an 
interaction between the sulfonamide group of AZA and both arginine 216 and glycine 
209 (Huber et al., 2007). As compared to AQP4, AQP1 was less sensitive to AZA, with 
an IC50 value estimated at 5.5±0.5 μM (Seeliger et al., 2013).     
 
2.2  Regulation of AQP1 ion channel activity 
The passage of water and ions occurs through pharmacologically distinct pathways in 
AQP1 (Saparov et al., 2001; Yool et al., 2002). The cGMP-gated cation permeation 
pathway is thought to be in the central pore of the tetramer, based on molecular 
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dynamic simulations (Yu et al., 2006) and effects of site-directed mutations on altering 
ionic conductance properties (Campbell et al., 2012). Conduction of ions in AQP1 
channels is inhibited by Cd2+ but not tetraethylammonium ion (TEA+); whereas water 
transport which occurs through the individual pores located in each subunit is sensitive 
to TEA+, AqB013, AqF026, but not Cd2+ (Boassa et al., 2006; Brooks et al., 2000; 
Migliati et al., 2009; Yool et al., 2002; Yool et al., 2013). ln silico docking identified 
possible extracellular binding by TEA+ (Detmers et al., 2006), but indicated 
intracellular sites of action for the arylsulfonamides, supported by results of site-
directed mutations and biological assays. AqB013 is thought to occlude the water pore 
at the internal vestibule whereas the AQP agonist, AqF026, appears to potentiate 
water channel activity by interacting with an intracellular gate (loop D) between the 4th 
and 5th transmembrane domains (Yool et al., 2013). 
The loop D domain serves as a gate for AQP channel activity in mammalian AQP1 
(Yu et al., 2006), AQP4 (Zelenina et al., 2002), amoeba AQP-B (von Bulow et al., 
2012) and plant AQP (Tornroth-Horsefield et al., 2006). In AQP1, loop D domain is 
involved in the regulation of cation channel activity activated by cGMP (Yu et al., 
2006). The loop D sequence is highly conserved across species in AQP1 channels 
from fish to mammals, yet mutations in this domain do not impact water channel 
activity, suggesting that loop D is essential for AQP1 functions other than water 
permeability. Mutations at specific loop D positions in AQP1 remove ion channel 
activity without impairing water channel activity (Yu et al., 2006). The retention of water 
channel functionality showed that the mutation did not interfere with expression, 
trafficking or assembly of AQP1 channel. 
Other regulatory domains in AQP1 have been suggested in the carboxy-terminal 
domain. A putative cGMP-dependent modulatory domain with sequence similarity to 
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the cGMP-phosphodiesterase selectivity domain was identified in the AQP1 C-
terminus (Boassa and Yool, 2002; Boassa and Yool, 2003). Mutations of conserved 
phosphodiesterase-like residues in this domain did not remove cGMP-dependent 
activation of AQP1, but reduced the efficacy of cGMP by right-shifting the dose-
response curve. An EF-hand motif found in calcium binding proteins (Grabarek, 2006) 
has been proposed in the carboxyl terminal domain of AQP1 but its functional role has 
not yet been defined (Fotiadis et al., 2002). A tyrosine phosphorylation site in the 
carboxyl terminal serves a modulatory role in governing the availability of AQP1 to be 
gated as a cGMP-dependent cation channel (Campbell et al., 2012). A PDZ protein-
protein ligand domain identified in AQP1 (Ile260 to Arg264) in the C terminus was 
shown to be important for targeting AQP1 into a membrane complex needed to 
maintain vestibular fluid balance in the inner ear (Cowan et al., 2000). Regulatory 
domains and transmembrane pore regions in AQPS are both attractive candidates for 
the development of drug agents. 
 
3  Translational promise of pharmacological modulators of aquaporin channels 
in brain edema, cancer and other disorders 
Pharmacological control of the direct fluid flow pathways between blood and brain 
could provide for invaluable therapeutic interventions in cerebral pathologies involving 
abnormal water fluxes such as stroke, hydrocephalus, and brain tumors. Aquaporin-4 
is a logical choice as a molecular target for drug development (Papadopoulos and 
Verkman, 2007; Yool et al., 2009). It is abundantly expressed in the central nervous 
system near the blood-brain barrier at glial cell endfeet, and provides a major pathway 
for fluid homeostasis (Amiry-Moghaddam and Ottersen, 2003).  
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3.1 Targeting AQP4 channels in brain edema   
Conventional approaches have relieved intracranial pressure with hyperventilation, 
hyperosmotic agents, diuretics and decompressive craniectomy (Diedler et al., 2009; 
Park et al., 2008; Werner and Engelhard, 2007), but are limited in effectiveness by 
treating symptoms rather than causes of edema. A major challenge has been the lack 
of interventions for controlling fluid movement in brain edema. Astrocytes have been 
proposed to have a bimodal contribution, with a positive role in fluid homeostasis and 
limiting brain injury, and a negative role in worsening the neuroinflammation, cerebral 
edema, and elevated intracranial pressure associated with secondary brain injury 
following neurotrauma (Laird et al., 2008). 
Now with the characterization of novel AQP agonists and antagonists, it will be 
possible to investigate potential pharmacological treatments for cerebral edema (Yool 
et al., 2009) with an intriguing capacity for bimodal regulation of AQP water channel 
activity. For example, in a rat model of cerebral edema induced by diffuse traumatic 
brain injury, a single intravenous application of the AQP antagonist AqB013 within five 
hours post-injury dramatically reduced edema formation, and single administration of 
the AQP agonist AqF026 at 1 to 2 days post-injury accelerated the resolution of brain 
edema (Burton, Vink and Yool, 2015; MS submitted). Each modulator was beneficial 
alone; however, of interest was the observation that a sequential treatment of 
antagonist followed by agonist each at their optimal single timepoints provided a 
powerful combination that further enhanced protection of motor function, reduced 
brain swelling and decreased brain albumin content post-injury. Understanding the 
biphasic role of AQP4 in cerebral edema and the actions of aquaporin pharmacological 
modulators will be likely to open new avenues for development of therapeutic 
interventions after traumatic brain injury. 
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3.2   Differential regulation of expression of AQP channel types in cancer cells   
Evidence emerging within the past decade is providing increasingly strong support for 
the role of selected classes of AQPs as important constituents in cancer cell biological 
mechanisms. Data show a strong positive correlation between AQP expression levels 
and tumor severity (Machida et al., 2011). Tumor cells selectively increase levels of 
expression of different specific types of AQPs; in some cases there is an increase in 
an AQP class normally expressed in the cell type (Saadoun et al., 2002a), but in other 
cancers the upregulated class of AQP is not found at appreciable levels in the original 
tissue (Moon et al., 2003). AQPs are linked with a variety of properties of cancer cells, 
such as tumor size expansion, edema, cell adhesion, migration, and proliferation, that 
enhance tumor growth and metastasis (Hu and Verkman, 2006; Saadoun et al., 
2002a; Saadoun et al., 2002b).  
For AQP1 and AQP5 channels, de novo expression has been observed in early stage 
colorectal carcinoma development, but is not detectable in normal colonic epithelium 
(Moon et al., 1997; Moon et al., 2003) for purposes that remain incompletely 
understood in the context of cancer progression. When transfected into melanoma 
and breast cancer cell lines, increased AQP1 expression was associated with an 
increase in both in vitro cell migration and in vivo metastasis (Hu and Verkman, 2006). 
When melanoma cells B16F10 were implanted subcutaneously, AQP1 null mice 
showed slower melanoma tumor growth and impaired tumor angiogenesis as 
compared with wild type mice (Saadoun et al., 2005).  
AQP1 contributes to cell migration and angiogenesis and facilitates tumor growth and 
metastasis through mechanisms that remain to be defined. In its proposed activity as 
a dual water and ion channel (Yool and Weinstein, 2002), AQP1 could be one 
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mechanism used for enhancing migration rate in a subset of classes of aggressive 
cancers. Facilitation of cell migration appears to be achieved in other types of cells by 
colocalization of water-selective aquaporins in combination with ion transporters (Chai 
et al., 2013; Stroka et al., 2014). 
AQP3 increased migration and proliferation of corneal epithelial cells in wild-type as 
compared with Aqp1-null mice, and was important in peritoneal fibrosis and wound 
healing (Ryu et al., 2012). In squamous skin cell carcinomas and bronchioloaveolar 
carcinomas, AQP3 upregulation influenced metastasis and proliferation (Hara-
Chikuma and Verkman, 2008a; Machida et al., 2011). After si-RNA knockdown of 
AQP3 expression, weaker cell adhesion and impaired cell growth were observed 
(Kusayama et al., 2011). In non-small cell lung cancer, AQP3 knockdown suppressed 
tumor growth and reduced angiogenesis (Xia et al., 2014). In agreement, AQP3 null 
mice show reduced glycerol transport, and were more resistant to skin cancer 
formation (Hara-Chikuma and Verkman, 2008b).  
AQP4 appears to assist with water balance in the tumor environment, and has been 
postulated to play a role in cell-cell adhesion, possibly via an extracellular helical 
domain in loop C that could interact with adjacent cells. Expression of AQP4 conferred 
adhesive properties in cells that lacked classic adhesion molecules, as shown by L-
cell cluster formation in AQP4-positive cells but not control cells (Hiroaki et al., 2006); 
however other work has not confirmed the idea (Zhang and Verkman, 2008). More 
studies will be required to determine what factors influence a putative role of AQP4 in 
tumor cell adhesion. AQP4 can be phosphorylated by protein kinase C (PKC) at Ser-
180. Phosphorylation level is inversely proportional to water permeability. Mutation of 
Ser-180 to alanine increased AQP4 water permeability by approximately two-fold 
(McCoy et al., 2010). In AQP4-transfected glioma D54MG cells, both AQP4 water 
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permeability and tumor cell migration were decreased when protein kinase C (PKC) 
was activated by phorbol ester treatment. It is postulated that cells with suppressed 
AQP4 activity have a compromised ability to adjust cell shape during migration (McCoy 
et al., 2010). In contrast, when D54MG cells were transfected with AQP1, neither of 
the properties of water channel activity or cell migration were affected by PKC 
modulators (McCoy et al., 2010).  
AQP5 expression is increased in pancreatic, colon cancers and myelogenous 
leukemia cells (Machida et al., 2011; Woo et al., 2008). Proliferation of human ovarian 
cancer cells has also been correlated with AQP5 expression levels (Chae et al., 
2008a). The involvement of AQP5 in cancer invasion has been demonstrated to 
depend on phosphorylation of Ser-156 located in the loop-D domain through a c-Src 
signaling pathway (Chae et al., 2008b). Deletion of AQP5 but not AQP1 nor AQP3 
was correlated with decreased activation of the epithelial growth factor receptor signal 
cascade (EGFR/ERK/MAPK) which regulated cancer cell migration and proliferation 
(Zhang et al., 2010). Results from many studies now show that AQP3 and AQP5 
contribute to processes of tumor proliferation, but the link from aquaporin function to 
the regulation of growth remains to be defined.    
As depicted in Figure 1, AQP expression can be polarized in the lamellipodia of 
migrating cells, together with transporters such as the Na+/H+, the Cl-/HCO3- 
exchanger or the Na+-K+-Cl- co-transporter. Localized ion fluxes are proposed to 
create a driving force for osmotic water fluxes, in parallel with the osmotic effects of 
actin polymerization and depolymerization, that could drive the membrane protrusions. 
This concept has been presented as an 'osmotic engine model' (Stroka et al., 2014) 
based on studies of AQP5 and Na+/H+ exchangers polarized to the leading edges in 
mouse S180 sarcoma cells migrating in a confined environment. 
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3.3 Targeting AQP1 channels in cell migration and metastasis  
Tumor cell migration enables metastasis and tissue invasion, and is a major cause of 
death in patients with cancer (Bogenrieder and Herlyn, 2003). A review of literature 
shows that AQP1 expression is upregulated in a subset of aggressive cancers; 
whereas AQP1 deletion or downregulation impedes migration of AQP1-expressing 
cancer cells in vitro and reduces metastasis in vivo (Deb et al., 2012; Verkman et al., 
2008; Yool et al., 2009). Wound-healing and transwell migration assays have 
demonstrated impaired migration of tumor cells lacking AQP1 as compared to wild 
type (Jiang, 2009; Jiang et al., 2009; Jiang and Jiang, 2010; Li et al., 2006). Cell 
migration rate in AQP1-knockdown cells can be rescued by adenovirus-mediated 
AQP1 expression. Similarly, transfection of AQP1 into tumor cells that lack 
endogenous AQP1 show accelerated cell migration rate in vitro as compared to control 
cells (Hu and Verkman, 2006; McCoy and Sontheimer, 2007). 
Manipulation of tumor cell migration rate via AQP1 expression levels has been 
explored in rodent models in vivo. Increased AQP1 expression increased tumor cell 
extravasation, quantified by the numbers of fluorescently-tagged tumor cells which 
infiltrated mouse lung tissue after injection into tail vein (Hu and Verkman, 2006). In a 
mouse model that spontaneously developed well-differentiated, luminal-type breast 
adenomas with lung metastases, genetic deletion of AQP1 correlated with reductions 
in lung metastases, tumor mass, and tumor volume with abnormal microvascular 
anatomy and reduced vessel density as compared to wild type mice (Esteva-Font et 
al., 2014). AQP1 expression facilitated endothelial cell migration, and augmented 
tumor growth in vivo by the facilitation of angiogenesis (El Hindy et al., 2013; Nicchia 
et al., 2013). Impaired melanoma growth was observed in AQP1-null mice after 
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subcutaneous tumor cell implantation, and attributed to reduced aortic endothelial cell 
migration (Saadoun et al., 2005).  
AQP1 is an attractive therapeutic target for controlling tumor growth and migration. 
Pharmacological modulation of AQP1 could be a pivotal adjunct to existing cancer 
therapies, improving the prognosis for cancer patients by slowing cancer angiogenesis 
and metastases. 
 
4 New avenues for aquaporin drug discovery from traditional and alternative 
medicines 
Complementary and alternative medicine practices provide an intriguing starting point 
in searches for novel pharmacological modulators for aquaporin channels, drawing on 
cultural insights of native botanical agents from Asian, indigenous Australian, 
American, Indian and other sources of cultural knowledge. Given the importance of 
aquaporins in human health and disease, AQP modulatory agents have a compelling 
potential to benefit research and health care globally. Scientific evidence is needed to 
understand the molecular mechanisms that underlay therapeutic actions of alternative 
medicines which have been used around the world from ancient times to treat fluid 
imbalance disorders and diseases (de Morais Lima et al., 2011; Karou et al., 2011; 
Kong et al., 2015; Nie et al., 2013). Possible agents for aquaporin channels might be 
present in native botanical agents used for treating conditions such as kidney and 
gastrointestinal disorders, swelling, brain edema, and inflammation, which in theory 
could be benefiting from altered AQP channel activity in mitigating the dysfunctions. 
Botanical compounds over many centuries have been an important source of useful 
drugs. As reviewed by Wachtel-Galor and Benzie (2011; CRC Press 'Herbal 
Medicines: Biomedical and Clinical Aspects'), about 25% of the drugs prescribed 
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worldwide are derived from plants, including morphine derived from poppy seeds 
(Papaver somniferum), digoxin from foxglove (Digitalis lanata), aspirin from willow 
bark, antimalarials such as quinine from Cinchona bark (Cinchona officinalis), and 
artemisinin derived from Artemisia annua. The potential value for translation into a 
novel pharmacology for AQP channels is immense. Expanding the pharmacological 
portfolio for aquaporins will not only benefit basic research but could also prompt 
strategies for therapeutic interventions in cancers, lung and cardiac edema, secretory 
and digestive dysfunctions, and other conditions involving tissues in which AQPs are 
expressed.  
Two principal groups of phytochemicals of interest appear to be emerging from the 
data available thus far: (i) polysaccharides (glucans) extracted from aqueous fractions; 
and (ii) triterpenes (polyporusterones) extracted from organic fractions of medicinal 
plants. A meta-analysis of published data on extracts and isolated compounds from 
an edible mushroom Polyporus umbellatus show it acts as a diuretic, anti-cancer, 
immunostimulant and hepatoprotective agent (Zhao, 2013). An aqueous fraction of 
the Chinese medicinal fungus Fu Ling Poria cocos contains multiple saccharides, and 
has been reported to attenuate renal AQP2 expression at the transcription and 
translational levels (Lee et al., 2012b). Extracts of Fu Ling also act as a diuretic and 
suppress the growth and invasiveness of various tumor cell lines (Cheng et al., 2013; 
Ling et al., 2011; Zhao et al., 2012). Similar to P. umbellatus, various triterpenes have 
been extracted and identified from P. cocos (Rios, 2011).  In a study of papilloma 
carcinogenesis, poricoic acid C was demonstrated to decrease the incidence to 27% 
as compared with 100% in the control group (Akihisa et al., 2007). A bioactive 
compound (ginsenoside Rg3) found in the ginseng root extract was shown to attenuate 
cell migration via inhibition of AQP1 expression in PC-3M prostate cancer cells in vitro, 
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and demonstrated the potential usefulness of pharmacological modulation of AQP1 in 
manipulating tumor cell migration (Pan et al., 2012). 
Diverse classes of channels and transporters are modulated by curcumin (isolated 
from tumeric in the ginger family), including voltage-gated K+ and Ca2+ channels, the 
volume-regulated anion channel VRAC, the Ca2+ release-activated Ca2+ channel 
CRAC, AQP4 channels, glucose transporters, and others (Zhang et al., 2014). As 
compared with vehicle-injected rats, a lower level of AQP4 expression was observed 
in rats injected with 40 mg/kg curcumin. In the same experiment, a neuroprotective 
effect of curcumin was demonstrated in a rat model of hypoxic ischemic brain damage 
(Yu et al., 2012).  
Bacopa (Bacopa monnieri), a water hyssop also known as Brahmi in traditional Indian 
medicine, has been used in complementary medicine remedies for centuries to 
improve memory and treat anxiety and depression (Russo and Borrelli, 2005). The 
main active components are triterpenes (bacosides, bacopasides and bacosaponins) 
(Russo and Borrelli, 2005).  Some of the beneficial effects of Bacopa could potentially 
involve aquaporin channels;  however, the diverse group of candidate targets of action 
remains to be investigated. Tumor size decreased when mice with subcutaneously 
implanted S180 sarcoma cells were treated with bacopa extracts (Peng et al., 2010). 
Bacopa confers neuroprotective effects after ischemic brain injury (Liu et al., 2013; 
Saraf et al., 2010), which might suggest testing for a possible link with AQP4, known 
to be a key contributor in pathological outcomes of brain injury (Kim et al., 2010; Lee 
et al., 2012a; Shin et al., 2011). Bacopa also has also been used for control of epilepsy 
(Shanmugasundaram et al., 1991), and some anti-epileptic drugs have been 
demonstrated inhibit AQP4 water permeability (Huber et al., 2009).  
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Plant derived polysacharride and triterpenes compounds possess diverse 
pharmacological functions. A subset of them appear to have theoretical potential 
(based simply on the nature of their cellular and systemic effects in vivo), to regulate 
AQP levels of expression or function directly or indirectly. A sample of interesting 
phytochemical candidates and their structures are listed in Table 2. While still 
speculative at this point, the concept is worth further investigation. More research is 
needed focusing on phytochemicals as sources of candidate pharmacological agents 
for aquaporins. Intriguing connections between botanical medicinal agents and 
aquaporins remain to be investigated, but could be a valuable source of new lead 
compounds for broadening the field of aquaporin pharmacology, and better 
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Figure 1. Schematic diagram of the colocalization of AQP channels with ion 
transporters, other channels and exchangers at the leading edge of a lamellipodium 
in a migrating cell.
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TABLE 2   Phytochemicals derived from medicinal plants traditionally used for 















































CHAPTER 2: AQUAPORIN-1 ION 
CHANNELS IN CANCER CELL 






Bumetanide derivatives AqB007 and AqB011 selectively block the Aquaporin-1 
ion channel conductance and slow cancer cell migration. 
 
AIM: To test various bumetanide derived chemicals (AqBs) for function as AQP1 
modulators and to test their effects on cancer cell migration. 
 
HYPOTHESIS: Various AqBs can block AQP1 ionic conductance and inhibit cancer 
cell migration with different efficacies that correlate with structural properties of the 
modulatory agents.  
 
CONCLUSIONS: 
1. Various structurally related bumetanide derivatives were tested for function as 
AQP1 ion channel antagonists. The order of potency for inhibition of the ionic 
conductance was AqB011> AqB007>> AqB006≥ AqB001.  
2. The potency of inhibition matched with in silico modelling of the predicted order 
of energetically favoured binding. It was predicted that AqB011 interacts with 
poly-arginine region of loop D region. 
3. Migration of human colon cancer (HT29) cells was assessed with a wound-
closure assay in presence of a mitotic inhibitor. AqB011 and AqB007 
significantly reduced migration rates of AQP1-positive HT29 cells without 
affecting viability. 
4. Inhibition of the AQP1 ionic conductance could be a useful adjunct therapeutic 
approach for reducing metastasis in cancers that upregulate AQP1 expression. 
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COMMENTARY: 
New AQP1 modulators presented in this chapter were the first agents demonstrated 
to act as selective AQP1 ion channel blockers. This chapter also provided the 
evidence for conclusions summarized in Chapter 1 on the role of the AQP1 ion 
conductance in cell migration. The significance of this work is the identification of the 
AQP1 ion channel as a key target for anti-cancer drug development, for the subset of 
aggressive cancer cells that rely on upregulation of AQP1 for rapid motility. Cancer 
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Aquaporins (AQPs) in the major intrinsic family of proteins mediate fluxes of water and 
other small solutes across cell membranes. AQP1 is a water channel, and under 
permissive conditions, a nonselective cation channel gated by cGMP. In addition to 
mediating fluid transport, AQP1 expression facilitates rapid cell migration in cell types 
including colon cancers and glioblastoma. Work here defines new pharmacological 
derivatives of bumetanide that selectively inhibit the ion channel but not the water 
channel activity of AQP1. Human AQP1 was analyzed in the Xenopus laevis oocyte 
expression system by two-electrode voltage clamp and optical osmotic swelling 
assays.  AqB011 was the most potent blocker of the AQP1 ion conductance (IC50 14 
µM) with no effect on water channel activity (at up to 200 µM). The order of potency 
for inhibition of the ionic conductance was AqB011> AqB007>> AqB006≥ AqB001. 
Migration of human colon cancer (HT29) cells was assessed with a wound-closure 
assay in presence of a mitotic inhibitor. AqB011 and AqB007 significantly reduced 
migration rates of AQP1-positive HT29 cells without affecting viability. The order of 
potency for AQP1 ion channel block matched the order for inhibition of cell migration, 
as well as in silico modeling of the predicted order of energetically favored binding. 
Docking models suggest that AqB011 and AqB007 interact with the intracellular loop 
D domain, a region involved in AQP channel gating. Inhibition of AQP1 ionic 
conductance could be a useful adjunct therapeutic approach for reducing metastasis 




Osmotic water transport across biological membranes is facilitated by membrane 
proteins known as aquaporins (AQPs), found in all kingdoms of life (Campbell et al., 
2008; Park and Saier, 1996; Reizer et al., 1993). To date, at least fifteen mammalian 
subfamilies have been identified, AQP0-AQP14 (Finn et al., 2014; Ishibashi, 2009) . 
Aquaporin is organised as a tetramer of subunits, each comprising six transmembrane 
domains and five loops (A to E), and carrying a monomeric pore that allows the 
movement of water or other small solutes (Fu et al., 2000; Jung et al., 1994; Sui et al., 
2001).     
There is increasing recognition that certain classes of aggressive cancers depend on 
upregulation of AQP1 for fast migration and metastasis (Monzani et al., 2007). Though 
the precise mechanism for AQP1-enhanced motility remains unknown, both ion 
channels and water channels are essential in the cellular migration process (Schwab 
et al., 2007). AQP1 expression has been linked to metastasis and invasiveness of 
colon cancer cells (Jiang, 2009; Yoshida et al., 2013). In mammary and melanoma 
cancer cells, AQP1 facilitates tumor cell migration in vitro and metastasis in vivo (Hu 
and Verkman, 2006). Increased levels of AQP1 expression in astrocytoma correlate 
with clinical grade, serving as a diagnostic indicator of poor prognoses (El Hindy et al., 
2013).  AQP1-facilitated cell migration in glioma cannot be substituted by AQP4, 
indicating more than simple water channel function is involved in the migration-
enhancing mechanism (McCoy and Sontheimer, 2007).     
A subset of aquaporins have been shown to have ion channel function, including 
AQP0, AQP1, AQP6, plant nodulin, and Drosophila Big Brain (Yool and Campbell, 
2012). In AQP1, multiple lines of evidence have shown the cGMP-dependent 
monovalent cation channel is located in the central pore at the four-fold axis of 
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symmetry, and is pharmacologically distinct from the monomeric water pores (Anthony 
et al., 2000; Boassa and Yool, 2003; Saparov et al., 2001; Yu et al., 2006; Zhang et 
al., 2007).  The AQP1 ion channel has a unitary conductance of 150 pS in 
physiological saline, slow activation and deactivation kinetics, and is permeable to 
Na+, K+, and Cs+ but not divalent cations (Anthony et al., 2000; Yool et al., 1996). Loop 
D has been shown previously to be involved in cGMP-dependent gating of AQP1 ion 
channels (Yu et al., 2006). The low proportion of AQP1 water channels available to be 
gated as ion channels in reconstituted bilayers and heterologous expression systems 
has prompted uncertainty regarding the physiological relevance of the dual water and 
ion channel function in AQP1 (Saparov et al., 2001; Tsunoda et al., 2004). Further 
work has indicated that the availability of AQP1 ion channels to be activated by cGMP 
depends in part on tyrosine phosphorylation at the carboxyl terminal domain 
(Campbell et al., 2012).   
Our characterization here of selective non-toxic pharmacological blockers of the AQP1 
ion channel opens the first opportunity to define the functional roles of the AQP1 ion 
conductance. Prior to 2009, available AQP1 blockers were limited by low potency, lack 
of specificity, or toxicity. Mercury potently blocks AQP1 water permeability by covalent 
modification of a cysteine residue in loop E (Preston et al., 1993) but is highly toxic. 
Tetrethylammonium ion blocks the AQP1 water pore  though not in all cell types 
(Brooks et al., 2000; Detmers et al., 2006; Sogaard and Zeuthen, 2008), and cadmium 
ion blocks the AQP1 ion channel (Boassa et al., 2006); but both lack selectivity for 
aquaporins. Effective compounds discovered recently include the arylsulfonamides 
AqB013 which blocks AQP1 and AQP4 water channel permeability (Migliati et al., 
2009), and AqF026 which strongly potentiates AQP1 water channel activity (Yool et 
al., 2013).  Other arylsulfonamides have been proposed as blockers of AQP4 channels 
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(Huber et al., 2009). A distinct class of agents acting on the external side of the 
membrane to block human AQP1 water flux has been identified as a source of 
candidate lead compounds for drug development (Seeliger et al., 2013).  
Work here characterizes a novel set of AqB compounds (Aq: aquaporin ligand; B: 
bumetanide derivative) that differentially block the AQP1 ion channel without affecting 
water permeability.  The most potent of these, AqB011, is a promising tool for 
dissecting the role of the AQP1 ion channel, while sparing osmotic water permeability. 
Understanding functional roles and regulation of AQP1 is essential for determining the 
full range of physiological roles it might serve, and its possible value as a therapeutic 
target in cancer metastasis. 
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Materials and Methods 
 Oocyte preparation and injection 
 The use of animals in this study has been carried out in accord with the Guide for the 
Care and Use of Laboratory Animals, licensed under the South Australian Animal 
Welfare Act 1985, with protocols approved by University of Adelaide Animal Ethics 
Committee. Unfertilized oocytes were harvested from anesthetized Xenopus laevis  
frogs and defoliculated by incubation in Type 1A collagenase (2 mg/ml) with trypsin 
inhibitor (0.3 mg/ml) in OR-2 saline (82 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 5 mM 
HEPES; pH 7.3) at 16-18°C for 2-3 hours.  Human Aquaporin-1 cDNA was provided 
by Prof P Agre (Preston et al., 1992; GenBank accession number NM_198098). AQP1 
subcloned into a X. laevis b-globin plasmid was linearized with BamHI and transcribed 
in vitro (T3 mMessage mMachine; Ambion Inc., Austin TX USA), and cRNA was 
resuspended in sterile water. Prepared oocytes were injected with 50 nl of water (non-
AQP1-expressing control oocytes), or 50 nl of water containing 1 ng of AQP1 cRNA, 
and incubated for 2 or more days at 16°C in ND96 saline (96 mM NaCl, 2 mM KCl, 1 
mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, pH 7.3) to allow protein expression.  
Successful expression was confirmed by osmotic swelling assays. Batches of AQP1-
expressing oocytes which lacked robust cGMP-activated conductance responses 
were further incubated overnight in ND96 saline with the tyrosine phosphatase 
inhibitor bisperoxovanadium (100 µM; Santa Cruz Biotechnology, Dallas TX USA) as 
per published methods (Campbell et al., 2012). Chemicals were purchased from 
Sigma-Aldrich (St. Louis MO USA) unless otherwise specified.  
 
 
AqB compounds: synthesis and preparation  
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The AqB compounds (custom-designed bumetanide derivatives) were synthesized by 
Dr G Flynn (Spacefill Enterprises LLC, Oro Valley AZ USA) as described in US-
8,835,491-B2. To make AqB001, bumetanide was mixed with diazomethane (CH2N2) 
generated by reaction with Diazald® to create bumetanide methyl ester (MW 344.8; 
ClogP 2.10), which was dissolved in hot CHCl3, diluted with hexanes, and allowed to 
cool to provide the purified methyl ester as white flakes, whose mass and NMR spectra 
were consistent with the desired product.  Reaction of bumetanide with 1.2 equivalents 
of 1,1'-carbonyldiimidazole (CDI) in ethyl acetate (EtOAC) under argon with heating 
afforded an intermediate imidazolide, which upon cooling formed a white solid that 
could be isolated by filtration and stored under argon for later use. Alternatively, the 
imidazolide solution could be reacted in situ with 2 equivalents of an amine to form the 
corresponding amides.  In a typical reaction, the reaction mixture would be partitioned 
between water and ethyl acetate (EtOAc), the organic layer washed with brine, the 
solution filtered and concentrated, and the residue crystalized to form EtOAc/hexanes. 
AqB-006 (MW 413.9; ClogP 1.04) was prepared using morpholine as the amine; 
AqB007 (MW 470.0; ClogP 0.79) resulted from 2-(4-methylpiperazine-1-yl) 
ethylamine; and AqB011 (MW 434.9; ClogP 1.80) was prepared using 2-(morpholine-
1-yl) ethylamine. The structures of all compounds were confirmed by high resolution 
mass spectrometry and NMR analysis.   Chemicals were purchased from Sigma-
Aldrich (St. Louis MO USA) unless otherwise specified. 
Powdered compounds were dissolved in dimethyl sulfoxide (DMSO) to create 1000x 
stock solutions for each desired final dosage. An equal dilution of DMSO (0.1%) alone 
in saline was used as the vehicle control.  
Quantitative Swelling Assay 
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For double-swelling assays, each oocyte served as its own control. Swelling rates 
were assayed first without drug treatment (S1), then oocytes incubated for 2 h in 
isotonic saline with or without the AqB compounds were reassessed in a second 
swelling assay (S2). Swelling rates in 50% hypotonic saline (isotonic Na saline diluted 
with an equal volume of water) were quantified by relative increases in oocyte cross-
sectional area imaged by videomicroscopy (charge-coupled device camera; Cohu, 
San Diego, CA) at 0.5 frames per second for 30s using NIH ImageJ software. Rates 
were measured as slopes of linear regression fits of relative volume as a function of 
time using Prism (GraphPad Software Inc., San Diego CA USA).  
Electrophysiology  
For two-electrode voltage clamp, capillary glass electrodes (1–3 MΩ) were filled with 
1 M KCl.  Recordings were done in standard Na+ bath saline containing 100 mM NaCl, 
2 mM KCl, 4.5 mM MgCl2, and 5 mM HEPES, pH 7.3. cGMP was applied 
extracellularly at a final concentration of 10-20 µM using the membrane-permeable 
cGMP analog [Rp]-8-[para-chlorophenylthio]-cGMP. Ionic conductance was 
monitored for at least 20 min after cGMP addition to allow development of maximal 
plateau responses. Conductance was determined by voltage step protocols from +60 
to -110mV from a holding potential of -40 mV.  Recordings were made with a 
GeneClamp amplifier and pClamp 9.0 software (Molecular Devices, Sunnyvale CA 
USA).  
Circular Wound Closure Assay 
The cancer cell lines used in this study were HT29 human colorectal adenocarcinoma 
cells (Chen et al., 1987) purchased from ATCC (HTB-38; American Type Culture 
Collection; Manassas VA USA) which strongly express endogenous AQP1; and 
SW480 human colorectal adenocarcinoma cells (CCL-228; from ATCC) which 
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express AQP5 but show little AQP1 expression. mRNA levels were evaluated by 
quantitative PCR and protein levels by western blot (H Dorward et al., MS in review). 
Confluent cultures of HT29 and SW480 cells were used in migration assays to 
measure effects of AqB treatments on rates of wound closure. Cells were plated in 
flat-bottom 96-well plates at 1.25 x 105 cells/well in DMEM media with 10% fetal bovine 
serum, and incubated at 37°C and 5% CO2 for 12-18 hours to allow monolayer 
formation. Circular wounds were created by aspirating a central circle of cells with a 
p10 pipette. Wells were washed 2-3 times with phosphate-buffered saline to remove 
cell debris. Culture media (DMEM with 2% bovine calf serum) containing either vehicle 
or drug treatments in the presence of a mitotic inhibitor 5-fluoro-2'-deoxyuridine (100 
ng/ml) were administered into the wells. Cultures were imaged at 0 and 24 h, and 
analysed using ImageJ software to calculate percent wound closure by the change in 
area:   
 ((Area0 – Area24)/Area0) x 100  
Cytotoxicity Assay 
Cell viability was quantified using the AlamarBlue cell viability assay (Molecular 
Probes, Eugene OR USA). Cells were plated at 104 cells/well in 96-well plates, and 
fluorescence signal levels were measured with a FLUOstar Optima microplate reader 
after 24 h incubation with concentrations of AqB011 from 1 to 80 µM, to obtain 
quantitative measures of cell viability. Mercuric chloride (20 µM) was used as a positive 
control for cytotoxicity. 
Molecular Modelling 
In silico modeling was conducted with methods reported previously (Yool et al., 2013).  
The crystal structure of human AQP1 was obtained from the Protein Data Bank (PDB 
ID: 1FQY). The tetrameric model (Supplemental Data) was generated in Pymol 
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(Version 1.7.4 Schrödinger, LLC) using coordinates provided in the pdb file. 
Renderings of the AqB ligands were generated in Chemdraw (Version 13.0, 
PerkinElmer), then converted into pdb format using the on-line SMILES translation tool 
(National Cancer Institute, US Dept Health and Human Services). Both AQP1 and 
ligand coordinates were prepared for docking using MGLtools (Version 1.5.4, Scripps 
Institute, San Diego CA USA). The docking was carried using Autodock Vina (Trott 
and Olson, 2010) with a docking grid covering the intracellular face of tetrameric pore.  
Data Compilation and Statistics  
Results compiled from replicate experiments are presented as box plots. The boxes 
represent 50% of the data, the error bars indicate the full range, and the horizontal 
bars are the median values. n values are in italics above the x-axis. Statistical 
differences were analyzed with one-way ANOVA and post-hoc Bonferroni tests and 
reported as  ** p< 0.0001, * p<0.05, and not significant (NS; p>0.05). 
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Results 
AQP1 ion channel inhibition by novel bumetanide derivatives 
 A set of four related compounds with structural modifications at the carboxylic acid 
moiety of bumetanide were tested for effects on the cGMP-activated ionic 
conductance in AQP1-expressing oocytes. Two-electrode voltage clamp recordings of 
AQP1-expressing oocytes (Figure 1) illustrate inhibition of the ionic conductance by 
extracellular application of AqB007 (200 µM) and AqB011 (20 µM), but no appreciable 
block of the AQP1 ion channel with 200 µM AqB001 or AqB006. Initial recordings 
before cGMP application, and responses to the first application of cGMP recordings 
showed typical cGMP-dependent activation, as described previously (Anthony et al., 
2000). Oocytes were then transferred into saline with the indicated agents for 2 hours, 
during which time the ionic conductances uniformly recovered to initial levels (Figure 
2).  In response to the second application of cGMP, oocytes treated with vehicle 
(DMSO), AqB001 or AqB006 showed increases in conductance comparable to the first 
response. However, the cGMP-activated conductance responses were inhibited after 
treatment with AqB007 or AqB011.  
Trend plots (Fig 2A) show that the ionic conductance in AQP1-expressing oocytes 
was initially low, and was activated by the first bath application of membrane 
permeable cGMP. The ionic conductance then recovered to basal level during a 2h 
incubation without cGMP, and was tested for reactivation by a second application of 
cGMP after treatment with vehicle or AqB compounds.  Recordings for oocytes 
incubated in saline without DMSO during the recovery period were comparable to 
those for the DMSO-treated group (not shown). Non-AQP1-expressing control oocytes 
showed no ionic conductance response to cGMP and no effect of the vehicle or drug 
treatments (Fig 2B).    
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Compiled data for the cGMP-activated ionic conductance values in AQP1-expressing 
oocytes are shown in the box plot (Fig 3A), and indicate the levels of block by 200 µM 
AqB007 and 20 µM AqB011 were statistically significant as compared with vehicle 
treated AQP1-expressing oocytes.  Dose-response relationships (Fig 3B) yielded 
estimated IC50 values of 14 µM for AqB011 and 170 µM for AqB007. 
AqB ion channel blockers have no effect on osmotic water permeability  
Data for oocyte volumes standardized as a percentage of initial volume at time zero 
illustrate the mean swelling responses over 60 seconds after introduction of the 
oocytes into 50% hypotonic saline (Fig 4A). AQP1-expressing oocytes showed 
consistent osmotic swelling which was unaffected by treatment with vehicle (DMSO 
0.1%) or AqB compounds at 200 µM each. Non-AQP1-expressing control oocytes 
showed little osmotic water permeability.   
To analyze possible effects of the AqB compounds on water channel activity, a double-
swelling assay was used (Fig 4B). After the first swelling (S1) in hypotonic saline, 
oocytes were incubated in isotonic saline with or without the AqB compounds (200 
µM) for 2 h before assessing the second swelling response (S2).  There were no 
significant differences between the first and second swelling rates in any of the 
treatment groups, confirming that the AqB ion channel agents did not affect AQP1 
osmotic water permeability. 
 
 
Molecular modelling of candidate intracellular binding sites 
Putative binding sites on the AQP1 ion pore for AqB011 and AqB007 in the intracellular 
loop D domain can be suggested based on structural modelling and docking analyses 
(Figure 5). In silico modeling suggested the sites for the most favorable energies of 
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interaction for AqB007 and AqB011 were located at the intracellular face of the central 
pore (Fig 5A). Interestingly, the model predicted hydrogen bonding between the 
uniquely elongated moieties of the two effective AqB ligands and the initial pairs of 
arginine residues in the highly conserved loop D motifs from two adjacent subunits 
(Fig 5B); the same arginines (R159 and R160 in human AQP1) have been shown to 
be involved in AQP1 ion channel gating but not water channel activity in prior work (Yu 
et al., 2006). The more compact AqB006 docked weakly at a different position in the 
central vestibule (not shown). While in silico modeling does not define actual binding 
sites, it provides a testable hypothesis for future work, and offers intriguing support for 
the role of loop D in modulating AQP1 ion channel gating. The most favorable energy 
of interaction was calculated for AqB011 (at -9.2 kcal/mol). The next most favorable 
energy of interaction for AqB compounds with the AQP1 channel was for AqB007 (at 
-7.0 kcal/mol), followed by AqB006 (at -6.0 kcal/mol). This order of interaction strength 
for the AqB series matched their order of efficacy for inhibition of the AQP1 ion channel 
conductance (Figure 3). 
Inhibition of AQP1 ion channel activity slows cancer cell migration  
The effects of AqB006, AqB007 and AqB011 were tested in migration assays of 
human HT29 colon cancer cells (Figure 6) which natively express AQP1. Net 
migration rates were calculated from the percent closure of a circular wound area at 
24 h (Fig 6A). Results showed that cancer cell migration was not impaired by AqB006, 
but was impaired significantly by AqB007 at 100 µM, and AqB011 at 50 µM and 100 
µM, as compared with vehicle-treated control HT29 cells (Fig 6B).  AqB011 was more 
effective than AqB007 in blocking migration, consistent with relative efficacies of the 
agents as blockers of the ion channel conductance. In contrast, AqB011 at 100 µM 
had no effect on the migration rate of SW480 colon cancer cells (Fig. 6B) which 
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express AQP5, but not AQP1, suggesting that the inhibitory effect of AqB011 appears 
to be selective for AQP1. 
AqB compounds show low cytotoxicity  
There was no significant difference in viability between vehicle-treated and untreated 
cells, and no effect of treatment with AqB011 for HT29 cells (Table 1). Cell viability 
was assessed with alamarBlue assays. The persistence of the fluorescent signal at 
24 h confirmed there was no appreciable cytotoxic effect of AqB011 treatment on 
HT29 cells at concentrations up to 80 µM.  Mercuric chloride as a positive control 
caused significant cell death, measured as a decrease in fluorescence.  AqB011 at 
doses used to block the AQP1 ionic conductance and cancer cell migration did not 




The aim of this study was to search for selective small-molecule pharmacological 
agents capable of blocking the cGMP-activated cationic conductance in AQP1.  
Discovery of pharmacological modulators for AQP1 channels has been an important 
goal in the aquaporin field. AQP1 antagonist and agonist agents are expected to be 
useful for defining the complex roles of aquaporins in fundamental biological 
processes, as well as for characterizing AQP1 modulators as potential clinical agents 
in various conditions, such as cancer metastasis (Yool et al., 2009). AQP1 expression 
is upregulated in subtypes of aggressive cancer cells in which it facilitates cancer 
migration. Results here show that selective blockers of the AQP1 ion channel slow 
migration of human colon cancer cells in culture. Pharmacological inhibition of AQP1 
is predicted to have a protective effect in reducing metastasis in cancer, but remains 
to be demonstrated in vivo. 
Using bumetanide as a starting scaffold, we created an array of novel synthetic 
derivatives.  Based on pilot data indicating a small inhibitory effect of AqB050 on the 
AQP1 ion channel at high doses (unpublished observations), we investigated a series 
of structurally related derivatives AqB006, AqB007, and AqB011, as well as a simple 
methylated version of bumetanide AqB001, to test for possible inhibitors of the AQP1 
ionic conductance. Our findings demonstrated that AqB007 and AqB011 are effective 
inhibitors of the central ion pore of AQP1, with estimated IC50 values of 170 and 14 
µM, respectively. Both AqB007 and AqB011 showed dose-dependent inhibition of the 
central ion pore, whereas the intrasubunit water pores were unaffected, enabling the 
first dissection of physiological roles of the distinct channel functions. Measuring 
fluorescence signal intensity with the alumarBlue cell viability assay showed that 
AqB011 was not cytotoxic at doses that produced maximal ion channel inhibition. 
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The inhibition by AqB011 of AQP1 ionic conductance was consistent with molecular 
docking studies suggesting the site of interaction is at the intracellular face of the 
central pore. Results revealed that AqB011 is the most energetically favored 
compound followed by AqB007. The predicted interaction site of AqB011 and AqB007 
with AQP1 is at the loop D domain. Differences in the structures and efficacies of 
AqB006, AqB007 and AqB011 indicate that the structure-activity relationship of ion 
channel inhibition is sensitive to specific chemical modifications at the carboxylic acid 
position of bumetanide. The length and structure of the modification appears to be 
critical, and appears based on in silico modeling to be the region that interacts with 
the AQP1 channel gating loop D domain. The absence of cytotoxic effects of AqB011 
at doses sufficient to block the AQP1 ion channel activity indicates that the inhibition 
of migration is not due indirectly to cell death. The observation that AqB011 inhibited 
migration in AQP1-expressing HT29 colon cancer cells, but had no effect on the 
migration of AQP-5 expressing SW480 colon cancer cells provides support for the 
idea that AqB011 is selective for AQP1.  The inhibition of migration seen with AqB011 
is unlikely to result from off-target effects on general metabolic function, cytoskeletal 
organization, actin polymerization, or signaling pathways involved in cell motility, since 
SW480 cell migration remained unaffected by the presence of AqB011.  
AQP1 is present in barrier epithelia involved in fluid movement in the body, including 
proximal tubule and choroid plexus (Agre et al., 1993). It is also expressed in 
peripheral microvasculature, dorsal root ganglion cells, eye ciliary epithelium and 
trabecular meshwork, heart ventricle, and other regions in which a direct role for 
osmotic water flux is less evident (Yool, 2007).  Additional roles suggested for AQP1 
include angiogenesis (Nicchia et al., 2013); signal transduction (Oshio et al., 2006); 
increased mechanical compliance to changes in pressure (Baetz et al., 2009);  axonal 
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regeneration of spinal nerves (Zhang and Verkman, 2015); recovery from injury (Hara-
Chikuma and Verkman, 2006); and exocytosis (Arnaoutova et al., 2008). Relative 
contributions of the ion and the water channel functions in these diverse processes 
remain to be defined. 
A possible role for the AQP1 ionic conductance (potentially in combination with water 
fluxes) in the control of cell volume associated with migration was supported by the 
results of the wound closure assays with AQP1-expressing HT29 cells.  Cell migration 
was significantly impaired by AqB011 and AqB007, but not by AqB006.   The greatest 
efficacy of migration block was seen with administration of AqB011. The comparable 
orders of efficacy for block of AQP1 ion channels in the oocyte expression system, 
and for block of cell migration in HT29 cultures, support the idea that the AqB011 effect 
on migration is mediated by block of the AQP1 ion channels directly.   These data 
provide evidence that the ion channel activity of AQP1 has physiological relevance. 
Further work is needed to evaluate effects of blocking both water and ion channel 
activities of AQP1 together in migrating cells. 
AqB011 is a new research tool for probing the physiological role of the AQP1 ion 
channel function in biological systems.  This compound holds future promise as a 
possible adjunct clinical intervention in cancer metastasis.  Exciting opportunities are 
likely to emerge from continuing discovery of pharmacological modulators for 
aquaporins for new treatments in cancers and other diseases. 
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Figure Legends  
Figure 1. Chemical structures of selected bumetanide derivatives and 
electrophysiology traces showing representative effects of AqB001, AqB006, 
AqB007, and AqB011 on the ionic conductance responses activated by bath 
application of CPT-cGMP, before and after 2 h incubation in saline with and without  
the AqB compounds.  See Methods for details.  
Figure 2.  Trend plots showing the ionic conductance responses for individual 
oocytes measured prior to cGMP (initial), after the first cGMP application, after 2 h 
incubation in saline without cGMP containing DMSO (vehicle) or AqB agents, and 
after the second application of cGMP.  Reversible cGMP-dependent activation of an 
ionic conductance in AQP1-expressing oocytes (A) was not seen in non-AQP1 
control oocytes (B). Inhibition was seen after treatment with AqB007, and AqB011, 
but not with vehicle, AqB001, or AqB006. 
Figure 3. Dose-dependent block of the AQP1 ionic conductance. (A) Compiled box 
plot data showing statistically significant block of the cGMP-activated ionic 
conductance in AQP1-expressing oocytes by AqB007 and AqB011, but not with 
vehicle, AqB001, or AqB006. See Methods for details. (B) Dose response curves 
showing percent block of the activated ionic conductance in AQP1 expressing 
oocytes and estimated IC50 values.  n values for dose-response data (in order of 
increasing concentration) for AqB007 were 8, 4, 2, 8; and for AqB011 were 8, 2, 2, 3, 
6, 4, 3. 
Figure 4.  Lack of effect of AqB compounds on AQP1 osmotic water permeability 
measured by optical swelling assays. (A) Mean oocyte volume, standardized as a 
percentage of the initial volume for each oocyte, as a function of time after 
introduction into 50% hypotonic saline, with and without 2 h pre-treatment with AqB 
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compounds at 200 µM, or vehicle (0.1% DMSO). (B) Compiled boxplot data showing  
the absence of any statistically significant differences between the first and second 
swelling rates, measured before (S1) and after (S2) 2 h incubations in saline alone or 
saline with 200 µM AqB compounds as indicated. See Methods for details. 
Figure 5. In silico modeling of the energetically favored binding site for AqB011 in 
the center of the tetrameric channel of AQP1 (grey) at the intracellular side, 
bracketed by the gating loop D domains (green).  The putative binding site suggests 
an interaction with two of the loop D domains from adjacent subunits. (A) is the full 
view of the tetramer, and (B) is a closer view slightly rotated to show proximity of the 
ligand to the conserved arginine residues in loop D.  
Figure 6. Block of cell migration in AQP1-expressing HT29 but not SW480 cells 
treated with AqB011. (A) Illustrative diagram of the circular wound healing method, 
showing substantial closure of the wounded area in normal culture medium by 24 
hours.  (B) Compiled boxplot data from wound closure assays showing the dose-
dependent inhibitory effects of AqB007 and AqB011, compared to DMSO and 
AqB006,  on wound closure at 24 h in HT29 cell cultures. Migration of SW480 cells 
was not altered by AqB011. 
Supplemental Data.  Molecular modelling data in Protein Data Bank (pdb) format 
showing the compound AqB011 docked at the intracellular side of the tetrameric 
human AQP1 channel (PDB ID: 1FQY), and interacting with loop D domains of 
subunits surrounding the central pore. 
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Table 1.  HT29 cell levels of cytotoxicity after treatment with furfural, structurally 
related compounds, or HgCl2 in the culture medium. 
Agent             
[AqB011] (µM) 
Mean normalized cell 
viability (%)  ± SEM § 
n value  
0 (untreated) 100.0  ±  0.70 8 --- 
0 (0.1% DMSO) 103.9  ±  0.91 8 NS 
1 104.0  ±  1.06 4 NS 
5 102.3  ±  2.26 4 NS 
10 110.6  ±  2.12 4 NS 
20 114.0  ±  0.84 4 NS 
40 111.8  ±  1.33 4 NS 
80 102.4  ±  2.95 4 NS 
HgCl2  (100 µM)   16.2  ±  0.20 3 ** 
 
§  Percent viability was standardized as a percentage of the untreated mean value, 
measured as changes in alumarBlue fluorescence signal intensity. See Methods for 
details.  
         
 



























CHAPTER 3: THE DISCOVERY OF 
NOVEL PHYTOCHEMICALS THAT 






Differential inhibition of water and ion channel activities of mammalian 
Aquaporin-1 by two structurally related bacopaside compounds derived from 
the medicinal plant Bacopa monnieri. 
 
 
AIM: To test the effect of two structurally related bacopaside compounds on AQP1 
and AQP4 water and ionic conductance and to test the effect of both compounds on 
cancer cell migration.  
 
HYPOTHESIS: Two bacopaside compounds can block either AQP1 or AQP4 water or 
ionic conductance at various degrees based on their structural differences. Both 
bacopaside compounds can impair cancer cell migration.    
 
CONCLUSIONS: 
1. Medicinal plant Bacopa monnieri was selected as the candidate from meta-
analysis of literature conducted in Chapter 1. 
2. Two triterpene saponins (Bacopaside I and Bacopaside II) were isolated and 
identified from the crude plant extract that were able to block AQP1 water 
permeability. 
3. Results showed bacopaside I blocked both the water (IC50 117 µM) and ion 
channel activities of AQP1 but did not alter AQP4 activity, whereas bacopaside 
II selectively blocked the AQP1 water channel (IC50 18 µM) without impairing 
the ionic conductance. 
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4. Bacopaside I (IC50 48 µM) and bacopaside II (IC50 14 µM) impaired migration 
of HT29 cells which has higher AQP1 expression, but had minimal effect on 
SW480 cell migration, which has lower AQP1 exprerssion. 
5. Bacopasides could serve as novel lead compounds for pharmaceutical 
development of selective aquaporin modulators.   
 
COMMENTARY: 
The discovery of new AQPs modulators, as presented in this chapter, adds to the 
portfolio of compounds available for altering AQP-mediated functions, and expands 
our understanding of the structure-activity relationship of pharmacological blockers of 
AQP1 channels. This work was the evidence for the some of the conclusions 
summarized in Chapter 1, and the first to demonstrate that identified phytochemical 
compounds from traditional herbal medicines are valuable candidates for new AQP 
modulators. The proposal that AQP1 is a key target for anti-cancer drug development 
is confirmed by results here. Cancer cell migration was impaired by blocking the AQP1 
ionic conductance. This chapter, together with Chapter 2, highlight a broad array of 
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 Abstract  
  
Aquaporin-1 (AQP1) is a major intrinsic protein that facilitates flux of water and other 
small solutes across cell membranes. In addition to its function as a water channel in 
maintaining fluid homeostasis, AQP1 also acts as a non-selective cation channel 
gated by cGMP, a property shown previously to facilitate rapid cell migration in a 
AQP1-expressing colon cancer cell line. Here we report two new modulators of AQP1 
channels, bacopaside I and bacopaside II, isolated from the medicinal plant Bacopa 
monnieri. Screening was conducted in the Xenopus oocyte expression system, using 
quantitative swelling and two-electrode voltage clamp techniques. Results showed 
bacopaside I blocked both the water (IC50 117 µM) and ion channel activities of AQP1 
but did not alter AQP4 activity, whereas bacopaside II selectively blocked the AQP1 
water channel (IC50 18 µM) without impairing the ionic conductance. These results fit 
with predictions from in silico molecular modeling. Both bacopasides were tested in 
migration assays using HT29 and SW480 colon cancer cell lines, with high and low 
levels of AQP1 expression respectively. Bacopaside I (IC50 48 µM) and bacopaside II 
(IC50 14 µM) impaired migration of HT29 cells, but had minimal effect on SW480 cell 
migration. Results here are the first to identify differential AQP1 modulators isolated 
from a medicinal plant.  Bacopasides could serve as novel lead compounds for 
pharmaceutical development of selective aquaporin modulators.   
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Introduction  
Aquaporin (AQP) water channels are in the family of major intrinsic proteins found 
from bacteria to humans (Agre et al., 1993; Calamita et al., 1995; Reizer et al., 1993), 
and are targets for the discovery of selective pharmacological modulators.  Classes of 
aquaporins transport water and small uncharged molecules such as glycerol and urea 
through individual pores located in each subunit (Fu et al., 2000; Tajkhorshid et al., 
2002).  
An expanding role for aquaporins as multifunctional channels is being recognized 
(Yool and Campbell, 2012). In addition to facilitating water flux through intrasubunit 
pores, AQP1 also functions as a non-selective monovalent cation channel using the 
central pore at the four-fold axis of symmetry (Campbell et al., 2012; Yool and 
Weinstein, 2002; Yu et al., 2006). The ion channel conductance is activated by 
interaction of cGMP in the intracellular Loop D domain, and modulated by the carboxyl 
terminal domain (Anthony et al., 2000; Boassa and Yool, 2003; Saparov et al., 2001; 
Zhang et al., 2007). cGMP appears to trigger opening of cytoplasmic hydrophobic 
barriers in the central pore, allowing hydration and cation permeation (Yu et al., 2006).  
Inhibition of the AQP1 ion channel has been shown to slow cell migration rates in a 
colon cancer cell line that expresses high levels of AQP1 (Kourghi et al., 2016).   
Defining pharmacological modulators of aquaporins has been an area of keen interest 
(Devuyst and Yool, 2010; Papadopoulos and Verkman, 2008; Seeliger et al., 2013). 
Early work identified blockers such as mercury (Preston et al., 1993), silver and gold 
(Niemietz and Tyerman, 2002), acetazolamide (Gao et al., 2006), and 
tetraethylammonium ion  (Brooks et al., 2000; Detmers et al., 2006; Yool et al., 2002), 
but these remained limited in usefulness because of toxicity, lack of specificity, or 
variable efficacy across experimental systems (Yang et al., 2006; Yool, 2007). More 
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recently, small molecule pharmacological agents with therapeutic potential have been 
identified. Complexes of gold-based compounds have promise for the selective block 
of specific classes of aquaporins; functionalized bipyrene and terpyridines 
coordinating Au(III) were shown to block aquaglyceroporin AQP3 with little effect on 
AQP1 (Martins et al., 2013). Intracellular arylsulfonamide modulators of AQP1 include 
the bumetanide derivative, AqB013, which blocks AQP1 and AQP4 water permeability 
(Migliati et al., 2009); AqB011 which blocks the AQP1 cation channel (Kourghi et al., 
2016); and the furosemide derivative AqF026 which potentiates water channel activity 
of AQP1 (Yool et al., 2013). Other arylsulfonamide agents have been proposed as 
blockers of AQP4 (Huber et al., 2009; Huber et al., 2007). , Growing evidence is 
demonstrating that specific arylsulfonamides act as AQP modulators in vitro and in 
vivo (Pei et al., 2016).  Diverse small molecules acting at the extracellular side present 
a valuable array of novel inhibitors of AQP1 (Seeliger et al., 2013), indicating that other 
compounds in addition to coordinated metal ligands and arylsulfonamides are of 
interest for the development of AQP modulators.  Lack of effects for a broad panel of 
AQP modulators tested in one study might reflect problems with synthesis or 
solubilization of the agents, or could indicate that the type of bioassay used influences 
apparent drug efficacy (Esteva-Font et al., 2016).  
The present study was aimed at broadening the panel of AQP modulatory agents by 
evaluating natural medicinal plants as sources of active compounds. Quantitative 
swelling assays of mammalian AQP1 and AQP4 channels in the Xenopus expression 
system were used for screening extracts from a variety of traditional medicinal herbs, 
and identified Bacopa monnieri as one of several promising sources. Work here tested 
the hypothesis that chemical constituents of B. monnieri could be identified and 
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characterized as pharmacological agents that modulate mammalian AQP1 by 
interacting at domains associated with pore functions.  
Data here show that bacopaside I blocks both the water and ion channel activities of 
AQP1 but does not alter AQP4 activity, and bacopaside II selectively blocks the AQP1 
water channel without impairing the ionic conductance. Results fit well with in silico 
docking for predicted energies of interaction at a pore-occluding intracellular site. 
Bacopasides I and II showed the same order of efficacy in blocking migration of AQP1-
expressing HT29 colon cancer cells, with minimal effects on SW480 cells that express 
AQP1 at low levels. Results here are the first to identify AQP1 channels as one of the 
candidate targets of action of the Ayurvedic medicinal plant, water hyssop, and to 
define new lead compounds for the development of AQP modulators.   
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Materials and Methods 
Bacopa methanol extraction and fractionation 
Bacopa monnieri stems and leaves were obtained with permission from The Botanic 
Gardens of Adelaide (Adelaide, South Australia). Chopped bacopa plant material (100 
g) was dried, then refluxed in 500ml of methanol for 2 hours at room temperature. The 
suspension was filtered using Whatman No. 1 paper to obtain a methanol extract of 
whole bacopa (meWB). Half of the meWB extract was aliquoted into microfuge tubes, 
dried under vacuum (SpeedVac) into a solid brown paste, and reconstituted in saline 
for oocyte swelling assays. The other half of the meWB was fractionated using small-
scale reverse phase C18 silica column (Alltech Prevail C18, Grace; Deerfield, IL). The 
mobile phases used for fractionation were a series of six water-methanol mixtures with 
H2O:CH3OH ratios ranging from 5:0 to 0:5. The fractions were dried in under vacuum 
and reconstituted in saline for oocyte swelling assays. Fractions containing AQP1 
blocking activity were analyzed with mass spectrometry by Flinders Analytical 
(Flinders University, South Australia). Bacopaside I was identified by precise 
molecular weight as a major component in the active fractions, and bacopasides I and 
II were purchased from a commercial source (Chromadex; Irvine CA USA), solubilized 
in methanol to yield 100x stock solutions, and stored at -20°C. Experimental solutions 
were prepared by mixing the bacopaside stocks (1 part in 100) with isotonic saline or 
culture medium to yield final concentrations of 10 to 200 µM.  Vehicle control salines 
were made using the same volume of methanol alone in isotonic saline or culture 
medium.       
Oocyte preparation and cRNA injection 
Unfertilized oocytes were isolated from Xenopus laevis frogs in accord with University 
Animal Ethics Committee-approved protocols, defolliculated by treatment with 
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collagenase (type 1A, 2 mg/ml; Sigma, St. Louis, MO) and trypsin inhibitor  (0.67 
mg/ml; Sigma, St. Louis, MO) in OR-2 saline (82 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 
and 5 mM HEPES; pH 7.6) at 16°C for 1.5 hours, washed in OR-2 saline, and then 
incubated in isotonic oocyte saline [96 mM NaCl, 2 mM KCl, 0.6 mM CaCl2, 5 mM 
MgCl2, and 5 mM HEPES supplemented with 10% horse serum (Sigma, St. Louis, 
MO), 100 U/ml penicillin, 100 µg/ml streptomycin and 50 µg/ml tetracycline, pH 7.6] at 
16°C. Oocytes were injected with 1-4 ng of AQP1, AQP4 or AQP1 R159A+R160A 
cRNA in 50 nl sterile water and incubated for 2 to 3 days at 16-18°C to allow protein 
expression. Oocytes not injected with cRNA served as non-AQP-expressing control 
cells.  
Human AQP1 (National Center for Biotechnology Information NCBI GenBank: 
BC022486.1) and rat AQP4 (AF144082.1) cDNAs from P. Agre (The Johns Hopkins 
University, Baltimore, MD) were subcloned into a modified Xenopus b-globin 
expression plasmid.   The double mutant construct human AQP1 R159A+R160A 
cDNA was generated by site-direct mutation (QuikChange; Stratagene, La Jolla, CA) 
and sequenced to confirm no errors were introduced (Yu et al., 2006). cDNAs were 
linearized with BamHI and transcribed using T3 polymerase (T3 mMessage 
mMachine; Ambion Inc., Austin, TX). cRNAs were resuspended in sterile water and 
stored at -80°C. 
Quantitative oocyte swelling assays 
Immediately prior to swelling assays, control and AQP-expressing oocytes were 
preincubated in isotonic saline (serum- and antibiotic-free) with or without meWB or 
bacopaside compounds or with methanol vehicle at 16-18°C, for incubation periods 
as indicated. Osmotic water permeability was determined as the linear rate of change 
in volume as a function of time, immediately after introduction into 50% hypotonic 
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saline (isotonic saline diluted with equal volume of water).  Oocytes were imaged using 
a computer controlled charge-coupled-device grayscale camera (Cohu, San Diego, 
CA) mounted on a dissecting microscope (Olympus SZ-PT; NSW Australia). Images 
were taken at 0.5 frames per second for 60 seconds; cross-sectional areas were 
quantified using ImageJ software (Research Services Branch; National Institutes of 
Health, MD USA). Swelling rates were calculated as the slopes of linear regression 
fits of volume as a function of time in hypotonic saline. Data were analyzed and 
compiled for multiple batches of oocytes for statistical analyses and to generate dose-
response curves, which were fit by sigmoidal non-linear variable-slope dose-response 
regression functions using Prism (GraphPad Software Inc., San Diego, CA USA).    
Molecular docking    
In silico modeling was done with methods reported previously (Yool et al., 2013). The 
protein crystal structures for human AQP1 (PDB ID. 1FQY) and human AQP4 (PDB 
ID. 3GDB) were obtained from the protein data bank (NCBI Structure). Bacopaside I 
and II structures were obtained from PubChem (NCBI) and converted into a software-
compatible 3D structures in .pdb format using the Online SMILES Translator and 
Structure File Generator (National Cancer Institute, US Dept Health and Human 
Services). Ligand and receptor coordinates were prepared for docking using Autodock 
(Version 4.2, Scripps Research Institute, La Jolla, CA USA). Autodock Vina (Trott and 
Olson, 2010) was used to run the flexible ligand docking simulations with two docking 
grids covering both intracellular and extracellular faces of the monomeric pores. 3D 
docking result files and docking energy values were exported from Autodock, and 
results were viewed using PyMol software (Version 1.8, Schrödinger, LLC).  Data for 
AQP1 and AQP4 docking results in .pse format are provided as Supplemental Files 1 
and 2.  
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Electrophysiology 
For two-electrode voltage clamp, capillary glass electrodes (1–3 MW) were filled with 
1 M KCl. Recordings were done in standard isotonic Na
+
 bath saline containing 100 
mM NaCl, 2 mM KCl, 4.5 mM MgCl2, and 5 mM HEPES, pH 7.3. cGMP was applied 
extracellularly at a final concentration of 10-20 µM using the membrane-permeable 
cGMP analog [Rp]-8-[para-chlorophenylthio]-cGMP (Sigma Chemical, Castle Hill 
NSW Australia). Ionic conductance was monitored for at least 20 min after cGMP 
addition to allow development of maximal plateau responses. Conductance was 
determined by linear fit of the current amplitude as a function of voltage, with a step 
protocol from +60 to -110mV and holding potential of -40 mV.  After the first activation 
by cGMP, oocytes were incubated in isotonic saline with or without bacopaside I or 
bacopaside II for two hours to allow recovery. After incubation, a second application 
of cGMP was used to test for reactivation, to determine if any block of the ionic 
conductance was evident. Using the same protocol, AQP1-expressing oocytes were 
demonstrated previously to show cGMP-dependent activation, complete recovery 
during a 2 h incubation in saline alone, and full reactivation of the ionic conductance 
response to a second application of cGMP, whereas non-AQP1-expressing control 
oocytes showed a low ionic conductance and no significant response to drug 
treatments throughout the same protocol (Kourghi et al., 2016). Recordings were 
made with a GeneClamp amplifier and pClamp 9.0 software (Molecular Devices, 
Sunnyvale CA USA). 
Cancer cell culture and migration assays 
HT29 and SW480 colon cancer cell lines (from American Type Culture Collection 
ATCC, Manassas, VA USA) were cultured in complete medium composed of 
Dulbecco's Modified Eagles Medium (DMEM) supplemented with 1 x glutaMAX™ (Life 
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Technologies Mulgrave, VIC, Australia), penicillin and streptomycin (100 U/ml each) 
and 10% fetal bovine serum (FBS). Cultures were maintained in 5% CO2 at 37°C. 
Cells were seeded in a flat-bottom 96-well plates at 1.25 x 10
6
 cells/ml to produce a 
confluent monolayer. For 12 to 18 hours prior to wounding, cells were serum-starved 
in 2% FBS, in the presence of 400 nM of the mitotic inhibitor 5-fluoro-2'-deoxyuridine, 
FUDR (Parsels et al., 2004). For wounding, a sterile p10 pipette tip was attached to 
the end of a vacuum tube, and a circular wound was created by brief perpendicular 
contact of the tip with base of the well. Each well was then washed three times with 
phosphate buffered saline (PBS) to remove detached cell debris. Cultures were 
maintained during the wound closure assay in 2% FBS medium with FUDR. Wound 
images were imaged at 10x magnification with a Canon 6D camera mounted on a 
Olympus inverted microscope. Image dimensions and pixel density were standardized 
across each image series using XnConvert software. Linear outlines and areas of the 
wound were generated using ImageJ software (National Institutes of Health). Wound 
closure data as a function of time were calculated as a percentage of the initial wound 
areas for the same wells. 
Quantitative RT-PCR 
Cells at 70-80% confluence were harvested and RNA extracted using the PureLink
TM
 
RNA Mini kit (Life Technologies). RNA was quantified using the NanoDrop 2000 
spectrophotometer (Thermo Scientific, Waltham, MA, USA) and the integrity (RIN 
score) assessed using the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA). RNA (500 ng) was reverse transcribed using the iScript
TM
 cDNA synthesis kit 
(Bio-rad, Carlsbad, CA, USA). qPCR of AQP1 and the reference gene 
phosphomannose mutase 1 (PMM1) was performed using multiplex Taqman 
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expression assays (Life Technologies) and SsoFast™ probes supermix (Bio-rad) in 
triplicate in the Rotorgene 6000 (Qiagen).  
Western blot 
Cultured cells were lysed with RIPA buffer containing 1% β-mercaptoethanol, 1% 
HALT protease inhibitor 100X solution, 150 U Benzonase (all from Sigma, St Louis, 
MO, USA) on ice for 10 minutes, homogenized by passing through a 21 gauge syringe 
and centrifuged 14,000 x g for 15 minutes at 4◦C to pellet the cell debris. Protein was 
quantified (EZQ® assay, Life Technologies). Each sample (50 µg) was resolved by 
SDS-PAGE on a 12% Mini-PROTEAN® TGX Stain-Free™ Gels (Bio Rad) and 
transferred to PVDF membranes using the Trans-Blot® Turbo™ Transfer Pack and 
System (Bio Rad). Membranes were blocked with TBST containing 5% skim milk for 
1hour and incubated overnight at 4◦C with anti- AQP1 (H-55) (1/500; Santa Cruz, 
USA).  Following three washes in TBST, membranes were incubated with goat anti-
rabbit IgG HRP secondary antibody (1/ 2000) and Streptactin-HRP Conjugate 
(1/10000) (both Bio-Rad) at room temperature for 1h, and washed.  
Chemiluminescence using Clarity™ Western ECL Blotting Substrate (Bio-Rad) was 
used for detection and blots imaged using the ChemiDoc™ Touch Imaging System 
(Bio-Rad). Image Lab™ Software was used to validate western blotting data via total 
protein normalization (Bio-Rad). 
Immunocytochemistry   
HT29 and SW480 cells grown on coverslips to 50% confluence were fixed with 4% 
paraformaldehyde and permeabilized with 0.5% Triton X-100.  Image-iT® FX Signal 
Enhancer (Life Technologies) was used as per manufacturer’s instructions.  AQP1 
was labelled with a 1/400 dilution of rabbit polyclonal anti-human AQP1 (Abcam®, 
Cambridge, UK), visualized with a secondary antibody at 1/200 dilution (goat anti 
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rabbit IgG H&L Alexa Fluor® 568; Life Technologies).  Cells were counterstained with 
NucBlue® Fixed Cell Ready ProbesTM Reagent (Life Technologies). Coverslips were 
mounted in ProLong® Gold antifade reagent (Life Technologies) and imaged with a 
Zeiss LSM 700 microscope (Carl Zeiss, Jena, Germany). 
Live cell imaging 
Cells were seeded on an 8-well uncoated Ibidi µ-Slide (Ibidi, Munich Germany) at a 
density of 1.0 x 10
6
 cells/ml.  For 12 to 18 hours prior to wounding, cells were serum-
starved in medium with 2% FBS in the presence of FUDR (400 nM).  Five circular 
wounds were created in each well using techniques described for the migration assays 
(above). The slide was mounted on a Nikon Ti E Live Cell Microscope (Nikon, Tokyo 
Japan) in an enclosed chamber kept at 37 °C with 5% CO2.  Images were taken at 5 
min intervals for 24 hours, using Nikon NIS-Elements software (Nikon, Japan). AVI 
files were exported from NIS-Elements and converted into TIFF files using ImageJ 
(NIH). Converted files were analyzed using Fiji software (Schindelin et al., 2012) with 
the Manual Tracking plug-in.   
Cytotoxicity assay 
HT29 cell viability was quantified using the AlamarBlue assay (Molecular Probes, 
Eugene, OR USA). Cells were plated at 10
4
 cells/well in 96-well plates, and 
fluorescence signal levels were measured with a FLUOstar Optima microplate reader 
after 24 h incubation with concentrations of bacopaside I from 0 to 100 µM or 
bacopaside II from 0 to 30 µM, to obtain quantitative measures of cell viability. Mercuric 
chloride (100 µM) was used as a positive control for cytotoxicity. 
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Results 
Extracted compounds from Bacopa monnieri inhibited AQP1 water channel 
activity.  Methanol-extracted whole Bacopa (meWB) reconstituted in isotonic saline 
inhibited the water permeability of AQP1-expressing oocytes (Fig 1A). After 2 hours 
preincubation in 1 mg/ml meWB, swelling rates of AQP1-expressing oocytes were 
significantly reduced (p<0.001) as compared with untreated AQP1-expressing 
oocytes. Fractionated samples of meWB reconstituted at 0.1 mg/ml each were tested 
for biological activity using oocyte swelling assays (Fig 1B) after 2 hours preincubation. 
AQP1-mediated swelling was significantly decreased by fractions 3 and 4; other 
fractions had no effect. Combined fractions 3 and 4 were analyzed by mass 
spectrometry and revealed the presence of a major compound identified by precise 
molecular weight as bacopaside I. Commercially purchased bacopasides I and II were 
found to block osmotic water permeability in AQP1-expressing oocytes (Fig 1C) and 
showed a dose-dependent effect (Fig 1D).  The inhibition of AQP1-mediated osmotic 
water fluxes showed IC50 values of approximately 18 µM for bacopaside II, and 
approximately 117 µM for bacopaside I. 
Inhibition  bacopasides I and II was time-dependent and reversible. AQP4-
expressing oocytes showed no block of water channel activity after 2 h preincubation 
in isotonic saline containing bacopaside I at 178 µM (Fig 2A).  The blocking effect of 
bacopaside was specific for AQP1.  The inhibitory effect of bacopasides I and II on 
AQP1 water channel activity took time to develop, with near maximum block achieved 
by approximately 2 h (Fig 2B).  The magnitude of inhibition of AQP water flux increased 
as a function of the duration of preincubation in 178 µM bacopaside I or 35 µM 
bacopaside II. For bacopaside I, half-maximal block was reached after approximately 
50 min, and maximum block after 120 min of preincubation. For bacopaside II, half-
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maximal block was reached after approximately 30 min, and maximum block after 80 
min of preincubation. Longer times provided no appreciable further enhancement of 
the magnitude of inhibition. Comparably slow time-dependent onset of block has been 
noted previously for other AQP1 ligands such as AqB013, AqB011 and AqF026, which 
are thought to bind at the intracellular side of the channel (Kourghi et al., 2016; Migliati 
et al., 2009; Yool et al., 2013), and require time to travel across the plasma membrane 
to the cytoplasmic side.  
The blocking effects of bacopasides I and II on AQP1 water channel activity were 
reversible (Fig 2C). AQP1 channels were preincubated 2 hours with 178 µM 
bacopaside I or 35 µM bacopaside II, followed by washout of the drug with isotonic 
saline.  The osmotic water permeability showed approximately 25% recovery by 120 
min after the washout of bacopaside I, and half-maximal recovery by 160 min. For 
bacopaside II, water permeability showed 25% recovery by 150 min after washout of 
the blocker, and half-maximal recovery by 200 min.   
The ion channel conductance of AQP1 was inhibited by bacopaside I but not by 
bacopaside II. Two-electrode voltage clamp recordings from AQP1-expressing 
oocytes demonstrated the cGMP-dependent activation of the ionic conductance (Fig 
3A) as described previously (Anthony et al., 2000), which was reversible by 2 h 
incubation in saline without membrane-permeable cGMP (Kourghi et al., 2016). Re-
activation of the ionic response by a second dose of cGMP was partly blocked in 
AQP1-expressing oocytes after 2 h incubation in 50 µM bacopaside I, and strongly 
blocked at 100 µM bacopaside I.  In contrast, the reactivation of the ion conductance 
was unimpaired after incubation with 10 µM or 20 µM bacopaside II (Fig 3B). 
Identification of candidate intracellular binding sites. Protein crystal structures of 
AQP1 and AQP4, and three-dimensional structural renditions of bacopaside I and 
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bacopaside II were prepared and run on interaction simulations using Autodock Vina 
software to identify predicted binding sites. An array of candidate docking sites for 
bacopasides I and II on AQP1 and -4 channels were considered with in silico 
computational docking analyses. Of a total of 8 possible positions evaluated for 
bacopaside I, the dominant energetically-favored configurations for intracellular 
binding yielded values of -9.2 Kcal/mol for AQP1, and -8.0 Kcal/mol for AQP4. 
Similarly out of all possible positions evaluated, the energetically-favored 
configurations for bacopaside II yielded values of -9.3 Kcal/mol for AQP1, and -7.8 
Kcal/mol for AQP4.    
In the poses reflecting the most favored docking positions, the intracellular face of the 
water pore was effectively occluded by bacopasides I and II in AQP1, but not in AQP4 
channels (Fig 4A,B,C,D).  For AQP1, the bacopasides appeared to nest well into the 
internal vestibule of the intrasubunit water pore. For AQP4 the optimal interaction was 
seen for bacopaside sitting in a groove between transmembrane domains 4 and 5, a 
position where subunits interface near the central pore that might not be accessible in 
the assembled tetrameric channel.  
Closer inspection of specific amino acid residues in the predicted AQP1 docking site 
(using Chimera visualization software) suggested that the poly-arginine motif in the 
Loop D domain could enable hydrogen bond formation with the sulfonyl moiety on the 
glucopyranosyl sugar of bacopaside I (Fig 4E) at residues corresponding to R159 and 
R160 in human AQP1. These arginines are part of a highly conserved amino acid 
pattern seen in AQP1 channels from diverse species, and required for cGMP gating 
of the AQP1 ionic conductance (Yu et al., 2006).  The site-directed double mutation of 
arginines R159 and R160 to alanines did not prevent normal expression of AQP1-
mediated osmotic water permeability, indicating that the AQP1 mutant constructs were 
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expressed and targeted to the oocyte plasma membrane as described previously (Yu 
et al., 2006); however, the efficacy of bacopaside I in inhibiting osmotic water 
permeability was abolished in the mutant construct at doses up to 100 µM (Figure 1D, 
supporting the suggested role of the loop D arginine residues in stabilizing the docking 
of the bacopaside I ligand.   
Bacopaside II was more effective than bacopaside I in blocking migration of 
AQP1-expressing colon cancer cells.  HT29 cells have a higher endogenous level 
of AQP1 expression as compared with SW480 cells, as demonstrated by quantitative 
RT-PCR (Fig. 5A), western blot (Fig. 5B), and immunocytochemistry (Fig 5C) 
analyses.   
Wound closure assays showed robust migration of HT29 cells in medium with vehicle 
(Fig 6A), resulting in little open area remaining at 24 h. In contrast, treatment with 
bacopaside II (Fig. 6B) substantially reduced the amount of wound closure.Dose-
dependent block of cell migration measured by wound closure (Fig 6C) was observed 
for both bacopaside I and bacopaside II on HT29 cells. The calculated IC50 value for 
bacopaside I was approximately 48 µM and for bacopaside II was 14 µM in HT29 cells. 
There was a small reduction of migration observed for SW480 cells treated with 
bacopaside II (Fig 6C), which was consistent with the relatively low expression of 
AQP1 channels in this cell line. 
Time-lapse imaging demonstrated bacopasides I and II differentially decreased 
the rate of migration of AQP1-expressing HT29 colon cancer cells.  Cultured 
HT29 cancer cells showed different rates of migration into the open wound areas in 
vehicle, bacopaside I and bacopaside II treatment conditions (Fig 7A,B,C). Time lapse 
images showed the rates of cell migration were significantly impeded in 50 µM 
bacopaside I and in 15 µM bacopaside II (Fig 7B,C) as compared with vehicle-treated 
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HT29 cells (Fig 7A). No appreciable difference in cell viability was observed in any of 
the treatment groups during the 24 time course of the experiment.    
In the vehicle-treated group, trajectory plots of individual cells sampled at 50 min 
intervals over 24 h (Fig 7D) showed generally directional movements of HT29 cells 
into the open wound spaces. In bacopaside I treatment group, the HT29 cells lacked 
directional migration and moved short distances between successive frames. In the 
bacopaside II treated group, the impairment of movement was evident but less severe. 
The collective trend of trajectories of the vehicle-treated group appeared to be linear 
and extended, whereas that in the bacopaside I treated group was recursive and 
compressed; the bacopaside II group showed an intermediate level of restriction of 
movement.  
The net displacement (distance travelled) per time interval was greater in the vehicle 
treated than the bacopasides I or II treated groups.  Frequency histograms showing 
the number of events observed were compiled as binned values of distances travelled 
per 50 min interval (Fig 7E), and showed that more cells travelled longer distances in 
the vehicle treated group as compared with the bacopasides I and II treated groups. 
Distances moved per 50 min interval were well fit by Gaussian distributions. The 
decreased mean distances moved in both bacopaside I and II treated groups were 
seen as a left shift in the peaks of the frequency histograms. Compiled data in a 
summary histogram (Fig 7F) confirmed the significant decrease in mean total distance 
travelled by cells during the 24 hours of tracking in bacopaside I or II as compared with 
vehicle treated cells.  Analysis of cytotoxicity by AlamarBlue assay showed that 
bacopaside I had no significant effect on cell viability at 50 or 75 µM, and bacopaside 
II had no effect on viability at 15 or 20 µM (Table 1). Concentrations of bacopasides 
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that significantly blocked AQP1 water channel activity and HT29 cell migration were 
not appreciably cytotoxic.  
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Discussion  
Results here demonstrated that two structurally similar compounds, bacopaside I and 
bacopaside II derived from a medicinal herb, act differentially as pharmacological 
inhibitors of mammalian aquaporin channels. In silico modeling predicted that 
bacopasides I and II have favorable energies of interaction at the intracellular vestibule 
of AQP1, occluding the intrasubunit water pore. Modeling results were consistent with 
observed effects of these agents as AQP1 inhibitors. Predicted energies of interaction 
for docking on AQP1 were higher for bacopaside II than bacopaside I, fitting the 
observed order of efficacy in blocking AQP1-mediated swelling of oocytes and the 
same order of efficacy in blocking migration of AQP1-expressing HT29 colon cancer 
cells, with minimal effects on SW480 cells that express little AQP1. The docking of 
bacopasides I and II to occlude the water pore appeared principally to involve the 
trisaccharide rings, which projected down into the AQP1 intrasubunit pore. Future 
work exploring polysaccharides and related osmolytes as endogenous modulators of 
AQP channels could be of interest.  The lack of a favorable docking interaction of 
bacopaside with the AQP4 water pore was consistent with the insensitivity of AQP-4 
expressing oocytes to bacopaside I in osmotic swelling assays. Based on the docking 
model, candidate residues that could contribute to the proposed binding of bacopaside 
sugar rings in the hAQP1 intracellular water pore appear to include amino acids serine 
71 in the loop B region, and  tyrosine 97 in the adjacent membrane spanning domains, 
but remain to be defined. 
Inhibition of AQP1 water channel activity by bacopasides I and II showed a slow onset 
that was consistent with prerequisite transit of the agent across the plasma membrane 
to access the intracellular side. The latency period (approximately 2 h) was 
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comparable to that described for other aquaporin modulators AqB013 and AqF026, 
also thought to act at the cytoplasmic side (Migliati et al., 2009; Yool et al., 2013).   
Accumulating evidence suggests pharmacological agents can be defined with subtype 
selectivity for AQP classes. Prior work showed that external application of AqF026 
potentiated water permeability in AQP1 (EC50 3.3 µM), but a 15-fold higher 
concentration was required to potentiate AQP4 (Yool et al., 2013). Metal complexes 
acted as blockers of glycerol permeability in AQP3 (at an external site predicted to 
involve  cysteine (C40) and arginine (R218) residues), with comparatively small effects 
on AQP1 water permeability (Martins et al., 2013). Results here for bacopaside I 
showed block of osmotic water permeability for AQP1 but not AQP4 channels. This 
difference in bacopaside sensitivity between related aquaporins suggests that the 
inhibitory effects seen for AQP1 are exerted directly on the heterologously expressed 
channel, and not due to side effects on endogenous oocyte channels or transporters.  
The reversibility of block indicated that functional properties and expression of the 
channels in plasma membrane were not impaired.  Data here cannot rule out possible 
actions of bacopasides on other molecules not yet assessed; however, the lack of 
effect of bacopaside treatment on migration in a cancer cell line SW480 with low AQP1 
expression suggests the mechanism of action is reasonably selective, and does not 
appreciably impact diverse signaling and transport processes needed for basic 
maintenance and non-AQP1 dependent motility. Cytotoxicity assays showed that the 
viability of AQP1-expressing HT29 cancer cells was not affected by bacopasides I and 
II at doses that significantly blocked ion flux and cell migration. 
Bacopasides I and II are triterpene glycosides, composed of a hydrophobic pentacyclic 
terpene backbone (estimated logP value approximately 9; enabling membrane 
permeability), and three linked polar sugar groups (arabinofuranosyl—
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glucopyranosyl—arabinopyranose in bacopaside I; and arabinofuranosyl—sulfonyl-
glucopyranosyl—glucopyranose in bacopaside II) that appear from in silico modeling 
to lodge via H-bonds into the water pore entrance of AQP1, with the exception of the 
sulfonyl group which appears to require an interface with positively charged residues 
(arginines in the adjacent AQP1 Loop D domain).  Mutation of the key Loop D 
arginines to alanines appeared to cause destabilization of the overall binding of the 
bacopaside I compound on AQP1, seen as a decreased efficacy of water pore block 
and increased IC50 value in the R159A+R160A mutant.  
The ability of modulators to differentially block the ionic conductance is an important 
consideration in processes such as rapid cell migration which appear to require AQP1 
cation channel function (Kourghi et al., 2016).  Interaction of the sulfonyl group with 
Loop D arginines was consistent with the observed block of the cGMP-activated ionic 
conductance by bacopaside I not II.  Bacopaside I showed a lower IC50 value for 
inhibiting HT29 cancer cell migration (~48 µM) than for inhibiting the AQP1 ionic 
conductance alone (~117 µM), and the cell migration trajectories in bacopaside I-
treated group were more compressed than those in the bacopaside II-treated group, 
suggesting that simultaneous block of both water and ion channel activities of AQP1 
might be more effective in blocking AQP1-dependent cell migration than impairing 
either function alone.  
Although the overall amino acid sequence similarity between AQP1 and AQP4 
channels is high (>40% identity and 60% homology), AQP4-mediated osmotic swelling 
was not sensitive to block by bacopaside I. The docking model suggested the bulky 
terpene might sterically hinder docking near the AQP4 water pore. As well, the Loop 
D domain of AQP4 lacks the key arginines 159 and 160 suggested here to be 
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important for the sulfonyl group coordination, showing instead serine and lysine in the 
equivalent positions, which might be less effective as putative coordination sites.  
The identification of bacopasides as novel AQP modulators expands the database of 
pharmacophore properties of AQP ligands.  Bacopasides I and II themselves might 
not be ideal as drug candidates, exceeding limits of Lipinski's Rule of Five for 
molecular weight, hydrophobicity, and numbers of hydrogen bond donors and 
acceptors— although natural products often show biological activity as exceptions to 
the rule (Ganesan, 2008). Bacopasides administered in vivo are likely to act as 
metabolic derivatives as well as intact compounds. More work is needed to define in 
vivo metabolites of bacopasides and characterize their effects on aquaporins. 
Nonetheless, bacopasides could serve as lead compounds for the design of small-
molecule blockers of aquaporins. Results here suggest the trisaccharide moiety is a 
key component. An intriguing idea would be to design compact membrane-permeable 
trisaccharides for blocking water flux; while addition of key sulfonyl or other groups 
could inhibit parallel AQP functions. Endogenous polysaccharide osmolytes in cells 
might function as natural modulators of aquaporin channels, a concept that has not to 
our knowledge been considered previously.  
Bacopa monnieri extract (also known as brahmi) has been used in Ayurvedic remedies 
since ancient times to improve memory and treat anxiety and depression (Russo and 
Borrelli, 2005). Brahmi has been suggested to have beneficial effects on psychological 
state, cognitive performance, and memory in human subjects and animal models; 
neuroprotective effects after ischemic brain injury; and anti-inflammatory actions in 
processes linked to neurodegenerative disorders (Aguiar and Borowski, 2013; 
Downey et al., 2013; Kongkeaw et al., 2014; Liu et al., 2013; Rehni et al., 2007; Sairam 
et al., 2002; Saraf et al., 2010; Singh and Dhawan, 1982; Williams et al., 2014; Zhou 
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et al., 2007).  A meta-analysis of human clinical studies (generally with B. monnieri 
administered 250-450 mg/day for up to several months) improved mental response 
time and attention, and had potential benefits on memory (Kongkeaw et al., 2014). No 
serious adverse events were noted; minor side effects included diarrhea and dry 
mouth.  
Beneficial outcomes ascribed to brahmi could in part involve block of AQP1 channels. 
AQP1 is expressed abundantly in brain choroid plexus where cerebral spinal fluid is 
produced (Boassa and Yool, 2005; Johansson et al., 2005), and in proximal kidney to 
facilitate water reabsorption (Nielsen and Agre, 1995).  AQP1 is found in peripheral 
vasculature endothelia, red blood cells, and other cell types (Nielsen et al., 1993). 
Block of AQP1 could contribute to the anti-inflammatory benefits of brahmi treatment. 
Macrophages express AQP1 channels, which are required for IL-1b release and 
neutrophilic inflammation responses (Rabolli et al., 2014). An alcoholic extract of B. 
monnieri decreased TNF-alpha production in mouse macrophages preincubated for 1 
h, with an IC50 near 1 mg/ml  (Williams et al., 2014).   
Pharmacological inhibitors of AQP1 channels could be useful for intervention in many 
conditions, including slowing metastasis in AQP1-positive cancer subtypes. In a 
subset of aggressive cancers, AQP1 expression is upregulated (El Hindy et al., 2013; 
Moon et al., 2003; Saadoun et al., 2002; Yool et al., 2009). AQP1 channels located at 
lamellipodial edges have been implicated in enhancing migration and metastasis (Hu 
and Verkman, 2006; McCoy and Sontheimer, 2007). Block of the AQP1 ion channel 
has been shown to slow migration in AQP1-expressing HT29 colon cancer cells 
(Kourghi et al., 2016).   
A comprehensive portfolio of effective and selective aquaporin modulators is needed 
for clinical and basic research. Further exploration of AQP modulators in traditional 
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herbal medicines is merited (Pei et al., 2016). New ligand modulators of aquaporin 
channel activity could be present in the armamentarium of traditional herbal 
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Table 1.  Analysis of cytotoxicity in HT29 colon cancer cells at 24 h treatment, using an 
AlumarBlue fluorescence assay. 
 
Concentration (µM) Mean normalized cell n value  signif          
  viability (%), mean ± SEM §  
 
   
  bacopaside I 	
 0 108 ± 4.8 17   NS 
 0 (vehicle) 100 ± 3.1 17  --- 
 50 97 ± 2.1  8  NS 
 75 79 ± 4.2  8  NS 
 100   59 ± 3.2  8   *
 
bacopaside II 	
 0 113 ± 6.2 16   NS 
 0 (vehicle) 100 ± 5.7 16  --- 
 15 104 ± 18  8  NS 
 20 123 ± 17  8  NS 
 30   47 ± 5.7  8   *
 
	     HgCl2  
 100    16.1 ± 4.6  6   * 
§
  Percent viability was standardized as a percentage of the vehicle-treated mean 
value, measured as changes in AlumarBlue fluorescence signal intensity. See 
Methods for details.  
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* Statistically significant differences (p<0.05), compared with vehicle-treated, were 
analyzed by ANOVA with post-hoc Dunnett's multiple comparison test (GraphPad 
Prism). NS is not significant.
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Figure Legends 
Figure 1.  Block of osmotic water permeability in AQP1-expressing oocytes by water 
hyssop (Bacopa monnieri) extract, and constituent compounds bacopaside I and 
bacopaside II.  A. Mean swelling responses of AQP1-expressing oocytes in 50% 
hypotonic saline, standardized to the initial volume V0, were blocked by 2 h 
preincubation in reconstituted extract of water hyssop (at 1 mg/ml). Control non-
AQP1 oocytes showed little change in volume. Data are mean values for all oocytes 
assessed from a single batch of oocytes; error bars are SEM; n values are 6 per 
treatment group.   B. Column elution of methanol-extracted Bacopa identified two 
active fractions which caused block of AQP1 osmotic water permeability at 0.1 
mg/ml each (which were further analyzed by mass spectroscopy to identify 
candidate compounds). Data are mean ± SEM, n values in italics are above the x-
axis.   C. Candidate compounds bacopaside I and bacopaside II at 50 µM 
differentially blocked osmotic water permeability in AQP1-expressing oocytes, 
causing a decrease in the rate of swelling as compared with untreated AQP1-
expressing oocytes. Data are mean ± SEM; n values are 8 (AQP1 untreated), 5 
(bacopaside I), 7 (bacopaside II), and 8 (non-AQP1 control).  D. Dose-dependent 
block of AQP1-mediated osmotic swelling by bacopasides I and II, with estimated 
IC50 values of 117 µM and 18 µM, respectively.  No sensitivity to bacopaside I was 
seen for the AQP1 R159,160A double mutant at doses up to 100 µM.    E.  Chemical 
structures of bacopasides I and II. 
 
Figure 2.  Subtype selectivity and temporal properties of block onset and recovery 
with bacopaside I in AQP1-but not AQP4-expressing oocytes.   A.  Mean swelling 
responses of AQP4-expressing oocytes in 50% hypotonic saline were not affected 
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after 2 h preincubation in 178 µM bacopaside I. Data are mean ± SEM;  n values 
are 8 (AQP4 alone), 8 (AQP4 with bacopaside I), and 6 (non-AQP4 control).  B.  
Time-dependent establishment of block of AQP1-mediated osmotic water 
permeability required preincubation of oocytes in 178 µM bacopaside I or 35 µM 
bacopaside II, with approximately 2 h needed to achieve maximal inhibition.  n 
values are 12 to 14 oocytes per time point; each oocyte was used for a single 
measurement.  C. Time-dependent recovery from block in AQP1-expressing 
oocytes preincubated 2 h in 178 µM bacopaside I or 35 µM bacopaside II, and 
assessed at different intervals after transfer back into standard isotonic saline at 
time 0 ('washout'). n values are 10 to 13 oocytes per time point; each oocyte was 
used for a single measurement. 
 
Figure 3.  Block of the cGMP-dependent ionic conductance of AQP1-expressing 
oocytes by bacopaside I, but not bacopaside II.   A. Representative sets of traces 
recorded by two-electrode voltage clamp of AQP1-expressing oocytes showing the 
initial conductance; the response induced by the first application of membrane-
permeable cGMP; the recovery of the response to near initial levels after 2 h 
incubation in isotonic saline containing bacopaside I (50 or 100 µM) or bacopaside 
II (10 or 20 µM); and the final response to a second application of cGMP.   B. Trend 
plots showing the amplitude of the ionic currents, before and after the first activation 
by GMP, the recovery after incubation, and the response reactivated by a second 
cGMP application. Consistent recovery was seen after 10 or 20 µM bacopaside II, 
but not after incubation with 50 or 100 µM bacopaside I indicating establishment of 
ion channel block. n values are between 3 to 6 for each treatment.  
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Figure 4. In silico docking models illustrating predictions for the most favorable sites 
of interaction of bacopaside I and bacopaside II on AQP1 and AQP4 subunit 
proteins.  AQP subunit models were assembled from crystal structural data for 
human AQP1 (PDB ID. 1FQY) and human AQP4 (PDB ID. 3GDB); see Methods 
for details.  Subunit views are from the cytoplasmic side with the water pore in the 
center. The intracellular domain for Loop D, adjacent to the channel tetrameric axis 
of symmetry, is highlighted in dark gold. A.  Bacopaside I is predicted by in silico 
docking to occlude the cytoplasmic side of the intrasubunit water pore in AQP1.   B.  
Favorable interactions at the AQP4 water pore are not evident for bacopaside I; this 
ligand appears to interact poorly with AQP4, and the best fit is seen near 
membrane-spanning domains distant from the pore (inset).  C. Bacopaside II is 
predicted to have the most favorable energy of interaction at a position occluding 
the cytoplasmic side of the AQP1 water pore.  D. Predicted binding of bacopaside 
II with AQP4 is distant from the water pore (inset), in a position similar to that seen 
for bacopaside I.  E. Enlarged view of the predicted interaction of the sugar-linked 
sulfur group of bacopaside I with the conserved Loop D arginine residues in AQP1. 
F. Enlarged view of the predicted binding of the trisaccharide moiety of bacopaside 
II deep into the cytoplasmic vestibule of the AQP1 water pore. 
 
Figure 5. HT29 cells have higher level of AQP1 expression than SW480 cells.   A. 
The AQP1 RNA level was higher in HT29 cell line as compared to SW480 cellas 
demonstrated using quantitative RT-PCR.  B. The AQP1 protein level was higher 
in HT29 than SW480 cells as demonstrated by western blot.  C. The AQP1 positive 
signal (green) was stronger in HT29 than in SW480 cells. Cell nucleii were 




Figure 6.  Dose-dependent inhibition of migration by bacopasides I and II in AQP1-
expressing HT29 cells, but not in SW480 cells with low AQP1 expression. Cell 
migration was assessed in the presence of a mitotic inhibitor by rates of closure of 
circular wounds created by aspiration with a pipette tip in confluent cultures (see 
Methods for details).   A, B.  Cell migration was assessed in vehicle (A) or with 15 
µM bacopaside II (B), added immediately after wounding. Images are shown for 
confluent HT29 cultures after initial wounding at time 0 (upper panels) and at 24 h 
(lower panels).     C. Dose-dependent block of HT29 cell migration was seen with 
bacopasides I and II, with IC50 values estimated at 48 and 14 µM respectively.  
Partial block of SW480 migration at the highest doses tested did not exceed 20%.  
Doses beyond the ranges shown were not considered valid due to the onset of 
concomitant cytotoxicity.  
 
Figure 7.  Live-cell imaging of the inhibitory effect of bacopaside I and II on migration 
of HT29 cells. Single cells at the boundaries of circular wounds were tracked with 
time-lapse images taken at 25 minute intervals for 10 hours at 37°C.  A, B, C. 
Panels of six images each from time-lapse series for clarity shown at 50 minute 
intervals.  (A) HT29 cells with vehicle treatment (upper set);   (B) HT29 cells treated 
with 50 mM bacopaside I; and  (C)  HT29 cells treated with 15 mM bacopaside II.   
D. Trajectory plots of 10 individual cells per treatment group, monitored by cell 
nucleus position as a function of time.  Data were converted to absolute values and 
referenced to the starting position at time 0. Plots illustrate the cumulative total 
movement of 10 single cells over a duration of 600 min, with vehicle, bacopaside I 
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or with bacopaside II.    E. Frequency histograms of the distances moved by 
individual cells per 50-minute interval over 600 min of imaging, sampled for 10 cells 
per treatment group. Histograms were fit with Gaussian distribution functions (R
2
 
values >0.94); best-fit values for the mean distances moved per cell per 50 min 
interval were 10.1 ± 0.5 for untreated, 4.7 ± 0.2 for bacopaside I treated and 7.8 ± 
0.2 for bacopaside II treated (mean ± SEM).  F. Summary histogram showing the 
total distance travelled by single cells in 600 min, showing significant inhibition of 
cell motility by both bacopaside I and II compared to vehicle treated cells (ANOVA 
test; p < 0.05).  Data are mean ± SEM; n values are 10 cells per treatment group. 





































CHAPTER 4: DISCOVERY OF A 
NOVEL LITHIUM SENSOR FOR 
THE REAL-TIME ANALYSIS OF 






Real-time Analysis of Ion Conductance in Aquaporin-1 
 
 
AIM: To synthesize a novel photo-switchable Li+ ion sensor and to visualize the real-
time ion conductance mediated by (Aquaporin-1) AQP1 channels in living cells. 
 
HYPOTHESIS: A novel photo-switchable lithium probe (designated "SHL") can be 
used to demonstrate the sites of transmembrane cation influx across plasma 
membrane that are colocalized with AQP1 channels.     
 
CONCLUSIONS: 
1. A novel synthetic cation sensor designated as SHL is highly specific for Li+ in 
the monovalent cation family. SHL contains a photochromic spiropyran that can 
be reversibly switched between a non-fluorescent isomer (SP) and a charge-
delocalized fluorescent merocyanine isomer (MC) when interacting with an 
appropriate metal ion such as Li+.   
2. SHL yielded a sensitive Li+-dependent signal that could be photoswitched 
repeatedlly in living cells, in accord with characterized chemical properties of 
the probe. 
3. In AQP1- expressing colon cancer HT29 cells, punctate Li+ hot spots were 
observed submembrane domains. Application of the AQP1 ion channel blocker 
AqB011 or the replacement of extracellular Li+ with an equivalent concentration 
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of tetraethylammomium ion (TEA+) abolished the SHL hot spot signals, 
demonstrating the responses were due to Li+ entry across the membrane, and 
relied on functional AQP1 ion channels.   
4. Li+ hot spots were observed at the leading edges of migrating HT29 cells but 
were not observed in colonn cancer SW620 cells lacking comparable AQP1 
expression.  
5. Hot spots of monovalent cation entry are colocalized with AQP1 channels in 
migrating HT29 cells. 
 
COMMENTARY: 
The novel synthesis, characterization and biological application of a photo-switchable 
sensor that detects Li+ ions is reported in this chapter. Results show this sensor will 
be a valuable tool for monitoring cation fluxes across cell membranes. The ionic 
conductance of AQP (reviewed in Chapter 1), and its physiological relevance (for 
example in cancer migration as shown in Chapters 2 and 3), has been difficult to 
evaluate in full in the past because of the lack of pharmacological agents (Jeyaseelan 
et al., 2006; Verkman et al., 2008), prior to the discovery of the AQP1 ion channel 
blocker AqB011 (Kourghi et al, 2016).  In this chapter, we demonstrate for the first 
time the imaging of real-time ion fluxes associated with AQP1, providing another 
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Aquaporin 1 channels are located at the leading edges of certain classes of aggressive 
cancer cells, where they are necessary to enable fast migration.  AQP1 has pores for 
water present in each of the four channel subunits, thought to enable local volume 
changes needed for process extension.  An additional contribution of the AQP1 
monovalent cation conductance (via the central pore of the tetrameric channel) in 
cancer cell migration has been suggested previously from selective pharmacological 
inhibition, but not demonstrated directly. Work here is the first to use a newly designed 
Li+-selective photoswitchable probe named 'SHL' in living colon cancer cells to monitor 
AQP1 ion channel activity in real time by the appearance of lithium hot spots, detected 
by confocal microscopy.  The Li+ hot spots are clustered in the lamellipodial leading 
edges of AQP1-expressing HT29 colon cancer cells, and are blocked by the AQP1-
ion channel antagonist AqB011. Lithium hot spots are not evident in a poorly-migrating 
colon cancer cell line SW620 that lacks comparable membrane expression of AQP1. 
The Li+ probe loaded in living cells shows the expected chemical signature properties 
of ionic selectivity, and the capacity to be reset for fluorescence signaling by 
illumination at bandwidths that induce photoswitching.  The correlation between the 
subcellular distribution and the visualized ion channel activity of AQP1 channels in 
cancer cells supports the proposed role of the AQP1 ion channel in cell migration.  The 
AQP1 ion channel is a novel candidate for therapeutic interventions that could be used 
to manage metastasis in aggressive AQP1-dependent cancers.   
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INTRODUCTION 
Aquaporins enable the flux of water and small solutes across membranes1. In addition 
to regulating fluid balance, they provide a key role in cell migration and hence the 
development and maintenance of multicellular organisms.2,3 They are central to critical 
processes of repair, regeneration, immune protection and cancer metastasis.4-6 
Thirteen classes of  human AQP subtypes are known, with aquaporin-1 (AQP1) 
playing a pivotal role in enhancing mobility in of some of the most motile cells such as 
T-cells, fibroblasts, cancer and amoebae.7 While the exact mechanism for this has yet 
to be determined,  we do know that elevated expression of AQP1 is apparent at the 
leading edges of lamellipodia in certain classes of migrating cells.  Genetic knockdown 
of AQP1 expression has been shown to impair cell migration significantly8,9 whereas 
reintroduction of AQP1 restored motility.  With substitution of aquaporin-4 (AQP4), 
also a strong water channel, cell motility remained impaired.  A major difference 
between the channel classes is that AQP1 but not AQP4 also functions as an ion 
channel that can be gated by cGMP10-12. Thus, while the mechanism of AQP1 action 
on cell migration remains unknown, it seems likely to involve ion fluxes. Unravelling 
the unique properties of AQP1, and defining the role of AQP1 ion channel function in 
rapid cell motility would advance our knowledge of how aquaporin channels enable 
enhanced cell motility seen in cancer, stem cells and regenerating tissues, and 
uncover the basic mechanisms governing cell migration that might be targeted for 
intervention, for example in cancer metastasis. 
  
Here we confirm the role of AQP1 as a nonselective monovalent cation channel, 
demonstrate AQP1-mediated ion influx using real-time imaging, and show the 
punctate signals are clustered in the lamellipodia of migrating cancer cells.  This was 
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accomplished using a reversible lithium sensor (SHL) in combination with an ion 
channel blocker (AqB011), to modulate the AQP1-mediated Li+ entry in the cells. SHL 
was specifically developed to be selective for a low abundance monovalent ions such 
as Li+ over Na+ or K+.  Results here show that ion binding to the sensor intracellularly 
is dependent on exogenous Li+ transport into the cell. Selective blocking of AQP1 with 
AqB011 shows that Li+ transport is occurring through AQP1. These results provide the 
first evidence of ‘hot-spots’ that correlate with ion movement through AQP1 channels, 
as confirmed by properties of pharmacological sensitivity, ion selectivity, and levels of 




Results and Discussion 
 
Design and characterization of the reversible and selective lithium (Li+) sensor 
(SHL). 
The sensor described here (see Figure 1A for sensor SHL structure) contains a 
photochromic spiropyran that can be reversibly switched between a non-fluorescent 
isomer (SP) and a charge-delocalized fluorescent merocyanine isomer (MC) when 
interacting with an appropriate metal ion such as Li+ (see Figure 1A)13. The ability to 
switch between the two states is advantages for visualizing Li+ transport into the cell 
as SHL will only have enhanced fluorescence when complexed to Li+ (e.g. MC-Li+ 
complex in Figure 1A), while maintaining low background fluorescence in the absence 
of the ion (SP isomer in Figure 1A). This is a desirable sensor characteristic for 
visualizing ion binding with confocal microscopy and would result in better resolution 
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in terms of signal-to-background as compared with standard fluorescent probes.14,15 
A more critical sensor characteristic is the selectivity of SHL for Li+ over other 
biologically relevant ions.  Spiropyrans can be readily modified to bear cation ion 
binding domains that will interact with phenolate group in the ring-opened MC isomer 
(Figure 1A) to achieve ion affinity and selectivity.  This was achieved by incorporating 
a 1-aza-15-crown-5 substituent at C8’ and a hydroxyethyl substituent at N1 
respectively (labeled in Figure 1A). Finally, we incorporated a NO2 substituent at C6’ 
of the benzopyran ring as electron-withdrawing groups at that position are known to 
stabilize the ring-opened MC form thus favoring ion binding. Details on the synthesis 
of SHL are reported in the Synthesis section of the Supporting Information.  Briefly, 
the Li+ sensor was prepared from 1-aza-15-crown-5 and 1-(2-hydroxyethyl)-2,3,3-
trimethyl-3H-indol-1-ium to give SHL with an overall yield of 40 - 50 % using a 
modification to existing methodology16,17.  
 
The addition of excess Li+ (100 µM) to SHL (50 µM) gave rise to strong fluorescence 
(λex = 532 nm) at approximately λem = 635 nm as shown in Figure 1B (insert), which is 
consistent with the formation of the MC(SHL)-Li+ complex as expected based on our 
sensor design. Importantly, the red fluorescence is advantageous as it represents an 
emission bandwidth that is distinct from the blue nuclear stain (Hoescht 33258) and 
green cellular auto-fluorescence emissions. Additional spectroscopic properties of 
SHL such as absorbance, detection limits, photoswitching and quantum yields are 
detailed in the 'Supporting information' section. More importantly, the selectivity of SHL 
for Li+ against other biologically relevant ions was confirmed through ion binding assay 
with excess Li+ and other biologically relevant metal ions (Na+, K+, Cs+, Mg2+, Mn2+, 
Cu2+ and Zn2+).  Results in Figure 1B showed that SHL has highest affinity for Li+, and 
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relatively little response to similar monovalent ions such as Na+ and K+. The red-
emitting properties and selectivity of SHL for Li+ are critical for demonstrating that the 
emission observed in the cell is not due auto fluorescence or interaction of the sensor 
with other endogenous ions; the signal is specific to the MC(SHL)-Li+ complex.  
 
AQP1 ion channel is permeable to Li+ and can be blocked by AqB011.  
AQP1-expressing Xenopus oocytes were recorded by two-electrode voltage clamp in 
in isotonic saline with 137 mM Li+ substituted for Na+. Currents (Fig 2A) in isotonic Li+ 
saline were measured for AQP1-expressing Xenopus oocytes and non-expressing 
control oocytes before ('initial') and after treatment with a membrane permeable 
analog of cGMP (CPT-cGMP; See Supporting Information for details), confirming 
activation of the ionic conductance. Oocytes were then incubated 2 h in 30 µM AqB011 
and reactivated by cGMP ("AqB011") in Li+ saline.  Results (Figure 2B) showed that 
approximately 90% of the cGMP-induced current in AQP1-expressing oocytes was 
successfully blocked by AqB011; whereas control oocytes (AQP1-) lacked appreciable 
cGMP-activated current responses.  
 
Real time analysis of the kinetics and magnitude of Li+ fluxes in live cells. 
The relative ability of SHL to chelate and sense Li+ in live cells was investigated using 
confocal microscopy. HT29 colon cancer cells were used in this study as they are 
known to have high AQP1 expression19, providing a good model for cellular imaging 
of Li+ passage through AQP1.  
 
SHL (50 µM in physiological saline) was incubated with the HT29 cells for 2 h prior to 
imaging to allow the uptake of SHL by the cells. The cells were co-labelled with 
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Hoescht 33258 as a counterstain for the nuclei.  The cells were illuminated with green 
laser light to activate the MC(SHL)-Li+ complex, which resulted intracellularly in a red 
fluorescence signal characteristic of this chemical interaction (see Figure 3).  
Subsequent exposure of the cells to visible light for 10 min restored a low level of 
fluorescence, consistent with the expected photoswitching from the fluorescent 
MC(SHL)-Li+ complex to back to the non-fluorescent SP isomer (see Figure 1A).  
Fluorescence intensity decreased as a function of time following a single-phase decay 
when the cells were illuminated with standard white light, with measurements taken 
every 2 min. Specifically, the normalized intensity decreased from 100 Relative 
Fluorescence Units (RFU) to 44.51 RFU after 10 min of visible light radiation (labelled 
OFF2 in Figure 3C). Under these experimental conditions, the half-life was determined 
to be 4.13 minutes with a τ value estimated at 5.95 minutes. The images of cells after 
each episode of visible light radiation are illustrated in Figure 3B. The cells were then 
incubated in the dark for 10 min to allow the formation of the MC isomer, and the 
binding of Li+ to form the MC(SHL)-Li+ complex (labelled ON1 in Figure 3A) with the 
normalized intensity at 84.65 RFU (labelled ON2 in Figure 3A). Repeated cycles of 
photoswitching performed on same cells gave reproducible changes in fluorescence, 
demonstrating the ability of SHL to reversibly photoswitch in living cells. This 
innovation defines a new probe for monitoring changes in intracellular Li+ in a biological 
sample over time, without loss of sensitivity imposed by photobleaching of the sensor. 
The photoswitching property allows direct comparison of functions over multiple 
experimental parameters, and provides additional advantages in biological assays 
where sample availability is often limited.  
Importantly, results in Figure 4C show distinct punctate Li+ signals in the HT29 cells 
when imaged in Li+ substituted extracellular saline (Figure. 4C-1), which we refer to 
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as lithium 'hot spots'. The removal of Li+ from the extracellular saline by equimolar 
substitution of Na+, caused a loss of ‘hot spot’ events. Similar losses of ‘hot spot' 
events were observed after treatment with 20 µM AqB011 for 2 h, after which only a 
faint background fluorescence was observed (Figure 4C-2).  Further validation that 
the observed ‘hot spots' are a result of Li+ induced binding was achieved using HT29 
cells that were imaged in saline with equimolar tetraethylammonium (TEA) substituted 
for Na+ or Li+ (as detailed in the Supporting Information section), where a similar loss 
of ‘hot spot’ activity was observed. The Li+-selective fluorescent signal was two-fold 
greater in normal HT29 cells imaged in Li+ saline, as compared with HT29 cells in 
which Li+ entry was compromised by pharmacological block (AqB011) or removal of 
Li+ ion from the saline by equimolar replacement with other cations such as Na+ or 
TEA+ (Figure 4D). Collectively, these results confirm that the bright punctate Li+ signals 
are dependent on the presence of extracellular Li+ and the presence of functional 
AQP1 ion channels (Figure 4C-3 and -4).  These data rule out the possibility that the 
observed ‘hot spots' were a generated by non-selective interaction of SHL with other 
intracellular cations. This finding is significant in that it shows the flux of Li+ across the 
membrane is required to activate the intracellular Li+ signal seen with SHL, and 
supports the conclusion that intracellular lithium hot spots are caused by Li+ entry into 
the cell through AQP1 cation channel.      
 
Li+ hot spots at the leading edges of migrating HT29 cells were not observed in 
SW620 cells lacking comparable AQP1 expression.  
The role of AQP1 ion channels in mediating the lithium 'hot spot' events was tested by 
evaluation of another colon cancer cell line (SW620), that is similar to HT29 in having 
an adherent epithelial phenotype20, but different in that rates of migration are very slow 
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and levels of AQP1 expression are 2.6-fold lower in SW620 than HT29 cells (Figure 
4A).  HT29 cells and SW620 cells were pre-incubated in SHL for 2 hours in Li+-
substituted saline and imaged as described above.  Results in Figure 4 show that the 
lithium ‘hot spots’ were more abundant and brighter in HT29 cells (Figures 4B 1-3) 
than in SW620 cells (Figures 4B 4-6).  In migrating HT29 cells, lithium 'hot spots' were 
concentrated in leading edges of the cells (Figures 4B 2 and 3) compared to uniformly 
distribution in non-migrating cells (Figure 4B 1). This observation is consistent with the 
known clustering of AQP1 channels in the leading edges of specific classes of cells 
during migration, where it is proposed to facilitate fluid movement needed for volume 
change during extension, and to compensate for changes in osmotic pressure 
associated with actin polymerization and depolymerisation8,19. 
  
AQP1 Expression levels were as determined by immunofluorescent imaging with 
confocal microscopy (as detailed in the Supporting Information section).   AQP1 
channels were localized using excitation of the immunolabeled cells with 488 nm laser 
to cause green fluorescence emission characteristic of AQP1 immunolabeling and 
visualization with a AlexaFluor 488 tagged secondary antibody. HT29 cells 
demonstrated significantly higher AQP1 expression compared to SW620 cells (Figure 
4A).  
 
Results with SW620 cells demonstrate that the observed lithium ‘hot spots’ are directly 
dependent on the presence of AQP1 channels, and cannot readily be attributed to 
fluxes through other membrane channels and transporters. In combination, results 
here from pharmacology, ion substitution and comparison of cell lines with different 
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patterns of AQP1 expression provide evidence that lithium 'hot spots' measured by 
the novel probe SHL mark the locations of active AQP1 ion channels. 
 
Lithium hot spots are colocalized with AQP1 channels in HT29 cells 
The spatial correlation between the locations of the lithium ‘hot-spots’ and the AQP1 
channels was assessed using confocal microscopy. The signal intensities using Z-
stacked compiled images were measured as a function of distance across the cell 
diameter (indicated by straight lines crossing the cell centers; for two cross-sections 
per cell).  Signals were plotted as a function of X-Y distance to quantify the 
correspondence between the SHL Li+ fluorescence intensity (red channel; MC(SHL)-
Li+ complex) and the AQP1 protein signal intensity (green channel; autofluorescence). 
Results in Figure 5A show that the two fluorescence signals were strongly co-localized 
in HT29 cells (with superimposed red and green signals being represented by yellow), 
yielding relative fluorescence units (RFU) ranging from 50 to 200  which were 
consistent with data shown in Figure 4A. The spatial profiles of red and green signal 
distributions as a function of position across the diameters of cell are illustrated by 
plots of signal intensity (Figure 5C). Li+ and AQP1 signals in HT29 cells were found to 
be strongly correlated with R2 values ranging 0.61 to 0.68. In contrast, SW620 cells 
(Figures 5C 3 and 4), showed poor spatial correlation and low intensities, with most 
signal values ranging from 0 to 50 RFU. Signal intensity data from SW620 cells 
showed little correlation with R2 values ranging from 0.06 to 0.09. This work opens 
avenues never before imagined for the real-time visualization of cation channel 
function and the localization of active channel domains in living cells, with particular 




Our results define a new Li+ selective sensor, SHL, and demonstrate its translational 
potential in addressing fundamental signaling mechanisms, here explored by the 
visual monitoring of cation entry through AQP1 cation channels in cancer cell 
migration.  The SHL photoswitchable sensor, which maintains stable emission after 
prolonged excitation, offers exciting potential applications for optical studies of 
dynamic ion fluxes in active moving cells.  The novel Li+ selective fluorophore SHL 
promises to be a valuable addition to the ion sensor field.  
 
The initial proposal that AQP1 works as a non-selective cation channel in addition to 
its known role as a water channel18 generated controversy.  Subsequent analyses 
from different groups confirmed the capacity of AQP1 to function as a dual water and 
ion channel, showing the ion channel activity is gated directed by intracellular cGMP 
and indirectly regulated by intracellular signalling cascades including tyrosine 
phosphorylation10,11,12, but left unclear the physiological relevance of the dual water 
and ion channel function.  Recent work has since demonstrated that the AQP1 ion 
conductance is essential for rapid cell movement in a subset of cancer cells that show 
high metastasis or invasiveness and a corresponding upregulation of AQP1 channels 
in the leading edges8,9,19, demonstrating a functional role for the AQP1 ion channel in 
cell motility.  
 
 Here confocal imaging confirmed cation entry through AQP1 ion channels monitored 
using a permeable monovalent cation Li+ that could be monitored visually with the new 
probe SHL. The two colon cell lines used in this study that have different endogenous 
levels of AQP1 expression; AQP1 is high in fast moving HT29 cells, and low in the 
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slowly migrating SW620 cells.  Lithium hot spots were abundant in HT29 cells, and 
rare in SW620 cells. The spatial resolution of AQP1 ion channel sites of activity at the 
leading edges of HT29 cells was an exciting observation, suggesting future studies 
might go further in the characterization of the temporal and spatial dynamic properties 
of the ion fluxes in migrating responding cells 
.  
AQP1 channels are not the only pathway for Li+ transport across cell membranes. For 
example, Li+ is permeable through voltage-gated Na+ channels22,23,24 and Na+-proton 
exchanger21. Some of the Li signal described here might involve additional channels 
or transporters. However, the alternative hypothesis that the lithium signal observed 
in HT29 cancer cells was due entirely to other mechanisms unrelated to AQP1 seems 
unlikely for several reasons.  First, results here showed that pharmacological inhibition 
with the AQP1 ion channel blocker, AqB011, significantly diminished the Li+ signal to 
a level similar to the response observed in cells imaged in saline with TEA+ (which 
does not bind to SHL).  Other AQP modulators in the library of bumetanide derivatives 
that include AqB011 have been shown to be selective for specific AQP classes without 
off-target effects on other signaling and transport mechanisms25,26. Second, the 
punctate Li+ signal pattern was not evident in SW620 cells that have low levels of 
AQP1 expression but otherwise express various channels and transporters required 
for basic cellular function and low level motility.  Third, the cells used for the studies 
would not be expected to have appreciable levels of voltage-gated Na channel 
expression. Lastly, the co-localization of AQP1 expression and Li+ signals showed a 
strong correlation, and was consistent with other work indicating that the expression 
of AQP1 in migrating cells is localized strongly in the leading edges.  In sum, evidence 
presented here supports the proposal that AQP1 is not just a water channel, but also 
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works as a monovalent cation channel. The AQP1 ion channel is an attractive 
candidate for the development of therapeutic interventions that could be used to 








Two electrode voltage clamp recordings were used to investigate if AQP1 ionic pore 
is permeable to Lithium ions. Recording were performed at room temperature, in 
standard isotonic Na+ saline and in Li+ substituted isotonic saline containing 100 mM 
Nacl or 100mM LiCl, 2 mM KCl, 4.5 mM MgCl2, and 5 mM HEPES, pH 7.3.  1 M KCl 
was used to fill capillary glass electrodes (1–3 MΩ) for recordings. cGMP was applied 
to the bath saline at a final concentration of 10-20 µM using the membrane-permeable 
cGMP analog [Rp]-8-[para-chlorophenylthio]-cGMP (Sigma-Aldrich, Castle Hill NSW 
Australia). Ion conductance was determined by linear fit of the current amplitude as a 
function of voltage, with a step protocol from +60 to -110 mV and holding potential of 
-40 mV. Ionic conductance was monitored over 25 minutes after the bath application 
of cGMP to allow sufficient time to achieve maximal response. Conductance was 
determined by linear fit of the current amplitude as a function of voltage, with a step 
protocol from +60 to -110mV and holding potential of -40 mV. Recordings were made 




Cells were cultured using 8 well Ibidi µ-Slide (Ibidi, Munich Germany) to achieve 50% 
confluency prior to experiment. To begin the immunostaining procedure cells were 
rinsed with PBS and fixed in 4% paraformaldehyde for 20 minutes at room temperature 
(RT). Then washed 4 times in PBS (5 minute washes at RT) on a rocker. Cells were 
permealised with 0.1% PBS Tween for 5 minutes and washed three times with PBS 
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at room temperature for 5 minutes, on a rocker. Next cells were blocked with 10% 
horse serum in PPS (GS/PBS) for 40 minutes at room temperature on a rocker and 
incubated with the rabbit anti-AQP1 antibody (ab15080, Abcam, Victoria, Australia) in 
0.1%GS/PBS for 2 hours at room temperature. The cells were then washed three 
times in PBS for 7 minutes at room temperature on a rocker and incubate with 
Alexa488 conjugated sheep anti-rabbit antibody (ab150181, Abcam, Victoria, 
Australia) diluted in 0.1%GS/PBS for 35 minutes at room temperature in the dark. Next 
cells were washed three times in PBS for 7 minutes at room temperature, on a rocker 
and incubated with Hoescht (diluted 1:1000 in PBS) for 5 minutes in the dark. The 
cells were rinsed with PBS twice and mounted using hydromount mounting media 
(Sigma-Aldrich, Castle Hill NSW Australia). 
 
 
Cancer cell culture and Confocal imaging 
HT29 and SW620 colorectal cancer cell lines and the MDA-293 breast cancer cell line 
(American Type Culture Collection ATCC, Manassas, VA USA) were cultured in 
complete medium composed of Dulbecco's Modified Eagles Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), penicillin and streptomycin (100 
U/ml each) and 1 x glutaMAX™ (Life Technologies Mulgrave, VIC, Australia). Cultures 
were maintained in 5% CO2 at 37°C.  Cells were seeded on an 8-well uncoated Ibidi 
µ-Slide (Ibidi, Munich Germany) at a density of 1.0 x 105 cells/ml and allowed 24 hours 
to settle.   
 
All imaging experiment was performed in a darkroom. Prior to imaging, cells were 
incubated with 50 µM of sensor for 2 hours then washed twice with lukewarm 
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phosphate buffered saline (PBS). For AqB011 treated group, cells were then 
incubated with 20 µM AqB011 for 2 hours. All cells were treated with 0.5 mg/mL of 
Hoechst 34580 for 20 mins. Either Li+ saline (137 mM LiCl, 3.5 mM KCl, 0.68 mM 
KH2PO4, 5 mM HEPES, 10 mM glucose and 4.4 mM MgSO4) or TEA+ saline (137 mM 
TEACl, 3.5 mM KCl, 0.68 mM KH2PO4, 5 mM HEPES, 10 mM glucose and 4.4 mM 
MgSO4) was used for the imaging. The µ-Slide was mounted on a Leica TCS SP5 
laser scanning confocal microscope (Leica, Germany) with 63x objective selected. For 
signal emitted by sensor, Ex=513 nM/Em=550 nm~700 nM setting was used. For 
signal emitted by Hoechst 34580 staining, Ex=405 nM/Em= 425 nM~ 500 nM setting 
was used.   
 
In cell photo switching experiment 
Plate was mounted on microscope with UV lamp and table light over hanging. First 
image was taken after the plate was transferred from incubator to microscope and 
been exposed under white light for 10 minutes (OFF1). Then the plate was exposed 
under UV (632nM) light for 10 minutes and second image was taken (ON1). In the 
next 10 minutes, one image was taken after every 2 minutes of white light exposure. 
The seventh image was labelled as OFF2. Last image was taken after the plate was 
incubated in total dark for 10 minutes (ON2). Fluorescent intensity was quantified 
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Figure 1. (A) Spiropyran (SP) and merocyanine-lithium complex of sensor SHL 
(MC(SHL)-Li+).  The ring-closed spiropyran is weakly fluorescent.  The ring-opened 
merocyanine is expected to be more fluorescent.  Shown is the proposed mode for 
reversible binding of Li+ to SHL. (B) insert. Fluorescence spectra of SHL in water (50 
µM). Black spectra represent SHL with no added Li+; blue spectra represent SHL with 
excess Li+ (100 µM). (B) Bar graph showing fluorescence of SHL (50 µM) in the 
presence of Li+ or other biologically relevant metal ions. Excitation wavelength = 532 
nm; emission wavelength = 625 nm for (B) 
 
Figure 2. Electrophysiology traces demonstrating that AQP1 central ion pore is 
permeable to Li2+ ions and blocked by AqB011 compound. (A) Recordings were 
performed in Li+ substituted isotonic saline. After the initial recordings (Initial), the ionic 
conductance response in oocytes expressing AQP1 was activated by CPT-cGMP over 
25 min in Li+ saline (cGMP), which was not observed in non-AQP1 expressing 
controls. Post 2 h incubation in AqB011, the channels remain closed and inactivated 
to second application of cGMP (AqB011). (B) Trend plots showing the ionic 
conductance responses for individual oocytes measured before (initial), after the 
application of first bath cGMP (cGMP), post 2hour incubation in saline containing 30 
µM AqB011 (AqB011). The cGMP activated cationic response in AQP1-expressing 
oocytes is not observed in non-AQP1 control oocytes. After incubation in saline 
containing AqB011, the AQP1 cationic conductance remains closed and unresponsive 
to second bath application of cGMP, which is not observed in control oocytes. 
Figure 3. Confocal images of SHL in HT29 cells. HT29 cells were incubated with 50 
µM SHL for 2 h prior to imaging. Cell nucleus were labelled with Hoescht 33258 (Blue) 
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and SHL sensors (Red) were activated with green laser light. (A) Four distinctive 
states of the sensor during the photoswitch cycles were illustrated here. Cells were 
first illuminated under visible light radiation for 10 min to convert majority of the sensor 
back to non-fluorescent SP isomer (OFF1). Then, cells were illuminated under UV light 
for 10 min to convert SP isomer to fluorescent MC(SHL)-Li+ complex (ON1), followed 
by exposure under white light for 10 min with measurement taken every 2 min (OFF2). 
Finally, cells were incubated in the dark for 10 min to allow the formation of the MC 
isomer, and the binding of Li+ to form the MC(SHL)-Li+ complex (OFF2). (B) 10 min 
white light illumination was applied to cells after ON1 state, images were taken every 
2 min and illustrated here. Red SHL signals were gradually fade away with time. (C) 
Red fluorescent signals were measured for individual cells in the field of view and 
values were normalized to ON1 state. Data are mean ± S.E.M.; n value is 43. A single-
phase decay function was fitted to values between ON1 (100 RFU) and OFF2 (44.51 
RFU) state, the half-life was determined to be 4.13 minutes with a τ value estimated 
at 5.95 minutes. After 10 min incubation in dark, sensors were converted back to MC 
isomer, and the normalized intensity increased from 44.51 RFU (OFF2) to 84.65 RFU 
(ON2). 
 
Figure 4. Characterization of lithium hot spots. (A) Cells were labeled with Hoescht 
for nucleus (blue) and AQP1 antibody (Green). HT29 cells have 2.6-fold higher AQP1 
expression than SW620 cells. (B) HT29 cells (1, 2, 3) and SW620 cells (4, 5, 6) were 
incubated with SHL for 2 h prior to imaging. Strong Li+ signal was observed in all HT29 
cells compared with minimal Li+ signal observed in SW620 cells. In non-migrating HT 
cells, Li+ ‘hot spots’ were observed across the whole cytosolic area (1). In migrating 
HT29 cells, lithium 'hot spots' were concentrated in leading edges of the cells (2, 3). 
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(C) Distinctive punctate Li+ hot spots were observed in HT29 cells imaged in Li 
substituted extracellular saline (1). In cells that were pre-treated with 20 µM AqB011 
for 2 h, Li+ hot spots were not observed (2). Similar losses of ‘hot spot’ events were 
observed after the removal of Li+ from the extracellular saline by equimolar substitution 
of TEA+ (3). Pre-incubation in 20 µM AqB011 for 2 h didn’t cause any further decrease 
of Li+ signal (4). (D) Li+-selective fluorescent signals were quantified by measuring red 
fluorescent intensity of each individual cells. Intensities were normalized to normal 
HT29 cells imaged in Li+ saline. Li+ entry was significantly compromised by 
pharmacological block (AqB011) or removal of Li+ ion from the saline by equimolar 
replacement with other cations such as TEA+. White scale bars represent 5 µm.                
 
Figure 5. Quantitative analysis of confocal images. HT29 cells (A) and SW620 cells 
(B) were pre-incubated with SHL (Red)and then fixed and labelled with AQP1 primary 
antibody together with AlexaFluro-488 conjugated secondary antibody (Green). 
Nucleus were stained with Hoescht (Blue). All three channels were stacked and 
illustrated in the far-right panel. Consistent with data shown above, both Li+ and AQP1 
signals were more abundant in HT29 cells compared with SW620 cells. In the stacked 
images, fluorescence signals from MC(SHL)-Li+ complex and AQP1 are strongly co-
localized in HT29 cells but not in SW620 cells (combined red and green signals are 
colored yellow). C 2 cross-sections were chosen for each cell, 1 and 2 for HT29 cell, 
3 and 4 for SW620 cell. Both red Li+ signals and green AQP1 signals along the cross-
sections were plotted as a function of X-Y distance across the cell. In HT29 cells, high 
levels of Li+ signals and AQP1 expression were observed and 2 traces were strongly 
correlated. In contrast, SW620 cells showed poor spatial correlation and low 
intensities for both Li+ signals and AQP1 expression. D Li+ signals and AQP1 
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expression in C were plotted against each other to illustrated the correlation between 
them. Linear regression was fitted and R2 values were calculated in Prism 7.  Two 
channels were strongly correlated in HT29 cells with R2 values ranging 0.61 to 0.68. 
In contrast, signals were poorly correlated in SW620 cells and with R2 values ranging 
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With approximately 60% of human body being composed of water1, maintaining 
water homeostasis is critical for basic functions of the human body such as  urine 
concentration2, spinal cord fluid formation3 . Multiple classes of ion channels and 
transporters play important roles in regulating body fluid homeostasis4,5, including 
Na+-K+-ATPase pumps6, Na+, K+ and Cl- channels7-9, transporters10, and the 
aquaporin family11. The ancient family of aquaporin channels, present across many 
kingdoms of life12, are well-known pathways for passive water flux13. As described 
in this thesis. a handful of plant, invertebrate, and vertebrate aquaporins have been 
found to conduct ions, including human aquaporin-1 (AQP1). In addition to the well-
characterised water transport role,AQP1 plays an important role in the conduction 
of monovalent cations (Na+ and K+) in  physiological conditions14.  
 
Cell migration plays acritical role in many aspects of cell physiology. It is essential 
for embryogenesis, development, and cancer metastasis15. During oogenesis in the 
drosophila ovary, several epithelial cells are recruited by anterior polar cells to form 
a cluster to initiate cell migration. These recruited epithelial cells can extend 
protrusions and sense chemoattractant signals16,17. During the development of 
Xenopus laevis, the neural crest initially formed in the dorsal part of the embryo 
followed by the migration alongside the neural tube18. In order to initiate migration, 
neural crest cells first undergo epithelial-mesenchymal transition (EMT). 
Disassociated cells migrate as a cluster by exchanging chemotactic signals within 
the cluster19. Another physiological process that involves cell migration is cancer 
metastasis. Melanoma cells, for example, can spread from the epidermis of the skin 
to distal organs. Melanoma cells also migrate in cluster and along extra cellular 
matrix20.          
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In a migrating cell, actin filaments are assembled and polymerised at the leading 
edge of the cell, which create the physical driving force for cell protrusion21. Actin 
polymerization is accompanied by specific classes of membrane proteins in the 
domains of membrane extension. Various classes of aquaporins have be shown to 
enhance cell migration and invasion, including AQP1, -3, and -4. AQP1 has been 
observed at the leading edge of lamellipodia in migrating cells, and knockdown of 
AQP1 expression has been shown to impair cell migration significantly22,23. For 
example, experiments have demonstrated that the knockdown of AQP1 in the 
endothelial cell will reduce the cell migration, thus limiting tumour angiogenesis and 
proliferation24. AQP3 and -4 are also crucial for cell migration and invasion as 
demonstrated via in-vitro AQP1-knockdown studies, or in-vivo AQP1-deficient 
studies. The decreasing AQP4 expression in astrocytes slows cell migration25. 
Impaired cell migration also been observed in cells from AQP3-deficient animal26. 
Thus, it is important to understand the mechanisms of AQP-facilitated cell migration.          
 
Similar to AQP1, AQP4 also facilitates osmotic water permeability, but the over-
expression of AQP4 does not mimic the function of AQP1 in terms of enhancing cell 
motility27. Unlike AQP4, AQP1 also functions as monovalent cation channel that can 
be gated by cGMP11,28,29. The ion channel function of AQP1 is essential for cell 
migration in a subset of cell types that express the channel in their leading 
edges30,31. As reviewed in Chapter 1, pharmacological modulators are important in 
order to evaluate and understand the function of AQP1 in cancer metastasis and in 
normal cell motility. Since the first evidence showing that AQP1 channels function 
as a non-selective cation channel by Yool and colleagues in 1996, this novel finding 
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has attracted interest and controversy in the field32,33. The ion channel activity was 
replicated in other laboratories33,34, though the physiological relevance of the dual 
water and ion channel function of AQP1 remained to be defined. Differences in 
experimental outcomes across preparations suggested multiple levels of regulation 
controlled the ion channel activity levels of AQP1 channels, including tyrosine 
phosphorylation in the carboxyl terminal domain35. Characterizing the ion 
conductance of AQP1 was essential for enabling the additional roles of AQP1 to be 
considered for understanding the mechanisms that govern cell migration.    
 
My studies have advanced the field of aquaporin pharmacology. Prior to the work 
presented in this thesis, no modulators that targeted the AQP1 ionic conductance 
had been discovered. My dissertation research has defined two new AQP1 ion 
channel antagonists (AqB011 and bacopaside I) and one new AQP1 water channel 
antagonist (bacopaside II), all now published. The ion channel blocker AqB011 was 
used to selectively block the AQP1 ion channel and was found to inhibit migration 
without altering viability or proliferation of AQP1-expressing colon cancer cells30. 
The water channel blocker bacopaside II was found to only block the AQP1 water 
channel but not ion channel and slow cell migration when treated on AQP1 
expressing cancer cells31.  The agent bacopaside I interestingly is a blocker of both 
the water and ion channel activities of AQP1, and was also found to inhibit the 
migration of cancer cells31. In summary, the novel pharmacological tools identified 
in my dissertation research have created a powerful pharmacological toolbox 




Ion currents through AQP1 have been recorded using electrophysiology techniques, 
but have not previously been visualized with ion-selective probes.  Other types of 
ionic sparks have been characterized by imaging with ion-selective sensors36,37. 
Fluo-4 AM, a commercially available Ca2+ sensor has been used to detect Ca2+ 
sparks in various tissue sections, which contribute new sights in excitation 
contraction in cardiomyocytes and the circadian rhythm origin in suprachiasmatic 
nucleus37,38. Results in this dissertation demonstrated the first real-time analysis and 
imaging of AQP1-mediated ion entry into lamellipodia of migrating cancer cells. This 
was achieved with a reversible and selective lithium (Li+) sensor (SHL). By 
performing the imaging of Li+ entry through AQP1 channels, the function of AQP1 
as ion channels has been further substantiated. SHL is a novel spiropyran-based 
ion sensor that is specific for lithium ions (Li+) in the monovalent cation family. 
Beside the specificity, SHL also works as a photoswitchable sensor. The ring-
opened spiropyran isomer (OFF) and ring-opened merocyanine-Li2+ (ON) complex 
can be switched repeatedly under different wavelength without significant lose of 
fluorescent intensity. This photo-switchable property is consistent with other 
spiropyran-based ion sensors39-41.This is not the first example of ion channel activity 
leading to the appearance of spark-like events monitored optically in living cells.  
Other studies have successfully monitored the zinc –sparks during the very early 
stage of fertilization in mouse oocyes42,43. This zinc-sparks can be used clinically as 
a bio-marker for oocyte quality43. 
 
For Bacopa monnieri, two phytochemicals (Bacopaside I and II) were successfully 
identified and characterised as reported in Chapter III of this dissertation.  Future 
work could follow on from unpublished pilot studies conducted during my PhD work. 
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For example, during the screening for medicinal plant candidates as AQP1 
modulators, in addition to Bacopa monnieri, I found three more plants with promise 
as sources of new modulators. These medicinal herbs were selected based on 
reports in literature of traditional uses for dysfunctions or diseases potentially linked 
to AQP1-mediated activity. There were Poria cocos, Rheum rhuababarum and 
Panax ginseng. The details of these plants and possible active compounds are listed 
in Table 1. The crude extracts of the three plants were tested on AQP1-expressing 
oocytes, and all acted as antagonists of the AQP1 water flux (data not shown). Due 
to limited time available, no extended follow-up studies were carried out for Poria 
cocos or Panax ginseng, but these merit investigations in future work. For Rheum 
rhuababarum, active phytochemicals were enriched by extraction and column 
separation, but identification of the final pure active compound was handicapped by 
technical limitations given the highly glycosylated composition of the enriched crude 
extract. Chemicals with properties consistent with an expected partition into the 
enriched active fraction were selected for study; these were Epicatechin gallate 
(ECG) and Epigallocatechin gallate (EGCG), which are present in extracts of in 
Rheum rhuababarum. Both ECG and EGCG belong to the catechin flavonoid family 
known to have high bioactivity44. Preliminary tests demonstrated that both ECG and 
EGCG were able to block AQP1 water conductance significantly at 50 µM; and when 
tested on cancer cell migration, both chemicals were able to slow down SW480 
colorectal cancer cell migration at 50 µM (data not shown). These preliminary 
studies have successfully lead to a new PhD project that is currently in progress. 
 
In this dissertation, my focus has been on human AQP, but I have had the 
opportunity to evaluate AQPs from different species during my PhD studies that 
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have resulted in co-authored publications that are not included as chapters in this 
thesis, but are available in the Appendix of Published Work.  
(i) Insect aquaporins: New AQPs from two different insect species were identified 
and characterized in collaboration with Jeff Fabric's research group in Arizona USA. 
From Lygus hesperus, a pest insect that impacts crops in western North America, 
five new AQPs were cloned and I carried out their functional characterization using 
the Xenopus oocyte expression system.  The published results showed that all five 
identified Lygus AQPs (LhAQP1-5) transported water but not glycerol, placing them 
as members of the classical AQP family15. Further investigation of the candidate 
pharmacological blockers for these LhAQPs might shed light to the development of 
new species-targeted pesticides. A possible future project will be to screen all the 
AQP modulators reported in this dissertation and their structural homologs for 
possible block of the insets LhAQPs.  
(ii) Molluscan aquaporin: A candidate AQP gene was cloned from the squid 
(Doryteuthis opalescens) by Dan Morse and colleagues in California USA.  In the 
squid, the AQP (DoAQP) channel is expressed in iridocytes, which are cells that can 
reflect specific wavelengthvia controlling using neurotransmitters.  I carried out the 
functional swelling assays, showing DoAQP1 is a classical AQP that is permeable 
to water but not glycerol (data not shown). This finding may contribute to ongoing 
work in the Morse lab aimed at answering the question of how squid regulate the 
changes in their skin iridescence needed for camouflage. Inside the iridocytes, 
protein plates called reflectin are stacked together. Reflectin with high refractive 
index is separated by low refractive index space to form multilayer reflectors, thus 
enable the iridocyte to reflect certain wavelengths. Data thus far have shown that 
iridescence changes via the rapid polymerization and depolymerisation of reflectin 
	 196	
proteins in the iridocyte. This rapid change requires fast water flow which appears 
to be conducted through DoAQPs expressed on the surface of iridocytes. These 
findings of new AQPs from different species contribute to the diversity of functions, 
expanding understanding in the AQP research field.  
For future directions, there are an array of projects that can lead on from my PhD 
studies based on the preliminary findings outlined above. One area of particular 
interest would be a detailed study of all the medicinal plants that could potentially 
contribute new compounds to the AQP modulator collection. Some of the natural 
agents could serve as lead compounds that might be further refined and optimised.  
For example, both of the bacopasides have relative high molecular weight and do 
not fit into the Lipinski’s five rules45 for a pro-drug molecule, I noted that from my in 
silico docking results that the key moiety which interfaced with the AQP protein in 
both bacopaside chemicals is the tri-saccharide, not the terpene backbone. In the 
next stage of research, it would be of interest to chemically isolate the tri-saccharide 
part and test it directly for a role as an AQP blocker. In this way, the molecular weight 
of the active compounds could be reduced dramatically and still in theory retain the 
essential docking domain, which is predicted to cause water channel block. Initial 
studies are now in progress through collaboration with Dr Sabrina Heng in the 
synthetic chemistry group at University of Adelaide. A commercial with structural 
similarities to the tri-saccharide component of bacopasides was selected as the 
template. The candidate agent is being modified to increase the lipophilicity, as the 
proposed blocking site is positioned at the intracellular face of the AQP1 water pore. 
The candidate blocker will be tested both in the oocyte expression system and in 
various cancer cell lines for its possible function as an AQP channel modulator, and 
an inhibitor of cancer cell migration.      
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In this dissertation, diverse agents such as bacopasides and other medicinal plant 
products, as well as synthetic AqB modulators were studied in vitro; however, a 
systematic study in vivo is needed reveal the translational values of these diverse 
modulators in terms of effective anti-metastasic effects. Preliminary studies are 
being carried out by collaborators in Adelaide.  Tail-vein injections of tagged cancer 
cells in mice are being used to test whether intraperitoneal administration of 
AqB013, an AQP1 water channel blocker, can slow down the proliferation and 
migration of cancer cells in vivo. Both live animal CT scan and autopsy studies will 
be performed in this study. Other modulators reported in this dissertation can be 
tested using the same protocol. A new and expanding array of pharmacological 
modulators of AQP1 and other AQPs is likely to offer exciting opportunities for 
intervention in diseases involving mechanisms of fluid and volume homeostasis 




Table 1. Summary of Selected Candidate Medicinal Plants 
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ABSTRACT
Fluid homeostasis in the body is well known to be regulated by ion channels and  transporters, but equally important are the co-expressed classes of aquaporin 
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pharmacology is expanding rapidly with the new identification of small molecule drug-
like agents with distinctive properties in AQP modulation, allowing exploration of poten-
tial therapeutic applications in brain edema, cancer and other disorders. Pharmacological 
agents could modulate AQPs by direct occlusion of the water pore itself, by acting at dis-
tinct sites that confer other channel properties, or by altering levels of protein expres-
sion or membrane targeting. Expanding the pharmacological portfolio will benefit basic 
research and promote new therapeutic strategies in many conditions involving AQPs in 
the symptoms or disease processes. Exploring herbal alternative medicines as sources of 
pharmacological agents for AQPs is likely to have a substantial impact on the field of AQP 
research, which has keenly awaited the development of chemical interventions as a plat-
form for therapeutic approaches. Recent work is providing an enhanced understanding of 
the molecular mechanisms of action of traditional herbal medicines as novel sources of 
AQP modulators.
14.1 INTRODUCTION
Aquaporins (AQPs) found throughout the kingdoms of life (Zardoya, 2005) are channel 
proteins which facilitate water and small solute movement across plasma membranes based 
on chemical, osmotic and hydrostatic gradients (Hachez and Chaumont, 2010; Ishibashi 
et al., 2011; Madeira et al., 2014). The existence of water channels in red blood cells and 
barrier membranes and their hallmark sensitivity to block by mercury (Benga et al., 1986; 
Macey, 1984; Macey et al., 1972; Naccache and Sha’afi, 1974) was deduced before AQP1 
cDNA was cloned and characterized in the early 1990s (Preston and Agre, 1991; Preston 
et al., 1992). Progress since has defined 13 mammalian subtypes of AQPs, their relative 
protein abundance, tissue-specific distributions and expression levels under various con-
ditions. AQP crystal structures have provided insights into the homotetrameric channel 
structure and the location of the water pores within each of the four subunits (Ishibashi 
et al., 2009; Jensen et al., 2003; Sui et al., 2001). AQP1 is a tetrameric channel with water 
pores located within each of the four individual subunits (Fu et al., 2000; Sui et al., 2001). 
Review articles have emphasized the compelling need for development of AQP modulators 
as candidate treatments for a variety of disorders (Castle, 2005; Frigeri et al., 2007; Huber 
et al., 2012; Jeyaseelan et al., 2006). However, prior to 2009, the discovery of AQP phar-
macological agents had not progressed substantially beyond mercuric compounds, which 
lacked translational potential due to toxicity, and agents that affected multiple targets and 
lacked potency. Recent advances have shown that drug-like lead compounds are emerging, 
complementing work that has investigated the functional roles of AQPs by overexpression 
or targeted genetic knockdown and deletion.
14.2  OVERVIEW OF AQUAPORIN CHANNEL FUNCTIONS IN 
BRAIN FLUID HOMEOSTASIS AND CELL MIGRATION
Fluid homeostasis in the body is regulated by partnerships of ion channels and transport-
ers with co-expressed classes of AQP channels (Conde et al., 2010; Fischbarg, 2010). The 
13 classes of mammalian AQP water channels (AQPs 0–12) are expressed in tissue-specific 
patterns in the body and are essential in regulating the movement of fluid across barrier 
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membranes and contributing to control of cell volume, production of cerebral spinal 
fluid, edema formation and recovery, mediating renal function and more (Ishibashi, 2009; 
Nielsen et al., 2007). Under pathological conditions, dysfunctions in the control of fluid 
movement create serious problems. The physiological importance of AQP channels and 
their compelling potential value as therapeutic targets has motivated researchers to work 
toward defining a pharmacological panel of chemical modulators for AQPs. A compre-
hensive pharmacological portfolio for all classes of AQPs will provide an array of new 
therapeutic opportunities that will continue to expand as new roles for AQP channels are 
uncovered. Two major areas of current interest in AQP-based mechanisms of disease are 
brain swelling after injury or stroke and the migration of cancer cells in the process of 
metastasis.
14.2.1 AQP4 in Cerebral Edema
An area of intense interest for new therapies directed at AQPs is aimed at reducing brain 
swelling after acute traumatic injury or stroke (Mack and Wolburg, 2013; Yool et al., 2009). 
Cerebral edema and increased intracranial pressure are life-threatening sequelae of severe 
brain injuries, associated with a poor prognosis as evidenced by a mortality rate near 
60%–80% (Feickert et al., 1999; Hacke et al., 1996). Traumatic brain injury affects an esti-
mated 10 million people annually; according to the World Health Organization, it will be 
the major cause of death and disability by the year 2020 (Hyder et al., 2007). Nearly one-
third of hospitalized traumatic brain injury patients die from injuries that are secondary 
to the initial trauma, including neuroinflammation, excitotoxicity, brain edema and intra-
cranial hypertension (Miller et al., 1992). Traumatic brain injury reduces life expectancy 
and compromises the quality of life (Schiehser et al., 2014) with increased incidences of 
seizures, sleep disorders, neurodegenerative disease, neuroendocrine dysregulation, psy-
chiatric problems and non-neurological disorders that can persist years after the injury 
event (Masel and DeWitt, 2010). The burden of mortality and morbidity makes traumatic 
brain injury a pressing public health and medical concern, but there is currently no tar-
geted pharmacological treatment for reducing the secondary damage (Park et al., 2008).
Cerebral ischemia following severe traumatic brain injury involves a combination of 
cytotoxic and vasogenic events (Hossmann, 1994; Papadopoulos et  al., 2004; Shi et  al., 
2012; Tourdias et al., 2011). Brain edema commonly occurs when cerebral blood flow drops 
beneath 10 mL/100 g/min and essential ionic pump activity is impaired. During the first 
5 h of ischemia, blood–brain barrier integrity can be maintained without substantial brain 
swelling (Betz et al., 1989), but upon reperfusion, a rise in brain water content can occur in 
conjunction with an elevation in intracranial pressure depending on the extent of ischemia 
and the delay until cerebral blood flow is restored (Avery et al., 1984). Conventional treat-
ments focus on reducing edema and intracranial pressure using hyperventilation, man-
nitol, diuretics, corticosteroids or barbiturates (Manno et al., 1999; Winter et al., 2005). 
Decompressive craniectomy involves the surgical removal of a part of the skull, creating 
a space for the swollen brain tissue to expand. This surgical method improves survival 
but does not fully address pathological outcomes as many patients are left moderately or 
severely disabled (Fischer et al., 2011; Vahedi et al., 2007).
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Work in animal models relies on optimizing the reliability and reproducibility of the 
injury event. The middle cerebral artery occlusion model in rodents has been a standard 
method for testing experimental therapeutic agents but is difficult in part because of 
unexplained variability in infarct volumes. When analyzed with computed tomography 
cerebral blood volume maps, variability was found to result from unintended occlusion 
of a second artery (the anterior choroidal artery) in a subset of animals, causing expanded 
infarct areas (McLeod et al., 2013). Brain computed tomography perfusion imaging pro-
vides a powerful tool for improving the experimental method by fully defining the arteries 
affected by occlusion and accurately identifying the infarct core and penumbra domains 
(McLeod et al., 2011).
The concept of edema as being the primary cause of increased intracranial pressure has 
been challenged; small ischemic strokes in rats resulted in minimal amounts of edema 
but were associated with a substantial elevation in intracranial pressure at 24  h, which 
was effectively countered by application of hypothermia soon after the stroke event. 
Mechanisms in addition to cerebral edema alone must be considered as important drivers 
of intracranial pressure elevation (Murtha et al., 2014a,b). Assessing the regulated contri-
butions of transporters and channels including AQP1 and AQP4 might offer insight into 
possible molecular mechanisms generating the distinct outcomes.
AQP4 is the predominant water channel in the brain, localized to the blood–brain bar-
rier, ependymal cells lining the ventricles, subependymal astrocytes and the glia limitans 
(Amiry-Moghaddam and Ottersen, 2003; Nagelhus and Ottersen, 2013; Xiao and Hu, 2014) 
for their involvement in water movement both in and out of the brain (Mack and Wolburg, 
2013). Studies in AQP4-deficient mouse models showing partial protection from water 
intoxication and edema after stroke (Manley et  al., 2000; Papadopoulos and Verkman, 
2008) support the idea that ligand modulators of AQP4 could revolutionize clinical treat-
ment of brain edema. To date, progress in the field has been limited by the lack of avail-
ability of pharmacologic modulators of the AQP channels. Identification of agonists and 
antagonists of AQP4 remains an important goal in the field of cerebral edema research. 
AQP4 channels subserve water movement during cerebral edema formation (Jullienne and 
Badaut, 2013; Manley et al., 2000), highlighting them as an attractive therapeutic target for 
non-surgical management of cerebral edema (Yool, 2007a; Yool et al., 2009).
Alterations in levels of AQP expression in response to cerebral fluid imbalance can 
offer clues for understanding the functional roles of water channels, assuming the goal is 
to restore homeostasis. In experimental models of cerebral ischemia, expression levels of 
AQP4 were reduced in the initial period post injury and significantly increased thereafter 
(Taniguchi et al., 2000; Yamamoto et al., 2001). Regulation of AQP4 expression appears to 
correlate with levels of the transcription factor hypoxia-inducible factor 1-alpha (HIF-1α) 
(Kaur et al., 2006). Early after traumatic brain injury (5 h), levels of HIF-1α were low and 
increased to peak at 24–48 h post injury (Ding et al., 2009; Higashida et al., 2011). Inhibition 
of HIF-1α correlated with decreased AQP4 and attenuated swelling post injury (Shenaq 
et  al., 2012). The temporal pattern of AQP4 regulation suggests that downregulation of 
channels early after injury could be a protective response to limit the influx of fluid into 
the brain, whereas delayed upregulation might serve to enable fluid export and to restore 
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fluid homeostasis. However, altered gene expression responses are not spatially uniform. 
A reduction in AQP4 expression occurred in astrocytes within the ischemic core, while 
an elevation in AQP4 expression was seen in glial endfeet in the surrounding penumbra, 
in a middle cerebral artery occlusion model (Frydenlund et al., 2006). Spatially selective 
regulation of AQP4 might limit water influx into the ischemic core without preventing 
the amelioration of vasogenic edema in the penumbra. The loss of AQP4 was not linked 
to a decrease in the astrocyte marker, glial fibrillary acidic protein (Friedman et al., 2009), 
indicating that decreased AQP4 expression was not an indirect effect of glial cell loss in the 
injured domain.
AQP4 water channels are dynamically regulated components of brain fluid homeostasis, 
being mobilized or deactivated as needed to reduce damage arising from shifts or distur-
bances in cerebral fluid homeostasis. The temporal and spatial patterns of AQP4 regulation 
are contingent upon the extent and duration of injury and stage of pathology. AQP phar-
macological agents will be advantageous for intervention in brain fluid disorders particu-
larly if administered with an understanding of the dynamic mechanisms of AQP channel 
regulation.
14.2.2 AQP1 in Cell Migration
Cell migration is essential in development, repair, regeneration and immune protection 
in multicellular organisms. In 1937, the neuroanatomist Ramon y Cajal pondered: ‘What 
mysterious forces stimulate the migrations of cells…?’ (Kater and Letourneau, 1985). 
Currently, it is thought that branched assemblies of actin filaments, actively polymerizing 
at the leading edge, generate the primary force, which pushes out thin ruffled membrane 
extensions known as lamellipodia (Le Clainche and Carlier, 2008). Parallel arrays of actin 
are stalled by small loads on the order of 1 pN (Footer et al., 2007), but branched actin net-
works with many points of contact can generate nN of force per μm2, on the scale needed 
for movement through viscous extracellular environments (Marcy et  al., 2004; Parekh 
et al., 2005). Cell adhesions at the leading edge hold the new position, while the trailing 
edge detaches, and the cell resets for the next push forward.
AQPs found in all the kingdoms of life facilitate fluxes of water and small solutes across 
membranes (King et al., 2004). In diverse motile cells from amoeba to human, specific 
AQPs are localized in lamellipodial leading edges. When these cells are made AQP defi-
cient (e.g. by genetic knockout or RNA-interference techniques), cell migration is greatly 
impaired. Reintroduction of AQP restores rates of movement, but interestingly, the effects 
of different AQPs are not interchangeable (McCoy and Sontheimer, 2007).
Of the 13 known mammalian classes of AQPs, the three often associated with migration 
thus far are AQPs 1, 3 and 5. In the ‘World Cell Race’ event held at the American Society for 
Cell Biology meeting in 2011, cell lines were submitted by teams around the world; the win-
ner was a bone marrow stem cell which covered the 400 μm track at a speed of 5.2 μm/min. 
Bone marrow stem cells express lamellipodial AQP1 that is required for migration (Meng 
et al., 2014). The need for AQPs in migration extends to life forms other than mammals. 
The amoeba Dictyostelium discoideum migrates in a chemotactic response to external cyclic 
adenosine monophosphate (cAMP) signals and expresses an AQP orthologous to human 
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AQP1 (48% amino acid sequence similarity) which is localized in lamellipodia (von Bulow 
et al., 2012). If D. discoideum had been in the competition, it might have taken the hon-
ors, moving at up to 11 μm/min in response to cAMP chemotactic stimuli (Van Duijn and 
Inouye, 1991). Other contenders could have included activated T-cells moving at >10 μm/min 
(Katakai et al., 2013), which express AQPs 1, 3 and 5 (Moon et al., 2004), and fibroblasts 
moving at up to 9 μm/min (Ware et al., 1998), which express AQP1 (Minami et al., 2001).
Even though AQP1 and AQP4 are both highly functional water channels, the expres-
sion of AQP1 enables rapid cell movement, whereas expression of AQP4 does not. One 
important difference is that AQP1 but not AQP4 can function as a gated monovalent cat-
ion channel (Anthony et al., 2000; Yool and Campbell, 2012). AQP1 ion channel activity 
has been replicated in other laboratories (Saparov et al., 2001; Zhang et al., 2007), but its 
physiological significance remains unknown. During migration, changes in cytoplasmic 
volume are required. Fluid flux is commonly thought of as a passive process in which water 
follows salt. Yet the observation that water channels cannot simply be swapped between 
cells suggests that other properties in addition to water channel function are needed. The 
pro-migratory effect of AQP1 and its orthologs appears to be a convergent target of evolu-
tion across phyla.
14.3  SMALL MOLECULE DRUG DISCOVERY 
FOR AQUAPORIN CHANNELS
Inhibitors of AQPs have long been heralded as an important goal in the field. A database of 
structurally diverse compounds will be of substantial value in expanding our understand-
ing of drug structure–activity relationships and molecular sites of action for AQP pharma-
cological modulators. Pharmacological agents could modulate AQPs by direct occlusion 
of the water pore itself, by acting at distinct sites that confer other channel properties or 
by altering levels of protein expression or membrane targeting. Regulatory domains in 
AQPs can control membrane localization, interaction with proteins to create signalling 
complexes and scaffolds, and gated permeation of small solutes other than water through 
AQPs (Cowan et al., 2000; Yool, 2007a,b).
Much of the work to date has focused on the agents that act to occlude the water pore. The 
existence of water channels in cell membranes and their hallmark sensitivity to block by mer-
cury was deduced before the first AQP1 cDNA was cloned (Preston and Agre, 1991; Preston 
et al., 1992). Finding non-mercurial AQP blockers has been essential for AQP drug discovery 
(Table 14.1). Silver and gold compounds were reported to block water channel activity of both 
plant and human AQPs (Niemietz and Tyerman, 2002; Tyerman et al., 2002). Membrane-
permeable derivatives of the loop diuretic drugs bumetanide and furosemide have proven 
useful as pharmacological antagonist AqB013 (Migliati et al., 2009) and agonist AqF026 (Yool 
et al., 2013) agents for AQP1 and AQP4 water channel activities. Characterized in vitro and in 
rodent models in vivo, these candidate AQP drugs appear to be effective and well tolerated. 
In a mouse model of peritoneal dialysis, the lack of effect of the agonist AqF026 in AQP1 
knockout animals indicated specificity of action without appreciable off-target effects (Yool 
et al., 2013). Other groups also have investigated arylsulfonamides as AQP blockers (Gao 
et al., 2006; Huber et al., 2007; Ma et al., 2004; Seeliger et al., 2013). Acetazolamide (AZA) 
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has been reported to inhibit AQP4 water permeability with an IC50 value of 0.9 μM. In silico 
docking suggested an interaction between the sulfonamide group of AZA and both arginine 
216 and glycine 209 (Huber et al., 2007). As compared to AQP4, AQP1 was less sensitive to 
AZA, with an IC50 value estimated at 5.5 ± 0.5 μM (Seeliger et al., 2013).
The passage of water and ions occurs through pharmacologically distinct pathways in 
AQP1 (Saparov et al., 2001; Yool et al., 2002). The cyclic guanosine monophosphate (cGMP)-
gated cation permeation pathway is thought to be in the central pore of the tetramer, based 
on molecular dynamic simulations (Yu et al., 2006) and effects of site-directed mutations 
on altering ionic conductance properties (Campbell et  al., 2012). Conduction of ions in 
AQP1 channels is inhibited by Cd2+ but not tetraethylammonium ion (TEA+), whereas 
water transport which occurs through the individual pores located in each subunit is sensi-
tive to TEA+, AqB013, AqF026 but not Cd2+ (Boassa et al., 2006; Brooks et al., 2000; Migliati 
et al., 2009; Yool et al., 2002, 2013). In silico docking identified possible extracellular bind-
ing by TEA+ (Detmers et al., 2006) but indicated intracellular sites of action for the arylsul-
fonamides, supported by results of site-directed mutations and biological assays. AqB013 
is thought to occlude the water pore at the internal vestibule, whereas the AQP agonist, 
AqF026, appears to potentiate water channel activity by interacting with an intracellular 
gate (loop D) between the fourth and fifth transmembrane domains (Yool et al., 2013).
The loop D domain serves as a gate for AQP channel activity in mammalian AQP1 
(Yu et  al., 2006), AQP4 (Zelenina et  al., 2002), amoeba AQP-B (von Bulow et  al., 2012) 
and plant AQP (Tornroth-Horsefield et al., 2006). In AQP1, loop D domain is involved in 
the regulation of cation channel activity activated by cGMP (Yu et al., 2006). The loop D 
sequence is highly conserved across species in AQP1 channels from fish to mammals, yet 
mutations in this domain do not impact water channel activity, suggesting that loop D is 
essential for AQP1 functions other than water permeability. Mutations at specific loop D 
positions in AQP1 remove ion channel activity without impairing water channel activity 
(Yu et al., 2006). The retention of water channel functionality showed that the mutation did 
not interfere with expression, trafficking or assembly of AQP1 channel.
Other regulatory domains in AQP1 have been suggested in the carboxyl terminal 
domain. A putative cGMP-dependent modulatory domain with sequence similarity to 
the cGMP-phosphodiesterase selectivity domain was identified in the AQP1 C-terminus 
(Boassa and Yool, 2002, 2003). Mutations of conserved phosphodiesterase-like residues in 
this domain did not remove cGMP-dependent activation of AQP1 but reduced the efficacy 
of cGMP by right shifting the dose–response curve. An EF-hand motif found in calcium-
binding proteins (Grabarek, 2006) has been proposed in the carboxyl terminal domain 
of AQP1, but its functional role has not yet been defined (Fotiadis et al., 2002). A tyrosine 
phosphorylation site in the carboxyl terminal serves a modulatory role in governing the 
availability of AQP1 to be gated as a cGMP-dependent cation channel (Campbell et al., 
2012). A PDZ protein–protein ligand domain identified in AQP1 (Ile260 to Arg264) in 
the C-terminus was shown to be important for targeting AQP1 into a membrane com-
plex needed to maintain vestibular fluid balance in the inner ear (Cowan et  al., 2000). 
Regulatory domains and transmembrane pore regions in AQPS are both attractive candi-
dates for the development of drug agents.
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14.4  TRANSLATIONAL PROMISE OF PHARMACOLOGICAL 
MODULATORS OF AQUAPORIN CHANNELS IN BRAIN 
EDEMA, CANCER AND OTHER DISORDERS
14.4.1 Targeting AQP4 Channels in Brain Edema
Conventional approaches have relieved intracranial pressure with hyperventilation, hyper-
osmotic agents, diuretics and decompressive craniectomy (Diedler et al., 2009; Park et al., 
2008; Werner and Engelhard, 2007) but are limited in effectiveness by treating symptoms 
rather than causes of edema. A major challenge has been the lack of interventions for con-
trolling fluid movement in brain edema. Pharmacological control of the direct fluid flow 
pathways between blood and brain could provide for invaluable therapeutic interventions 
in cerebral pathologies involving abnormal water fluxes such as stroke, hydrocephalus 
and brain tumours. AQP4 is a logical choice as a molecular target for drug development 
(Papadopoulos and Verkman, 2007; Yool et al., 2009). It is abundantly expressed in the cen-
tral nervous system near the blood–brain barrier at glial cell endfeet and provides a major 
pathway for fluid homeostasis (Amiry-Moghaddam and Ottersen, 2003). Astrocytes have 
been proposed to have a bimodal contribution, with a positive role in fluid homeostasis and 
limiting brain injury, and a negative role in worsening the neuroinflammation, cerebral 
edema and elevated intracranial pressure associated with secondary brain injury following 
neurotrauma (Laird et al., 2008).
Now with the characterization of novel AQP agonists and antagonists, it will be pos-
sible to investigate potential pharmacological treatments for cerebral edema (Yool et al., 
2009) with an intriguing capacity for bimodal regulation of AQP water channel activity. 
For example, in a rat model of cerebral edema induced by diffuse traumatic brain injury, 
a single intravenous application of the AQP antagonist AqB013 within 5 h post-injury dra-
matically reduced edema formation, and single administration of the AQP agonist AqF026 
at 1–2 days post-injury accelerated the resolution of brain edema (Burton et al., unpub-
lished data). Each modulator was beneficial alone; however, of interest was the observa-
tion that a sequential treatment of antagonist followed by agonist each at their optimal 
single time points provided a powerful combination that further enhanced the protec-
tion of motor function, reduced brain swelling and decreased brain albumin content post 
injury. Understanding the biphasic role of AQP4 in cerebral edema and the actions of AQP 
pharmacological modulators will be likely to open new avenues for the development of 
therapeutic interventions after traumatic brain injury.
14.4.2 Differential Regulation of Expression of AQP Channel Types in Cancer Cells
Evidence emerging within the past decade is providing increasingly strong support for the 
role of selected classes of AQPs as important constituents in cancer cell biological mecha-
nisms. Data show a strong positive correlation between AQP expression levels and tumor 
severity (Machida et al., 2011). Tumor cells selectively increase levels of expression of dif-
ferent specific types of AQPs; in some cases, there is an increase in an AQP class normally 
expressed in the cell type (Saadoun et al., 2002a), but in other cancers, the upregulated class 
of AQP is not found at appreciable levels in the original tissue (Moon et al., 2003). AQPs are 
linked with a variety of properties of cancer cells, such as tumour size expansion, edema, 
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cell adhesion, migration and proliferation, which enhance tumour growth and metastasis 
(Hu and Verkman, 2006; Saadoun et al., 2002a,b).
For AQP1 and AQP5 channels, de novo expression has been observed in early stage 
colorectal carcinoma development but is not detectable in normal colonic epithelium 
(Moon et al., 1997, 2003) for purposes that remain incompletely understood in the  context 
of cancer progression. When transfected into melanoma and breast cancer cell lines, 
increased AQP1 expression was associated with an increase in both in vitro cell migra-
tion and in vivo metastasis (Hu and Verkman, 2006). When melanoma cells B16F10 were 
implanted subcutaneously, AQP1 null mice showed slower melanoma tumour growth and 
impaired tumour angiogenesis as compared with wild-type mice (Saadoun et al., 2005).
AQP1 contributes to cell migration and angiogenesis and facilitates tumour growth 
and metastasis through mechanisms that remain to be defined. In its proposed activity 
as a dual water and ion channel (Yool and Weinstein, 2002), AQP1 could be one mech-
anism used for enhancing migration rate in a subset of classes of aggressive cancers. 
Facilitation of cell migration appears to be achieved in other types of cells by colocal-
ization of water-selective AQPs in combination with ion transporters (Chai et al., 2013; 
Stroka et al., 2014).
AQP3 increased migration and proliferation of corneal epithelial cells in wild type 
as compared with Aqp1 null mice and was important in peritoneal fibrosis and wound 
healing (Ryu et al., 2012). In squamous skin cell carcinomas and bronchioloalveolar car-
cinomas, AQP3 upregulation influenced metastasis and proliferation (Hara-Chikuma 
and Verkman, 2008a; Machida et al., 2011). After si-RNA knockdown of AQP3 expres-
sion, weaker cell adhesion and impaired cell growth were observed (Kusayama et  al., 
2011). In non-small cell lung cancer, AQP3 knockdown suppressed tumour growth and 
reduced angiogenesis (Xia et al., 2014). In agreement, AQP3 null mice show reduced glyc-
erol transport and were more resistant to skin cancer formation (Hara-Chikuma and 
Verkman, 2008b).
AQP4 appears to assist with water balance in the tumour environment and has been 
postulated to play a role in cell–cell adhesion, possibly via an extracellular helical domain 
in loop C that could interact with adjacent cells. Expression of AQP4 conferred adhesive 
properties in cells that lacked classic adhesion molecules, as shown by L-cell cluster forma-
tion in AQP4-positive cells but not control cells (Hiroaki et al., 2006); however, other work 
has not confirmed the idea (Zhang and Verkman, 2008). More studies will be required to 
determine what factors influence a putative role of AQP4 in tumour cell adhesion. AQP4 can 
be phosphorylated by protein kinase C (PKC) at Ser-180. Phosphorylation level is inversely 
proportional to water permeability. Mutation of Ser-180 to alanine increased AQP4 water 
permeability by approximately twofold (McCoy et al., 2010). In AQP4-transfected glioma 
D54MG cells, both AQP4 water permeability and tumour cell migration were decreased 
when PKC was activated by phorbol ester treatment. It is postulated that cells with sup-
pressed AQP4 activity have a compromised ability to adjust cell shape during migration 
(McCoy et al., 2010). In contrast, when D54MG cells were transfected with AQP1, neither 
of the properties of water channel activity or cell migration were affected by PKC modula-
tors (McCoy et al., 2010).
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AQP5 expression is increased in pancreatic, colon cancers and myelogenous leukemia 
cells (Machida et al., 2011; Woo et al., 2008). Proliferation of human ovarian cancer cells has 
also been correlated with AQP5 expression levels (Chae et al., 2008a). The involvement of 
AQP5 in cancer invasion has been demonstrated to depend on phosphorylation of Ser-156 
located in the loop D domain through a cellular sarcoma kinase (c-Src) signalling path-
way (Chae et al., 2008b). Deletion of AQP5 but not AQP1 nor AQP3 was correlated with 
decreased activation of the epithelial growth factor receptor signal cascade (EGFR/ERK/
MAPK) which regulated cancer cell migration and proliferation (Zhang et al., 2010). Results 
from many studies now show that AQP3 and AQP5 contribute to processes of tumour pro-
liferation, but the link from AQP function to the regulation of growth remains to be defined.
As depicted in Figure 14.1, AQP expression can be polarized in the lamellipodia of migrat-
ing cells, together with transporters such as the Na+/H+, the Cl−/HCO3− exchanger or the Na+–
K+–Cl− co-transporter. Localized ion fluxes are proposed to create a driving force for osmotic 
water fluxes, in parallel with the osmotic effects of actin polymerization and depolymerization, 
that could drive the membrane protrusions. This concept has been presented as an ‘osmotic 
engine model’ (Stroka et al., 2014) based on studies of AQP5 and Na+/H+ exchangers polarized 
to the leading edges in mouse S180 sarcoma cells migrating in a confined environment.
14.4.3 Targeting AQP1 Channels in Cell Migration and Metastasis
Tumour cell migration enables metastasis and tissue invasion and is a major cause of death 
in patients with cancer (Bogenrieder and Herlyn, 2003). A review of literature shows that 
AQP1 expression is upregulated in a subset of aggressive cancers, whereas AQP1 deletion or 
downregulation impedes migration of AQP1-expressing cancer cells in vitro and reduces 
metastasis in vivo (Deb et al., 2012; Verkman et al., 2008; Yool et al., 2009). Wound-healing 
and transwell migration assays have demonstrated impaired migration of tumour cells 
lacking AQP1 as compared to wild type (Jiang, 2009; Jiang et al., 2009; Jiang and Jiang, 
2010; Li et  al., 2006). Cell migration rate in AQP1 knockdown cells can be rescued by 
adenovirus-mediated AQP1 expression. Similarly, transfection of AQP1 into tumour cells 
that lack endogenous AQP1 show accelerated cell migration rate in vitro as compared to 
control cells (Hu and Verkman, 2006; McCoy and Sontheimer, 2007).
Manipulation of tumour cell migration rate via AQP1 expression levels has been 











FIGURE 14.1 Schematic diagram of the colocalization of AQP channels with ion transporters, 
other channels and exchangers at the leading edge of a lamellipodium in a migrating cell.
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extravasation, quantified by the numbers of fluorescently tagged tumour cells which infil-
trated mouse lung tissue after injection into tail vein (Hu and Verkman, 2006). In a mouse 
model that spontaneously developed well-differentiated, luminal-type breast adenomas 
with lung metastases, genetic deletion of AQP1 correlated with reductions in lung metasta-
ses, tumour mass and tumour volume with abnormal microvascular anatomy and reduced 
vessel density as compared to wild-type mice (Esteva-Font et al., 2014). AQP1 expression 
facilitated endothelial cell migration and augmented tumour growth in vivo by the facili-
tation of angiogenesis (El Hindy et  al., 2013; Nicchia et  al., 2013). Impaired melanoma 
growth was observed in AQP1 null mice after subcutaneous tumour cell implantation and 
attributed to reduced aortic endothelial cell migration (Saadoun et al., 2005).
AQP1 is an attractive therapeutic target for controlling tumour growth and migration. 
Pharmacological modulation of AQP1 could be a pivotal adjunct to existing cancer ther-
apies, improving the prognosis for cancer patients by slowing cancer angiogenesis and 
metastases.
14.5  NEW AVENUES FOR AQUAPORIN DRUG DISCOVERY 
FROM TRADITIONAL AND ALTERNATIVE MEDICINES
Complementary and alternative medicine practices provide an intriguing starting point 
in searches for novel pharmacological modulators for AQP channels, drawing on cultural 
insights of native botanical agents from Asian, indigenous Australian, American, Indian 
and other sources of cultural knowledge. Given the importance of AQPs in human health 
and disease, AQP modulatory agents have a compelling potential to benefit research and 
health care globally. Scientific evidence is needed to understand the molecular mechanisms 
that underlay therapeutic actions of alternative medicines which have been used around 
the world from ancient times to treat fluid imbalance disorders and diseases (de Morais 
Lima et al., 2011; Karou et al., 2011; Kong et al., 2015; Nie et al., 2013). Possible agents for 
AQP channels might be present in native botanical agents used for treating conditions 
such as kidney and gastrointestinal disorders, swelling, brain edema and inflammation, 
which in theory could be benefiting from altered AQP channel activity in mitigating the 
dysfunctions.
Botanical compounds over many centuries have been an important source of useful 
drugs. As reviewed by Wachtel-Galor and Benzie (2011; CRC Press Herbal Medicines: 
Biomolecular and Clinical Aspects), about 25% of the drugs prescribed worldwide are 
derived from plants, including morphine derived from poppy seeds (Papaver somniferum), 
digoxin from foxglove (Digitalis lanata), aspirin from willow bark, antimalarials such as 
quinine from cinchona bark (Cinchona officinalis) and artemisinin derived from Artemisia 
annua. The potential value for translation into a novel pharmacology for AQP channels is 
immense. Expanding the pharmacological portfolio for AQPs will not only benefit basic 
research but could also prompt strategies for therapeutic interventions in cancers, lung 
and cardiac edema, secretory and digestive dysfunctions, and other conditions involving 
tissues in which AQPs are expressed.
Two principal groups of phytochemicals of interest appear to be emerging from the 
data available thus far: (1) polysaccharides (glucans) extracted from aqueous fractions and 
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(2) triterpenes (polyporusterones) extracted from organic fractions of medicinal plants. 
A meta-analysis of published data on extracts and isolated compounds from an edible 
mushroom Polyporus umbellatus shows it acts as a diuretic, anti-cancer, immunostimulant 
and hepatoprotective agent (Zhao, 2013). An aqueous fraction of the Chinese medicinal 
fungus Fu Ling Poria cocos contains multiple saccharides and has been reported to attenu-
ate renal AQP2 expression at the transcription and translational levels (Lee et al., 2012b). 
Extracts of Fu Ling also act as a diuretic and suppress the growth and invasiveness of 
various tumour cell lines (Cheng et al., 2013; Ling et al., 2011; Zhao et al., 2012). Similar to 
P. umbellatus, various triterpenes have been extracted and identified from P. cocos (Rios, 
2011). In a study of papilloma carcinogenesis, poricoic acid C was demonstrated to decrease 
the incidence to 27% as compared with 100% in the control group (Akihisa et al., 2007). 
A bioactive compound (ginsenoside Rg3) found in the ginseng root extract was shown 
to attenuate cell migration via inhibition of AQP1 expression in PC-3M prostate cancer 
cells in vitro and demonstrated the potential usefulness of pharmacological modulation of 
AQP1 in manipulating tumour cell migration (Pan et al., 2012).
Diverse classes of channels and transporters are modulated by curcumin (isolated from 
turmeric in the ginger family), including voltage-gated K+ and Ca2+ channels, the volume-
regulated anion channel (VRAC), the Ca2+ release-activated Ca2+ channel (CRAC), AQP4 
channels, glucose transporters and others (Zhang et al., 2014). As compared with vehicle-
injected rats, a lower level of AQP4 expression was observed in rats injected with 40 mg/kg 
curcumin. In the same experiment, a neuroprotective effect of curcumin was demonstrated 
in a rat model of hypoxic ischemic brain damage (Yu et al., 2012).
Bacopa (Bacopa monnieri), a water hyssop also known as Brahmi in traditional Indian 
medicine, has been used in complementary medicine remedies for centuries to improve 
memory and treat anxiety and depression (Russo and Borrelli, 2005). The main active 
components are triterpenes (bacosides, bacopasides and bacosaponins) (Russo and 
Borrelli, 2005). Some of the beneficial effects of bacopa could potentially involve AQP 
channels; however, the diverse group of candidate targets of action remains to be inves-
tigated. Tumour size decreased when mice with subcutaneously implanted S180 sarcoma 
cells were treated with bacopa extracts (Peng et al., 2010). Bacopa confers neuroprotective 
effects after ischemic brain injury (Liu et al., 2013; Saraf et al., 2010), which might sug-
gest testing for a possible link with AQP4, known to be a key contributor in pathological 
outcomes of brain injury (Kim et al., 2010; Lee et al., 2012a; Shin et al., 2011). Bacopa also 
has also been used for control of epilepsy (Shanmugasundaram et al., 1991), and some 
anti-epileptic drugs have been demonstrated to inhibit AQP4 water permeability (Huber 
et al., 2009).
Plant-derived polysaccharide and triterpene compounds possess diverse pharmacologi-
cal functions. A subset of them appear to have theoretical potential (based simply on the 
nature of their cellular and systemic effects in vivo) to regulate AQP levels of expression or 
function directly or indirectly. A sample of interesting phytochemical candidates and their 
structures is listed in Table 14.2. While still speculative at this point, the concept is worth 
further investigation. More research is needed focusing on phytochemicals as sources of 
candidate pharmacological agents for AQPs. Intriguing connections between botanical 
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TABLE 14.2 Phytochemicals Derived from Medicinal Plants Traditionally Used for Treating 
Potentially Aquaporin-Related Diseases
Plant Source Compound Structure
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medicinal agents and AQPs remain to be investigated but could be a valuable source of new 
lead compounds for broadening the field of AQP pharmacology and better understanding 
the molecular mechanisms of action of alternative medicinal agents.
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ABSTRACT
Aquaporins (AQPs) in the major intrinsic family of proteins
mediate fluxes of water and other small solutes across cell
membranes. AQP1 is a water channel, and under permissive
conditions, a nonselective cation channel gated by cGMP. In
addition to mediating fluid transport, AQP1 expression facilitates
rapid cell migration in cell types including colon cancers and
glioblastoma. Work here defines new pharmacological deriva-
tives of bumetanide that selectively inhibit the ion channel, but
not the water channel, activity of AQP1. Human AQP1 was
analyzed in the Xenopus laevis oocyte expression system by
two-electrode voltage clamp and optical osmotic swelling
assays. The aquaporin ligand bumetanide derivative AqB011
was the most potent blocker of the AQP1 ion conductance (IC50
of 14 mM), with no effect on water channel activity (at up to
200 mM). The order of potency for inhibition of the ionic
conductance was AqB011 . AqB007 .. AqB006 $ AqB001.
Migration of human colon cancer (HT29) cells was assessed with
a wound-closure assay in the presence of a mitotic inhibitor.
AqB011 and AqB007 significantly reduced migration rates of
AQP1-positive HT29 cells without affecting viability. The order of
potency for AQP1 ion channel block matched the order for
inhibition of cell migration, as well as in silico modeling of the
predicted order of energetically favored binding. Docking models
suggest that AqB011 and AqB007 interact with the intracellular
loop D domain, a region involved in AQP channel gating. Inhibition
of AQP1 ionic conductance could be a useful adjunct therapeutic
approach for reducing metastasis in cancers that upregulate
AQP1 expression.
Introduction
Osmotic water transport across biologic membranes is
facilitated by membrane proteins known as aquaporins
(AQPs), which are found in all kingdoms of life (Reizer et al.,
1993; Park and Saier, 1996; Campbell et al., 2008). To date, at
least 15 mammalian subfamilies have been identified: AQP0–
AQP14 (Ishibashi, 2009; Finn et al., 2014). Aquaporin is
organized as a tetramer of subunits, each comprising six
transmembrane domains and five loops (A–E) and carrying a
monomeric pore that allows the movement of water or other
small solutes (Jung et al., 1994; Fu et al., 2000; Sui et al.,
2001).
There is increasing recognition that certain classes of
aggressive cancers depend on upregulation of AQP1 for fast
migration andmetastasis (Monzani et al., 2007). Although the
precise mechanism for AQP1-enhanced motility remains un-
known, both ion and water channels are essential in the
cellular migration process (Schwab et al., 2007). AQP1
expression has been linked to metastasis and invasiveness of
colon cancer cells (Jiang, 2009; Yoshida et al., 2013). In
mammary and melanoma cancer cells, AQP1 facilitates tu-
mor cell migration in vitro and metastasis in vivo (Hu and
Verkman, 2006). Increased levels of AQP1 expression in astro-
cytoma correlate with the clinical grade, serving as a diagnostic
indicator of poor prognoses (El Hindy et al., 2013). AQP1-
facilitated cell migration in glioma cannot be substituted by
AQP4, indicating more than a simple water channel function is
involved in the migration-enhancing mechanism (McCoy and
Sontheimer, 2007).
A subset of aquaporins have been shown to have ion channel
function, including AQP0, AQP1, AQP6, plant nodulin, and
Drosophila big brain (Yool and Campbell, 2012). In AQP1,
multiple lines of evidence have shown the cGMP-dependent
monovalent cation channel is located in the central pore at the
4-fold axis of symmetry and is pharmacologically distinct from
the monomeric water pores (Anthony et al., 2000; Saparov
et al., 2001; Boassa and Yool, 2003; Yu et al., 2006; Zhang
et al., 2007). The AQP1 ion channel has a unitary conductance
of 150 picosiemens in physiologic saline, slow activation and
deactivation kinetics, and is permeable to Na1, K1, and Cs1,
but not divalent cations (Yool et al., 1996; Anthony et al.,
2000). Loop D has been shown previously to be involved in
cGMP-dependent gating of AQP1 ion channels (Yu et al.,
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2006). The low proportion of AQP1 water channels that are
available to be gated as ion channels in reconstituted bilayers
and heterologous expression systems has prompted uncer-
tainty regarding the physiologic relevance of the dual water
and ion channel function in AQP1 (Saparov et al., 2001;
Tsunoda et al., 2004). Further work has indicated that the
availability of AQP1 ion channels to be activated by cGMP
depends in part on tyrosine phosphorylation at the carboxyl
terminal domain (Campbell et al., 2012).
Our characterization here of selective nontoxic pharmaco-
logical blockers of the AQP1 ion channel opens the first
opportunity to define the functional roles of the AQP1 ion
conductance. Prior to 2009, available AQP1 blockers were
limited by low potency, lack of specificity, or toxicity. Mercury
potently blocks AQP1 water permeability by covalent modifi-
cation of a cysteine residue in loop E (Preston et al., 1993), but
is highly toxic. The tetrethylammonium ion blocks the AQP1
water pore, although not in all cell types (Brooks et al., 2000;
Detmers et al., 2006; Sogaard and Zeuthen, 2008), and the
cadmium ion blocks the AQP1 ion channel (Boassa et al.,
2006), but both lack selectivity for aquaporins. Effective
compounds discovered recently include the arylsulfonamides
AqB013, which blocks AQP1 and AQP4 water channel per-
meability (Migliati et al., 2009), and AqF026, which strongly
potentiates AQP1 water channel activity (Yool et al., 2013).
Other arylsulfonamides have been proposed as blockers of
AQP4 channels (Huber et al., 2009). A distinct class of agents
acting on the external side of the membrane to block human
AQP1 water flux has been identified as a source of candidate
lead compounds for drug development (Seeliger et al., 2013).
Work here characterizes a novel set of aquaporin ligand
bumetanide derivative (AqB) compounds that differentially
block the AQP1 ion channel without affecting water perme-
ability. The most potent of these, AqB011, is a promising tool
for dissecting the role of the AQP1 ion channel while sparing
osmotic water permeability. Understanding the functional
roles and regulation of AQP1 is essential for determining the
full range of physiologic roles it might serve and its possible
value as a therapeutic target in cancer metastasis.
Materials and Methods
Oocyte Preparation and Injection. The use of animals in this
study has been carried out in accordance with the Guide for the Care
and Use of Laboratory Animals, licensed under the South Australian
AnimalWelfareAct 1985, with protocols approved by theUniversity of
Adelaide Animal Ethics Committee. Unfertilized oocytes were har-
vested from anesthetized Xenopus laevis frogs and defoliculated by
incubation in type 1A collagenase (2 mg/ml) with a trypsin inhibitor
(0.3 mg/ml) in OR-2 saline (82 mM NaCl, 2.5 mM KCl, 1 mM MgCl2,
and 5 mM HEPES; pH 7.3) at 16–18°C for 2 to 3 hours. Human
aquaporin-1 cDNA was provided by Professor P. Agre (Preston et al.,
1992; GenBank accession number NM_198098). AQP1 subcloned into
a X. laevis b-globin plasmid was linearized with BamHI and tran-
scribed in vitro (T3 mMessage mMachine; Ambion Inc., Austin, TX),
and cRNA was resuspended in sterile water. Prepared oocytes were
injected with 50 nl of water (non–AQP1-expressing control oocytes)
or 50 nl of water containing 1 ng of AQP1 cRNA and incubated for 2 or
more days at 16°C in ND96 saline (96 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2, and 5 mM HEPES, pH 7.3) to allow protein
expression. Successful expression was confirmed by osmotic swelling
assays. Batches of AQP1-expressing oocytes that lacked robust
cGMP-activated conductance responses were further incubated
overnight in ND96 saline with the tyrosine phosphatase inhibitor
bisperoxovanadium (100 mM; Santa Cruz Biotechnology, Dallas, TX)
per published methods (Campbell et al., 2012). Chemicals were
purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise
specified.
AqB Compounds: Synthesis and Preparation. The AqB com-
pounds (custom-designed bumetanide derivatives) were synthesized
by Dr. G. Flynn (Spacefill Enterprises LLC, Oro Valley, AZ) as
described in U.S. patent 8,835,491-B2. To make AqB001, bumetanide
was mixed with diazomethane (CH2N2) generated by reaction with
Diazald to create bumetanide methyl ester [molecular weight (MW)
344.8; ClogP 2.10], which was dissolved in hot CHCl3, diluted with
hexanes and allowed to cool to provide the purified methyl ester as
white flakes, whose mass and NMR spectra were consistent with the
desired product. Reaction of bumetanide with 1.2 equivalents of 1,19-
carbonyldiimidazole in ethyl acetate (EtOAC) under argon with
heating afforded an intermediate imidazolide, which upon cooling,
formed a white solid that could be isolated by filtration and stored
under argon for later use. Alternatively, the imidazolide solution could
be reacted in situ with two equivalents of an amine to form the
corresponding amides. In a typical reaction, the reaction mixture
would be partitioned between water and EtOAC, the organic layer
would be washed with brine, the solution would be filtered and
concentrated, and the residue would be crystallized to form EtOAc/
hexanes. AqB-006 (MW 413.9; ClogP 1.04) was prepared using
morpholine as the amine; AqB007 (MW 470.0; ClogP 0.79) resulted
from2-(4-methylpiperazine-1-yl) ethylamine; andAqB011 (MW434.9;
ClogP 1.80) was prepared using 2-(morpholine-1-yl)ethylamine. The
structures of all the compounds were confirmed by high-resolution
mass spectrometry and NMR analysis. Chemicals were purchased
from Sigma-Aldrich unless otherwise specified.
Powdered compounds were dissolved in dimethylsulfoxide (DMSO)
to create 1000! stock solutions for each desired final dosage. An equal
dilution of DMSO (0.1%) alone in saline was used as the vehicle
control.
Quantitative Swelling Assay. For double-swelling assays, each
oocyte served as its own control. Swelling rates were assayed first
without drug treatment (S1), and then oocytes incubated for 2 hours in
isotonic saline with or without the AqB compounds were reassessed in
a second swelling assay (S2). Swelling rates in 50% hypotonic saline
(isotonic Na saline diluted with an equal volume of water) were
quantified by relative increases in the oocyte cross-sectional area
imaged by videomicroscopy (charge-coupled device camera; Cohu, San
Diego, CA) at 0.5 frames per second for 30 seconds using National
Institutes of Health ImageJ software (Bethesda, MD). Rates were
measured as the slopes of the linear regression fits of relative
volume as a function of time using Prism (GraphPad Software Inc.,
San Diego, CA).
Electrophysiology. For the two-electrode voltage clamp, capil-
lary glass electrodes (1–3 MV) were filled with 1 M KCl. Recordings
were done in standard Na1 bath saline containing 100 mM NaCl,
2 mM KCl, 4.5 mM MgCl2, and 5 mM HEPES, pH 7.3. cGMP was
applied extracellularly at a final concentration of 10–20 mM using the
membrane-permeable cGMP analog (Rp)-8-(para-chlorophenylthio)-
cGMP. Ionic conductance was monitored for at least 20 minutes after
cGMP addition to allow development of maximal plateau responses.
Conductance was determined by voltage step protocols from 160 to
2110 mV from a holding potential of240 mV. Recordings were made
with a GeneClamp amplifier and pClamp 9.0 software (Molecular
Devices, Sunnyvale, CA).
Circular Wound Closure Assay. The cancer cell lines used in
this study were HT29 human colorectal adenocarcinoma cells (Chen
et al., 1987) purchased from American Type Culture Collection (HTB-
38; Manassas, VA), which strongly express endogenous AQP1, and
SW480 human colorectal adenocarcinoma cells (CCL-228; from
American Type Culture Collection), which express AQP5 but show
little AQP1 expression. mRNA levels were evaluated by quantita-
tive polymerase chain reaction and protein levels by western blot
(H. Dorward et al., submitted manuscript). Confluent cultures of
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HT29 and SW480 cells were used in migration assays to measure
the effects of AqB treatments on rates of wound closure. Cells were
plated in flat-bottom 96-well plates at 1.25 ! 105 cells/well in
Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum
and incubated at 37°C and 5% CO2 for 12–18 hours to allow
monolayer formation. Circular wounds were created by aspirating
a central circle of cells with a p10 pipette. Wells were washed 2 to 3
times with phosphate-buffered saline to remove cell debris. Cul-
ture media (Dulbecco’s modified Eagle’s medium with 2% bovine
calf serum) containing either vehicle or drug treatments in the
presence of a mitotic inhibitor 5-fluoro-29-deoxyuridine (100 ng/ml)
were administered into the wells. Cultures were imaged at 0 and
24 hours and analyzed using ImageJ software to calculate the
percent wound closure by the change in area:
½ðArea0 2Area24Þ=Area0% ! 100
Cytotoxicity Assay. Cell viability was quantified using the
alamarBlue cell viability assay (Molecular Probes, Eugene, OR). Cells
were plated at 104 cells/well in 96-well plates, and fluorescence signal
levels were measured with a FLUOstar Optima microplate reader
(BMG Labtech, Victoria, Australia) after 24-hour incubation, with
concentrations of AqB011 ranging from 1 to 80 mM, to obtain
quantitative measures of cell viability. Mercuric chloride (20 mM) was
used as a positive control for cytotoxicity.
Molecular Modeling. In silico modeling was conducted with
methods reported previously (Yool et al., 2013). The crystal structure
of human AQP1 was obtained from the Protein Data Bank (PDB)
(identity 1FQY). The tetrameric model (Supplemental Material) was
generated in Pymol (Version 1.7.4; Schrödinger, LLC; Mannheim,
Germany) using coordinates provided in the pdb file. Renderings of
the AqB ligands were generated in Chemdraw (Version 13.0;
PerkinElmer, MA) and then converted into the pdb format using the
online SMILES translation tool (National Cancer Institute, U.S.
Department Health and Human Services, Washington, DC). Both
AQP1 and ligand coordinates were prepared for docking using
MGLtools (Version 1.5.4; Scripps Institute, San Diego, CA). The
docking was carried using Autodock Vina (Trott and Olson, 2010),
with a docking grid covering the intracellular face of tetrameric pore.
Data Compilation and Statistics. The results compiled from
replicate experiments are presented as box plots. The boxes represent
50% of the data, the error bars indicate the full range, and the
horizontal bars are the median values. The n values are in italics
above the x-axis. Statistical differences were analyzed with one-way
analysis of variance and post hoc Bonferroni tests and reported as
**P , 0.0001, *P , 0.05, and N.S. (P . 0.05).
Results
AQP1 Ion Channel Inhibition by Novel Bumetanide
Derivatives. A set of four related compounds with structural
modifications at the carboxylic acid moiety of bumetanide was
tested for effects on the cGMP-activated ionic conductance in
AQP1-expressing oocytes. Two-electrode voltage clamp re-
cordings of AQP1-expressing oocytes (Fig. 1) illustrate the
inhibition of the ionic conductance by extracellular application
of AqB007 (200 mM) and AqB011 (20 mM), but no appreciable
block of the AQP1 ion channel with 200 mM AqB001 or
AqB006. Initial recordings before cGMP application and
responses to the first application of cGMP recordings showed
typical cGMP-dependent activation, as described previously
(Anthony et al., 2000). Oocytes were then transferred into
salinewith the indicated agents for 2 hours, duringwhich time
the ionic conductances uniformly recovered to initial levels
(Fig. 2). In response to the second application of cGMP, oocytes
treated with vehicle (DMSO), AqB001, or AqB006 showed
increases in conductance that were comparable to the first
response. However, the cGMP-activated conductance
responses were inhibited after treatment with AqB007
or AqB011.
Trend plots (Fig. 2A) show that the ionic conductance in
AQP1-expressing oocytes was initially low and activated by
the first bath application of membrane-permeable cGMP. The
ionic conductance then recovered to the basal level during
2-hour incubation without cGMP and was tested for reactiva-
tion bya secondapplication of cGMPafter treatmentwith vehicle
or AqB compounds. Recordings for oocytes incubated in saline
without DMSO during the recovery period were comparable to
Fig. 1. Chemical structures of selected bumetanide
derivatives and electrophysiology traces showing
representative effects of AqB001, AqB006, AqB007,
and AqB011 on the ionic conductance responses
activated by bath application of CPT-cGMP before
and after 2-hour incubation in saline with and
without the AqB compounds. See Materials and
Methods for details.
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those for the DMSO-treated group (not shown). Non–AQP1-
expressing control oocytes showed no ionic conductance re-
sponse to cGMP and no effect of the vehicle or drug treatments
(Fig. 2B).
Compiled data for the cGMP-activated ionic conductance
values in AQP1-expressing oocytes are shown in the box plot
(Fig. 3A) and indicate the levels of block by 200 mM AqB007
and 20 mM AqB011 were statistically significant as compared
with initial responses to cGMP prior to treatment. Dose-
response relationships (Fig. 3B) yielded estimated IC50 values
of 14 mM for AqB011 and 170 mM for AqB007.
AqB Ion Channel Blockers Have No Effect on
Osmotic Water Permeability. Data for oocyte volumes
that were standardized as a percentage of the initial volume
at time zero illustrate the mean swelling responses over 60
seconds after introduction of the oocytes into 50% hypotonic
saline (Fig. 4A). AQP1-expressing oocytes showed consistent
osmotic swelling, which was unaffected by treatment with
vehicle (DMSO 0.1%) or AqB compounds at 200 mM each.
Non–AQP1-expressing control oocytes showed little osmotic
water permeability.
To analyze the possible effects of theAqB compounds onwater
channel activity, a double-swelling assay was used (Fig. 4B).
Fig. 2. Trend plots showing the ionic conductance responses for individual
oocytesmeasuredprior to cGMP(initial), after the first cGMPapplication, after
2-hour incubation in saline without cGMP containing DMSO (vehicle) or AqB
agents, and after the second application of cGMP.Reversible cGMP-dependent
activation of an ionic conductance inAQP1-expressing oocytes (A)was not seen
in non-AQP1 control oocytes (B). Inhibition was seen after treatment with
AqB007 and AqB011, but not with vehicle, AqB001, or AqB006.
Fig. 3. Dose-dependent block of theAQP1 ionic conductance. (A) Compiled
box plot data showing a statistically significant block of the cGMP-
activated ionic conductance in AQP1-expressing oocytes by AqB007 and
AqB011, but not with vehicle, AqB001, or AqB006. See Materials and
Methods for details. (B) Dose-response curves showing percent block of the
activated ionic conductance in AQP1-expressing oocytes and estimated
IC50 values. n values for dose-response data (in order of increasing
concentration) for AqB007 and AqB011 were 8, 4, 2, 8 and 8, 2, 2, 3, 6, 4, 3,
respectively.
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After the first swelling (S1) in hypotonic saline, oocytes were
incubated in isotonic saline with or without the AqB com-
pounds (200 mM) for 2 hours before assessing the second
swelling response (S2). There were no significant differences
between the first and second swelling rates in any of the
treatment groups, confirming that the AqB ion channel agents
did not affect AQP1 osmotic water permeability.
Molecular Modeling of Candidate Intracellular
Binding Sites. Putative binding sites on the AQP1 ion pore
for AqB011 and AqB007 in the intracellular loop D domain
can be suggested based on structural modeling and docking
analyses (Fig. 5). In silico modeling suggested the sites for
the most favorable energies of interaction for AqB007 and
AqB011 were located at the intracellular face of the central
pore (Fig. 5A). Interestingly, the model predicted hydrogen
bonding between the uniquely elongated moieties of the
two effective AqB ligands and the initial pairs of arginine
residues in the highly conserved loop D motifs from two
adjacent subunits (Fig. 5B). The same arginines (R159 and
R160 in human AQP1) have been shown to be involved in
AQP1 ion channel gating, but not water channel activity, in
prior work (Yu et al., 2006). The more compact AqB006
docked weakly at a different position in the central vestibule
(not shown). Although in silico modeling does not define
actual binding sites, it provides a testable hypothesis for
future work and offers intriguing support for the role of loop
D in modulating AQP1 ion channel gating. The most
Fig. 4. Lack of effect of AqB compounds on AQP1 osmotic water
permeability measured by optical swelling assays. (A) Mean oocyte
volume, standardized as a percentage of the initial volume for each oocyte,
as a function of time after introduction into 50% hypotonic saline, with and
without 2-hour pretreatment with AqB compounds at 200 mM or vehicle
(0.1% DMSO). (B) Compiled box plot data showing the absence of any
statistically significant differences between the first and second swelling
rates measured before (S1) and after (S2) 2-hour incubations in saline
alone or saline with 200 mM AqB compounds as indicated. See Materials
and Methods for details.
Fig. 5. In silico modeling of the energetically favored binding site for
AqB011 in the center of the tetrameric channel of AQP1 (gray) at the
intracellular side and bracketed by the gating loop D domains (green). The
putative binding site suggests an interaction with two of the loop D
domains from adjacent subunits. (A) is the full view of the tetramer, and
(B) is a closer view slightly rotated to show proximity of the ligand to the
conserved arginine residues in loop D.
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favorable energy of interaction was calculated for AqB011 (at
29.2 kcal/mol). The next most favorable energy of interaction
for AqB compounds with the AQP1 channel was for AqB007
(at 27.0 kcal/mol), followed by AqB006 (at 26.0 kcal/mol).
This order of interaction strength for the AqB series matched
their order of efficacy for inhibition of the AQP1 ion channel
conductance (Fig. 3).
Inhibition of AQP1 Ion Channel Activity Slows
Cancer Cell Migration. The effects of AqB006, AqB007,
and AqB011 were tested in migration assays of human HT29
colon cancer cells (Fig. 6), which natively express AQP1. Net
migration rates were calculated from the percent closure of a
circular wound area at 24 hours (Fig. 6A). The results showed
that cancer cell migration was not impaired by AqB006, but
was significantly impaired by AqB007 at 100 mM and AqB011
at 50 and 100 mM, as compared with vehicle-treated control
HT29 cells (Fig. 6B). AqB011 was more effective than AqB007
in blocking migration, which is consistent with the relative
efficacies of the agents as blockers of the ion channel
conductance. In contrast, AqB011 at 100 mM had no effect on
themigration rate of SW480 colon cancer cells (Fig. 6B), which
express AQP5, but not AQP1, suggesting that the inhibitory
effect of AqB011 appears to be selective for AQP1.
AqB Compounds Show Low Cytotoxicity. There was
no significant difference in the viability of vehicle-treated and
untreated cells and no effect of treatment with AqB011 for
HT29 cells (Table 1). Cell viability was assessed with
alamarBlue assays. The persistence of the fluorescent signal
at 24 hours confirmed there was no appreciable cytotoxic effect
of AqB011 treatment on HT29 cells at concentrations of up to
80mM.Mercuric chloride as a positive control caused significant
cell death, which was measured as a decrease in fluorescence.
AqB011 at doses used to block the AQP1 ionic conductance and
cancer cell migration did not impact cell viability.
Discussion
The aim of this study was to search for selective small-
molecule pharmacological agents that are capable of blocking
the cGMP-activated cationic conductance in AQP1. Discovery
of pharmacological modulators for AQP1 channels has been an
important goal in the aquaporin field. AQP1 antagonist and
agonist agents are expected to be useful for defining the
complex roles of aquaporins in fundamental biologic processes
as well as characterizing AQP1 modulators as potential
clinical agents in various conditions, such as cancer metasta-
sis (Yool et al., 2010). AQP1 expression is upregulated in
subtypes of aggressive cancer cells, in which it facilitates
cancer migration. The results here show that selective
blockers of the AQP1 ion channel slow themigration of human
colon cancer cells in culture. Pharmacological inhibition of
AQP1 is predicted to have a protective effect in reducing
metastasis in cancer, but remains to be demonstrated in vivo.
Using bumetanide as a starting scaffold, we created an
array of novel synthetic derivatives. Based on pilot data
indicating a small inhibitory effect of AqB050 on the AQP1
ion channel at high doses (unpublished data), we investigated
a series of structurally related derivatives, AqB006, AqB007,
and AqB011, as well as a simple methylated version of
bumetanide, AqB001, to test for possible inhibitors of the
AQP1 ionic conductance. Our findings demonstrated that
AqB007 and AqB011 are effective inhibitors of the central
ion pore of AQP1, with estimated IC50 values of 170 and
14 mM, respectively. Both AqB007 and AqB011 showed dose-
dependent inhibition of the central ion pore, whereas the
intrasubunit water pores were unaffected, enabling the first
dissection of physiologic roles of the distinct channel functions.
Measuring fluorescence signal intensity with the alamarBlue
Fig. 6. Block of cell migration in AQP1-expressing
HT29, but not SW480, cells treated with AqB011. (A)
Illustrative diagram of the circular wound healing
method showing substantial closure of the wounded
area in normal culture medium by 24 hours. (B)
Compiled box plot data from wound closure assays
showing the dose-dependent inhibitory effects of
AqB007 and AqB011 compared with DMSO and
AqB006 on wound closure at 24 hours in HT29 cell
cultures. Migration of SW480 cells was not altered by
AqB011.
TABLE 1
HT29 cell levels of cytotoxicity after 24-hour incubation in culture
medium with vehicle, AqB011, or HgCl2




0 (untreated) 100.0 6 0.70 8 —
0 (0.1% DMSO) 103.9 6 0.91 8 N.S.
1 104.0 6 1.06 4 N.S.
5 102.3 6 2.26 4 N.S.
10 110.6 6 2.12 4 N.S.
20 114.0 6 0.84 4 N.S.
40 111.8 6 1.33 4 N.S.
80 102.4 6 2.95 4 N.S.
HgCl2 (100 mM) 16.2 6 0.20 3 **
aPercent viability was standardized as a percentage of the untreated mean value
measured as changes in alamarBlue fluorescence signal intensity. See Materials and
Methods for details.
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cell viability assay showed that AqB011 was not cytotoxic at
doses that produced maximal ion channel inhibition.
The inhibition by AqB011 of AQP1 ionic conductance was
consistent with molecular docking studies, suggesting the
site of interaction is at the intracellular face of the central
pore. The results revealed that AqB011 is the most energet-
ically favored compound, followed by AqB007. The predicted
interaction site of AqB011 and AqB007 with AQP1 is at the
loop D domain. Differences in the structures and efficacies of
AqB006, AqB007, and AqB011 indicate that the structure-
activity relationship of ion channel inhibition is sensitive to
specific chemical modifications at the carboxylic acid position
of bumetanide. The length and structure of the modification
appears to be critical and based on in silico modeling to be the
region that interacts with the AQP1 channel gating loop D
domain. The absence of cytotoxic effects of AqB011 at doses
sufficient to block the AQP1 ion channel activity indicates
that the inhibition of migration is not indirectly due to cell
death. The observation that AqB011 inhibited migration in
AQP1-expressing HT29 colon cancer cells, but had no effect
on the migration of AQP-5–expressing SW480 colon cancer
cells, provides support for the idea that AqB011 is selective
for AQP1. The inhibition of migration seen with AqB011 is
unlikely to result from off-target effects on general metabolic
function, cytoskeletal organization, actin polymerization, or
signaling pathways involved in cell motility since SW480 cell
migration remained unaffected by the presence of AqB011.
AQP1 is present in barrier epithelia involved in fluid
movement in the body, including the proximal tubule and
choroid plexus (Agre et al., 1993). It is also expressed in
peripheral microvasculature, dorsal root ganglion cells, eye
ciliary epithelium and trabecular meshwork, heart ventri-
cles, and other regions, in which a direct role for osmotic
water flux is less evident (Yool, 2007). Additional roles
suggested for AQP1 include angiogenesis (Nicchia et al.,
2013), signal transduction (Oshio et al., 2006), increased
mechanical compliance to changes in pressure (Baetz et al.,
2009), axonal regeneration of spinal nerves (Zhang and
Verkman, 2015), recovery from injury (Hara-Chikuma and
Verkman, 2006), and exocytosis (Arnaoutova et al., 2008).
Relative contributions of the ion and water channel func-
tions in these diverse processes remain to be defined.
A possible role for the AQP1 ionic conductance (poten-
tially in combination with water fluxes) in the control of cell
volume associated with migration was supported by the
results of the wound closure assays with AQP1-expressing
HT29 cells. Cell migration was significantly impaired by
AqB011 and AqB007, but not by AqB006. The greatest
efficacy of migration block was seen with administration of
AqB011. The comparable orders of efficacy for the block of
AQP1 ion channels in the oocyte expression system and for
the block of cell migration in HT29 cultures support the idea
that the AqB011 effect on migration is mediated by direct
block of the AQP1 ion channels. These data provide evidence
that the ion channel activity of AQP1 has physiologic
relevance. Further work is needed to evaluate the effects
of blocking both water and ion channel activities of AQP1
together in migrating cells.
AqB011 is a new research tool for probing the physiologic
role of the AQP1 ion channel function in biologic systems.
This compound holds future promise as a possible adjunct
clinical intervention in cancermetastasis. Exciting opportunities
are likely to emerge from continuing discovery of pharmaco-
logical modulators for aquaporins for new treatments in
cancers and other diseases.
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ABSTRACT
Aquaporin-1 (AQP1) is amajor intrinsic protein that facilitates flux
of water and other small solutes across cell membranes. In
addition to its function as a water channel in maintaining fluid
homeostasis, AQP1 also acts as a nonselective cation channel
gated by cGMP, a property shown previously to facilitate rapid
cell migration in a AQP1-expressing colon cancer cell line. Here
we report two new modulators of AQP1 channels, bacopaside I
and bacopaside II, isolated from the medicinal plant Bacopa
monnieri. Screening was conducted in the Xenopus oocyte
expression system, using quantitative swelling and two-
electrode voltage clamp techniques. Results showed bacopa-
side I blocked both the water (IC50 117 mM) and ion channel
activities of AQP1 but did not alter AQP4 activity, whereas
bacopaside II selectively blocked the AQP1 water channel (IC50
18mM) without impairing the ionic conductance. These results fit
with predictions from in silico molecular modeling. Both bacopa-
sides were tested in migration assays using HT29 and SW480
colon cancer cell lines, with high and low levels of AQP1
expression, respectively. Bacopaside I (IC50 48mM) and bacopa-
side II (IC50 14 mM) impaired migration of HT29 cells but had
minimal effect on SW480 cell migration. Our results are the first
to identify differential AQP1modulators isolated from amedicinal
plant. Bacopasides could serve as novel lead compounds for
pharmaceutic development of selective aquaporin modulators.
Introduction
Aquaporin (AQP) water channels are in the family of major
intrinsic proteins found from bacteria to humans (Agre et al.,
1993; Reizer et al., 1993; Calamita et al., 1995) and are targets
for the discovery of selective pharmacologicmodulators. Classes
of aquaporins transport water and small uncharged molecules
such as glycerol and urea through individual pores located in
each subunit (Fu et al., 2000; Tajkhorshid et al., 2002).
An expanding role for aquaporins as multifunctional chan-
nels is being recognized (Yool and Campbell, 2012). In
addition to facilitating water flux through intrasubunit pores,
AQP1 also functions as a nonselective monovalent cation
channel using the central pore at the 4-fold axis of symmetry
(Yool and Weinstein, 2002; Yu et al., 2006; Campbell et al.,
2012). The ion channel conductance is activated by interaction of
cGMP in the intracellular loop D domain, and modulated by the
carboxyl terminal domain (Anthony et al., 2000; Saparov et al.,
2001; Boassa and Yool, 2003; Zhang et al., 2007). Cyclic GMP
appears to trigger opening of cytoplasmic hydrophobic barriers
in the central pore, allowing hydration and cation permeation
(Yu et al., 2006). Inhibition of the AQP1 ion channel has been
shown to slow cell migration rates in a colon cancer cell line that
expresses high levels of AQP1 (Kourghi et al., 2016).
Defining pharmacologic modulators of aquaporins has been
an area of keen interest (Papadopoulos and Verkman, 2008;
Devuyst and Yool, 2010; Seeliger et al., 2013). Early work
identified blockers such as mercury (Preston et al., 1993),
silver and gold (Niemietz and Tyerman, 2002), acetazolamide
(Gao et al., 2006), and tetraethylammonium ion (Brooks et al.,
2000; Yool et al., 2002; Detmers et al., 2006), but these
remained limited in usefulness because of toxicity, lack of
specificity, or variable efficacy across experimental systems
(Yang et al., 2006; Yool, 2007).
More recently, small molecule pharmacologic agents with
therapeutic potential have been identified. Complexes of
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gold-based compounds have promise for the selective block of
specific classes of aquaporins; functionalized bipyrene and
terpyridines coordinating Au(III) were shown to block aqua-
glyceroporin AQP3 with little effect on AQP1 (Martins et al.,
2013). Intracellular arylsulfonamide modulators of AQP1
include the bumetanide derivative, AqB013, which blocks
AQP1 and AQP4 water permeability (Migliati et al., 2009);
AqB011, which blocks the AQP1 cation channel (Kourghi
et al., 2016); and the furosemide derivative AqF026, which
potentiates water channel activity of AQP1 (Yool et al., 2013).
Other arylsulfonamide agents have been proposed as blockers
of AQP4 (Huber et al., 2007, 2009). Growing evidence has
demonstrated that specific arylsulfonamides act as AQP
modulators in vitro and in vivo (Pei et al., 2016).
Diverse small molecules acting at the extracellular side
present a valuable array of novel inhibitors of AQP1 (Seeliger
et al., 2013), indicating that other compounds in addition to
coordinated metal ligands and arylsulfonamides are of in-
terest for the development of AQP modulators. Lack of effect
for a broad panel of AQPmodulators tested in one studymight
reflect problems with synthesis or solubilization of the agents
or could indicate that the type of bioassay used influences
apparent drug efficacy (Esteva-Font et al., 2016).
Our study has broadened the panel of AQP modulatory
agents by evaluating natural medicinal plants as sources of
active compounds. Quantitative swelling assays of mamma-
lian AQP1 and AQP4 channels in the Xenopus expression
system, used for screening extracts from a variety of tradi-
tional medicinal herbs, have identified Bacopa monnieri as
one of several promising sources. Work here tested the
hypothesis that chemical constituents of B. monnieri could
be identified and characterized as pharmacologic agents that
modulate mammalian AQP1 by interacting at domains asso-
ciated with pore functions.
Data here show that bacopaside I blocks both the water and
ion channel activities of AQP1 but does not alter AQP4
activity, and bacopaside II selectively blocks the AQP1 water
channel without impairing the ionic conductance. These
results fit well with in silico docking for predicted energies of
interaction at a pore-occluding intracellular site. Bacopasides
I and II showed the same order of efficacy in blocking
migration of AQP1-expressing HT29 colon cancer cells, with
minimal effects on SW480 cells that express AQP1 at low
levels. Our results are the first to identify AQP1 channels as
one of the candidate targets of action of the Ayurvedic
medicinal plant water hyssop, and to define new lead com-
pounds for the development of AQP modulators.
Materials and Methods
Bacopa Methanol Extraction and Fractionation. Bacopa
monnieri stems and leaves were obtained with permission from the
Botanic Gardens of Adelaide (Adelaide, South Australia). Chopped
Bacopa plant material (100 g) was dried, then refluxed in 500 ml of
methanol for 2 hours at room temperature. The suspension was
filtered using Whatman No. 1 paper to obtain a methanol extract of
whole Bacopa (meWB). Half the meWB extract was aliquoted into
microfuge tubes, dried under vacuum (SpeedVac; Thermo Fisher
Scientific, Waltham, MA) into a solid brown paste, and reconstituted
in saline for oocyte swelling assays. The other half of the meWB was
fractionated using small-scale reverse phase C18 silica column
(Alltech Prevail C18; Grace, Deerfield, IL). The mobile phases used
for fractionation were a series of six water–methanol mixtures with
H2O:CH3OH ratios ranging from 5:0 to 0:5. The fractions were dried in
under vacuum and reconstituted in saline for oocyte swelling assays.
Fractions containing AQP1 blocking activity were analyzed with
mass spectrometry by Flinders Analytical (Flinders University, South
Australia). Bacopaside I was identified by precise molecular weight as
a major component in the active fractions, and bacopasides I and II
were purchased from a commercial source (Chromadex, Irvine CA),
solubilized in methanol to yield 100! stock solutions, and stored at
-20°C. Experimental solutions were prepared by mixing the bacopa-
side stocks (1 part in 100) with isotonic saline or culture medium to
yield final concentrations of 10 to 200mM.Vehicle control salines were
made using the same volume of methanol alone in isotonic saline or
culture medium.
Oocyte Preparation and cRNA Injection. Unfertilized oocytes
were isolated from Xenopus laevis frogs in accord with the university
animal ethics committee-approved protocols, defolliculated by treat-
ment with collagenase (type 1A, 2 mg/ml; Sigma-Aldrich, St. Louis,
MO) and trypsin inhibitor (0.67 mg/ml; Sigma-Aldrich) in OR-2 saline
(82mMNaCl, 2.5mMKCl, 1mMMgCl2, and 5mMHEPES; pH 7.6) at
16°C for 1.5 hours, washed in OR-2 saline, and then incubated in
isotonic oocyte saline [96 mM NaCl, 2 mM KCl, 0.6 mM CaCl2, 5 mM
MgCl2, and 5 mM HEPES supplemented with 10% horse serum
(Sigma-Aldrich), 100 U/ml penicillin, 100 mg/ml streptomycin, and
50 mg/ml tetracycline, pH 7.6] at 16°C. Oocytes were injected with
1–4 ng of AQP1, AQP4, or AQP1 R159A1R160A cRNA in 50 nl of
sterile water and incubated for 2 to 3 days at 16–18°C to allow
protein expression. The oocytes not injected with cRNA served as
non-AQP-expressing control cells.
Human AQP1 [National Center for Biotechnology Information
(NCBI) GenBank: BC022486.1] and rat AQP4 (AF144082.1) cDNAs
from P. Agre (Johns Hopkins University, Baltimore, MD) were
subcloned into a modified Xenopus b-globin expression plasmid. The
double mutant construct human AQP1 R159A1R160A cDNA was
generated by site-direct mutation (QuikChange; Stratagene, La Jolla,
CA) and sequenced to confirm no errors were introduced (Yu et al.,
2006). The cDNAs were linearized with BamHI and transcribed using
T3 polymerase (T3 mMessage mMachine; Ambion, Austin, TX). The
cRNAs were resuspended in sterile water and stored at 280°C.
Quantitative Oocyte Swelling Assays. Immediately before the
swelling assays, the control and AQP-expressing oocytes were pre-
incubated in isotonic saline (serumand antibiotic free) with or without
meWB or bacopaside compounds or withmethanol vehicle at 16–18°C,
for incubation periods as indicated. Osmotic water permeability was
determined as the linear rate of change in volume as a function of time,
immediately after introduction into 50% hypotonic saline (isotonic
saline diluted with equal volume of water).
Oocytes were imaged using a computer controlled charge-coupled-
device grayscale camera (Cohu, San Diego, CA) mounted on a
dissecting microscope (Olympus SZ-PT; Olympus, Macquarie Park,
Australia). Images were taken at 0.5 frames per second for 60 seconds;
cross-sectional areas were quantified using ImageJ software (Re-
search Services Branch,National Institutes of Health, Bethesda,MD).
Swelling rates were calculated as the slopes of linear regression fits of
volume as a function of time in hypotonic saline. Data were analyzed
and compiled for multiple batches of oocytes for statistical analyses
and to generate dose–response curves, which were fit by sigmoidal
nonlinear variable-slope dose–response regression functions using
Prism (GraphPad Software, San Diego, CA).
Molecular Docking. In silico modeling was performed with
methods reported previously elsewhere (Yool et al., 2013). The protein
crystal structures for human AQP1 (PDB ID 1FQY) and human AQP4
(PDB ID 3GDB) were obtained from the protein data bank (NCBI
Structure). Bacopaside I and II structures were obtained from
PubChem (NCBI) and converted into a software-compatible 3D
structures in .pdb format using the Online SMILES Translator and
Structure File Generator (National Cancer Institute, U.S. National
Institutes of Health, Bethesda, MD). Ligand and receptor coordinates
were prepared for docking using Autodock (version 4.2; Scripps
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Research Institute, La Jolla, CA). Autodock Vina (Trott and Olson,
2010) was used to run the flexible ligand docking simulations with two
docking grids covering both intracellular and extracellular faces of the
monomeric pores. The three-dimensional docking result files and
docking energy values were exported from Autodock, and the results
were viewed using PyMOL software (version 1.8; Schrödinger,
Cambridge, MA). Data for AQP1 and AQP4 docking results in .pdb
format are provided as supplemental data files.
Electrophysiology. For two-electrode voltage clamp, capillary
glass electrodes (1–3 MV) were filled with 1 M KCl. Recordings were
done in a standard isotonic Na1 bath saline containing 100 mM NaCl,
2mMKCl, 4.5mMMgCl2, and 5mMHEPES, pH7.3.Weapplied cGMP
extracellularly at a final concentration of 10–20 mM using the
membrane-permeable cGMP analog [Rp]-8-[para-chlorophenylthio]-
cGMP (Sigma Chemical, Castle Hill, Australia). Ionic conductance
was monitored for at least 20 minutes after cGMP addition to allow
development of maximal plateau responses. Conductance was deter-
mined by linear fit of the current amplitude as a function of voltage, with
a step protocol from160 to2110mV and holding potential of 240 mV.
After the first activation by cGMP, oocytes were incubated in isotonic
saline with or without bacopaside I or bacopaside II for 2 hours to allow
recovery. After incubation, a second application of cGMP was used to
test for reactivation, to determine whether any block of the ionic
conductance was evident. Using the same protocol, AQP1-expressing
oocytes were demonstrated previously to show cGMP-dependent acti-
vation, complete recovery during a 2-hour incubation in saline alone,
and full reactivation of the ionic conductance response to a second
application of cGMP, whereas non-AQP1-expressing control oocytes
showed a low ionic conductance and no significant response to drug
treatments throughout the same protocol (Kourghi et al., 2016).
Recordings were made with a GeneClamp amplifier and pClamp 9.0
software (Molecular Devices, Sunnyvale, CA).
Cancer Cell Culture and Migration Assays. HT29 and SW480
colon cancer cell lines (from American Type Culture Collection
[ATCC], Manassas, VA) were cultured in complete medium composed
of Dulbecco’s modified Eagle’s medium supplemented with 1! gluta-
MAX (Life Technologies, Mulgrave, Australia), penicillin and strep-
tomycin (100 U/ml each), and 10% fetal bovine serum. Cultures were
maintained in 5% CO2 at 37°C. Cells were seeded in a flat-bottom
96-well plates at 1.25! 106 cells/ml to produce a confluent monolayer.
For 12 to 18 hours before wounding, cells were serum-starved in 2%
fetal bovine serum (FBS), in the presence of 400 nM of the mitotic
inhibitor 5-fluoro-2ʹ-deoxyuridine (FUDR) (Parsels et al., 2004). For
wounding, a sterile p10 pipette tipwas attached to the end of a vacuum
tube, and a circular wound was created by brief perpendicular contact
of the tip with base of the well. Each well was then washed 3 times
with phosphate-buffered saline to remove detached cell debris.
Cultures were maintained during the wound closure assay in 2%
FBS medium with FUDR.
Wound images were imaged at 10! magnification with a Canon
EOS 6D camera (Canon, Macquarie Park, Australia) mounted on an
Olympus inverted microscope (Olympus Corp., Waltham, MA). Image
dimensions and pixel density were standardized across each image
series using XnConvert software (XnSoft, Reims, France). Linear
outlines and areas of the wound were generated using ImageJ
software (National Institutes of Health). Wound closure data as a
function of time were calculated as a percentage of the initial wound
areas for the same wells.
Quantitative Reverse-Transcription Polymerase Chain Re-
action. Cells at 70%–80% confluence were harvested, and the RNA
was extracted using the PureLink RNA Mini kit (Life Technologies,
Carlsbad, CA). RNA was quantified using the NanoDrop 2000 spec-
trophotometer (Thermo Scientific) and the integrity (RIN score)
assessed using the 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA). The RNA (500 ng) was reverse transcribed using the
iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA).
Quantitative reverse-transcription polymerase chain reaction (qRT-
PCR) of AQP1 and the reference gene phosphomannose mutase
1 (PMM1) was performed using multiplex Taqman expression assays
(Life Technologies) and SsoFast probes supermix (Bio-Rad Laborato-
ries) in triplicate in the Rotorgene 6000 (Qiagen).
Western Blot Analysis. Cultured cells were lysed with RIPA
buffer containing 1% b-mercaptoethanol, 1%HALT protease inhibitor
100! solution, 150 U Benzonase (all from Sigma-Aldrich) on ice for
10 minutes, homogenized by passing through a 21-gauge syringe and
centrifuged 14,000g for 15 minutes at 4°C to pellet the cell debris.
Protein was quantified (EZQ Assay; Life Technologies). Each sample
(50 mg) was resolved by SDS-PAGE on a 12% Mini-PROTEAN TGX
Stain-Free Gels (Bio-Rad Laboratories) and transferred to polyviny-
lidene fluoride membranes using the Trans-Blot Turbo Transfer Pack
and System (Bio-Rad Laboratories). Membranes were blocked with
Tris-buffered salinewith Tween 20 containing 5% skimmilk for 1 hour
and incubated overnight at 4°C with anti-AQP1 (H-55) (1/500; Santa
Cruz). After three washes in Tris-buffered saline with Tween 20,
membranes were incubated with goat anti-rabbit IgG horseradish
peroxidase secondary antibody (1/2000) and Strep-Tactin-HRP Con-
jugate (1/10,000) (both Bio-Rad Laboratories) at room temperature for
1 hour, and washed.
Chemiluminescence using Clarity Western ECL Blotting Substrate
(Bio-Rad Laboratories) was used for detection and blots imaged using
the ChemiDoc Touch Imaging System (Bio-Rad Laboratories). Image
Laboratory Software was used to validate the Western blotting data
via total protein normalization (Bio-Rad Laboratories).
Immunocytochemistry. HT29 and SW480 cells grown on cover-
slips to 50% confluence were fixed with 4% paraformaldehyde and
permeabilized with 0.5% Triton X-100. Image-iT FX Signal Enhancer
(Life Technologies) was used as per manufacturer’s instructions.
AQP1 was labeled with a 1/400 dilution of rabbit polyclonal anti-
human AQP1 (Abcam, Cambridge, United Kingdom) and visualized
with a secondary antibody at 1/200 dilution (goat anti rabbit IgGH&L
Alexa Fluor 568; Life Technologies). Cells were counterstained with
NucBlue Fixed Cell Ready Probes Reagent (Life Technologies).
Coverslips were mounted in ProLong Gold antifade reagent (Life
Technologies) and imaged with a Zeiss LSM 700 microscope (Carl
Zeiss, Jena, Germany).
Live Cell Imaging. Cells were seeded on an eight-well uncoated
Ibidi m-Slide (Ibidi, Munich, Germany) at a density of 1.0! 106 cells/ml.
For 12 to 18 hours before wounding, cells were serum-starved in
medium with 2% FBS in the presence of FUDR (400 nM). Five
circular wounds were created in each well using techniques described
earlier for the migration assays. The slide was mounted on a Nikon Ti
E Live Cell Microscope (Nikon, Tokyo, Japan) in an enclosed chamber
kept at 37°C with 5% CO2. Images were taken at 5-minute intervals
for 24 hours, using Nikon NIS-Elements software. AVI files were
exported from NIS-Elements and converted into TIFF files using
ImageJ (U.S. National Institutes of Health). Converted files were
analyzed using Fiji software (Schindelin et al., 2012) with the Manual
Tracking plug-in.
Cytotoxicity Assay. HT29 cell viability was quantified using the
AlamarBlue assay (Molecular Probes, Eugene, OR). The cells were
plated at 104 cells/well in 96-well plates, and the fluorescence signal
levels weremeasuredwith a FLUOstarOptimamicroplate reader (BMG
Labtech, Ortenberg, Germany) after 24 hours of incubation with
concentrations of bacopaside I from 0 to 100 mM or bacopaside II from
0 to 30 mM, to obtain quantitative measures of cell viability. Mercuric
chloride (100 mM) was used as a positive control for cytotoxicity.
Results
Extracted Compounds from Bacopa monnieri
Inhibited AQP1 Water Channel Activity. Methanol-
extracted whole Bacopa (meWB) reconstituted in isotonic
saline (“water hyssop extract”) inhibited the water permeabil-
ity of AQP1-expressing oocytes (Fig. 1A). After 2 hours
preincubation in 1 mg/ml meWB, the swelling rates of
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AQP1-expressing oocytes were significantly reduced (P ,
0.001) as compared with untreated AQP1-expressing oocytes.
Fractionated samples of meWB reconstituted at 0.1 mg/ml
each were tested for biologic activity using oocyte swelling
assays (Fig. 1B) after 2 hours of preincubation. AQP1-
mediated swelling was significantly decreased by fractions
3 and 4; other fractions had no effect.
Combined fractions 3 and 4 were analyzed by mass spec-
trometry and revealed the presence of a major compound
identified by precise molecular weight as bacopaside I.
Commercially purchased bacopasides I and II were found to
block osmotic water permeability in AQP1-expressing oocytes
(Fig. 1C) and showed a dose-dependent effect (Fig. 1D). The
inhibition of AQP1-mediated osmotic water fluxes showed
IC50 values of approximately 18 mM for bacopaside II, and
approximately 117 mM for bacopaside I. The chemical struc-
tures are shown in Fig. 1E.
Inhibition by Bacopasides I and II Was Time-
Dependent and Reversible. AQP4-expressing oocytes
showed no block of water channel activity after 2 hours of
preincubation in isotonic saline containing bacopaside I at
178 mM (Fig. 2A). The blocking effect of bacopaside was
specific for AQP1. The inhibitory effect of bacopasides I and
II on AQP1 water channel activity took time to develop, with
near maximum block achieved by approximately 2 hours (Fig.
2B). The magnitude of inhibition of AQP water flux increased
as a function of the duration of preincubation in 178 mM
bacopaside I or 35 mM bacopaside II. For bacopaside I, half-
maximal block was reached after approximately 50 minutes,
and maximum block after 120 minutes of preincubation. For
bacopaside II, half-maximal block was reached after approx-
imately 30 minutes, and maximum block after 80 minutes of
preincubation. Longer times provided no appreciable further
enhancement of the magnitude of inhibition. A comparably
slow time-dependent onset of block has been noted previously
for other AQP1 ligands such as AqB013, AqB011, and AqF026,
which are thought to bind at the intracellular side of the
channel (Migliati et al., 2009; Yool et al., 2013; Kourghi et al.,
2016) and require time to travel across the plasma membrane
to the cytoplasmic side.
Fig. 1. Block of osmotic water permeability in AQP1-
expressing oocytes by water hyssop (Bacopa monnieri)
extract, and constituent compounds bacopaside I and baco-
paside II. (A) Mean swelling responses of AQP1-expressing
oocytes in 50% hypotonic saline, standardized to the initial
volume V0, were blocked by 2 hours of preincubation in
reconstituted extract of water hyssop (at 1 mg/ml). Control
non-AQP1 oocytes showed little change in volume. Data are
mean values for all oocytes assessed from a single batch of
oocytes; error bars are S.E.M.; n values are 6 per treatment
group. (B) Column elution of methanol-extracted Bacopa
identified two active fractions which caused block of AQP1
osmotic water permeability at 0.1 mg/ml each (which were
further analyzed by mass spectroscopy to identify candidate
compounds). Data are mean6 S.E.M.; n values in italics are
above the x-axis. (C) Candidate compounds bacopaside I and
bacopaside II at 50 mM differentially blocked osmotic water
permeability in AQP1-expressing oocytes, causing a de-
crease in the rate of swelling as compared with untreated
AQP1-expressing oocytes. Data aremean6 S.E.M.; n values
are 8 (AQP1 vehicle), 5 (bacopaside I), 7 (bacopaside II), and
8 (non-AQP1 control). (D) Dose-dependent block of AQP1-
mediated osmotic swelling by bacopasides I and II, with
estimated IC50 values of 117 mM and 18 mM, respectively.
No sensitivity to bacopaside I was seen for the AQP1
R159,160A double mutant at doses up to 100 mM. (E)
Chemical structures of bacopasides I and II.
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The blocking effects of bacopasides I and II on AQP1 water
channel activity were reversible (Fig. 2C). AQP1-expressing
oocytes were preincubated 2 hours with 178 mM bacopaside
I or 35 mM bacopaside II, followed by washout of the drug
with isotonic saline. The osmotic water permeability showed
approximately 25% recovery by 120minutes after the washout
of bacopaside I, and half-maximal recovery by 160 minutes.
For bacopaside II, water permeability showed 25% recovery by
150 minutes after washout of the blocker, and half-maximal
recovery by 200 minutes.
Ion Channel Conductance of AQP1 Was Inhibited by
Bacopaside I but Not by Bacopaside II. Two-electrode
voltage clamp recordings from AQP1-expressing oocytes demon-
strated the cGMP-dependent activation of the ionic conductance
(Fig. 3A) as described previously elsewhere (Anthony et al., 2000),
which was reversible by 2 hours of incubation in saline without
membrane-permeable cGMP (Kourghi et al., 2016). Reactivation
of the ionic response by a second dose of cGMPwas partly blocked
in AQP1-expressing oocytes after 2-hour incubation in 50 mM
bacopaside I, and strongly blocked at 100 mM bacopaside I (Fig.
3B). In contrast, the reactivation of the ion conductance was
unimpaired after incubation with 10 mMor 20 mMbacopaside II.
Identification of Candidate Intracellular Binding
Sites. Protein crystal structures of AQP1 and AQP4, and
three-dimensional structural renditions of bacopaside I and
bacopaside II were prepared and run on interaction simula-
tions using Autodock Vina software to identify predicted
binding sites. An array of candidate docking sites for bacopa-
sides I and II on AQP1 and AQP4 channels were considered
with in silico computational docking analyses. Of a total of
eight possible positions evaluated for bacopaside I, the
dominant energetically favored configurations for intracellu-
lar binding yielded values of 29.2 kcal/mol for AQP1 (Data
Supplement 1), and 28.0 Kcal/mol for AQP4 (Data Supple-
ment 2). Similarly out of all possible positions evaluated, the
energetically favored configurations for bacopaside II yielded
values of 29.3 kcal/mol for AQP1 (Data Supplement 3), and
27.8 kcal/mol for AQP4 (Data Supplement 4).
In the poses reflecting themost favored docking positions, the
intracellular face of the water pore was effectively occluded by
bacopasides I and II in AQP1, but not in AQP4 channels (Fig. 4,
A–D). For AQP1, the bacopasides appeared to nest well into the
internal vestibule of the intrasubunit water pore. For AQP4 the
optimal interaction was seen for bacopaside sitting in a groove
between transmembrane domains 4 and 5, a position where
subunits interface near the central pore that might not be
accessible in the assembled tetrameric channel.
Closer inspection of specific amino acid residues in the
predicted AQP1 docking site (using Chimera visualization
software) suggested that the poly-arginine motif in the loop D
domain could enable hydrogen bond formation with the
sulfonyl moiety on the glucopyranosyl sugar of bacopaside I
(Fig. 4E) at residues corresponding to R159 and R160 in
human AQP1. These arginines are part of a highly conserved
amino acid pattern seen in AQP1 channels from diverse
species, and they are required for cGMP gating of the AQP1
ionic conductance (Yu et al., 2006). The site-directed double
Fig. 2. Subtype selectivity and temporal properties of block onset and
recovery with bacopasides I and II in AQP-expressing oocytes. (A) Mean
swelling responses of AQP4-expressing oocytes in 50% hypotonic saline
were not affected after 2 hours of preincubation in 178 mM bacopaside I.
Data are mean 6 S.E.M.; n values are 8 (AQP4 alone), 8 (AQP4 with
bacopaside I), and 6 (non-AQP4 control). (B) Time-dependent establish-
ment of block of AQP1-mediated osmotic water permeability required
preincubation of oocytes in 178 mM bacopaside I or 35 mM bacopaside II,
with approximately 2 hours needed to achieve maximal inhibition. The
n values are 12 to 14 oocytes per time point; each oocyte was used for a
single measurement. (C) Time-dependent recovery from block in AQP1-
expressing oocytes preincubated 2 hours in 178 mMbacopaside I or 35 mM
bacopaside II, and assessed at different intervals after transfer back into
standard isotonic saline at time 0 (washout). The n values are 10 to
13 oocytes per time point; each oocyte was used for a single measurement.
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mutation of arginines R159 and R160 to alanines did not
prevent normal expression of AQP1-mediated osmotic water
permeability, indicating that the AQP1mutant constructs were
expressed and targeted to the oocyte plasma membrane as
described previously elsewhere (Yu et al., 2006); however, the
efficacy of bacopaside I in inhibiting osmotic water permeability
was abolished in the mutant construct at doses up to 100 mM
(Fig. 1D, supporting the suggested role of the loop D arginine
residues in stabilizing the docking of the bacopaside I ligand.
Bacopaside II Was More Effective Than Bacopaside
I in Blocking Migration of AQP1-Expressing Colon
Cancer Cells. HT29 cells have a higher endogenous level of
AQP1 expression as compared with SW480 cells, as demon-
strated by qRT-PCR (Fig. 5A), western blot (Fig. 5B), and
immunocytochemistry (Fig. 5C) analyses.
Wound closure assays showed robust migration of HT29
cells in medium with vehicle (Fig. 6A), resulting in little open
area remaining at 24 hours. In contrast, treatment with
bacopaside II (Fig. 6B) substantially reduced the amount of
wound closure. A dose-dependent block of cell migration
measured by wound closure (Fig. 6C) was observed for both
bacopaside I and bacopaside II on HT29 cells. The calculated
IC50 value for bacopaside I was approximately 48 mM and for
bacopaside II was 14 mM in HT29 cells. There was a small
Fig. 3. Block of the cGMP-dependent ionic conductance of AQP1-expressing oocytes by bacopaside I, but not bacopaside II. (A) Representative sets of
traces recorded by two-electrode voltage clamp of AQP1-expressing oocytes showing the initial conductance; the response induced by the first application
of membrane-permeable cGMP; the recovery of the response to near initial levels after 2 hours of incubation in isotonic saline containing bacopaside I
(50 or 100 mM) or bacopaside II (10 or 20 mM); and the final response to a second application of cGMP. (B) Trend plots showing the amplitude of the ionic
currents, before and after the first activation by GMP, the recovery after incubation, and the response reactivated by a second cGMP application.
Consistent recovery was seen after 10 or 20 mM bacopaside II, but not after incubation with 50 or 100 mM bacopaside I indicating establishment of ion
channel block. The n values are as shown; each line represents a series of recordings from one oocyte.
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reduction of migration observed for SW480 cells treated with
bacopasides I and II (Fig. 6C), which was consistent with the
relatively low expression of AQP1 channels in this cell line.
Time-Lapse Imaging Demonstrated Bacopasides I
and II Differentially Decreased the Rate of Migration
of AQP1-Expressing HT29 Colon Cancer Cells. Cultured
HT29 cancer cells showed differences in rates of migration
into the open wound areas in the vehicle, bacopaside I and
bacopaside II treatment conditions (Fig. 7, A–C). Time-lapse
images showed the rates of cell migration were significantly
impeded in 50 mM bacopaside I and in 15 mM bacopaside II
(Fig. 7, B and C) as compared with vehicle-treated HT29 cells
(Fig. 7A). No appreciable difference in cell viability was
observed in any of the treatment groups during the 24-hour
time course of the experiment.
In the vehicle-treated group, trajectory plots of individual
cells sampled at 50-minute intervals over 24 hours (Fig. 7D)
showed generally directional movements of HT29 cells into
the open wound spaces. In bacopaside I treatment group, the
HT29 cells lacked directional migration and moved short
distances between successive frames. In the bacopaside II
treated group, the impairment of movement was evident but
less severe. The collective trend of trajectories of the vehicle-
treated group appeared to be linear and extended, whereas
that in the bacopaside I treated group was recursive and
compressed; the bacopaside II group showed an intermediate
level of restriction of movement.
The net displacement (distance traveled) per time inter-
val was greater in the vehicle-treated group than in the
bacopasides I and II treatment groups. Frequency histograms,
summarizing all events observed, were compiled as the binned
values of distances traveled per 50-minute interval (Fig. 7E).
These histograms showed that more cells traveled longer
distances per time interval in the vehicle-treated group than
in the bacopaside-treated groups. Distributions moved were
well fit by Gaussian functions; the decreased mean distances
moved in the bacopaside treatments were seen as left shifts in
the peaks of the frequency histograms. Compiled data in a
summary histogram (Fig. 7F) confirmed the significant de-
crease in mean total distance traveled by cells during the
24 hours of tracking in bacopaside I or II as compared with
vehicle-treated cells. Analysis of cytotoxicity by AlamarBlue
assay showed that bacopaside I had no significant effect on cell
viability at 50 or 75 mM, and bacopaside II had no effect on
viability at 15 or 20 mM (Table 1). Concentrations of bacopa-
sides that significantly blocked AQP1 water channel activity
and HT29 cell migration were not appreciably cytotoxic.
Discussion
Our results have demonstrated that two structurally sim-
ilar compounds, bacopaside I and bacopaside II, derived from
a medicinal herb, act differentially as pharmacologic inhibi-
tors of mammalian aquaporin channels. In silico modeling
predicted that bacopasides I and II have favorable energies of
interaction at the intracellular vestibule of AQP1, occluding
the intrasubunit water pore. Modeling results were consistent
with the observed effects of these agents as AQP1 inhibitors.
Fig. 4. In silico docking models illustrating predic-
tions for the most favorable sites of interaction of
bacopaside I and bacopaside II on AQP1 and AQP4
subunit proteins. AQP subunit models were assem-
bled from crystal structural data for human AQP1
(PDB ID 1FQY) and human AQP4 (PDB ID 3GDB);
seeMaterials and Methods for details. Subunit views
are from the cytoplasmic side, with the water pore in
the center. The intracellular loop D domain, adjacent
to the channel tetrameric axis of symmetry, is
highlighted in dark gold. (A) Bacopaside I is predicted
by in silico docking to occlude the cytoplasmic side of
the intrasubunit water pore in AQP1. (B) Favorable
interactions at the AQP4 water pore are not evident
for bacopaside I; the best fit is seen near membrane-
spanning domains distant from the pore (inset). (C)
Bacopaside II is predicted to have the most favorable
energy of interaction at a position occluding the
cytoplasmic side of the AQP1 water pore. (D) Pre-
dicted binding of bacopaside II with AQP4 is distant
from the water pore (inset), in a position similar to
that seen for bacopaside I. (E) Enlarged view of the
predicted interaction of the sugar-linked sulfur group
of bacopaside I with the conserved loop D arginine
residues in AQP1. (F) Enlarged view of the predicted
binding of the trisaccharide moiety of bacopaside II
deep into the cytoplasmic vestibule of the AQP1
water pore.
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The predicted energies of interaction for docking on AQP1
were higher for bacopaside II than bacopaside I, fitting the
observed order of efficacy in blocking AQP1-mediated swelling
of oocytes and the same order of efficacy in blocking migration
of AQP1-expressing HT29 colon cancer cells, with minimal
effects on SW480 cells that express little AQP1. The docking of
bacopasides I and II to occlude the water pore appeared
principally to involve the trisaccharide rings, which projected
down into the AQP1 intrasubunit pore.
Future work exploring polysaccharides and related osmo-
lytes as endogenous modulators of AQP channels could be
of interest. The lack of a favorable docking interaction of
bacopaside with the AQP4 water pore was consistent with the
insensitivity of AQP-4 expressing oocytes to bacopaside I in
osmotic swelling assays. Based on the docking model, candi-
date residues that could contribute to the proposed binding of
bacopaside sugar rings in the hAQP1 intracellular water pore
appear to include amino acids serine 71 in the loop B region,
and tyrosine 97 in the adjacent membrane spanning domains,
but remain to be defined.
Inhibition of AQP1 water channel activity by bacopasides I
and II showed a slow onset that was consistent with pre-
requisite transit of the agent across the membrane to access
the intracellular side. The latency period (approximately
2 hours) was comparable to that described for other aquaporin
modulators AqB013 and AqF026, also thought to act at the
cytoplasmic side (Migliati et al., 2009; Yool et al., 2013).
Accumulating evidence suggests pharmacologic agents can
be defined with subtype selectivity for AQP classes. Prior work
showed external application of AqF026 potentiated water
permeability in AQP1 (EC50 3.3 mM), but a 15-fold higher
concentration was required to potentiate AQP4 (Yool et al.,
2013). Metal complexes acted as blockers of glycerol perme-
ability in AQP3 (at an external site predicted to involve
cysteine [C40] and arginine [R218] residues), with compara-
tively small effects on AQP1 water permeability (Martins
et al., 2013). Results here for bacopaside I showed block of
osmotic water permeability for AQP1 but not AQP4 channels.
This difference in bacopaside sensitivity between related
aquaporins suggests that the inhibitory effects seen for
AQP1 are exerted directly on the heterologously expressed
channel and are not due to side effects on endogenous oocyte
channels or transporters.
The reversibility of the block indicated that functional
properties and expression of the channels in plasma mem-
brane were not impaired. Data here cannot rule out actions of
bacopasides on other molecules not yet assessed; however, the
Fig. 6. Dose-dependent inhibition of migration by bacopasides I and II in
AQP1-expressing HT29 cells, but not in SW480 cells with low AQP1
expression. Cell migration in the presence of a mitotic inhibitor was
assessed by rates of closure of circular wounds, created by aspiration with a
pipette tip in confluent cultures (seeMaterials andMethods for details). (A,
B) Cell migration was assessed in vehicle (A) or with 15 mM bacopaside II
(B) added immediately after wounding. Images are shown for confluent
HT29 cultures after initial wounding at time 0 (upper panels) and at
24 hours (lower panels). (C) Dose-dependent block of HT29 cell migration
was seen with bacopasides I and II, with IC50 values estimated at 48 and
14 mM, respectively. Partial block of SW480migration at the highest doses
tested did not exceed 20%. Doses beyond the ranges shown were not
considered valid due to the onset of cytotoxicity.
Fig. 5. HT29 cells have higher level of AQP1 expression than SW480 cells.
(A) The AQP1 RNA level was higher in HT29 cells as compared with
SW480 cells as assessed using qRT-PCR. (B) The AQP1 protein level was
higher in HT29 than SW480 cells as demonstrated by Western blot, with
monomeric subunit band seen near the predicted size of 28 kD with higher
molecular mass glycosylated bands. (C) The AQP1 immunopositive signal
(green) associated with the cell membrane was stronger in HT29 than in
SW480 cells. Cell nuclei were counterstained (blue). See Materials and
Methods for details.
Inhibition of Aquaporin-1 by Bacopasides 503
 at A








lack of effect of bacopaside on migration in SW480 cells with
low AQP1 expression suggests the mechanism of action is
reasonably selective, and does not appreciably impact
diverse signaling and transport processes needed for basic
maintenance and non-AQP1 dependent motility. Cytotoxicity
assays showed the viability of AQP1-expressing HT29 cancer
cells was not affected by bacopasides I and II at doses that
significantly blocked ion flux and cell migration.
Fig. 7. Live-cell imaging of the inhibitory effects of bacopasides I and II onmigration of HT29 cells. Single cells at the boundaries of circular wounds were
tracked with time-lapse images taken at 25-minute intervals for 10 hours at 37°C. (A–C) Panels of six images each from time-lapse series are shown at
50-minute intervals: (A) HT29 cells with vehicle treatment. (B) HT29 cells treated with 50mMbacopaside I. (C) HT29 cells treated with 15mMbacopaside
II. (D) Trajectory plots of 10 individual cells per treatment group, monitored by cell nucleus position as a function of time. Data were converted to absolute
values and referenced to the starting position at time 0;X andY values are in pixels (7.45 pixels permm). Trajectory plots illustrate the total movement of
10 individual cells per treatment over a duration of 600 minutes, with vehicle, bacopaside I or with bacopaside II. (E) Frequency histograms of the
distances moved by individual cells per 50-minute interval over 600 minutes of imaging, for 10 cells per treatment group. Histograms were fit with
Gaussian distribution functions (R2 values . 0.94); best-fit values for the mean distances moved per cell per 50-minute interval were 10.1 6 0.5 for
untreated, 4.7 6 0.2 for bacopaside I treated, and 7.8 6 0.2 for bacopaside II treated (mean 6 S.E.M.). (F) Summary histogram showing the mean total
distance traveled by cells in 600minutes, showing significant inhibition of cell motility by both bacopaside I and II as compared with vehicle-treated cells
(analysis of variance test P , 0.05; post hoc Bonferroni *P , 0.05; ***P , 0.001). Data are mean 6 S.E.M.; n values are 10 cells per treatment group.
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Bacopasides I and II are triterpene glycosides, composed of
a hydrophobic pentacyclic terpene backbone (estimated logP
value approximately 9; enabling membrane permeability),
and three linked polar sugar groups (arabinofuranosyl—
glucopyranosyl—arabinopyranose in bacopaside I; and
arabinofuranosyl—sulfonyl-glucopyranosyl—glucopyranose
in bacopaside II) that appear from in silico modeling to lodge
via H-bonds into the water pore entrance of AQP1, with the
exception of the sulfonyl group which appears to require an
interface with positively charged residues (arginines in the
adjacent AQP1 loop D domain). Mutation of the key loop D
arginines to alanines appeared to cause destabilization of the
overall binding of the bacopaside I compound onAQP1, seen as
a decreased efficacy of water pore block and increased IC50
value in the R159A1R160A mutant.
The ability of modulators to block the central pore ionic
conductance is an important consideration in processes such as
rapid cell migration which appear to require the AQP1 cation
channel activity (Kourghi et al., 2016). Interaction of the sulfonyl
group with loop D arginines was consistent with the observed
block of the cGMP-activated ionic conductance by bacopaside I, not
II. Bacopaside II lacked an effect on the ionic conductance, and
showed similar IC50 values for the block of AQP1 water channel
activity in oocytes, and the block of cell migration inHT29 cells. In
contrast, bacopaside I showed a lower IC50 value for inhibiting
HT29 cancer cellmigration (∼48mM) than for inhibiting theAQP1
osmotic water flux in oocytes (∼117 mM), suggesting that
simultaneous block of both water and ion channel activities of
AQP1 might be more effective in blocking cell migration. This
is consistent with the observed migration trajectories, which
were more compressed in bacopaside I-treated group than in
the bacopaside II-treated group.
Although the overall amino acid sequence similarity be-
tween AQP1 and AQP4 channels is high (.40% identity and
60% homology), AQP4-mediated osmotic swelling was not
sensitive to block by bacopaside I. The docking model sug-
gested the bulky terpene might sterically hinder docking near
the AQP4 water pore. As well, the loop D domain of AQP4
lacks the key arginines 159 and 160, suggested here to be
important for the sulfonyl group coordination, showing in-
stead serine and lysine in the equivalent positions, which
might be less effective as putative coordination sites.
The identification of bacopasides as novel AQP modulators
expands the database of pharmacophore properties of AQP
ligands. Bacopasides I and II themselves might not be ideal as
drug candidates, exceeding limits of Lipinski’s Rule of Five for
molecular weight, hydrophobicity, and numbers of hydrogen
bond donors and acceptors—although natural products often
show biologic activity as exceptions to the rule (Ganesan,
2008). Bacopasides administered in vivo are likely to act as
metabolic derivatives as well as intact compounds. More work
is needed to define in vivo metabolites of bacopasides and
characterize their effects on aquaporins. Nonetheless, bacopa-
sides could serve as lead compounds for the design of small-
molecule blockers of aquaporins.
Our results suggest the trisaccharide moiety is a key
component. An intriguing idea would be to design compact
membrane-permeable trisaccharides for blocking water flux;
addition of key sulfonyl or other groups could inhibit parallel
AQP functions. Endogenous polysaccharide osmolytes in cells
might function as natural modulators of aquaporin channels,
a concept that has not to our knowledge been considered
previously.
Bacopa monnieri extract (also known as brahmi) has been
used in Ayurvedic remedies since ancient times to improve
memory and treat anxiety and depression (Russo and Borrelli,
2005). Brahmi has been suggested to have beneficial effects
on psychologic state, cognitive performance, and memory in
human subjects and animal models; neuroprotective effects
after ischemic brain injury; and anti-inflammatory actions in
processes linked to neurodegenerative disorders (Singh and
Dhawan, 1982; Sairam et al., 2002; Rehni et al., 2007; Zhou
et al., 2007; Saraf et al., 2010; Aguiar and Borowski, 2013;
Downey et al., 2013; Liu et al., 2013; Kongkeaw et al., 2014;
Williams et al., 2014). A meta-analysis of human clinical
studies (generally with B. monnieri administered 250–
450mg/day for up to several months) improvedmental response
time and attention, and had potential benefits on memory
(Kongkeaw et al., 2014). No serious adverse events were
noted; minor side effects included diarrhea and dry mouth.
Beneficial outcomes ascribed to brahmi could in part involve
block of AQP1 channels. AQP1 is expressed abundantly in brain
choroid plexus where cerebral spinal fluid is produced (Boassa
andYool, 2005; Johansson et al., 2005) and inproximal kidney to
facilitate water reabsorption (Nielsen and Agre, 1995). AQP1 is
found in peripheral vasculature endothelia, red blood cells, and
other cell types (Nielsen et al., 1993). Block of AQP1 could
contribute to the anti-inflammatory benefits of brahmi treat-
ment. Macrophages express AQP1 channels, which are required
for interleukin-1b release and neutrophilic inflammation re-
sponses (Rabolli et al., 2014). An alcoholic extract ofB. monnieri
decreased tumor necrosis factor-a production in mouse macro-
phages preincubated for 1 hour, with an IC50 near 1 mg/ml
(Williams et al., 2014).
Pharmacologic inhibitors of AQP1 channels could be use-
ful for intervention in many conditions, including slowing
metastasis in AQP1-positive cancer subtypes. In a subset
of aggressive cancers, AQP1 expression is up-regulated
(Saadoun et al., 2002; Moon et al., 2003; Yool et al., 2010; El
Hindy et al., 2013). AQP1 channels located at lamellipodial
edges have been implicated in enhancing migration and
TABLE 1
Analysis of cytotoxicity in HT29 colon cancer cells at 24 hours of
treatment, using an AlumarBlue fluorescence assay
Concentration (mM) Mean Normalized CellViability (%)a n value P value
bacopaside I
0 108 6 4.8 17 N.S.
0 (vehicle) 100 6 3.1 17 —
50 97 6 2.1 8 N.S.
75 79 6 4.2 8 N.S.
100 59 6 3.2 8 b
bacopaside II
0 113 6 6.2 16 N.S.
0 (vehicle) 100 6 5.7 16 —
15 104 6 18 8 N.S.
20 123 6 17 8 N.S.
30 47 6 5.7 8 b
HgCl2
100 16.1 6 4.6 6 b
aMean 6 S.E.M. The percentage of viability was standardized as a percentage of
the vehicle-treated mean value, measured as changes in AlumarBlue fluorescence
signal intensity. See Materials and Methods for details.
bStatistically significant differences (P , 0.05), compared with vehicle-treated,
were analyzed by analysis of variance with post hoc Dunnett’s multiple comparison
test (GraphPad Prism). N.S. is not statistically significant.
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metastasis (Hu and Verkman, 2006; McCoy and Sontheimer,
2007). Block of the AQP1 ion channel impairs migration in
AQP1-expressing HT29 colon cancer cells (Kourghi et al.,
2016).
A comprehensive portfolio of selective aquaporin modulators
is needed for clinical and basic research. Further exploration of
AQPmodulators in traditional herbal medicines is merited (Pei
et al., 2016). New ligand modulators of aquaporin channel
activity could be present in the armamentarium of traditional
herbal medicines, but they remain to be discovered.
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a b s t r a c t
Aquaporins (AQPs) are integral membrane channel proteins that facilitate the bidirectional transfer of
water or other small solutes across biological membranes involved in numerous essential physiological
processes. In arthropods, AQPs belong to several subfamilies, which contribute to osmoregulation,
respiration, cryoprotection, anhydrobiosis, and excretion. We cloned and characterized five novel AQPs
from the western tarnished plant bug, Lygus hesperus, a polyphagous insect pest of food and fiber crops
throughout western North America. The L. hesperus AQPs (LhAQP1-5) belong to different phylogenetic
subfamilies, have unique transcription profiles and cellular localizations, and all transport water (but not
glycerol) when heterologously expressed in Xenopus laevis oocytes. Our results demonstrate that mul-
tiple AQPs with possible compensatory functions are produced in L. hesperus that likely play important
roles in maintaining water homeostasis in this important insect pest.
Published by Elsevier Ltd.
1. Introduction
Aquaporins (AQPs) belong to the ancient class of major intrinsic
proteins (MIPs), which are integral membrane channel proteins
found in all kingdoms of life. These proteins facilitate the bidirec-
tional transfer of water or sometimes other small neutral solutes
across biological membranes involved in numerous essential
physiological processes (Hachez and Chaumont, 2010; Gomes et al.,
2009; King et al., 2004). AQPs are best known for their diverse roles
in water transport related to cell water balance regulation
[reviewed in Agre et al. (1998); Carbrey and Agre, 2009], but they
also transport a wide range of solutes, including urea and glycerol,
hydrogen peroxide, dissolved gasses (CO2, NO, NH3), and certain
metalloids (Cohen, 2013; Hachez and Chaumont, 2010). Whereas
most solutes permeate through the monomeric channel, AQPs
usually assemble as tetramers forming a fifth central pore that in
some cases functions to conduct ions (Yool and Weinstein, 2002;
Yool, 2007).
The functional diversity of AQPs is facilitated by key modifica-
tions to their structure. In general, members of theMIP superfamily
share a number of structural features, including six helical trans-
membrane (TM) domains connected by five alternating extracel-
lular/intracellular loops with intercellular amino and carboxyl
termini, two canonical Asp-Pro-Ala (NPA) motifs, and the aromatic/
arginine (ar/R) selectivity filter (Zardoya, 2005). Together, the ca-
nonical amino- and carboxyl-terminal halves form two tandem
repeats, each containing a single NPAmotif, forming the ‘aquaporin’
or ‘hourglass’ fold (Jung et al., 1994; Murata et al., 2000) and ulti-
mately shaping the selective TM channel. ‘Classical’ or ‘orthodox’
AQPs allow water diffusion through an extremely narrow and
electrostatically-selective pore that precludes the permeability of
large, hydrophobic, or incorrectly charged solutes (Murata et al.,
2000). In another functional class of AQPs known as the aqua-
glyceroporins, the composition of the ar/R constriction site and the
corresponding larger, more hydrophobic three-dimensional shape
of the pore enables permeation of additional solutes, such as
Abbreviations: AQP, aquaporin; MIPs, major intrinsic proteins; NPA motif,
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polyols (Fu et al., 2000; Hub and de Groot, 2008). Members of a
recently identified subfamily known as ‘superaquaporins’ or “S-
aquaporins” exhibit low sequence similarity with other AQPs,
altered NPA signature motifs, and anomalous subcellular localiza-
tion (Ishibashi, 2006, 2009; Nozaki et al., 2008; Calvanese et al.,
2013).
Whereas vertebrate AQPs have been studied extensively
[reviewed in King et al. (2004); Verkman 2008; and Ishibashi et al.,
2009], far less attention has been given to invertebrate AQPs. In
arthropods, AQPs are involved in regulating the movement of high
volume liquid diets, osmoregulation, respiration, cryoprotection
and anhydrobiosis [reviewed in Campbell et al. (2008); Spring et al.,
2009; and Cohen 2013]. Genome sequencing indicates that insects
may contain up to 5-8 genes encoding putative aquaporin-like
transcripts (Campbell et al., 2008; Drake et al., 2010), but the
complete repertoire from any single species is yet to be fully
characterized. Multiple functional AQPs have been found in several
insects, including three from Aedes aegypti (Duchesne et al., 2003;
Drake et al., 2010) and Bombyx mori (Kataoka et al., 2009a;
Azuma et al., 2012), and two from the oriental fruit moth, Graph-
olita molesta (Kataoka et al., 2009b), the pea aphid, Acyrthosiphon
pisum (Shakesby et al., 2009; Wallace et al., 2012), the sleeping
chironomid, Polypedilum vanderplanki (Kikawada et al., 2008), and
Drosophila melanogaster (DRIP and BiB) (Kaufmann et al., 2005;
Yanochko and Yool, 2002). For A. aegypti, studies have shown that
a water-specific DRIP (AeaAQP) is involved in water movement in
Malpighian tubules and tracheoles (Duchesne et al., 2003). RNA
interference (RNAi) knockdown further revealed a role in diuresis
in Malpighian tubules for three of the six putative AQPs (Drake
et al., 2010). Functional AQPs from B. mori include, AQP-Bom1 (a
water-specific DRIP), AQP-Bom2 (an aquaglyceroporin), and AQP-
Bom3 (a water-specific PRIP), all of which play important roles in
water reabsorption and recycling within the cryptonephric rectal
complex (Kataoka et al., 2009a; Azuma et al., 2012). G. molesta has a
functional water-specific DRIP (AQP-Gra1) and an aquaglyceroporin
(AQP-Gra2) (Kataoka et al., 2009b). In A. pisum, ApAQP1 was shown
to be a water-specific AQP (Shakesby et al., 2009) whereas ApAQP2
exhibited aquaglyceroporin activities, transporting water and
glycerol in Xenopus oocytes (Wallace et al., 2012). Two
P. vanderplanki AQPs (PvAQP1 and PvAQP2) facilitated water
permeation, but not transport of glycerol in Xenopus oocytes
(Kikawada et al., 2008). Among the D. melanogaster AQPs charac-
terized are a water-selective AQP called Drosophila integral protein
or DRIP, which is involved in excretion and osmoregulation
(Kaufmann et al., 2005), and the novel AQP known as Big Brain
(DmBIB), which does not permeate water, but functions as a cation
channel (Yanochko and Yool, 2002). Other arthropods having at
least one functionally characterized AQP include: Cicadella viridis
(La Caherec et al., 1997); Rhodnius prolixus (Echevarria et al., 2001);
Anopheles gambiae (Liu et al., 2011); Blattella germanica (Herraiz
et al., 2011); Eurosta solidaginis (Philip et al., 2011); Bemisia tabaci
(Mathew et al., 2011); Belgica antarctica (Goto et al., 2011); Anomala
cuprea (Nagae et al., 2013); and the ticks, Dermacentor variabilis
(Holmes et al., 2008), Rhipicephalus sanguineus (Ball et al., 2009),
and Ixodes ricinus (Campbell et al., 2010).
Numerous species within the hemipteran family Miridae are
important agricultural pests causing crop damage from feeding
with specialized piercing-sucking mouthparts (Wheeler, 2001).
One such mirid bug is Lygus hesperus Knight (the western tarnished
plant bug), a highly polyphagous pest causing economic losses in
numerous cropping systems in western North America (Wheeler,
2001). Lygus bugs are “cell rupture” feeders (previously termed
“lacerate-and-flush”) that first puncture host tissue and inject
saliva containing digestive enzymes (Miles, 1987; Strong and
Kruitwagen, 1968; Shackel et al., 2005; Backus et al., 2007). The
pre-digested fluid is then pumped through the food canal for ab-
sorption of nutrients primarily within the midgut epithelium of the
alimentary tract (Wheeler, 2001; Habibi et al., 2008). Some he-
mipterans use specialized biochemical processes or gut
morphology (e.g. filter chambers) to abate osmotic stress and
remove excess dietary fluid (Douglas, 2006; Gullan and Cranston,
2005; Lehane and Billingsley, 1996; Hubert et al., 1989; Mathew
et al., 2011). Lygus bugs lack the specialized filter chamber or
gastric cecae of sap feeding hemipterans, and instead have a simple,
cimicomorph type alimentary tract typical of other mesophyll
feeders (Goodchild, 1966; Habibi et al., 2008).
Here, we characterize five AQPs (LhAQP1-5) from L. hesperus.
Based on sequence conservation and phylogenetics, bioinformatic
predictions, cellular and tissue localization, temporal expression,
and functional analysis, the LhAQPs belong to different subfamilies
but all function as water-specific channel proteins. Localization
and transcription profiles for LhAQPs provide clues about the
putative roles these functionally redundant AQPs may play in
maintaining L. hesperus water homeostasis. The combination of
standard molecular cloning techniques and the mining of tran-
scriptome data for AQPs provides an unprecedented opportunity
to comprehensively identify and characterize AQPs within
L. hesperus.
2. Materials and methods
2.1. Insects
A laboratory colony of Lygus hesperus was maintained at the
USDA-ARS U.S. Arid Land Agricultural Research Center in Maricopa,
AZ, USA. The colony was fed green beans and artificial diet at 25 "C
under 20% humidity and with an L14:D10 photoperiod (Debolt,
1982; Patana, 1982).
2.2. cDNA isolation and 50-RACE of LhAQPs
Total RNA was extracted from 100 mg of L. hesperus adults and
2nde3rd instar nymphs using TRIzol! reagent (Invitrogen-Life
Technologies, Carlsbad, CA). cDNA was produced using random
hexamer primers and SuperScript III First-strand Synthesis System
(Invitrogen-Life Technologies) according to manufacturer’s rec-
ommendations. PCR primers 1LhAQP5-8LhAQP3 (Table 1) were
designed using Primer3Plus (Untergasser et al., 2007) from four
putative Lygus lineolaris AQPs obtained from a L. lineolaris tran-
scriptome sequencing project (O.P. Perera, unpublished). Four
partial LhAQPs (named LhAQP1-4) were PCR amplified using ExTaq
DNA polymerase premix (Takara-Clontech, Palo Alto, CA) and
primer pairs (Table 1). Products were electrophoresed on a 1%
agarose gel and visualized using SYBR Safe (Invitrogen-Life Tech-
nologies). Bands were gel-purified using Montage DNA Gel
Extraction Kit (EMD Millipore, Billerica, MA) and ligated into
pCR2.1-TOPO using TOPO TA Cloning Kit (Invitrogen-Life Technol-
ogies). Plasmid DNA was propagated in OneShot TOP10 chemically
competent Escherichia coli and purified using QIAprep Spin Mini-
Prep Kit (Qiagen, Valencia, CA). Inserts were sequencedwith T7 and
M13 Reverse vector primers by the Arizona State University DNA
Core Lab (Tempe, AZ).
The 50 and 30 ends of LhAQP1-4s were identified by rapid
amplification of cDNA ends (RACE) using the SMARTer RACE cDNA
Amplification Kit (Clontech). At least two sense and two antisense
primers were designed for each partial LhAQP consensus sequence
(Table 1). The primers were used with Universal Primer A (Clon-
tech) in fully nested PCR to amplify 50 and 30 ends (Table 1). PCR
products were sub-cloned into pCR2.1-TOPO (Invitrogen-Life
Technologies) and sequenced as indicated above.
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Table 1
Nucleotide primers used to obtain partial and full-length Lygus hesperus aquaporins (LhAQP1-5), rapid amplification of cDNA ends (50- and 30-RACE), reverse transcriptase-PCR
(RT-PCR) amplification of cDNA, and for sub-cloning into pIB expression vector.
Primer Primer DNA sequencea Direction LhAQP Application
AcF 50-ATGTGCGACGAAGAAGTTG-30 Sense e RT-PCR
AcR1 50-GTCACGGCCAGCCAAATC-30 Antisense e RT-PCR
1LhTub5 50-CACCAAGTCGTTCATGTTGG-30 Sense e RT-PCR
2LhTub3 50-GTCACCACTTGCCTCAGGTT-30 Antisense e RT-PCR
1LhAQP5 50-CAAACTCTGAGCCTTCCCACA-30 Sense 3 Partial cloningb
2LhAQP3 50-GTCGAGTCAACACGCTGGT-30 Antisense 3 Partial cloning
3LhAQP5 50-GTCGAGTCAACACGCTGGT-30 Sense 4 Partial cloning
4LhAQP3 50-CTTTTCCAAGCCGCTTCAT-30 Antisense 4 Partial cloning
5LhAQP5 50-TTGGGTACGGAGGATGTGG-30 Sense 1 Partial cloning
6LhAQP3 50-TTACAAATCGTAAGAACTGTCGTC-30 Antisense 1 Partial cloning
7LhAQP5 50-GGAAGTGTTTGGAGCAGAGC-30 Sense 2 Partial cloning
8LhAQP3 50-GCAGGTGGTGTAGAAAAGTGG-30 Antisense 2 Partial cloning
18LhAQP5 50-TGCCTCTGACTGGATCAGGA-30 Sense 1 30-RACEc
19LhAQP5 50-GTTGGACAGTGGGACAACCA-30 Sense 1 30-RACE
20LhAQP3 50-GCCTGACCCTCAGTGAGTCC-30 Antisense 1 50-RACE
21LhAQP3 50-CATCTGAACGACCGAAGCAA-30 Antisense 1 50-RACE
22LhAQP5 50-TGGCCCTCATCTTTCTGGTT-30 Sense 2 30-RACE
23LhAQP5 50-CCCCGTCAGAAGTCTTGGTC-30 Sense 2 30-RACE
24LhAQP3 50-TGATTGCTCCCATGATTTGC-30 Antisense 2 50-RACE
25LhAQP3 50-TGCCCCAGTACGTAGAATGC-30 Antisense 2 50-RACE
34LhAQP3 50-CTGGCGAGCAGCACATCGCGGGTCA-30 Antisense 2 50-RACE
35LhAQP3 50-CACCAACGCCCATGATTGCTCCCATGA-30 Antisense 2 50-RACE
36LhAQP5 50-TGCTGCTCTGCATCGGCTGCGCTTC-30 Sense 2 30-RACE
37LhAQP5 50-CCGCGATGTGCTGCTCGCCAGGACT-30 Sense 2 30-RACE
26LhAQP3 50-AGCGCCGAAATTTGGGGCAGTCCAG-30 Antisense 3 50-RACE
27LhAQP3 50-CGAGCGACATGTGCCCCATGACCAG-30 Antisense 3 50-RACE
28LhAQP5 50-GGTCATGGGGCACATGTCGCTCGTC-30 Sense 3 30-RACE
29LhAQP5 50-GACCGCCGGGTTTCTGCACCACTCA-30 Sense 3 30-RACE
30LhAQP3 50-GCGGGATTCATGCTGGAACCCGTGGA-30 Antisense 4 50-RACE
31LhAQP3 50-CGGCACCTCCGATGGCGCCAAGACA-30 Antisense 4 50-RACE
32LhAQP5 50-AAGGCGGTGGTGGCCGAAGCACTCG-30 Sense 4 30-RACE
33LhAQP5 50-TGGCGCCATCGGAGGTGCCGCTATG-30 Sense 4 30-RACE
38LhAQP5 50-ATGATGGGCGACCACAGTTCTATC-30 Sense 1 Cloning CDSd
39LhAQP3 50-TTACAAATCGTAAGAACTGTCGTCG-30 Antisense 1 Cloning CDS
40LhAQP5 50-ATGGTGACCGACTCGGGCGGGA-30 Sense 2A Cloning CDS
41LhAQP3 50-CTACGATTGGCCTCCCCTGAGGAA-30 Antisense 2A Cloning CDS
42LhAQP5 50-ATGGCTACTCCACTCGTTTTGAACAGGGTG-30 Sense 2B Cloning CDS
43LhAQP5 50-ATGGGAGTCACGACCGGATCGG-30 Sense 2C Cloning CDS
44LhAQP5 50-ATGAACAGTGGGAACAGCGTTTTTCTG-30 Sense 2D Cloning CDS
86LhAQP5 50-GGATCCATGACGATGAGCGAAT-30 Sense 2E Cloning CDS & pIB
45LhAQP5 50-ATGCCTCCGAGATCAAAAGCACG-30 Sense 3 Cloning CDS
46LhAQP3 50-TTATATGGTGGCGTCGACTTCTCTTGT-30 Antisense 3 Cloning CDS
47LhAQP5 50-ATGCCAGACAAGAGGAGTCGAGTCAA-30 Sense 4 Cloning CDS
48LhAQP3 50-TCATGCGTTGCTGTTTTCATTTCCT-30 Antisense 4 Cloning CDS
79LhAQP5 50-ATGGGGGGCATCTTCGG-30 Sense 5 Cloning CDS
80LhAQP3 50-TTAGAGATCTTTTTCTTTCCCCAGGA-30 Antisense 5 Cloning CDS
61LhAQP5 50-ATTCGATGCTGTTGGTAGGG-30 Sense 1 RT-PCRe
62LhAQP3 50-CTGATCCAGTCAGAGGCACA-30 Antisense 1 RT-PCR
63LhAQP5 50-GGAAGTGTTTGGAGCAGAGC-30 Sense 2 RT-PCR
64LhAQP3 50-TGCGCCAGTGTATTTACCAA-30 Antisense 2 RT-PCR
65LhAQP5 50-GGTGCTTAGTTTCGCTTTGG-30 Sense 3 RT-PCR
66LhAQP3 50-CGGTAGATCACTGCTGCAAA-30 Antisense 3 RT-PCR
67LhAQP5 50-CGGTAGATCACTGCTGCAAA-30 Sense 4 RT-PCR
68LhAQP5 50-CCCAGTGGTTATCCCATTTG-30 Antisense 4 RT-PCR
77LhAQP5 50-CGACTTACGCCCTCTTCTTG-30 Sense 5 RT-PCR
78LhAQP3 50-GGAACCGATCCAGTAGACGA-30 Antisense 5 RT-PCR
81LhAQP5 50-GGATCCATGGTGACCGACTC-30 Sense 2A pIB
82LhAQP3 50-AGGCCTCGATTGGCCTCCCCTG-30 Antisense 2A pIB
83LhAQP5 50-GGATCCATGGCTACTCCACTC-30 Sense 2B pIB
84LhAQP5 50-GGATCCATGGGAGTCACGACCGGAT-30 Sense 2C pIB
85LhAQP5 50-GGATCCATGAACAGTGGGAAC-30 Sense 2D pIB
86LhAQP5 50-GGATCCATGACGATGAGCGAAT-30 Sense 2E pIB
73LhAQP5 50-GGATCCATGCCTCCGAGATCAAAAGC-30 Sense 3 pIB
74LhAQP3 50-AGGCCTTATGGTGGCGTCGACTTCTCTTGT-30 Antisense 3 pIB
75LhAQP5 50-GGATCCATGCCAGACAAGAGGAGTCGA-30 Sense 4A pIB
76LhAQP3 50-AGGCCTTGCGTTGCTGTTTTCATTTCCTT-30 Antisense 4A pIB
89LhAQP5 50-GGAGAGAGCTCCACTGAGGTACGCATCAAGGTATTA-30 Sense 4A pIB
90LhAQP3 50-TAATACCTTGATGCGTACCTCAGTGGAGCTCTCTCC-30 Antisense 4A pIB
87LhAQP5 50-GGATCCATGGGGGGCATCTT-30 Sense 5 pIB
88LhAQP3 50-AGGCCTGAGATCTTTTTCTTTCC-30 Antisense 5 pIB
LhAQP1 Met3 F 50-ATGCCACGTTCTGAAGAAG-30 Sense 1 pIB
EGFP-LhAQP1 OE F 50-gacgagctgtacaagATGATGGGCGACCAC-30 Sense 1 Domain swap/pIB
(continued on next page)
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Concurrent with cloning the four putative partial cDNAs
(LhAQP1-4), we sequenced and de novo assembled a Roche 454
transcriptome from normalized cDNA libraries prepared from 0 to 5
day old post-eclosion L. hesperus adults (Hull et al., 2013). In
addition to confirming the presence of the LhAQP1-4 transcripts
(Table 2), the L. hesperus 454 transcriptome also revealed an addi-
tional putative full-length aquaporin-like transcript, designated as
LhAQP5.
Full-length LhAQP coding sequences (CDS) corresponding to
open reading frames (ORFs) were confirmed by PCR amplification
from L. hesperus adult cDNA using primer pairs (Table 1). All
products corresponding to full-length LhAQP CDS were PCR
amplified using ExTaq DNA polymerase (Takara-Clontech), sub-
cloned into pCR2.1-TOPO (Invitrogen-Life Technologies), and
sequenced as indicated above.
2.3. Bioinformatics and phylogeny
Sequences were analyzed in Vector NTI (Life Technologies) and
comparison against the non-redundant public sequence database
was made using BLAST search programs (Altschul et al., 1990).
Sequence analysis tools of the ExPASy Molecular Biology Server of
Swiss Institute of Bioinformatics, including Translate and Compute
pI/MW were used to analyze the deduced LhAQP protein se-
quences. Predictions of intra/extracellular domains and trans-
membrane helices were made using TMPred (Hofmann and Stoffel,
1993), TMHMM 2.0 (Krogh et al., 2001), Phobius (Käll et al., 2004),
RHYTHM (Rose et al., 2009), TOPCONS (Bernsel et al., 2009),
HMMTOP (Tusnady and Simon, 2001), and TopPredII (Claros and
von Heijne, 1994). Protein subcellular localization was predicted
using WolF PSORT (Horton et al., 2007). Multiple sequence align-
ments were performed using CLUSTALW (Larkin et al., 2007).
Phylogenetic analysis using predicted full-length AQP protein se-
quences was performed with the unweighted pair group method
with arithmetic mean (UPGMA, Sneath and Sokal, 1973), neighbor-
joining (Saitou and Nei, 1987), and minimum evolution and
maximum parsimony (Saitou and Nei, 1986) methods. Trees were
constructed with 10,000 bootstrap replicates using MEGA version 5
(Tamura et al., 2011). Only the UPGMA tree is shown, as all trees
were similar. Glycosylation predictions were made using post-
translational modification servers found at the Center for Biolog-
ical Sequence Analysis (http://www.cbs.dtu.dk/services/).
2.4. RNA extraction and semi-quantitative reverse transcription
PCR
Lygus representing different developmental stages (egg, 1st
instar nymph, 2nde3rd instar nymph, 4the5th instar nymph, and
adult) were collected, weighed, and frozen in liquid nitrogen. Total
tissue weight for each stage ranged from 60 to 112 mg. For tissue
distribution RT-PCR, heads, legs, accessory glands, testes, ovaries,
Table 1 (continued )
Primer Primer DNA sequencea Direction LhAQP Application
EGFP-LhAQP1 OE R 50-GTGGTCGCCCATCATcttgtacagctcgtc-30 Antisense 1 Domain swap/pIB
BtAQP1N-LhAQP1 F 50-TAGTTGCTGAGTTCCTGGGAAC-30 Sense 1 Domain swap/pIB
BtAQP1N-LhAQP1 R 50-GTTCCCAGGAACTCAGCAACTA-30 Antisense 1 Domain swap/pIB
LhAQP1N-BtAQP1 F 50-CGTCGCTGAGTTCGTAGGGAC-30 Sense 1 Domain swap/pIB
LhAQP1N-BtAQP1 R 50-GTCCCTACGAACTCAGCGACG-30 Antisense 1 Domain swap/pIB
LhAQP1-EGFP F 50-GTTCTTACGATTTGatggtgagcaagggcgag-30 Sense 1 Domain swap/pIB
LhAQP1-EGFP R 50-ctcgcccttgctcaccatCAAATCGTAAGAAC-30 Antisense 1 Domain swap/pIB
StuI-EGFP F 50-AGGCCTATGGTGAGCAAG-30 Sense e Domain swap/pIB
EGFP R stop 50-TTACTTGTACAGCTCGTCCATG-30 Antisense e Domain swap/pIB
20BtAQP3 50-TCAGAAATCATAAGAGCTCTCATC-3 Antisense e Domain swap/pIB
a Underlined sequence corresponds to restriction enzyme sites (G*GATCC ¼ BamHI, GGTAC*C ¼ KpnI, GAGCT*C ¼ SacI, AGG*CCT ¼ StuI). Sequence in lower case indicates
regions within primers corresponding to EGFP used in overlap extension PCR to produce LhAQP1 chimera with EGFP at amino- or carboxyl-terminus. Italicized sequence
corresponds to primer regions from BtAQP1 (ABW96354.1) used in overlap extension PCR to produce LhAQP1eBtAQP1 amino-terminal domain swaps.
b Partial LhAQPs 1e4 were PCR amplified using primer pairs 1LhAQP5 þ 2LhAQP3 (LhAQP1), 3LhAQP5 þ 4LhAQP3 (LhAQP2), 5LhAQP5 þ 6LhAQP3 (LhAQP3), and
7LhAQP5 þ 8LhAQP3 (LhAQP4).
c For 50 and 30 RACE at least two sense and two antisense primers were used to amplify ends of LhAQP1-4 (18LhAQP5 and 19LhAQP5 for 30-RACE of LhAQP1; 20LhAQP3 and
21LhAQP3 for 50-RACE of LhAQP1; 22LhAQP5, 23LhAQP5, 36LhAQP5, and 37LhAQP5 for 30-RACE of LhAQP2; 24LhAQP3, 25LhAQP3, 34LhAQP3, and 35LhAQP3 for 50-RACE of
LhAQP2; 26LhAQP3 and 27LhAQP3 for 50-RACE of LhAQP3; 28LhAQP5 and 29LhAQP5 for 30-RACE of LhAQP3; 30LhAQP3 and 31LhAQP3 for 50-RACE of LhAQP4; 32LhAQP5 and
33LhAQP5 for 30-RACE of LhAQP4).
d Full-length coding sequences for LhAQPs were confirmed by PCR amplification from adult Lygus hesperus cDNA using primer pairs 38LhAQP5 þ 39LhAQP3 (LhAQP1),
40LhAQP5 þ 41LhAQP3 (LhAQP2A), 42LhAQP5 þ 41LhAQP3 (LhAQP2B), 43LhAQP5 þ 41LhAQP3 (LhAQP2C), 44LhAQP5 þ 41LhAQP3 (LhAQP2D), 86LhAQP5 þ 41LhAQP3
(LhAQP2E), 45LhAQP5 þ 46LhAQP3 (LhAQP3), 47LhAQP5 þ 48LhAQP3 (LhAQP4), and 79LhAQP3 þ 80LhAQP (LhAQP5).
e For reverse transcriptase-PCR (RT-PCR), LhAQP-specific primers were used to amplify products fromwithin each ORF using primer pairs 61LhAQP5þ 62LhAQP3 (LhAQP1),
63LhAQP5 þ 64LhAQP3 (LhAQP2), 65LhAQP5 þ 66LhAQP3 (LhAQP3), 67LhAQP5 þ 68LhAQP3 (LhAQP4), and 77LhAQP5 þ 78LhAQP3 (LhAQP5).
Table 2
Aquaporin protein transcripts identified by cDNA cloning and from de novo-




















1 KF048092 2 864 287 5 864 287
2A KF048093 eg 789 262 e e e
2B KF048094 e 813 270 e e e
2C KF048095 e 885 294 e e e
2D KF048096 e 846 281 e e e
2E KF048097 9 768 255 2 768 255
3 KF048098 10 804 267 2 804 267
4A KF048099 1 837 278 e e e
4B KF048100 e 798 265 2 798 265
5 KF048101 5 798 265 e e e
a Total number of contigs comprising LhAQPs obtained from de novo-assembled
adult Lygus hesperus 454 transcriptome (Hull et al., 2013).
b Number of nucleotides comprising L. hesperus AQP coding sequences (CDS)
obtained from RACE and PCR cloning.
c Number of residues from translation of L. hesperus AQP CDS using ExPASy
Translate tool (http://web.expasy.org/translate/).
d Total number of putative AQP contigs obtained from de novo-assembled Lygus
lineolaris transcriptome sequencing libraries (personal communication from O.P.
Perera).
e Number of nucleotides comprising L. lineolaris CDS for AQP transcripts obtained
by aligning contigs and generating consensus sequences.
f Number of residues from translation of L. lineolaris AQP CDS using ExPASy
Translate tool (http://web.expasy.org/translate/).
g “e” indicates that for cloned AQP cDNAs no contigs/isotigs were found in de
novo-assembled Lygus hesperus or Lygus lineolaris transcriptomes.
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midguts, and Malpighian tubules were dissected from adults and
stored in RNAlater (Ambion-Life Technologies) at $80 "C. Tissue
samples were homogenized using Kontes pestles (Fisher Scientific,
Pittsburg, PA) and total RNA was extracted using TRIzol! reagent
(Invitrogen-Life Technologies). RNA concentration was determined
using a NanoDrop ND1000 spectrophotometer (NanoDrop Tech-
nologies/Thermo Scientific,Wilmington, DE). Total RNAwas treated
with DNA-free" DNase I (Ambion-Life Technologies) to remove
genomic DNA contamination, if any, carried over during total RNA
extraction. Integrity of the total RNA was confirmed on the Agilent
2100 Bioanalyzer using the RNA Nano 6000 LabChip kit (Agilent
Technologies, Santa Clara, CA) according to manufacturer’s
instructions.
Samples were diluted and 1 mg of DNase-treated total RNA was
used to prepare cDNA using random decamer primers according to
the protocol described in RetroScript cDNA Synthesis Kit (Ambion-
Life Technologies). For reverse transcriptase-PCR (RT-PCR), LhAQP-
specific primers were used to amplify 503e547-bp products from
within each ORF (Table 1). Nucleotide primer sequences for
63LhAQP5 and 64LhAQP3 are conserved in LhAQP2A-E and there-
fore, end-point RT-PCR products represent transcriptional profiles
for LhAQP2 as a group. Likewise, 67LhAQP5 and 68LhAQP3 primer
sequences are found in both LhAQP4A and LhAQP4B. The appro-
priate number of PCR cycles was determined empirically and
included 25, 28, and 30 cycles. Actin (AcF þ AcR1) and b-tubulin
(1LhTub5 þ 2LhTub3) were used as amplification controls for
stages and tissues, respectively (Hull et al., 2013). Products were
electrophoresed on 0.8% agarose gels and visualized using SYBR
Safe (Invitrogen-Life Technologies).
2.5. Expression in Tni cell culture and fluorescence microscopy
To observe cellular localization, recombinant LhAQPs were
expressed using the pIB/V5-His TOPO TA (Invitrogen-Life Technol-
ogies) insect cell expression vector in cultured Trichoplusia ni (Tni)
cells (Allele Biotechnology, San Diego, CA). Recombinant proteins
were expressed as chimeras with the enhanced green fluorescent
protein (EGFP) produced in frame with LhAQPs either at their
amino- or carboxyl termini.
A pIB/StuI-EGFP reporter cassette was modified from pIB/V5-
His TOPO TA (Life Technologies) and used to express chimeric
LhAQP2-5-EGFP recombinant proteins in cultured Tni cells. Full-
length LhAQP2A-E, LhAQP3, LhAQP4A-B, and LhAQP5 coding se-
quences were first cloned into pCR2.1-TOPO (Invitrogen-Life
Technologies) using PCR with KOD DNA polymerase (EMD Milli-
pore) and primers that introduced BamHI and StuI restriction sites
on the 50 and 30 ends of LhAQPs, respectively
[81LhAQP5 þ 82LhAQP3 (LhAQP2A), 83LhAQP5 þ 82LhAQP3
(LhAQP2B), 84LhAQP5 þ 82LhAQP3 (LhAQP2C),
85LhAQP5 þ 82LhAQP3 (LhAQP2D), 86LhAQP5 þ 82LhAQP3
(LhAQP2E), 73LhAQP5 þ 74LhAQP3 (LhAQP3),
75LhAQP5 þ 76LhAQP3 (LhAQP4A and 4B), and
87LhAQP5 þ 88LhAQP3 (LhAQP5)]. LhAQP/pCR2.1-TOPO plasmids
and pIB/StuI-EGFP were digested with BamHI-HF and StuI, gel-
purified using an EZNA gel extraction kit (Omega Bio-Tek, Nor-
cross, GA), and ligated using Mighty Mix DNA ligation kit (Takara-
Clontech). Because LhAQP4B is preferentially PCR amplified over
LhAQP4A, additional overlap extension PCR steps were needed to
make LhAQP4A/pCR2.1-TOPO with the appropriate restriction
sites. The first PCR amplified the 50 end of LhAQP4A with a 50
BamHI site but missing 36 bp from LhAQP4B using
75LhAQP5 þ 90LhAQP3. The second PCR amplified the 30end of
LhAQP4A including the unique 36 bp and a 30 SacI site using
89LhAQP5 þ 76LhAQP3. The final step involved PCR amplification
using the two previous reactions as templates with
75LhAQP5 þ 76LhAQP3. The resulting PCR product was cloned into
pCR2.1-TOPO (Invitrogen-Life Technologies), digested with BamHI
and StuI, and sub-cloned into pIB/StuI-EGFP as described above.
High-fidelity KOD DNA polymerase (EMD Millipore) was used for
all PCR amplifications. Orientation and correctness of the pCR2.1-
TOPO and pIB/StuI-EGFP inserts were confirmed by sequencing at
the ASU DNA Core Lab. All restriction enzymes were from New
England Biolabs (Ipswich, MA).
Because LhAQP1 has endogenous BamHI and StuI restriction
sites, we used overlap extension PCR to make the EGFP-LhAQP1 pIB
expression vector variants. To make LhAQP1-EGFP/pIB (chimeric
LhAQP1 with EGFP at carboxyl-terminus), the first PCR reactions
(38LhAQP5 þ LhAQP1-EGFP R and LhAQP1-EGFP F þ EGFP R stop)
amplified the coding sequences for LhAQP1 and EGFP, respectively.
The final PCR amplification used the two previous reactions as
templates with the LhAQP1 gene-specific sense primer 38LhAQP5
and the EGFP-specific antisense primer, EGFP R stop. Similarly, for
EGFP-LhAQP1/pIB (chimeric LhAQP1 with EGFP at amino-
terminus), the first PCR reactions (StuI-EGFP F þ EGFP-LhAQP1 OE
R and EGFP-LhAQP1 OE F þ 39LhAQP3) amplified the coding se-
quences for EGFP and LhAQP1, which were then used as templates
for final PCR using the sense primer StuI-EGFP F and the LhAQP1-
specific antisense primer, 39LhAQP3. Final products were sub-
cloned into pIB/V5-His-TOPO (Invitrogen-Life Technologies) and
DNA was sequenced at ASU DNA Core Lab.
An expression vector with a truncated LhAQP1 beginning at
base position 28 (corresponding to the third methionine in trans-
lated LhAQP1, see Supplemental Fig. 1) and a carboxyl-terminal
EGFP was prepared by overlap extension PCR. The first PCRs used
LhAQP1 Met3 F þ LhAQP1-EGFP R and LhAQP1-EGFP F þ EGFP R
stop to amplify the CDS corresponding to Met3-truncated LhAQP1
and EGFP, respectively. Products of these reactions were used as
templates for final amplification using LhAQP1 Met3 F þ EGFP R
stop and were sub-cloned in pIB/V5-His-TOPO (Invitrogen-Life
Technologies) and sequenced as above.
To compare the cellular localization of LhAQP1 with that of
B. tabaci aquaporin 1 (BtAQP1) we used EGFP-BtAQP1/pIB plasmid
DNA from Mathew et al. (2011) and prepared amino-terminal
domain swaps between LhAQP1 and BtAQP1. To make EGFP-
BtAQP1N-LhAQP1/pIB (chimeric LhAQP1 tagged at amino-
terminus EGFP with 117 bp from 50 of BtAQP1 replacing 207 bp
from LhAQP1 50 end), StuI-EGFP F þ BtAQP1N-LhAQP1 R and
BtAQP1N-LhAQP1 F þ 39LhAQP3 products were used as templates
for overlap extension PCR with StuI-EGFP F þ 39LhAQP3. For EGFP-
LhAQP1N-BtAQP1/pIB (chimeric BtAQP1 tagged at the amino-
terminus with EGFP and with 207 bp from the 50 end of LhAQP1
replacing the first 117 bp of BtAQP1), PCR products from StuI-EGFP
F þ LhAQP1N-BtAQP1 R and LhAQP1-BtAQP1 F þ 20BtAQP3 were
templates for overlap extension PCR with StuI-EGFP F þ 20BtAQP3.
The resulting products from final overlap extension PCR were sub-
cloned and sequenced as above.
Transfections and fluorescent imaging were performed ac-
cording to protocols largely based on those of Hull et al. (2012)
and Mathew et al. (2011). Tni cells maintained as adherent cul-
tures in serum-free insect culture media (Allele Biotechnology)
at 28 "C were transfected in 35 mm #1.5 glass bottom dishes
(In Vitro Scientific, Sunnyvale, CA) with 2 mg plasmid DNA using
Insect GeneJuice transfection reagent (Novagen/EMD Bio-
sciences, Madison, WI) for 5e12 h. Two days post transfection,
media was replaced with IPL1-41 insect media (Invitrogen-Life
Technologies) and cells were imaged using an Olympus FSX-100
fluorescence microscope with FSX-BSW imaging software
(Olympus, Center Valley, PA). Images were processed using
IrfanView (http://www.irfanview.com/) with gamma correction
set at 1.5.
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2.6. cRNA synthesis, Xenopus oocyte expression and permeability
assays
LhAQP ORFs were sub-cloned into a modified Xenopus laevis b-
globin plasmid expression vector (Anthony et al., 2000), linearized
with SacII, and transcribed in vitro (T3 mMessage mMachine;
Ambion-Life Technologies). In vitro-transcribed complementary
RNA (cRNA) corresponded to the full-length ORFs (residues 1e287
for LhAQP1, residues 1e262 for LhAQP2A,1e267 for LhAQP3,1e278
for LhAQP4A, 1e265 for LhAQP5). cRNA (20 ng mL$1) was sus-
pended in sterile water prior to injection.
Unfertilized X. laevis oocytes were defolliculated with collage-
nase (type 1A, 1.5 mg mL$1; Sigma, St. Louis, MO) and trypsin in-
hibitor (15 mg mL$1) in modified OR-2 saline [125 mM NaCl,
3.25 mM KCl, 2.5 mM MgCl2, and 10 mM 4-(2-Hydroxyethyl)
piperazine-1-ethanesulfonic acid (HEPES); pH 7.6] at 18 "C for 1.5 h,
washed in modified OR2 saline solution, and maintained in modi-
fied ND96 saline (96 mM NaCl, 2 mM KCl, 5 mM MgCl2, 0.6 mM
CaCl2, 5 mM HEPES, pH 7.6) supplemented with 100 mg/ml peni-
cillin and 100 U/ml streptomycin, and 10% (V/V) heat-inactivated
horse serum. Oocytes were injected with 50 nL of water contain-
ing 1 ng of LhAQP cRNA and were incubated for 2 or more days at
18 "C to allow protein expression.
For quantitative swelling assays, oocytes incubated in isotonic
modified ND96 saline (without serum or antibiotics) for 1e2 h at
room temperature were tested for water permeability by swelling
in 50% hypotonic saline (isotonic diluted with an equal volume of
water). Glycerol permeability was assayed by measuring swelling
rates of oocytes in saline in which NaCl was partially substituted by
glycerol [31mMNaCl, 130mM glycerol, 2 mMKCl, 5 mMMgCl2 and
5 mM HEPES]. Swelling rates were quantified by relative increases
in oocyte cross-sectional area imaged by videomicroscopy (charge-
coupled device camera; Cohu, San Diego, CA) at 0.5 frames per
second for 45 s using NIH ImageJ software. Rates were measured as
described previously (Anthony et al., 2000; Boassa and Yool, 2003)
using Prism (GraphPad Software Inc., San Diego, CA). Data for
oocyte volume (V), standardized to the initial volume (V0) as a
function of time, were fit by linear regression to determine the
swelling rate from the slope value (V/V0)(s$1 * 105). The University
of Adelaide Animal Ethics committee approved all surgical pro-
cedures and the procedures followed protocols approved under the
Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes.
3. Results
3.1. Cloning, topology and homology of LhAQPs
RT-PCR and primer pairs 1LhAQP5 þ 2LhAQP3,
3LhAQP5 þ 4LhAQP3, 5LhAQP5 þ 6LhAQP3, and
7LhAQP5 þ 8LhAQP3 (Table 1) amplified four partial LhAQP frag-
ments of 638, 759, 717, and 643 bp, respectively, from L. hesperus
2nde3rd instar nymph and adult cDNA. The cloned fragments were
sequenced and BLAST analysis revealed high similarity with the
aquaporin family (data not shown). Using the sequences from the
partial clones, we identified the 50 and 30 ends by RACE and full-
length LhAQP1-4 cDNAs were PCR-amplified, cloned, and
sequenced (Supplemental Fig. 1 and Table 2). Coincidental with the
process of cloning the full-length LhAQP cDNAs, we completed a de
novo assembled Roche 454 transcriptome of L. hesperus adults (Hull
et al., 2013) that independently validated LhAQP1-4 transcripts and
revealed an additional putative full-length aquaporin-like tran-
script, designated LhAQP5.
The 864-bp full-length coding sequence (CDS) of LhAQP1
(KF048092) corresponds to an open reading frame (ORF) encoding
287 amino acids (Supplemental Fig. 1 and Table 2). The predicted
isoelectric point (pI) and molecular weight of LhAQP1 is 5.6 and
29.7 kDa, respectively. While no N- or C-glycosylation sites are
predicted for LhAQP1, one O-glycosylation site is predicted at
Thr19. However, because LhAQP1 has no predicted signal peptide, it
is possible the mature protein is not exposed to glycosylation ma-
chinery. Like other members of the aquaporin superfamily (Murata
et al., 2000), LhAQP1 has two Asn-Pro-Ala (NPA) motifs and resi-
dues predicted to comprise the ar/R constriction (Phe100, His224,
Ser233, and Arg239) (Supplemental Figs. 1, Fig. 1, and Supplemental
Table 1). Seven different TM/topology prediction programs
revealed that LhAQP1 likely has six TM-spanning regions with
intracellular amino- and carboxyl-termini (Table 3 and
Supplemental Table 2), fitting the pattern known for other mem-
bers of the aquaporin superfamily.
Nested 50-RACE PCR using primers 24LhAQP3, 25LhAQP3,
34LhAQP3, and 35LhAQP3 revealed sequence variation resulting in
different start sites for LhAQP2 (Supplemental Fig. 1, Fig. 2, and
Table 2), including LhAQP2A (KF048093, 789-bp CDS encoding 262
amino acids), LhAQP2B (KF048094, 813-bp CDS encoding 270
amino acids), LhAQP2C (KF048095, 885-bp CDS encoding 294
amino acids), LhAQP2D (KF048096, 846-bp CDS encoding 281
amino acids), and LhAQP2E (KF048097, 768-bp CDS encoding 255
amino acids). While all variant LhAQP2s contain the 768-bp CDS
that comprise LhAQP2E, RT-PCR and cloning verified that tran-
scripts for all five full-length variant forms are present in
L. hesperus. Predicted pIs for LhAQP2A-E are 5.1, 5.2, 4.9, 5.6, and 5.4,
respectively. Molecular weights predicted by Compute pI/MW
ExPASy tool for LhAQP2A-E are 27.9, 28.7, 31.2, 30.0, and 28.8 kDa,
respectively. The same two putative N-glycosylation sites (NGSK
and NLTG) were predicted in all LhAQP2 translated sequences.
Several amino-terminal threonines (Thr3 for LhAQP2A-B, Thr4-5
for LhAQP2C, and Thr2 for LhAQP2E) are predicted to be O-glyco-
sylated. No C-glycosylation sites were predicted for LhAQP2A-E. As
for LhAQP1, all LhAQP2s are predicted to lack signal peptide,
glycosylation may not occur on those predicted motifs. In contrast
with many aquaporins that contain two NPA motifs, the LhAQP2s
have one conserved amino-terminal NPA motif and a second motif
comprised of Asn-Pro-Val (NPV). The four residues predicted to
comprise the ar/R selectivity filter (Phe, Ser, Ala, and Arg) are
conserved in all LhAQP2 translated sequences (Supplemental Fig. 1;
Fig. 1, and Supplemental Table 1). Analysis of transmembrane to-
pology indicates that LhAQP2A-E likely have six TM helices with
intracellular amino and carboxyl termini, although Phobius pre-
dicts only five TM helices for all LhAQP2 translated proteins and
RHYTHM and TOPCONS predict seven TM helices for LhAQP2C and
LhAQP2D, respectively (Table 3 and Supplemental Table 2).
LhAQP3 (KF048098) has an 804-bp full-length CDS containing
ORF encoding 267 amino acids (Supplemental Fig. 1 and Table 2).
The predicted pI and molecular weight of LhAQP3 is 5.9 and
28.8 kDa, respectively. While no C-mannosylation sites are pre-
dicted, two N-glycosylation motifs (20-NLSM-23 and 93-NVTW-
96) and three O-glycosylation sites (Thr141, Thr142, and Thr266)
are predicted for LhAQP3. LhAQP3 has an Asn-Pro-Cys (NPC) motif
at residues 89e91 and an NPA motif at residues 207e209
(Supplemental Figs. 1, Fig. 1, and Supplemental Table 1) with
conserved ar/R constriction residues Phe69, Ala195, Gly204, and
Arg210 (Supplemental Fig. 1 and Supplemental Table 1). Predicted
TM topology for LhAQP3 is consistent with known patterns of AQP-
folding, and all seven analyses predicted six TM-spanning regions
and intracellular amino and carboxyl termini (Table 3 and
Supplemental Table 2).
Two full-length LhAQP4 isoforms were identified by RT-PCR and
cloning, with LhAQP4A (KF048099) having CDS of 837 bp encoding
278 amino acids and LhAQP4B (KF048100) having CDS of 798 bp
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Fig. 1. Amino acid sequence alignment of LhAQPs. The deduced amino acid sequences of the LhAQPs were aligned using CLUSTALW. NPA motifs are shown with grey highlight
and residues that correspond to the ar/R constriction site (Phe56, His180, Cys189, and Arg195 from Homo sapiens AQP1, EAL24446.1) are shown in bold. A predicted mercury-
sensitive cysteine (Cys86) from LhAQP3 is shown with white text on black highlight. Identical residues in all sequences are shown as “*” and partial identity or residues with
conserved side chains are shown as “:” and “.”.
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Table 3
Prediction of intra/extracellular and transmembrane topology for Lygus hesperus aquaporins 1e5 (LhAQP1-5).
No. residues Number of predicted transmembrane helices by topology prediction toolsa Consensus positionb
TMPred TMHMM Phobius RHYTHM TOPCONS HMMTOP TopPredII N-terminus C-terminus
LhAQP1 287 6 6 6 6 6 6 6 Inside Inside
LhAQP2A 262 6 6 5 6 6 6 6 Inside Inside
LhAQP2B 270 6 6 5 6 6 6 6 Inside Inside
LhAQP2C 294 6 6 5 7 6 6 6 Inside Inside
LhAQP2D 281 6 6 5 6 7 6 6 Inside Inside
LhAQP2E 255 6 6 5 6 6 6 6 Inside Inside
LhAQP3 267 6 6 6 6 6 6 6 Inside Inside
LhAQP4A 278 6 6 6 6 6 6 6 Inside Inside
LhAQP4B 265 6 5 6 6 6 6 6 Inside Inside
LhAQP5 265 6 5 5 6 7 5 6 Outside Inside
a Predictions of intra/extracellular domains and transmembrane helices were made using TMPred (Hofmann and Stoffel, 1993), TMHMM 2.0 (Krogh et al., 2001), Phobius
(Käll et al., 2004), RHYTHM (Rose et al., 2009), TOPCONS (Bernsel et al., 2009), HMMTOP (Tusnady and Simon, 2001), and TopPredII (Claros and von Heijne, 1994).

























 XP 319584.4 Anopheles gambiae
 Q9NHW7.2 Aedes aegypti
 ABV60346.1 Lutzomyia longipalpis
 XP 001865732.1 Culex quinquefasciatus
 ADD19102.1 Glossina morsitans morsitans
 ADD20045.1 Glossina morsitans morsitans
 Q25074.1 Haematobia irritans exigua
 AAM68740 Drosophila melanogaster
 ABW96354.1 Bemisia tabaci
 Q23808.1 Cicadella viridis
 XP 002425393.1 Pediculus humanus corporis
 BAG72254.1 Coptotermes formosanus
 BAH47554.1 Grapholita molesta
 NP 001036919.1 Bombyx mori
 XP 624531.1 Apis mellifera
 XP 001607940.1 Nasonia vitripennis
 XP 972862.1 Tribolium castaneum
 ACO10737.1 Caligus rogercresseyi
 LhAQP1
 NP 001139377.1 Acyrthosiphon pisum
 NP 001139376.1 Acyrthosiphon pisum
 AAL09065.1 Pyrocoelia rufa
 LhAQP4A
 LhAQP4B
 XP 001607929.1 Nasonia vitripennis
 XP 394391.1 Apis mellifera
 XP 002429480.1 Pediculus humanus corporis
 XP 968342.1 Tribolium castaneum
 NP 001153661.1 Bombyx mori
 ADD19396. 1 Glossina morsitans morsitans
 NP 610686.1 Drosophila melanogaster
 BAF62090.1 Polypedilum vanderplanki
 BAI60044.1 Anopheles gambiae
 XP 001865728.1 Culex quinquefasciatus






 CAC13959.1 Rhodnius prolixus
 NM 001246042 Acyrthosiphon pisum
 BAF62091.1 Polypedilum vanderplanki
 XP 001650168.1 Aedes aegypti
 XP 970728.1 Tribolium castaneum
 NP 788433.2 Drosophila melanogaster
 NP 001106228.1 Bombyx mori
 XP 002430355.1 Pediculus humanus corporis
 XP 001601231.2 Nasonia vitripennis
 EGI59562.1 Acromyrmex echinatior
 EFN76752.1 Harpegnathos saltator
 XP 001948407.1 Acyrthosiphon pisum
 XP 001604170.1 Nasonia vitripennis
 XP 396705.2 Apis mellifera
 XP 002433221.1 Pediculus humanus corporis
 XP 968782.1 Tribolium castaneum
 NP 476837 Drosophila melanogaster
 XP 314890.4 Anopheles gambiae
 XP 001866597.1 Culex quinquefasciatus
 XP 001649747.1 Aedes aegypti
 LhAQP3
 NP 611810.1 Drosophila melanogaster
 XP 002430403.1 Pediculus humanus corporis
 ABI53034.1 Dermacentor variabilis
 XP 002424369.1 Pediculus humanus corporis
 LhAQP5











































Fig. 2. Phylogenetic analysis and classification of LhAQPs and other arthropod aquaporins. Translated LhAQP sequences were compared with other arthropod aquaporins and
the evolutionary history was inferred using the UPGMA method (Sneath and Sokal, 1973) in MEGA5 (Tamura et al., 2011). The bootstrap consensus tree inferred from 10,000
replicates (Felsenstein, 1985) and branches corresponding to partitions reproduced in less than 50% of bootstrap replicates are collapsed. The percentage of replicate trees in which
the associated taxa clustered together in the bootstrap test (10,000 replicates) are shown next to the branches. The evolutionary distances were computed using the Poisson
correction method (Zuckerkandl and Pauling, 1965) and are in units of the number of amino acid substitutions per site. The analysis involved 67 amino acid sequences. All positions
containing gaps and missing data were eliminated. A total of 147 positions were in the final dataset. Taxonomic name and accession number for each sequence is given. Repre-
sentatives from six major arthropod subfamilies (DRIPs, PRIPs, RPIPs, BiBs, DVIPs, and LHIPs) are shown. The proposed subfamily names follow the nomenclature proposed by
Campbell et al. (2008) and includes Drosophila intrinsic proteins DRIPs, Pyrocoelia rufa integral proteins PRIPs, Rhodnius prolixus integral proteins RPIPs, Big Brain BIBs, Dermacentor
variabilis integral proteins DVIPs, and Lygus hesperus integral proteins LHIPs. The group and clade (as indicated by superscript “*” and “**”) correspond to the four groups (1e4) [by
Kambara et al. (2009) and Goto et al. (2011)] or clades (AeD) [by Wallace et al. (2012)], respectively. Revised clades A-E are indicated.
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encoding 265 amino acids. The predicted pI and molecular weight
of LhAQP4A is 6.3 and 29.1 kDa, respectively, and 6.8 and 27.6 kDa
for LhAQP4B. The CDS for LhAQP4A and LhAQP4B are identical
except for 39 bp (positions 757e796) that are missing from
LhAQP4B. This difference likely results from alternative splicing of
an exon encoding 13 amino acids. The LhAQP4B transcript is either
more abundant in L. hesperus and/or preferentially cloned over
LhAQP4A, as 11 of the cloned 47LhAQP5 þ 48LhAQP3 PCR products
corresponded to LhAQP4B versus none for LhAQP4A. LhAQP4A is,
however, present in L. hesperus, as transcripts were found by RACE,
overlap extension PCR, and 454 transcriptome sequencing. Because
LhAQP4A and LhAQP4B only differ after residue 252, both have two
conserved NPA motifs at positions 80e82 and 196e198 and ar/R
residues Phe60, His184, Ser193 and Arg199 (Supplemental Figs. 1,
Fig. 1, and Supplemental Table 1). TM topology analysis indicated
the presence of six TM-helices for LhAQP4A and 5-6 helices for
LhAQP4B, with only TMHMM showing five and a weak probability
score for a sixth putative TM-spanning region corresponding to
residues 170e190 in LhAQP4B (Table 3 and Supplemental Table 2).
The 798-bp CDS of LhAQP5 (KF048101) encodes 265 amino
acids (Supplemental Fig. 1 and Table 2) with a predicted molecular
weight of 28.9 kDa and a pI of 5.6. No C-, N- or O-glycosylation sites
are predicted for LhAQP5. While the size of the translated LhAQP5
and presence of two NPA motifs is consistent with other insect
AQPs (Campbell et al., 2008), the positioning and sequence con-
servation of the motifs differ from those seen in previously char-
acterized insect AQPs. Based on alignment with the other LhAQPs,
the residues comprising what would be the LhAQP5 amino-
terminal NPA motif are instead Cys-Pro-Tyr (Supplemental Figs. 1,
Fig. 1, and Supplemental Table 1). An NPA motif sequence is located
89 residues downstream at position 180e182, however, the spatial
positioning of this motif is not consistent with the classical two-
NPA motif “hour-glass” aquaporin folding pattern (Jung et al.,
1994). A second NPA motif, conserved in the carboxyl terminal
domain in other aquaporins, is located at position 208e210.
Furthermore, other than Phe73, the predicted ar/R constriction
residues are not conserved with orthodox AQPs (Val196, Gly205,
and Leu211) (Supplemental Figs. 1, Fig. 1, and Supplemental
Table 1). TM topology predictions for LhAQP5 varied, but the
consensus topology from TmPred, TMHMM, RHYTHM, HMMTOP,
and TopPredII predicted six TM-spanning regions with intracellular
amino and carboxyl termini (Table 3 and Supplemental Table 2).
Phobius predicted five TM helices and TOPCONS predicted seven
TM regions (Table 3 and Supplemental Table 2).
We used CLUSTALW and MEGA 5.1 UPGMA, Maximum Likeli-
hood, Maximum Parsimony, and Neighbor-Joining phylogenetic
analysis to compare LhAQPs with other arthropod aquaporins
(Fig. 2). Invertebrate aquaporins were previously classified by
Campbell et al. (2008) and Mathew et al. (2011) into at least three
subfamilies (Drosophila intrinsic proteins - DRIPs, Big Brain proteins
- BIBs, and Pyrocoelia rufa integral proteins - PRIPs). More recently
they were grouped into four major clusters [groups 1e4 by
Kambara et al. (2009) and Goto et al. (2011)] or clades AeD (Wallace
et al., 2012). Sequence alignment and phylogenetic analysis of full-
length LhAQP protein sequences with 57 other invertebrate aqua-
porin sequences retrieved from GenBank showed the existence of
at least six distinct families of arthropod AQPs, including DRIPs,
PRIPs, R. prolixus integral proteins e RPIPs, BIBs, Dermacentor var-
iabilis integral proteins e DVIPs, and Lygus hesperus integral pro-
teins e LHIPs (Fig. 2). While analysis by Wallace et al. (2012)
includes BIBs, DRIPs, and PRIPs within a single clade (e.g., A),
analysis here and by others (Kambara et al., 2009; Drake et al.,
2010; Goto et al., 2011; Herraiz et al., 2011) indicates that BIBs are
sufficiently diverged from DRIPs and PRIPs to warrant classification
into a separate clade, which we term clade E using the
nomenclature of Wallace et al. (2012) (Fig. 2). Here, we classify six
subfamilies based on the nomenclature of Campbell et al. (2008)
that are contained within five clades (AeE). Whereas, clades B, C,
and D are identical to those from Wallace et al. (2012), the clade A
described here contains both the DRIP and PRIP subfamilies and
does not contain the BIBs (clade E). Furthermore, of the four AQP
groups from Kambara et al. (2009) and Goto et al. (2011), group 1
corresponds to subfamily DRIP, group 2 corresponds to BIB, group 3
contains both PRIPs and RPIPs, and group 4 corresponds to the new
subfamily LHIP (Fig. 2).
Based on phylogenetic analysis, the LhAQP proteins segregated
into different subfamilies comprising DRIPs (LhAQP1), PRIPs
(LhAQP4A and LhAQP4B), RPIPs (LhAQP2A-E), and LHIPs (LhAQP5).
LhAQP3 is unique and appears to fall outside currently classified
aquaporin-like sequences (Campbell et al., 2008; Kambara et al.,
2009; Goto et al., 2011) and may represent a novel subfamily/
clade of AQPs. Furthermore, while a BIB-like protein has been found
in the hemipteran A. pisum, no lygus BIB-like sequence has yet been
identified.
LhAQP1 alignedwithin the DRIP subfamily of clade A and overall
shares 42% identity with members of that subfamily. LhAQP1 is
most homologous (46% identity) to the B. mori (NP_001036919.1),
A. aegypti (Q9NHW7.2), and Coptotermes formosanus (BAG72254.1)
DRIP-like aquaporins. LhAQP4A and LhAQP4B aligned within the
PRIP subfamily, which also belongs to clade A (Fig. 2). LhAQP4B
shares 41% identity across the PRIP subfamily and is most closely
related with aquaporins from Tribolium castaneum (XP_968342.1)
(45% identity), Pediculus humanus corporis (XP_002429480.1) (45%
identity), Culex quinquefasciatus (XP_001865728.1) (44% identity),
and B. mori (NP_001153661.1) (43% identity).
The LhAQP2s aligned within the RPIP aquaporin subfamily or
clade B (Fig. 2). LhAQP2E shared an average of 36% identity with
other RPIPs, with themost closely related sequences corresponding
to aquaporins from R. prolixus (CAC13959.1) and A. pisum
(NM_001246042.2) having 42 and 35% identity, respectively.
LhAQP5 aligns within subfamily LHIP (clade D) and includes
other putative aquaporin sequences that lack functional charac-
terization (Fig. 2). LhAQP5 shares 41 and 52% identity with
P. humanus corporis (XP_002424369.1) and D. melanogaster
(AAF58409.2), respectively. BLASTanalysis (data not shown) reveals
that these LHIP subfamily members share significant sequence
similarity with vertebrate S-aquaporins 11 and 12, which, although
not well characterized, have highly deviated NPA motifs and are
thought to function in intracellular trafficking of water (Ishibashi,
2006, 2009).
3.2. Temporal expression and tissue localization
Transcriptional expression patterns of the LhAQPs were inves-
tigated using end-point RT-PCR over the life cycle of L. hesperus,
including eggs, nymphs (1st, 2nde3rd, 4the5th instars), and adults.
LhAQP1 transcripts are present in all development stages and most
highly abundant in eggs (Fig. 3A). LhAQP2 and LhAQP5 transcripts
have similar profiles through development, with little or no tran-
scripts evident in eggs, but constitutive expression in all nymphal
instars and adults. LhAQP3 and LhAQP4 transcripts are constitu-
tively present in all developmental stages.
End-point RT-PCR using RNA extracted from different adult
tissues show that LhAQP transcripts are differentially expressed
(Fig. 3B). All five LhAQPs were found in midguts and transcripts for
all but LhAQP5 were present in Malpighian tubules. LhAQP1 tran-
scripts were the only LhAQP abundant in ovaries. LhAQP2 and
LhAQP3 transcripts were found primarily in midguts and Malpi-
ghian tubules. LhAQP4 transcripts were most abundant in male
testes and Malpighian tubules. Surprisingly, in addition to midguts,
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LhAQP5 transcriptswere present in leg tissue. Faint bands were also
visible in leg tissue for LhAQP1, LhAQP3, and LhAQP4.
3.3. Cellular localization
All arthropod aquaporins characterized to date involve intra-
cellular protein synthesis and subsequent translocation to plasma
membranes, where they exhibit their transport function (Campbell
et al., 2008; Cohen, 2013). WOLF PSORT (Horton et al., 2007) pre-
dictions of subcellular localization of each translated sequence
were consistent with presumed functionality; all LhAQPs were
predicted to be associated with the plasma membrane (data not
shown). However, LhAQP2A, LhAQP2E, LhAQP3, LhAQP4A,
LhAQP4B, and LhAQP5 either had potential endoplasmic reticulum
(ER) retention signals, or in the case of LhAQP2A, LhAQP2E, and
LhAQP3, had PSORTII k-NN scores for ER equal to or above those for
the plasma membrane (data not shown).
To examine cellular localization of each LhAQP, chimeric re-
combinant LhAQP proteins taggedwith enhanced green fluorescent
protein (EGFP) were produced in cultured Tni cells. First, we made
LhAQP/pIB constructs with carboxyl-terminal-tagged EGFP
chimeric proteins (Fig. 4A, products #1e11). Examination of
transfected cells by fluorescence microscopy showed that
LhAQP2A-EGFP, LhAQP2B-EGFP, LhAQP2C-EGFP, LhAQP2D-EGFP,
LhAQP2E-EGFP, LhAQP3-EGFP, and LhAQP4B-EGFP recombinant
chimeras were produced and transported primarily to the plasma
membrane in Tni cells (Fig. 4B). LhAQP1-EGFP, LhAQP4A-EGFP, and
LhAQP5-EGFP were not detectable at the cell surface, but rather
were primarily intracellular with distribution patterns consistent
with either localization in the Golgi apparatus (Fig. 4B, panel c and
panel j for LhAQP1-EGFP and LhAQP4A-EGFP, respectively) or the
ER (Fig. 4B, panel l for LhAQP5-EGFP).
Our localization results for LhAQP1-EGFP were unexpected, as
other insect DRIP-like aquaporins are associated with the plasma
membrane (Le Caherec et al., 1997; Duchesne et al., 2003; Liu et al.,
2011; Mathew et al., 2011; Azuma et al., 2012) where they facilitate
transport of cellular and extracellular water. A Met3-LhAQP1-EGFP/
pIB construct (Fig. 4A, product #11) was made to test whether a
truncated LhAQP1 produced using the methionine located at base
27 as the start codon would influence Tni cellular localization. Like
LhAQP1-EGFP, Met3-LhAQP1-EGFP was intracellular (Fig. 4C, panel
a) and exhibited Golgi-like localization (Kawar and Jarvis, 2001).
Furthermore, placement of EGFP at the amino-terminus of LhAQP1
(EGFP-LhAQP1, Fig. 4A, product #12) did not alter the translocation
Fig. 3. Transcriptional profiles of LhAQPs through development and in different tissues. (A) Transcriptional expression of all five LhAQPs in L. hesperus developmental stages.
cDNA was prepared from 1.0 mg of DNase-treated total RNA from eggs (E), 1st instar nymphs (1), 2nde3rd instar nymphs (2), 4the5th instar nymphs (4), and adults (A). The
appropriate annealing temperatures and number of RT-PCR cycles was determined empirically with 25 and 28 cycles shown. Actin was amplified as an internal reference gene and
“e“ designates a no template control. (B) Transcriptional expression profile of all five LhAQPs from dissected L. hesperus tissues. cDNA made from female and male whole bodies (0e
2 d or 3e5 d old adults), heads (H), legs (L), accessory glands (AG), testis (T), ovaries (O), midguts (MG), and Malpighian tubules (MT) were analyzed by RT-PCR (results with 28
cycles is shown). b-tubulin was used as an amplification control for tissues. Products were electrophoresed on 0.8% agarose gels and visualized using SYBR Safe (Invitrogen). Lane M
corresponds to 1 kb Plus DNA Ladder (Invitrogen).
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Fig. 4. Cellular localization of LhAQPs heterologously expressed in cultured Tni cells. (A) Schematic diagram of LhAQPs produced as EGFP chimeras in cultured Tni cells. Re-
combinant LhAQPs were expressed as chimeras with the enhanced green fluorescent protein (EGFP) using the pIB/V5-His TOPO TA (Invitrogen-Life Technologies) insect cell
expression vector in Tni cells. Whereas LhAQP2-5 were all produced with EGFP at their carboxyl termini (products #1e9), recombinant LhAQP1 was produced with EGFP either at
the carboxyl terminus (Product #10) or at the amino terminus (product #12). Product #11 corresponds to a truncated LhAQP1 beginning at base position 28 (corresponding to third
methionine in translated LhAQP1) with EGFP at the amino terminus. Domain swapping was performed between LhAQP1 and B. tabaci AQP1 (BtAQP1) from Mathew et al. (2011)
with product #13 corresponding to the full-length BtAQP1 chimera with EGFP at the amino terminus. Product #14 corresponds to LhAQP1 with 69 residues from the amino
terminus replaced by the first 39 residues from BtAQP1. Product #15 corresponds to a chimeric protein having the first 39 residues of BtAQP1 replaced with 69 residues from the
amino terminus of LhAQP1 produced in frame with the final 223 residues from BtAQP1. (B) Expression of recombinant carboxyl-terminal EGFP-labeled LhAQPs in Tni cells. Cells
were transfected with 2 mg pIB plasmid DNA corresponding to LhAQP1-5-EGFP (panels c-l) using Insect GeneJuice transfection reagent (Novagen/EMD Biosciences) for 5e12 h with
microscopic imaging (top image detecting fluorescence and bottom image is phase contrast) performed two days post transfection. Panel (a) shows untransfected Tni cells and
panel (b) shows cells transfected with EGFP/pIB. Panels (c-l) show cells transfected with LhAQP-EGFP/pIB plasmid DNA. All proteins were produced as chimeras with carboxyl-
terminal EGFP. (C) Domain swapping of LhAQP1 and BtAQP1 amino termini and expression in Tni cells. Panel (a) corresponds to Met3-LhAQP1 (10 residues truncated from
LhAQP1). Panels (b) and (c) show localization of amino-terminal tagged LhAQP1 and BtAQP1, respectively. Panel (d) shows expression of LhAQP1 with the amino terminus of BtAQP1
is at the cell surface, whereas panel (e) shows expression of BtAQP1 with the amino terminus of LhAQP1 is subcellular. All cells were imaged using an Olympus FSX-100 fluorescence
microscope with FSX-BSW imaging software (Olympus, Center Valley, PA) and processed using IrfanView with gamma correction set at 1.5.
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of LhAQP1, indicating the position of EGFP was not responsible for
the observed intracellular localization (Fig. 4C, panel b).
To test the influence of the amino terminus of LhAQP1 on
cellular localization, we produced EGFP chimeras that switched the
first 69 amino acid residues from LhAQP1 with the first 39 residues
from the B. tabaci aquaporin 1 (BtAQP1) and vice versa. Whereas
the addition of the amino terminus of BtAQP1 to LhAQP1 (EGFP-
BtAQP1N-LhAQP1) rescued localization to the cellular plasma
membrane in Tni (Fig. 4C, panel d), the addition of the LhAQP1
amino terminus to BtAQP1 (EGFP-LhAQP1N-BtAQP1) resulted in
impaired translocation, with intracellular fluorescence primarily
limited to small punctae reminiscent of the Golgi apparatus (Fig. 4C,
panel e). These results indicate that the first 69 residues at the
amino terminus of LhAQP1 are responsible for intracellular locali-
zation of LhAQP1 in Tni cells.
3.4. Oocyte functional analysis
The functions of LhAQPs in water and glycerol transport were
tested using the Xenopus oocyte expression system, measuring
volume changes indicative of net influx of water or glycerol in hy-
potonic and isotonic solutions, respectively (Fig. 5A). We observed
significantly higher swelling rates (p < 0.01) in LhAQP1, 2, 3, 4, and
5-injected oocytes in hypotonic saline (mean % SEM 14.4 % 2.5 for
LhAQP1,14.2%1.2 for LhAQP2A, 27.1%2.6 for LhAQP3,19.0% 1.8 for
LhAQP4A, and 13.4 % 0.6 for LhAQP5 V/V0 & 105 & sec$1) compared
to water-injected control oocytes (5.1 % 0.5 V/V0 & 105 & sec$1)
(Fig. 5B). Furthermore, none of the LhAQP-injected oocytes showed
appreciable transport of glycerol, based on the absence of swelling.
Instead, observed negative slopes (Fig. 5A) indicated a slight
shrinkage in the glycerol-substituted saline ($3.1 % 1.3 for
LhAQP1, $5.6 % 2.6 for LhAQP2A, $3.1 %1.3 for LhAQP3, $5.8 % 1.2
for LhAQP4A, and $6.4 % 1.1 for LhAQP5; V/V0 & 105 & sec$1),
indicating relative aquaporin impermeability to glycerol.
4. Discussion
Aquaporins are integral membrane proteins belonging to a large
family of water channel proteins or MIPs that facilitate transport
water and/or other small solutes across cellular membranes (Benga,
2009; Kruse et al., 2006). Because water and solute transport are
universal requirements for living cells, these proteins are found in
most organisms. The total number of invertebrate AQPs identified
in insects is rapidly increasing, with genome sequencing impli-
cating at least 5e8 genes per organism encoding putative AQPs
(Campbell et al., 2008; Drake et al., 2010). High-throughput next
generation transcriptomic sequencing and de novo assembly pro-
vides an opportunity to obtain comprehensive “snapshots” of active
gene transcripts in organisms without prior genomic support (Hull
et al., 2013; Grabherr et al., 2011). Here, we gleaned the tran-
scriptomes of two mirid plant bugs, L. hesperus (Hull et al., 2013)
and L. lineolaris (O.P. Perera, unpublished), to identify expressed
sequence tag (EST) sequences encoding putative AQPs.
Arthropods have multiple functional AQPs, and based on other
animal systems these proteins likely play diverse physiological
roles (Campbell et al., 2008; Gomes et al., 2009). Unfortunately, for
most invertebrates comprehensive molecular and functional char-
acterization of AQPs trails their initial identification. For example,
D. melanogaster has eight putative AQPs, but only two have been
assigned functions (Kaufmann et al., 2005; Yanochko and Yool,
2002). A. aegypti has six putative AQPs and RNAi knockdown was
used to show that three have apparent roles in diuresis in Malpi-
ghian tubules (Drake et al., 2010). However, the roles of those
transcripts in mosquitoes not exhibiting an obvious phenotype are
yet to be defined, and biochemical characterization of all AeAQPs is
not complete. This report attempts to identify and characterize a
complement of AQPs from the hemipteran pest, L. hesperus.
Five full-length LhAQPs that likely represent the primary AQP
transcripts from L. hesperus were cloned and characterized. We
used phylogenetic alignments of LhAQPs with other arthropod
representatives to classify at least six subfamilies of arthropod
AQPs, including three (DRIPs, PRIPs, and BIBs) previously described
by Campbell et al. (2008). Three new subfamilies [named using
nomenclature described by Campbell et al. (2008)] include the
RPIPs (named for R. prolixus integral protein), DVIPs (named for
D. variabilis integral protein), and LHIPs (named for L. hesperus in-
tegral protein). Within these phylogenetic subfamilies, three
functional classes of AQPs have been characterized for arthropods,
including water-specific AQPs, aquaglyceroporins, and monovalent
cation channels (BIBs) (Campbell et al., 2008; Echevarria et al.,
Fig. 4. (continued).
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2001; Duchesne et al., 2003; Le Caherec et al., 1996; Shakesby et al.,
2009; Mathew et al., 2011; Kataoka et al., 2009a; Wallace et al.,
2012; Yanochko and Yool, 2002). An important distinction is that
the functional classes do not necessarily correspond with phylo-
genetic classifications. For example, the RPIP subfamily includes
some AQPs that function to transport water and glycerol/urea and
hence are aquaglyceroporins (Fig. 2). But, not all members of the
RPIP subfamily transport glycerol and are therefore not functional
aquaglyceroporins (includes PvAQP2 in Kikawada et al., 2008; the
LhAQP4 isoforms, Fig. 5) [see Supplemental Table 1 for phylogenetic
and functional classification of representative invertebrate AQPs].
Phylogenetic analysis assigned the LhAQP proteins to different
subfamilies, including DRIPs (LhAQP1), PRIPs (LhAQP4A and
LhAQP4B), RPIPs (LhAQP2A-E), and LHIPs (LhAQP5). The arthropod
DRIP subfamily includes a number of water-specific AQPs generally
promoting fluid homeostasis by moving water through tissues to
facilitate excretion and/or maintenance of osmotic potential
(Campbell et al., 2008; Mathew et al., 2011). Based on conserved
AQP motifs and sequence similarity (Fig. 2), predicted topology
(Table 3 and Supplemental Table 2), and formation of water-specific
pores in Xenopus oocytes (Fig. 5), LhAQP1 is a water-specific AQP
from the DRIP subfamily. Two LhAQP4 isoforms belong to the
arthropod PRIP subfamily which includes AQPs with diverse
physiological functions, such as water recycling in the crypto-
nephric rectal complex (Azuma et al., 2012), hydration and dehy-
dration responses to environmental stress (Kikawada et al., 2008),
and water and nitrogen homeostasis during oogenesis (Herraiz
et al., 2011). The LhAQP2 isoforms belong to the RPIP arthropod
subfamily, which contains a number of AQPs with putative multi-
functional transport channel functions, including the aqua-
glyceroporins. Members of the RPIP subfamily are important for
osmoregulation and Buchnera symbiosis in aphids (Wallace et al.,
2012), water homeostasis in fat body (Kikawada et al., 2008),
urine formation (Echevarria et al., 2001), and water homeostasis/
urea excretion in midgut and Malpighian tubules (Kataoka et al.,
2009a). We classify LhAQP5 into a new subfamily of arthropod
AQPs called the LHIPs. These proteins share similarity with
‘superaquaporins’ (Morishita et al., 2004) or “S-aquaporins”
(Ishibashi, 2006), which are quite diverged from other families of
AQPs. These divergences include altered NPAmotifs and anomalous
subcellular localization (Ishibashi, 2006, 2009; Nozaki et al., 2008;
Calvanese et al., 2013). Although LhAQP3 transports water (and not
glycerol) in Xenopus oocytes, it falls outside currently classified
aquaporin-like sequences and may represent an additional un-
classified subfamily of water-transporting AQPs (Fig. 2). Contigs
encoding a BiB-like protein were not found in our search of the
L. hesperus or L. lineolaris transcriptomes.
Two canonical NPAmotifs alongwith residues that comprise the
ar/R constriction site (Sui et al., 2001; Beitz et al., 2006) are critical
for determining the selectivity for solutes that transverse the AQP
channel. Of the LhAQPs, only LhAQP1 and LhAQP4 have two
conserved NPA motifs (Fig. 1 and Supplemental Table 1). Both
LhAQP3 and LhAQP5 have substitutions within the first NPA motif
(Asn-Pro-Cys for LhAQP3; Cys-Pro-Tyr for LhAQP5), and for LhAQP2
the second NPA motif is Asn-Pro-Val (Fig. 1 and Supplemental
Table 1). In human AQPs, four residues (Phe56, His180, Cys189,
and Arg195 from AQP1 and Phe77, His201, Ala210, and Arg216 from
AQP4) form the narrowest restriction point within the AQP water
channel that is only slightly larger than size of a single water
molecule (Sui et al., 2001; Beitz et al., 2006; Ho et al., 2009). The
corresponding ar/R constriction residues for LhAQPs include Phe/
His/Ser/Arg for LhAQP1, Phe/Ser/Ala/Arg for LhAQP2, Phe/Ala/Gly/
Arg for LhAQP3, Phe/His/Ser/Arg for LhAQP4, and Phe/Val/Gly/Leu
for LhAQP5 (Fig. 1 and Supplemental Table 1). Wallace et al. (2012)
reported that insect MIPs (including some aquaglyceroporins)
within the RPIP subfamily (clade B from Wallace et al., 2012) have
small neutral residues at position H5 that contribute to a wider,
more hydrophilic ar/R constriction, which is required for passage of
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Fig. 5. Osmotic water and glycerol permeability of Xenopus oocytes expressing LhAQPs. (A) Representative examples of mean swelling rates (%SEM) of control and LhAQP1-
expressing oocytes as a function of time after introduction of oocytes into 50% hypotonic saline or isotonic glycerol-substituted saline at time zero. Volumes of the oocytes at
each time point (V) are standardized to the initial area at time zero (Vo). (B) Compiled swelling rates (slope values of linear regression fits of V/Vo versus time) showed significant
osmotic water permeability of LhAQP-expressing oocytes (LhAQP1-5) compared with control oocytes (ANOVA and post-hoc Bonferroni tests, with ** indicating p < 0.01 and
***p < 0.001). No significant glycerol permeability was found using saline in which 130 mM glycerol replaced 65 mM NaCl. Box plots show 25th and 75th quartiles (box), median
values (solid horizontal line within box), and error bars span the full range of data points. Sample sizes (n) are shown near the x-axis.
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larger solutes. However, we found that none of the LhAQPs facilitate
the transport of glycerol in Xenopus oocytes, including LhAQP2,
LhAQP3, or LhAQP5, which contain similar ar/R residues to those
found in other insect aquaglyceroporins. Therefore, insect AQPs
may have diverse functional roles that are not necessarily predicted
by sequence conservation. Residues yet to be defined could addi-
tionally influence permeation pathways in the AQP channel and
participate in defining solute permeabilities.
Levels of LhAQP transcripts differed little during L. hesperus
development with all five apparently constitutively present in
nymphs and adults (Fig. 3A). LhAQP1, 3, and 4 transcripts were
detected in eggs (Fig. 3A), indicating a possible role in embryonic
development. It is not knownwhether these LhAQP transcriptswere
embryonic ormaternally derived. LhAQP transcripts are abundant in
various adult L. hesperus tissues (Fig. 3B), with all LhAQPs present in
Malpighian tubules and LhAQP1-4 present in the midgut. These
results are consistent with reports of other AQPs associated with
fluid absorption and excretion in arthropods (Spring et al., 2009; Le
Caherec et al., 1997; Echevarria et al., 2001; Kaufmann et al., 2005;
Kataoka et al., 2009a; Liu et al., 2011; Mathew et al., 2011; Azuma
et al., 2012). LhAQP1 is the only transcript found in ovaries, and
LhAQP4 is abundant inmale testes (Fig. 3B). The presence of LhAQPs
in reproductive tissues is not unprecedented, as 12 of 13 known
mammalian AQPs are expressed in female and male reproductive
systems [reviewed in Zhang et al., (2012)]. Vertebrate AQPs have
numerous known functions in males, including spermatogenesis,
seminal fluid production, and fluid transport in testis and numerous
ducts and tubules (Zhang et al., 2012). Vertebrate females have AQPs
that function in tubal fluid transport, water homeostasis of the
uterus, cervix, placenta, and oviduct, maintenance of amniotic fluid,
gamete transport and fertilization, early embryo development, and
implantation (Zhang et al., 2012). Arthropod AQPsmayalso function
in reproduction, including those found in ovaries of the tick
D. variabilis (Holmes et al., 2008), the cockroach B. germanica
(Herraiz et al., 2011), and the mosquitoes A. aegypti (Drake et al.,
2010) and A. gambiae (Liu et al., 2011). Interestingly, transcripts
from all five LhAQPs were detected in leg tissue, which could indi-
cate a possible role in muscle respiration. Indeed, water transport is
important in flight muscles during periods of high-energy demand
(Wigglesworth, 1965; Wigglesworth and Lee, 1982) and a water-
specific AQP identified in A. aegypti Malpighian tubules has been
shown to be involved in respiration by transporting water through
tracheolar cells (Duchesne et al., 2003).
Heterologous expression of LhAQP-EGFP chimeras in Tni cells
showed that LhAQP2 (isoforms A-E), LhAQP3, and LhAQP4B are
produced and transported to the cell surface (Fig. 4B). Carboxyl-
terminal EGFP-tagged LhAQP1, LhAQP4A, and LhAQP5 were like-
wise produced in Tni cells but did not localize at the plasma
membrane. They instead localized primarily to cytosolic punctae
(LhAQP1 and LhAQP4A) reminiscent of the Golgi apparatus (Kawar
and Jarvis, 2001) or exhibited a diffuse cytosolic distribution with a
prominent perinuclear ring (LhAQP5) similar to that described
(Thomas et al., 1998) for endoplasmic reticulum localization
(Figs. 4B, C). We also performed domain-swapping experiments
between LhAQP1 and the B. tabaci AQP1 (BtAQP1) previously
shown to translocate to the cell surface in cultured insect cells
(Mathew et al., 2011). Here, the replacement of the amino-terminus
of BtAQP1 with that of LhAQP1 prevented the chimera from
reaching the cell surface (Fig. 4C). Furthermore, when the amino
terminus of LhAQP1 was replaced with that of BtAQP1, localization
to the cellular plasmamembrane in Tni was rescued (Fig. 4C). These
results indicate that some LhAQPs may either have an intracellular
localization or that L. hesperus and Tni cells differ such that some
proteins are not correctly processed by the Tni intracellular protein
trafficking machinery. The latter is likely for LhAQP1. LhAQP5
however, might have subcellular function, as it resembles other
superaquaporins thought to function as intracellular water chan-
nels that regulate free and bound water movement across subcel-
lular organelle membranes (Ishikawa et al., 2005; Nozaki et al.,
2008; Ishibashi, 2006).
S-aquaporins or superaquaporins represent a subfamily of AQPs
characterized as having relatively poor sequence similarity with
other AQPs and atypical NPA motifs (Morishita et al., 2004;
Ishibashi, 2006). Here, we report the first functional S-aquaporin
(LhAQP5) from an insect. Both plants and animals have S-aqua-
porins with atypical amino-terminal NPA motifs (HsAQP11,
HsAQP12, SIP1.1, SIP1.2, and SIP2.1) (Supplemental Table 1). These
AQPs localize on the membrane of intracellular organelles
(Ishikawa et al., 2005; Morishita et al., 2005; Itoh et al., 2005) and
are thought to participate in the transport of intracellular water
through cell organelles, regulation of organelle volume, regulation
of intracellular waste products via secretory granules, and main-
tenance of cellular activities through the distribution of free water
(Nozaki et al., 2008). Several S-aquaporins have high lysine content
at their carboxyl termini that may act as ER-localization signals
(Cosson and Letourneur, 1994), including LhAQP5 with residues
261-KEKD-264 that resemble carboxyl terminal ER retention mo-
tifs. Furthermore, Guan et al. (2010) indicates that NPA motifs are
important for targeting orthodox AQPs to the plasma membrane
and the atypical NPA motifs of the S-aquaporins may aid in their
subcellular localization.
Water homeostasis is a critical function for all life. Animals
(including insects) have developed both behavioral and physio-
logical adaptations to facilitate osmoregulation and balance inter-
nal water equilibrium with water lost to the environment.
Terrestrial insects in particular are under continuous osmotic stress
and must balance water losses to evaporation through the cuticle,
respiratory transpiration, and excretion, and gain water by direct
ingestion of fluids, generation of metabolic water, and/or absorp-
tion of atmospheric water vapor (Cohen, 2013). Disrupting water
balance by targeting the osmoregulatory system including water
channel proteins in arthropod pests remains a promising avenue
for developing selective and environmentally compatible pest
control strategies (Cohen, 2013). However, there are no commer-
cially effective and selectivemethods yet available that target either
water channels or the regulatory pathways controlling water ho-
meostasis in arthropod pests. Furthermore, arthropods have
evolved mechanisms by which critical functions (such as embryo-
genesis, immunity, apoptosis, membrane transport, digestion,
metamorphosis, neural-motor function, to name a few) may have
redundant or compensatory routes of activity (Masel and Siegal,
2009; Moczek et al., 2011). Indeed, insects produce multiple AQPs
with overlapping tissue expression patterns (see Fig. 3B; Drake
et al., 2010) and knockdown of individual AQP transcripts by
RNAi does not necessarily lead to negative phenotypes (Shakesby
et al., 2009; Drake et al., 2010; Herraiz et al., 2011), which is
indicative of possible functional redundancy. Yet, the AQPs and the
mechanisms by which water homeostasis is maintained remain
promising areas of research that may lead to new controls for pests
of medical and agricultural importance (Cohen, 2013). Further
studies are needed to develop comprehensive models of arthropod
AQP function and novel strategies to disrupt osmoregulation.
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Pharmacological blockade of aquaporin-1
water channel by AqB013 restricts
migration and invasiveness of colon cancer
cells and prevents endothelial tube
formation in vitro
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Abstract
Background: Aquaporins (AQP) are water channel proteins that enable fluid fluxes across cell membranes,
important for homeostasis of the tissue environment and for cell migration. AQP1 knockout mouse models of
human cancers showed marked inhibition of tumor-induced angiogenesis, and in pre-clinical studies of colon
adenocarcinomas, forced over-expression of AQP1 was shown to increase angiogenesis, invasion and metastasis.
We have synthesized small molecule antagonists of AQP1. Our hypothesis is that inhibition of AQP1 will reduce
migration and invasiveness of colon cancer cells, and the migration and tube-forming capacity of endothelial cells
in vitro.
Methods: Expression of AQP1 in cell lines was assessed by quantitative (q) PCR, western blot and
immunofluorescence, while expression of AQP1 in human colon tumour tissue was assessed by
immunohistochemistry. The effect of varying concentrations of the AQP1 inhibitor AqB013 was tested on human
colon cancer cell lines expressing high versus low levels of AQP1, using wound closure (migration) assays, matrigel
invasion assays, and proliferation assays. The effect of AqB013 on angiogenesis was tested using an endothelial cell
tube-formation assay.
Results: HT29 colon cancer cells with high AQP1 levels showed significant inhibition of migration compared to
vehicle control of 27.9 % ± 2.6 % (p < 0.0001) and 41.2 % ± 2.7 (p <0.0001) treated with 160 or 320 μM AqB013
respectively, whereas there was no effect on migration of HCT-116 cells with low AQP1 expression. In an invasion
assay, HT29 cells treated with 160 μM of AqB013, showed a 60.3 % ± 8.5 % decrease in invasion at 144 hours
(p < 0.0001) and significantly decreased rate of invasion compared with the vehicle control (F-test, p = 0.001).
Almost complete inhibition of endothelial tube formation (angiogenesis assay) was achieved at 80 μM AqB013
compared to vehicle control (p < 0.0001).
Conclusion: These data provide good evidence for further testing of the inhibitor as a therapeutic agent in
colon cancer.
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Background
Colorectal cancer (CRC) is the third most commonly di-
agnosed cancer and the third leading cause of death
resulting from cancer in the USA [1]. In Australia it is
the second most commonly reported cancer diagnosis
after prostate cancer, and the second leading cause of
death after lung cancer [2]. A major determinant of pa-
tient prognosis is the stage at which the cancer is diag-
nosed, as surgery is considered curative in up to 70 % of
early stage cases. Screening programs have helped with
early diagnosis and intervention, but for those not par-
ticipating in such programs some 12-25 % of CRC pa-
tients still present with advanced (stage IV) disease [3].
Furthermore, up to 30 % of patients diagnosed with early
localised CRC (stage I or II) and up to 50 % with re-
gional spread to lymph nodes or adjacent organs (stage
III) eventually relapse with overt metastatic disease fol-
lowing ‘curative’ surgery [4]. Adjuvant chemotherapy is
offered to stage III patients to eradicate potentially exist-
ing micro-metastases but the indication for such treat-
ment in stage II disease is less certain where the benefit
shown in clinical trials is small in absolute terms and
thus the risk of fluorouracil toxicity likely outweighs the
benefit [5]. The dilemma is finding a balance between
the benefit of therapy, which may be incremental, and
risk of harm, and to that end discovery of new thera-
peutic targets and pharmacological agents is a continu-
ing goal for improving adjuvant cancer therapy.
Aquaporins (AQP) and their role in cancer progression
Mammalian aquaporins are a family of 13 classes of in-
trinsic membrane proteins that assemble as tetramers
(~30 kDa per subunit) and are known for their role in
fluid homeostasis and trans-membrane transport of
water and other small solutes [6, 7]. Specific classes of
AQP channels have been implicated in enhanced migra-
tion, angiogenesis and metastasis in a variety of cancer
types [8, 9], prompting the suggestion that inhibitors of
AQP channels might provide new tools for cancer ther-
apy [8]. The role of AQP1 in tumour migration and
angiogenesis was first demonstrated in a murine melan-
oma tumour model: in AQP1 null mice tumours were
smaller with fewer micro-vessels and more extensive ne-
crosis as compared to AQP1 wild type mice, suggesting
that AQP1 deletion impaired endothelial cell prolifera-
tion and angiogenesis [10]. AQP1 involvement in angio-
genesis has been confirmed in other studies: in a murine
melanoma tumour model, mice treated with AQP1 short
interfering (si) RNA had significantly smaller tumours
and lower microvessel and endothelial marker (factor
VIII) densities compared to control mice, suggesting
AQP1 knockdown impaired tumour growth and angio-
genesis [11]. In mice with genetic deletion of AQP1,
microvessel density was significantly reduced and also
the number of lung metastases (5 ± 1/mouse) as com-
pared with AQP1-expressing mice from the same gen-
etic background (31 ± 8/mouse, P < 0.005) [12]. Colon
tumour cells over-expressing AQP1 exhibited increased
migratory and invasive capacity in wound healing (mi-
gration) and transwell invasion assays [13]. Over-
expression of AQP1 in tumour cell lines resulted not
only in a predicted increase in cell membrane water per-
meability, but also a 2 to 3-fold accelerated migration
rate of the AQP1-expressing tumour cells as compared
to control cells in vitro. AQP1 over-expression in mice
increased the extravasation of tumour cells injected via
the tail vein compared to control mice, and increased by
3-fold the number of lung metastases [14].
It is through enhanced water flux mediated by the AQP
channels that cells are believed to acquire an enhanced
migratory and invasive phenotype [13, 15]. Interestingly,
AQP1 has been shown by our group to have dual water
channel and gated ion channel functions [16, 17]. The
AQP blocker AqB013, a derivative of bumetanide, has
been characterised as a dose-dependent inhibitor of os-
motic water fluxes mediated by mammalian AQP1 and
AQP4 channels analysed in the Xenopus laevis expression
system. AqB013 was shown to inhibit the AQP1 water
channel function when applied extracellularly, and is
thought to cross the membrane to occlude the water
channel pore from the cytoplasmic side of the AQP1
channel [18]. Work here is the first to test the efficacy of
AqB013 in inhibiting migration, invasion and angiogenesis
in colon cancer cell line models.
Methods
Cell lines and cell culture
HT29 and HCT-116 colon cancer cell lines (ATCC,
Manassas, USA) were cultured in complete medium com-
posed of DMEM (Life Technologies, Carlsbad, CA, USA)
supplemented with 1 x glutaMAX™ (Life Technologies), 1
x penicillin-streptomycin solution (Life Technologies) and
10 % foetal bovine serum (FBS). Cultures were maintained
in 5 % CO2 at 37 °C. Their authenticity was confirmed
(CellBank Australia, Melbourne, Vic). Human umbilical
vein endothelial cells (HUVEC) (PromoCell, Heidelberg,
Germany) were cultured in endothelial growth medium
(PromoCell) according to the protocol supplied, and
maintained in 5 % CO2 at 37 °C. Cells were confirmed to
be negative for mycoplasma using the Universal Myco-
plasma Detection kit (ATCC) according to the manufac-
turer's protocol.
Colon tissue samples
Human colon tumour and matched normal mucosal tis-
sue samples were obtained from 57 patients undergoing
surgery for CRC at The Queen Elizabeth Hospital. The
protocol was approved by The Queen Elizabeth Hospital
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Ethics of Human Research Committee (approval no.
1993059) and informed consent was obtained in all
cases.
Expression analysis of AQP1
Quantitative PCR
Cells at 70-80 % confluence were harvested and RNA
extracted using the PureLink™ RNA Mini kit (Life Tech-
nologies). RNA was extracted from the frozen archived
colon tumour and matched normal mucosa samples by
pulverizing tissue under liquid nitrogen, and extracting
RNA as before. RNA concentration was quantified using
the NanoDrop 2000 spectrophotometer (Thermo Scien-
tific, Waltham, MA, USA) and the integrity (RIN score)
assessed using the 2100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA). RNA (500 ng) was reverse
transcribed using the iScript™ cDNA synthesis kit (Bio-
rad, Carlsbad, CA, USA). qPCR of AQP1 and the refer-
ence gene phosphomannose mutase 1 (PMM1) [19] was
performed using multiplex Taqman expression assays
(Life Technologies), in triplicate via the CFX96™ Ther-
mal Cycler (Bio-Rad). Each reaction contained 0.75 μL
of each TaqMan® Gene Expression Assay (Life Technolo-
gies), 2 μL cDNA, 4.0 μL ultrapure water (Fisher Biotec,
Wembley, WA, Australia) and 7.5 μL SsoFast™ probes
supermix (Bio-rad) in a total volume of 15 μL. Results
were calculated according to the 2-ΔΔCt relative quantifi-
cation method.
Western blot
Cells were lysed with RIPA buffer containing 1 % β-
mercaptoethanol, 1 % HALT protease inhibitor 100X so-
lution, 150 U Benzonase (all from Sigma, St Louis, MO,
USA) on ice for 10 minutes, homogenized by passing
through a 21 gauge needle and centrifuged at 14,000 x g
for 15 minutes at 4 °C to pellet the cell debris. As AQP1
can be glycosylated [20], the supernatant was treated
with PNGaseF (Promega, Madison, WI, USA) to cleave
N-linked oligosaccharides. Protein was quantified (EZQ®
assay, Life Technologies) and 50 μg of each sample was
resolved by SDS-PAGE on a 12 % Mini-Protean® TGX
Stain-Free™ Gels (Bio-Rad) and transferred to PVDF
membranes using the Trans-Blot® Turbo™ Transfer Pack
and System (Bio-Rad). Membranes were blocked with
TBST containing 5 % skim milk for 1 hour and incu-
bated overnight at 4 °C with anti-AQP1 rabbit polyclonal
(H-55) (1/500; Santa Cruz Biotechnology Inc, Santa
Cruz, CA, USA). Following three washes in TBST, mem-
branes were incubated with goat anti-rabbit IgG HRP
secondary antibody (1/2000) and Streptactin-HRP
Conjugate (1/10000) (both from Bio-Rad) at room
temperature for 1 hour, and washed. Chemilumines-
cence substrate was applied (Clarity™ Western ECL
Blotting Substrate, Bio-Rad) and blots analysed using the
ChemiDoc™ Touch Imaging System (Bio-Rad). Image
Lab™ Software (Bio-Rad) was used for relative quantifica-
tion of bands, normalized to total protein loaded in each
lane.
Immunofluorescence
Cells grown on coverslips at 80 % confluence were fixed
with 4 % paraformaldehyde and permeabilized with 0.5
% triton X-100. Image-iT® FX Signal Enhancer (Life
Technologies) was applied directly to cover slips in ac-
cordance with manufacturer’s instructions. Cells were
stained with a 1/400 dilution of rabbit polyclonal anti-
human AQP1 (Abcam®, Cambridge, UK) and for the
antibody isotype matched control, a 1/400 dilution of
normal rabbit IgG was used (Cell Signaling Technology,
Beverly, MA, USA). Cells were then stained with a 1/200
dilution of goat anti rabbit IgG H&L (Alexa Fluor® 568)
secondary antibody (orange fluorescence) and the nuclei
stained with NucBlue® Fixed Cell Ready Probes™ Reagent
(blue fluorescence) (both from Life Technologies).
Coverslips were mounted on slides with ProLong® Gold
antifade reagent (Life Technologies), and images cap-
tured using the Zeiss LSM 700 microscope (Carl Zeiss
Microscopy, Jena, Germany).
Immunohistochemistry
Tissue sections (5 μm) were deparaffinised by heating at
55-60 °C for 2 hours, soaking in xylene and hydrating by
passing through a graded series of ethanol to water.
Antigen retrieval was carried out by microwaving the
slides in 10 mM sodium citrate for 20 mins. Endogenous
peroxidase was quenched by incubating the slides in
Peroxidazed I reagent (Biocare Medical, Concord, CA,
USA) for 5 min and background staining was blocked by
incubation in Background Sniper reagent (Biocare
Medical). Slides were stained using a 1:100 dilution of
AQP1 monoclonal antibody 10C11 (Abcam, Cambridge,
UK) and detected using the MACH 3™ mouse HRP poly-
mer detection system according to the manufacturer’s
protocol (Biocare Medical). Slides were counterstained
in haematoxylin (Sigma-Aldrich, St Louis, MO, USA).
AQP1 inhibitor and vehicle control
AqB013 was dissolved in dimethyl sulfoxide (DMSO) at
a 100 mM (stock solution), which was diluted into
complete medium to yield the indicated working con-
centrations for the experiments. DMSO was used as the
vehicle control at a dilution equivalent to that in the
highest dose of the drug used in the treatments.
Effect of AQP1 inhibition on cell migration (wound
healing assay)
HT29 or HCT-116 cells were grown in complete
medium (DMEM with 10 % FCS) to 80-90 % confluence
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in triplicate wells of a 24-well untreated plastic tissue
culture plate, serum starved overnight, then treated with
1 μg/mL mitomycin C in complete medium to prevent
cells from proliferating. Wells were treated with increas-
ing amounts of the inhibitor with vehicle (DMSO) as
control. A p10 pipette tip was used to scratch a wound
through the cell monolayer and cells were monitored as
they migrated across the wound using a Nikon Eclipse
microscope (40X magnification) at time 0, 16, 32, 48, 64
and 80 hours: 20 measurements were taken of the
wound width at each time point using the NIS-Elements
software and averaged. Wound closure was calculated as
a percentage relative to the initial wound width.
Spheroid basement membrane extract (BME) invasion
assay
Cells were cultured into spheres in an ultra-low attach-
ment plate according to the manufacturer's protocol
(Cultrex® 3D 96 Well Spheroid BME Cell Invasion
Assay, Trevigen™), then covered with Invasion Matrix (a
proprietary extracellular matrix blend comprised of
basement membrane extract, derived from murine EHS
sarcoma cells and collagen) together with the inhibitor
AqB013 from 0 (untreated) to 160 μM, and with vehicle
control. The area of the sphere was measured at each
time point to assess invasion into the surrounding
matrix, using the NIS-Elements software. The change in
sphere area was calculated as a percentage relative to the
initial sphere size; percent invasion of the test sphere
was subtracted from the percent invasion of the vehicle
control to indicate the extent of invasion into the
matrix.
Cell proliferation assay
HT29, HCT-116 or HUVEC were grown overnight, then
AqB013 was added to triplicate wells from 0 (untreated)
up to 320 μM. DMSO was added to triplicate wells as
vehicle control. Proliferation was quantified after 48
hours using the Cell Titer 96® Aqueous Non- Radio-
active cell Proliferation Assay (Promega) and absorbance
at 490 nm read on a FLUOstar OPTIMA 96 well micro-
plate reader (BMG Lab Tech, Ortenberg, Germany).
Angiogenesis assay
Human umbilical vein endothelial cells (HUVECs) were
seeded at 1 x 104 cells per well in a 96 well plate pre-
coated with BME (basement membrane extract: recon-
stituted protein matrix comprised of laminin, collagen
IV, entactin, and heparin sulphate proteoglycan) and in-
cubated in endothelial growth medium (PromoCell,
Heidelberg, Germany) containing VEGF according to
the Cultrex In Vitro Angiogenesis Assay Kit protocol
(Trevigen, Gaithersburg, MD, USA). Wells were treated
in triplicate with AqB013 from 0 (untreated) to 80 μM
and with vehicle as a control. Cells were stained with
Calcein AM dye at 24 hrs and imaged using a Nikon
Eclipse fluorescence microscope. Endothelial tube for-
mation was quantified as the number of junctions
formed.
Statistical analysis
Statistical analysis was carried out in Graph Pad® prism
5. A one-way ANOVA with Tukey’s multiple compari-
sons test was carried out for qRT-PCR results, for prolif-
eration assays and for the angiogenesis assays. For the
migration and invasion assays, a two-way ANOVA was
performed to determine the significance between the
data points of the final time point, also a first order poly-
nomial regression was fitted to the data sets and an F-
test used to determine significance (p < 0.05). Statistical
significance was accepted at p < 0.05.
Results
Expression of AQP1
Of the cell lines, the human umbilical vein endothelial
cells (HUVEC) showed the highest expression of AQP1,
HT29 showed a moderate level of expression, while
HCT-116 showed a low level of expression. The range of
expression levels was similar to that found in patients'
tumour samples (Fig. 1a). Using the 2-ΔΔCt relative quan-
tification method, AQP1 was over-expressed (by >1.6-
fold) in 22/57 (39 %) colon tumours compared to
matched normal mucosa (Fig. 1b). Western blot (Fig. 1c)
shows bands at approximately 28 KDa and relative quan-
tification confirmed that AQP1 expression in HCT-116
cells was reduced by 67 % compared to HT29 cells, and
by 72 % compared to HUVEC (Fig. 1d). Immunofluores-
cence staining showed both cytoplasmic and membrane
AQP1 expression in HT29 cells (Fig. 1e). Immunohisto-
chemistry of colon tumour sections showed that AQP1
is expressed variably in the apical membrane and in the
cytoplasm. The range in staining for AQP1 concurs with
the range of expression levels in tumour tissue at the
mRNA level (Fig. 1a). In malignant crypt epithelial cells
the expression of AQP1 varies from low intensity 1+
(Fig. 1f ), moderate intensity 2+ (Fig. 1g) and high inten-
sity 3 + (Fig. 1h): Endothelial cells of the micro-vessels
show high staining intensity (arrows in Fig. 1 f–h) and
reflects the high expression of AQP1 in endothelial cells
at the mRNA level (HUVEC Fig. 1a).
Treatment with AqB013 slows migration of colon cancer
cells expressing significant amounts of AQP1
At the final time-point HT29 cells treated with 160 μM
or 320 μM AqB013 had a significantly reduced wound
closure compared to vehicle control of 27.9 % ± 2.6 % (p
< 0.0001) and 41.2 % ± 2.7 (p <0.0001) respectively (2-
way ANOVA with Bonferroni post hoc test) (Fig. 2a).
Dorward et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:36 Page 4 of 9
The dose response curve showed that the IC50 was
132.7 μM, Hill Slope -2.8. Treatment of HCT-116 cells
(low level of AQP1 expression) with AqB013 showed no
significant effect on migration (Fig. 2b).
Treatment with AqB013 reduces invasion of colon cancer
cells
The area of the spheres was measured as the cells in-
vaded the surrounding matrix. For HT29 spheres
treated with 80 μM or 160 μM of AqB013, there was
a 59.5 % ± 1.4 % (p = 0.0003) or 60.3 % ± 8.5 % (p <
0.0001) decrease in invasion respectively at 144 hours
compared to the vehicle control (Fig. 2c). A reduced
rate of invasion was also found compared to the ve-
hicle control (F-test, p = 0.001). The IC50 was 55.6
μM, Hill Slope -5.17. Treatment of HCT-116 with
AqB013 showed no significant effect on spheroid in-
vasion (Fig. 2d). There was no appreciable cytotoxic
effect as there was no effect on proliferation of HCT-
116 at concentrations of AqB013 up to 320 μM, al-
though there was a small decrease in proliferation of



































































































Fig. 1 AQP1 expression. (a) relative expression of AQP1 (qPCR) in HUVEC, colon cancer cell lines, and human colon tumours (error bars show
mean ± SEM; ** p = 0.004 ANOVA); (b) relative expression of AQP1 in CRC patients’ tumours compared to their matched normal mucosa. (c)
western blot showing AQP1 monomer: lane 1 HUVEC, lane 2 HCT-116, lane 3 HT29. (d) corresponding quantification of bands using Image Lab™
Software (Bio-Rad); (e) immunofluorescence (IF) of HT29 colon cancer cells stained with anti-AQP1 and goat anti-rabbit secondary–Alexa 468
conjugate (orange) with NucBlue® stained nuclei overlay (63 x objective, scale bar = 10 μm). (f, g, h) immunohistochemistry of colon tumour
sections staining for AQP1: F low, G moderate, H high expression. Arrows show examples of strong AQP1 staining of microvessels (20 x objective,
scale bar = 0.1 mm)
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Treatment of endothelial cells with AqB013 markedly
inhibits tube formation
Compared to vehicle control, treatment of HUVECs
with 40 μM AqB013, showed a 43 % reduction in the
number of junctions formed (34.0 ± 3.0, p < 0.01) while
treatment with 80 μM AqB013 resulted in a reduction of
89.5 % (6.3 ± 2.4, p < 0.0001) (Fig. 3a–d). As expected
there was no significant difference in the number of
junctions formed between untreated and vehicle treated
HUVECs (64.3 ± 3.0 versus 60 ± 2.5 respectively) (Fig. 3e).
There was no effect on viability or proliferation of
HUVEC treated at up to 80 μM AqB013 (Fig. 3f ).
Discussion
Small molecule pharmaceuticals have an established
therapeutic use and our team has synthesised an AQP
inhibitor, based on bumetanide [21], that blocks AQP1-
mediated water flux [18]. Bumetanide is a loop diuretic
that has long been used to treat patients with oedema
[22]. Furthermore the incidence of clinically significant
side-effects of bumetanide therapy is very low compared
to that associated with chemotherapy drugs currently
given as adjuvant therapy for CRC, making it an attract-
ive alternative to current chemotherapeutics. AQP1 has




Fig. 2 Migration and invasion. a, HT29 cells treated with 160 μM or 320 μM AqB013 had a significantly reduced migration compared to vehicle
control. b, HCT-116 cells treated with up to 320 μM AqB013 showed no significant effect on wound closure. c, the effect of AqB013 on HT29 cell
invasion (n = 3) measured by an increase in sphere size (%) relative to vehicle control: in spheres treated with 80 μM or 160 μM of AqB013 there
was a significant decrease in invasion at 144 hours compared with vehicle. d, HCT-116 cells treated with up to 320 μM AqB013 (n = 3) showed no
significant effect on invasion. ** p = 0.004; ***p < 0.001 ****p < 0.0001. e, AqB013 treatment up to 320 μM had no effect on cell proliferation of
HCT-116, at 160 μM AqB013 HT29 showed 17% reduced proliferation (*p = 0.03 ANOVA). Proliferation measured in absorbance units at 490 nm.
The error bars show standard error of the mean
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models and may thus serve as a potential target for small
molecule inhibitors to treat cancer in subgroups express-
ing AQP1. The in vitro testing of drugs is the first step
in establishing the efficacy of targeting specific mole-
cules in abrogating the migration and invasion of cancer
cells, or in suppressing angiogenesis.
In this study, inhibition of AQP1 by the inhibitor
AqB013 was effective in reducing migration (wound
closure assay) and invasion (spheroid formation assay) in
the high AQP1-expressing HT29 cells, while not affect-
ing migration or invasion in HCT-116 cells that had
much lower expression of AQP1. As both untreated and
vehicle-treated HT29 and HCT-116 cells showed similar
efficiency of wound closure and invasion, these results
suggest that AQP1 was indeed the target of inhibition.
In breast cancer cells, AQP5 polarizes to the leading
edge of migrating MDA-MB-231 cells, and that knock-
down of AQP5 in these cells significantly suppressed cell
migration velocity in narrow channels [23]. Similarly,
knockdown of AQP5 in MCF7 breast cancer cells re-
sulted in significantly reduced proliferation and migra-
tion [24]. However we have shown that the expression
of AQP5 in HCT-116 is low (Additional file 1), similar




Fig. 3 Angiogenesis assay. HUVEC tube-forming assay measured by the number of junctions: a, untreated HUVEC; b, vehicle treated HUVEC; c,
HUVEC treated with 40 μM AqB013; d, HUVEC treated with 80 μM AqB013 (40 x magnification, scale bar = 0.5 mm); e, graph shows significant
inhibition of endothelial tube formation by AqB013 at 40 μM and 80 μM, **p <0.01, ****p < 0.0001 respectively (ANOVA). f, AqB013 treatment had
no effect on proliferation of HUVECs
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alternative mechanism of migration is used which would
explain why these cells are resistant to the inhibitory ef-
fect of AqB013. Migration in HCT-116 cells that express
low amounts of AQP1 and AQP5 may be enhanced by
expression of the calcium activated chloride channel
TMEM16A as it has recently been reported that the
high metastatic-potential colon cancer cell lines HCT-
116 and SW620 express TMEM16A while primary colon
cancer cell lines HCT8 and SW480 cells do not. Knock-
down of TMEM16A by short hairpin RNA in SW620
resulted in significantly reduced migration in wound-
closure assays [25]. In addition HCT-116 cells have been
shown to have high levels of micro RNA 224 which has
recently been shown to activate the Wnt-β catenin path-
way to promote migration and invasion of HCT-116
cells [26, 27], rendering the cells resistant to the effects
of AQP inhibition.
AQP1 has been shown to have dual water channel and
gated ion channel functions [16, 28, 29]. The AQP1-
mediated cationic conductance has been implicated in
influencing rates of net fluid transport in primary cul-
tures of choroid plexus [30], and similarly this mechan-
ism may be responsible for regulating net fluid flux in
migrating epithelial and endothelial cells. However work
by the Yool group has previously shown that endogen-
ous chloride conductance in X. laevis oocytes is not
blocked by AqB013. Furthermore in mouse intact gastric
antral muscle, the addition of AqB013 did not change
the resting membrane potential and had no substantial
effect on the rhythmic electrical conduction properties
[18]. Taken together these data suggest that the effect of
AqB013 on impeding the migration of human colon
cancer cells and endothelial cells expressing AQP1 is
mediated by blocking the water channel activity of
AQP1.
Conclusions
These studies have shown clear links between AQP1 ac-
tivity and cancer cell migration and invasion, and endo-
thelial cell tube–forming capacity, indicating the
importance of characterising suitable AQP1 blockers.
This study provides preliminary data showing that the
AQP1 inhibitor AqB013 abrogates endothelial tube for-
mation and reduces cancer cell migration and invasion
and will be further investigated in an in vivo mouse
xenotransplant model of human colon cancer. Small
molecule pharmaceuticals have an established thera-
peutic use and as this new drug is a modification of bu-
metanide, it should be well-tolerated in cancer patients
with far fewer side-effects than from currently used che-
motherapeutic drugs. Furthermore, in view of the docu-
mented role of AQP1 in murine tumour angiogenesis
[10, 12], it is envisaged that in metastatic CRC patients,
AQP1 inhibitors may have a role combined with anti-
vascular endothelial growth factor (VEGF) therapy, or as
an alternative anti-angiogenesis therapy in cases that be-
come resistant to anti-VEGF therapy. The inhibition of
AQP1 clinically may slow down the progression of CRC,
increasing the window for optimal treatment resulting in
better survival outcomes, particularly in early stage cases
where micro-metastatic disease is present.
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Additional file 1: Expression of AQP1 and AQP5. qPCR (2-ΔCt) results
normalised to reference gene PMM1. (PDF 95 kb)
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ORIGINAL ARTICLE
Rhubarb extract partially improves mucosal integrity in 
chemotherapy-induced intestinal mucositis
Basic Study




To investigate the effects of orally gavaged aqueous 
rhubarb extract (RE) on 5-fluorouracil (5-FU)-induced 
intestinal mucositis in rats. 
METHODS
Female Dark Agouti rats (n  = 8/group) were gavaged 
daily (1 mL) with water, high-dose RE (HDR; 200 mg/
kg) or low-dose RE (LDR; 20mg/kg) for eight days. 
Intestinal mucositis was induced (day 5) with 5-FU 
(150 mg/kg) via  intraperitoneal injection. Intestinal 
tissue samples were collected for myeloperoxidase 
(MPO) activity and histological examination. Xenopus 
oocytes expressing aquaporin 4 water channels were 
prepared to examine the effect of aqueous RE on cell 
volume, indicating a potential mechanism responsible 
for modulating net fluid absorption and secretion in 
the gastrointestinal tract. Statistical significance was 
assumed at P  < 0.05 by one-way ANOVA. 
RESULTS
Bodyweight was s ignif icant ly reduced in rats 
administered 5-FU compared to healthy controls (P  < 
0.01). Rats administered 5-FU significantly increased 
intestinal MPO levels (≥ 307%; P  < 0.001), compared 
to healthy controls. However, LDR attenuated this 
effect in 5-FU treated rats, significantly decreasing 
ileal MPO activity (by 45%; P  < 0.05), as compared 
to 5-FU controls. 5-FU significantly reduced intestinal 
mucosal thickness (by ≥ 29% P  < 0.001) as compared 
to healthy controls. LDR significantly increased ileal 
mucosal thickness in 5-FU treated rats (19%; P  < 0.05) 
relative to 5-FU controls. In xenopus oocytes expressing 
AQP4 water channels, RE selectively blocked water 
influx into the cell, induced by a decrease in external 
osmotic pressure. As water efflux was unaltered by 
the presence of extracellular RE, the directional flow of 
water across the epithelial barrier, in the presence of 
extracellular RE, indicated that RE may alleviate water 
loss across the epithelial barrier and promote intestinal 
health in chemotherapy-induced intestinal mucositis.
CONCLUSION
In summary, low dose RE improves selected parameters 
of mucosal integrity and reduces ileal inflammation, 
manifesting from 5-FU-induced intestinal mucositis. 
Key words: Fluorouracil; Inflammation; Mucositis; Rats; 
Rheum
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Aqueous rhubarb extract partially improved 
selected parameters of 5-fluorouracil (5-FU)-induced 
intestinal mucositis in rats. Exposure to 5-FU decreased 
bodyweight, yet high-dose rhubarb extract (RE) and low-
dose RE (LDR) showed no changes. Myeloperoxidase 
activity was significantly decreased in rats treated with 
LDR and 5-FU when compared to the intestinal mucositis 
control group. Ileal mucosal thickness was significantly 
improved (19%) in animals with intestinal mucositis 
and treated with LDR. In xenopus oocytes expressing 
AQP4 water channels, RE blocked swelling induced by a 
decrease in external osmotic pressure which indicated 
that water influx across the epithelial barrier was 
selectively blocked by RE.
Bajic JE, Eden GL, Lampton LS, Cheah KY, Lymn KA, Pei 
JV, Yool AJ, Howarth GS. Rhubarb extract partially improves 
mucosal integrity in chemotherapy-induced intestinal mucositis. 




Traditional herbal medicines have been used for 
centuries in the maintenance and improvement of 
health or the treatment of illnesses. Globally, ancient 
herbal remedies have been created based on theories, 
beliefs and experiences representing various cultures 
at different times throughout history[1]. Consequently, 
traditional herbal medicines are being investigated 
increasingly for their potential to treat and reduce 
the symptoms of a wide variety of diseases and dis-
orders, specifically cancer and its treatment-related 
side-effects. Many cancer patients seek alternative 
medicines that will complement their standard-care 
treatments with the hope that they will improve 
symptoms associated with either the cancer or their 
anti-cancer treatments[2]. 
Cancer is a life-threatening illness affecting millions 
of individuals world-wide. In westernized countries 
approximately 50% of the population will develop 
cancer before the age of 85[3]. Chemotherapy forms 
one of the most common strategies for cancer 
treatment. Cytotoxic chemotherapy drugs, such as 
5-fluorouracil (5-FU), act by inhibiting DNA synthesis 
of not only malignant cells, but also rapidly dividing 
cells lining the intestinal mucosa[4]. An increase in cell 
apoptosis stimulates the production of reactive oxygen 
species (ROS) and pro-inflammatory cytokines such 
as tumour necrosis factor-α (TNF-α), interleukin-1β 
(IL-1β) and IL-4 resulting in further tissue and blood 
vessel damage[5,6]. This cascade of events results 
in a range of debilitating clinical side-effects, from 
nausea and vomiting to inflammation and ulceration 
of the gastrointestinal tract; and sepsis may occur 
if untreated[7,8]. These painful and life-threatening 
side-effects collectively form a disorder known as 
intestinal mucositis which affects approximately 60% 
of patients undergoing chemotherapy[9]. Current 
therapies for intestinal mucositis seek to reduce the 
severity of symptoms rather than acting as a curative 
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or preventative measure[10,11]. Thus, treatments are 
required with the potential to eliminate or reduce the 
adverse side-effects of cancer chemotherapy.
Recently, in experimental systems, plant extracts 
such as grape seed extract (GSE) and Iberogast® have 
been investigated as potential treatments for intestinal 
mucositis on the basis of their anti-inflammatory and 
antioxidant constituents[12-14]. Indeed, plant-sourced 
molecules and compounds are commonly percei-
ved to be safer therapeutics compared to synthetic 
compounds[15]. There are limited studies on the phar-
macology of herbal medicines, yet such extracts may 
offer protection against intestinal mucositis in an 
experimental setting. The scientific study of further 
plant-based extracts is therefore warranted. 
Rhubarb, Rheum spp., is a herbaceous perennial 
plant with a long, fleshy stalk, commonly used for 
cooking and medicine. Dried rhubarb rhizomes were 
traditionally used in Chinese medicine as a natural 
remedy for gastrointestinal complications including 
diarrhoea, constipation and inflammation[16]. The 
pharmacological effects have been attributed to the 
stalk of the plant[17,18]. Two main active constituents 
(ethanol-soluble and water soluble) have been 
classified in rhubarb stalks. Anthraquinones form the 
main ethanol-soluble active constituent of rhubarb 
stalks[14]. These constituents have exhibited a diar-
rhoeal effect in mice providing a possible purgative 
mechanism of action[18]. In contrast, the aqueous 
extract of rhubarb has recently demonstrated anti-
diarrhoeal properties, believed to be mediated by 
tannins through regulation of intestinal water secre-
tion and absorption[18]. Importantly, chemotherapy 
recipients experiencing intestinal mucositis have 
altered membrane integrity and impaired water 
absorption and secretion[7,19].
Aquaporins (AQPs) are integral membrane proteins 
responsible for the regulation of water transport 
across a membrane via an osmotic gradient[20,21]. 
Aquaporin channels are tetramers with a water pore 
located in each subunit of the channel (Figure 1A). 
Water molecules move in single file through aquaporin 
pores, down osmotic and hydrostatic gradients. As 
one molecule enters via the extracellular region of 
the channel, another molecule is displaced into the 
cytoplasm and vice versa[22]. Currently, 13 mammalian 
AQPs have been identified (AQP 0-12). AQPs are 
abundant in tissues reliant on high water permeability 
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Figure 1  Directional blockade of water flux through an aquaporin-4 channel by reconstituted aqueous rhubarb extract. A: Diagram of a water channel 
illustrating the intra-subunit water pores in each subunit of the tetramer; B: Illustration of the volume changes induced by osmotic gradients in mammalian AQP4-
expressing Xenopus oocytes; C: Dose-dependent blockade of swelling but not shrinking responses by rhubarb extract (RE) in AQP4-expressing oocytes; D: Diagram 
of the hypothesized effect of blockade by extracellular RE at AQP4 channels present in the basolateral side of intestinal barrier epithelial cells, predicted to result in 
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were obtained for every 500 g of fresh rhubarb. 
Based on fractionation of the extract, the active agent 
appears to be a water-soluble ethanol-insoluble 
glycopeptide. Lectin array profiling has indicated that 
mannose and N-acetylglucosamine are predominant 
components of the carbohydrate structure. The precise 
chemical structure and possible presence of more 
than one isoform with biological activity remains to be 
determined.
Animal trial, metabolism data and disease Activity index
Six week old female Dark Agouti rats (n = 32; 
110-150 g) were sourced from the Animal Resources 
Centre (Western Australia) and Laboratory Animal 
Services (The University of Adelaide, South Australia). 
All animal experimentation was approved by the 
Animal Ethics Committee of the University of Adelaide 
(S-2010-111). The animal protocol described in this 
study was designed to minimise pain or discomfort 
to the animals and complied with the National Health 
and Medical Research Council Code of Practice for 
Animal Care in Research and Teaching. Prior to the 
experimentation period, rats were individually housed 
in Tecniplast™ (PA, United States) metabolism cages 
for 48 hours to acclimatise. Rats received ad libitum 
water and 18% Casein diet[30] and were exposed to 
a 12 h light-dark cycle in a temperature controlled 
room (22 ℃). After the acclimatisation phase, rats 
were randomly allocated to four treatment groups 
(n= 8/group): Water + Saline, Water + 5-FU, Low-
Dose Rhubarb (LDR; 20 mg/kg BW) + 5-FU and 
High-Dose Rhubarb (HDR; 200 mg/kg BW) + 5-FU. 
Water, HDR and LDR (1 mL) were administered daily 
via orogastric gavage on days 0 to 7. LDR dose for 
gavage was based on the estimated dose required to 
block aquaporin water channel activity in the oocyte 
expression system, and the dose HDR was selected as 
a 10 fold higher concentration for comparison.
Daily recordings of body weight, feed and water 
intake and faecal and urine output were conducted. 
Faecal pellets were collected daily, weighed and placed 
in a drying oven at 70 ℃ for 72 h. The percentage 
weight loss was used as an indication of moisture 
content in the faecal samples. On day 5, rats were 
injected with 5-FU (150 mg/kg BW; Hospira Australia 
Pty Ltd, Melbourne, Victoria) to induce intestinal 
mucositis. The single high dose of 5-FU used in the 
current study was determined from previous studies in 
our laboratory[31]. Following 5-FU administration, daily 
disease activity index (DAI) scoring was performed by 
a blinded researcher based on overall condition, weight 
loss and stool consistency. Each parameter was scored 
based on a scale of 0 (normal) to 3 (maximal severity) 
giving a maximum daily total of 9 for severely affected 
rats[32,33]. 
Blood, organ and tissue collection
Rats were humanely euthanized on day 8 via carbon 
dioxide asphyxiation. Day 8 of the experimental period 
to maintain correct function[21,23] and are involved 
in metabolic processes such as kidney, lung, brain 
and gastrointestinal function[24-26]. In the human 
gastrointestinal tract, AQPs 3, 7 and 8 are expressed 
throughout the mucosal epithelia, and AQP1 is present 
in endothelial cells of the vasculature. In early stage 
inflammatory bowel disease, tight junctions and 
transport systems are impaired, leading to a leaky 
epithelium. Clinical human biopsies showed that levels 
of expression of AQPs1 and 3 are reduced in Crohn’s 
Disease and AQPs 7 and 8 are decreased in ulcerative 
colitis, based on quantitative PCR and immunolabelling 
assays[27]. As well, the typical apical localisation of 
AQP8 in bowel was lost, and the appearance of a faint 
basolateral signal suggested intestinal epithelial cell 
polarity was disrupted. 
Aquaporin-4 (AQP 4) is believed to provide the 
principal mechanism for bidirectional water transport 
across the basolateral membrane of small intestinal 
enterocytes[28]. These water channels ensure that 
efficient water absorption and secretion is maintained, 
thus allowing for adequate hydration and optimal 
stool consistency[29]. Liu et al[17] demonstrated that 
the anti-diarrhoeal effect of rhubarb tannins extract 
occurred via the inhibition of AQP 2 and 3 expression 
in vitro and in a mouse model of magnesium sulphate-
induced diarrhoea. In addition, the water-soluble 
polysaccharides of rhubarb have protected the 
gastrointestinal tract against inflammation resulting 
from 2,4,6-trinitrobenzene sulfonic acid-induced 
colitis[17]. The anti-inflammatory mechanism of action 
underlying rhubarb extract (RE) remains unclear; 
however, it is thought that tannins may reduce the 
production of pro-inflammatory cytokines such as IL-4 
and IFN-γ[17]. Consequently, RE was explored for its 
anti-inflammatory potential in intestinal mucositis and 
its potential to influence water transport across the 
intestinal mucosa[17,18].
In the current study, an aqueous fraction of rhubarb 
was investigated for its potential to reduce intestinal 
damage induced by the antimetabolite chemotherapy 
drug, 5-FU in rats. It was hypothesised that RE 
would decrease the severity of intestinal mucositis by 
improving histopathological parameters and potentially 




Rhubarb stems (2.5 kg) were sectioned (1 cm) and 
boiled with absolute ethanol to remove alcohol-soluble 
components. Once cooled, the liquid was discarded 
and the residues were further boiled with water. 
The aqueous rhubarb components were retained 
for dehydration to obtain a concentrated powder[17]. 
Dehydration was conducted by freeze-drying at the 
South Australian Research and Development Institute, 
West Beach, South Australia. Four grams of powder 
Bajic JE et al . Rhubarb extract partially improves intestinal mucositis
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represented 3 d post 5-FU exposure and due to the 
acute nature of 5-FU-induced intestinal mucositis, 
this was determined to be the optimal day when 
histological damage in the intestine was most evident. 
The gastrointestinal tract was removed and emptied, 
then the lengths of each section [duodenum, jejunum, 
jejuno-ileum junction (JI), ileum and colon] were 
recorded and weighed. 
Segments (2 cm and 4 cm) of the small intestine 
tract were collected at approximately 10% (jejunum) 
and 90% (ileum) of the total small intestine length 
for histological and biochemical analysis, respectively. 
Samples for histological analysis were fixed in 10% 
buffered formalin for 24 h and transferred to 70% 
ethanol for preservation. Segments for biochemical 
analysis were weighed and snap-frozen in liquid 
nitrogen prior to storage at -80 ℃. The remaining 
thoracic and abdominal organs (thymus, lungs, heart, 
spleen, kidneys, liver, stomach and caecum) were 
weighed and discarded. 
Biochemical analysis
Myeloperoxidase (MPO) is an enzyme present in the 
intracellular granules of neutrophils and provides 
a quantitative analysis of acute inflammation. The 
assay was performed with slight modification from 
Beyer et al[34]. Segments of the small intestinal tract 
(jejunum, JI and ileum; 4 cm) were thawed and 
prepared for MPO assay via homogenization in 10 
mmol/L phosphate buffer (pH 6.1). Homogenised 
samples were centrifuged at 13000 rpm for 12 min 
and the supernatant was discarded. The remaining 
pellet was resuspended with 0.5% hexadecyltrimethyl 
ammonium bromide buffer and vortexed prior to a 
final centrifuge (13000 rpm for 2 min). Supernatant 
from each sample (50 µL aliquot) was dispensed into 
a 96-well plate and the MPO reaction was initiated 
with an O-dianisidine dihydrochloride solution (200 
µL/well; 4.2 mg O-dianisidine dihydrochloride, 12.5 
µL hydrogen peroxide (30%) in 2.5 mL potassium 
phosphate buffer (50 mmol/L, pH 6.1) and 22.5 mL 
distilled H2O). A spectrometer (Victor X4 Multilabel 
Reader, Perkin Elmer, Singapore) measured absor-
bance (450 nm) at one minute intervals over a 15 
min period. The change in absorbance was used to 
calculate MPO activity within a tissue sample (MPO 
units/g of intestinal tissue).
Histological analysis
Intestinal samples stored in 70% ethanol were 
embedded with paraffin wax and cross-sectioned at 4 
µm. Histological slides were stained with haematoxylin 
and eosin for qualitative and quantitative analysis. 
Qualitative measurements of 40 villus and crypts 
per intestinal section (jejunum, JI and ileum) were 
performed blinded using Image ProPlus software for 
Windows (version 5.1.1; Media Cybernetics, Silver 
Spring MD, United States) connected to a Nikon 
Eclipse 50i light microscope (Nikon Cooperation, 
Japan) and a ProGres C5 digital camera (Jenoptik, 
Germany). Intestinal sections were also analysed 
quantitatively using disease severity scores based on 
11 criteria described by Howarth et al[32]. Each criterion 
was scored on a scale of 0 (normal) to 3 (severely 
damaged) for five cross-sections of each intestinal 
region. The median score for each criterion was 
calculated and the scores of all criteria were summed 
to give an overall disease severity score; with a score 
of 33 indicating maximal tissue damage[32,33].
Xenopus oocyte preparation
Unfertilized oocytes from Xenopus laevis were prepared 
as described previously[35,36] and maintained in ND96 
saline (96 mmol/L NaCl, 2 mmol/L KCl, 1 mmol/L 
MgCl2, 1.8 mmol/L CaCl2, and 5 mmol/L HEPES, pH 
7.55) supplemented with 100 µg/mL penicillin,100 
U/mL streptomycin, and 10% horse serum. Oocytes 
were injected with 50 nL of water containing 1 ng of 
rat AQP4 wild-type cRNA and were incubated for 2 or 
more days at 16-18 ℃ prior to osmotic swelling and 
shrinking assays in saline without antibiotics or serum. 
Hypotonic saline (50%) was prepared by diluting 
isotonic saline with an equal volume of water, whilst 
200% hypertonic saline was prepared by doubling the 
NaCl concentration of the saline. Volume change rates 
were measured by videomicroscopy at 0.5 frames/s 
over 30 s using NIH ImageJ software (http://rsbweb.
nih.gov/ij/), as described previously[35,36].
Statistical analysis
Statistical analyses were conducted using IBM SPSS 
Statistics version 19 for Windows (SPSS Inc., Chicago, 
IL, United States) and GraphPad Prism 6.02 for 
Windows (GraphPad Software Inc., San Diego, CA, 
United States). Normality tests were performed on all 
data sets to determine parametric and non-parametric 
data. All parametric data (metabolic data, MPO activity 
and villus height/crypt depth measurements) was 
analysed using one-way ANOVA with Tukey post 
hoc test. Non-parametric data (DSS and DAI) was 
analysed using Kruskal-Wallis with Mann Whitney U 
post hoc test. All data were expressed as mean ± SEM 
with the exception of disease severity scores which 
were expressed as medians and range. Values of P < 
0.05 were considered significant. 
RESULTS
Dose-dependent blockade of AQP4 water channel 
activity by extracellular aqueous RE
Cloned rat AQP 4 water channels expressed in Xenopus 
oocytes were analysed quantitatively for osmotically-
driven changes in cell volume in the presence and 
absence of dried reconstituted aqueous RE. Decreased 
external osmotic pressure (50% hypotonic saline) 
induced a volume increase (swelling) that was blocked 
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by RE (Figure 1B and C). In contrast, the volume 
decrease (shrinking) induced by 200% hypertonic 
saline was not significantly altered by RE (Figure 1B 
and C), indicating that the blocking effect of RE was 
directional. In the presence of extracellular RE, water 
influx into the cell mediated by AQP4 was selectively 
blocked, whereas water efflux was not altered, 
providing a potentially useful tool for differentially 
modulating net fluid absorption and secretion in 
the gastrointestinal tract. The current ex vivo study 
predicted that RE would act on basolateral AQP 4 
channels and alleviate water loss across the barrier 
epithelium (Figure 1D), thereby promoting intestinal 
health in the experimental setting of chemotherapy-
induced intestinal mucositis. 
Metabolic data and faecal moisture content 
Low dose rhubarb (LDR) and high dose rhubarb 
(HDR) had no significant effect on metabolic 
parameters (bodyweight, feed and water intake and 
faecal and urine output) when compared to controls 
prior to administration of 5-FU (Table 1). After 5-FU 
administration, feed intake was significantly decreased 
(by 60%; P < 0.001) in comparison to healthy 
controls (Table 2). Furthermore, in 5-FU treated rats 
administered HDR, feed intake was further reduced 
by 55% when compared to 5-FU controls (P < 0.01). 
However, normal feed intake was maintained in 5-FU 
treated rats administered LDR. Although feed intake 
was significantly reduced in 5-FU controls, there was 
no reduction in wet faecal output compared to healthy 
controls. However, in 5-FU treated rats administered 
HDR, faecal output was reduced by 41% in comparison 
to 5-FU controls. There were no significant effects on 
water intake and urine output between control and RE 
treatment groups (Table 2). Similarly, no significant 
effects on faecal moisture content were evident 
among all treatment groups, before or after 5-FU 
administration (data not shown).
Bodyweight change
A reduction in feed intake was consistent with de-
creased bodyweight after 5-FU administration (Figure 
2). Prior to inducing intestinal mucositis with 5-FU, RE 
had no significant effect on bodyweight. Treatment with 
5-FU resulted in a significant reduction in bodyweight 
compared to normal controls (P < 0.01). However, 
compared to 5-FU controls, HDR and LDR had no effect 
on mean bodyweight following 5-FU administration.
DAI score 
Administration of 5-FU significantly increased DAI 
scores in comparison to healthy controls (P < 0.01; 
Figure 3). Days 6 and 8 produced significantly greater 
DAI scores in 5-FU treated rats administered HDR 
and LDR, respectively, compared to 5-FU controls; 
otherwise, RE treatments had no significant effect on 
symptomatic disease activity.
Visceral gastrointestinal organ weights and lengths
Visceral and gastrointestinal organ weights were 
expressed as a proportion of bodyweight (Tables 3 
and 4). Reductions in relative thymus (by ≥ 35%; P 
< 0.001) and relative spleen weight (by ≥ 23%; P 
Table 1  Total daily food (g) and water (mL) intake, and 
faecal (g) and urine (mL) output for the trial period prior to 
the administration of 5-FU (days 1 to 5)
Water LDR HDR
Food intake (g)   51.0 ± 0.7 52.3 ± 2.0   53.8 ± 1.0
Water Intake (mL) 122.5 ± 7.3 129.4 ± 12.0 115.0 ± 7.1
Wet faecal output (g)     6.2 ± 0.3   6.8 ± 0.3     6.6 ± 0.4
Urine output (mL)   79.3 ± 5.6 79.8 ± 6.1   85.8 ± 5.0
Rats were gavaged daily with water, LDR or HDR (1 mL); data expressed 
as mean (g or mL) ± SEM. LDR: Low-dose RE; HDR: High-dose RE; RE: 
Rhubarb extract.
Table 2  Total daily food (g) and water (mL) intake, and 
faecal (g) and urine (mL) output for the trial period after the 









Food intake (g) 29.1 ± 0.6  11.5 ± 1.6e     7.8 ± 0.6   5.2 ± 1.4d
Water intake (mL) 75.0 ± 4.3 94.4 ± 7.7 107.2 ± 5.1 90.6 ± 12.9
Wet faecal output (g)   3.3 ± 0.2   2.9 ± 0.3     2.1 ± 0.3  1.7 ± 0.3c
Urine output (mL) 47.5 ± 4.7 64.5 ± 6.7   71.0 ± 2.1 70.6 ± 10.4
Rats were gavaged daily with water, LDR or HDR (1 mL) and received an 
intraperitoneal injection of either saline or 5-FU on day 5. cP < 0.05, dP < 0.01 
vs water + 5-FU; eP < 0.001 vs water + saline. All values are expressed as 
mean [% relative to bodyweight (× 10-2)] ± SEM. LDR: Low-dose RE; HDR: 
High-dose RE; RE: Rhubarb extract.
Figure 2  Daily change in starting bodyweight (%) from days 0 to 8 in rats 
gavaged with water, LDR or HDR and intraperitoneally injected with saline 
or 5-FU on Day 5. Data are expressed as mean ± SEM. Mean values of 5-FU 
controls and 5-FU + LDR and 5-FU + HDR were significantly different when vs 
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< 0.001) were apparent in all rats treated with 5-FU 
when compared to healthy controls (Table 3). In 5-FU 
treated rats, HDR and LDR had no significant effect on 
visceral organ weights compared to 5-FU controls. 
A significant decrease in the combined jejunum 
and ileum relative weight (by ≥ 10%; P < 0.01) was 
evident in all 5-FU treated rats (Table 4). However, this 
effect was not present in the duodenum. There was also 
no effect of HDR or LDR on relative duodenum weight 
and the combined relative weights of jejunum and 
ileum in 5-FU treated rats, compared to 5-FU controls. 
Administration of 5-FU had no effect on relative colon 
weight in comparison to healthy controls. However, 
when compared to 5-FU controls, administration of 
LDR to 5-FU treated rats significantly increased colon 
weight (29%; P < 0.01). Additionally, 5-FU significantly 
reduced the combined jejunum and ileum length in 
comparison to healthy controls (Table 5). However, 
this effect was not evident in the duodenum and colon. 
The administration of HDR and LDR to 5-FU treated 
rats had no effect on gastrointestinal organ lengths in 
comparison to 5-FU controls. 
Disease severity score
Healthy small intestinal sections achieved median 
disease severity scores of ≤ 2. Administration of 5-FU 
caused significant damage to intestinal structure in 
the jejunum, JI and ileum; achieving median (range) 
scores of 21 (18-30), 21 (14-27) and 22 (17-25), 
respectively, when assessed by semi-quantitative 
histological scores based on 11 parameters (Figure 
4). However, RE had no significant effect on intestinal 
structure, relative to 5-FU controls. 
MPO activity
Increased intestinal MPO activity is a common feature 
of chemotherapy-induced intestinal mucositis[31]. 
When compared to healthy controls, 5-FU resulted 
in increased MPO activity by 780% in the jejunum 
and 310% in the JI and ileum (Figure 5). RE had 
no significant effect on MPO activity within the 
jejunum and the JI in 5-FU treated rats. However, 
administration of LDR to 5-FU treated rats resulted in 
reduced MPO activity by 45% (P < 0.05) in the ileum, 
compared to 5-FU controls. 
Villus height, crypt depth and mucosal thickness 
The combined measurements of villus height and 
crypt depth provided an overall indication of mucosal 
Figure 3  Effects of rhubarb extract and 5-fluorouracil on disease activity 
scores on days 6 to 8 of the experimental period. Rats received a daily 
water, HDR or LDR gavage for an 8-d trial period and an intraperitoneal 
injection of 5-FU or saline on day 5. Disease activity scores were assigned on 
Days 6 to 8 based on overall condition, weight loss, stool consistency and rectal 
bleeding. bP < 0.01, eP < 0.001 vs water + saline; cP < 0.05 vs water + 5-FU. 
LDR: Low-dose RE; HDR: High-dose RE; RE: Rhubarb extract.
Table 3  Visceral organ weights of rats gavaged daily with 
water, low-dose or high-dose rhubarb extract (1 mL) during 
an 8-d trial period and administered with an intraperitoneal 
injection of saline or 5-fluorouracil on day 5








Thymus   14.6 ± 1.3    6.6 ± 0.5e   9.4 ± 0.6     9.5 ± 0.9
Heart   37.5 ± 0.8 39.0 ± 1.0   39.4 ± 0.8   39.1 ± 0.7
Lung   60.0 ± 2.2 63.0 ± 2.5   67.3 ± 4.7   71.9 ± 3.0
Liver 362.9 ± 6.5 362.7 ± 11.0 358.8 ± 7.2 339.7 ± 7.2
Spleen   20.3 ± 0.5  15.6 ± 0.3e   15.2 ± 0.4   14.6 ± 0.5
Kidneys   75.6 ± 5.3 86.5 ± 1.7   88.7 ± 1.1   89.4 ± 2.7
Caecum   39.7 ± 1.1 43.7 ± 2.4   49.2 ± 2.5   47.0 ± 2.1
Stomach   57.3 ± 2.6 55.3 ± 1.1   58.8 ± 0.9   61.9 ± 1.2
eP < 0.001 vs water + saline. All values are expressed as mean [% relative 
to bodyweight (× 10-2)] ± SEM. LDR: Low-dose RE; HDR: High-dose RE; 
RE: Rhubarb extract.
Table 4  Gastrointestinal organ weights of rats gavaged daily 
with water, low-dose and high-dose rhubarb extract (1 mL) 
during an 8-d rial period and administered an intraperitoneal 









Duodenum 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
Jejunum and ileum 2.1 ± 0.1  1.9 ± 0.0b 1.9 ± 0.2 1.9 ± 0.1
Colon 0.5 ± 0.0 0.5 ± 0.0  0.7 ± 0.0d 0.6 ± 0.0
bP < 0.01 vs water + saline; dP < 0.01 vs water + 5-FU. All values are 
expressed as mean (% relative to bodyweight) ± SEM. LDR: Low-dose RE; 
HDR: High-dose RE; RE: Rhubarb extract.
Table 5  Gastrointestinal organ lengths of rats gavaged daily 
with water, low-dose and high-dose rhubarb extract (1 mL) 
during an 8-d trial period and administered an intraperitoneal 









Duodenum   5.5 ± 0.2   4.8 ± 0.1   5.1 ± 0.2   4.8 ± 0.2
Jejunum and ileum 71.6 ± 2.3  64.8 ± 0.9a 62.9 ± 1.8 63.5 ± 1.7
Colon 11.1 ± 0.3 10.6 ± 0.4 11.2 ± 0.2 10.8 ± 0.4
aP < 0.05 vs water + saline. All values expressed as mean (cm) ± SEM. LDR: 
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thickness and thus, damage (Figure 6). Administration 
of 5-FU significantly decreased mucosal thickness 
by 29% in the jejunum, and 34% in both the JI and 
ileum when compared to healthy controls. RE had no 
significant effect on villus height and crypt depth in 
the jejunum, compared to 5-FU controls. This effect 
was mirrored in the JI, with the exception of crypt 
depth which was significantly greater (P < 0.05) in 
5-FU treated rats receiving HDR. More importantly, 
administration of LDR to 5-FU treated rats resulted in 
significantly greater ileal villus heights and crypt depths 
relative to 5-FU controls; significantly increasing overall 
ileal mucosal thickness by 19% (Figure 7). 
DISCUSSION
Intestinal mucositis remains a debilitating side-
effect of chemotherapy treatment. The current 
study utilised a rat model of intestinal mucositis to 
investigate the potential for aqueous RE to protect 
against damage to the intestinal mucosa and regulate 
water transport in the intestine. The water-soluble 
components of rhubarb appeared to target more distal 
regions of the alimentary tract, partially improving 
selected parameters of the ileum, such as mucosal 
thickness and MPO activity associated with the clinical 
manifestations of 5-FU-induced intestinal mucositis.
Administration of 5-FU significantly decreased feed 
intake and bodyweight as previously described[12,31,37]. 
A reduction in feed intake and bodyweight is observed 
in cancer patients due to nausea and pain associated 
with chemotherapy treatment[38,39]. Interestingly, in 
the current study, daily administration of HDR to 5-FU 
treated rats further reduced appetite but maintained 
bodyweight. It is therefore plausible that the caloric 
index of HDR may have been contributing to the 
reduced appetite, yet maintenance of bodyweight in 
the rats receiving high dose RE. 
In the current study, intraperitoneal administration 
of 5-FU caused significant damage to small intestinal 
structure, further impacting on intestinal weight and 
length. Previous studies of experimental intestinal 
mucositis have noted a correlation between small 
Figure 4  Histological damage assessed by semi-quantitative disease 
severity score of the jejunum, jejuno-ileum and ileum of rats. Data are 
expressed as median score (range). Mean values were significantly different 
vs water + 5-FU (fP < 0.001). JI: Jejuno-ileum; LDR: Low-dose RE; HDR: High-
dose RE; RE: Rhubarb extract.
Figure 5  Myeloperoxidase activity present in the jejunum, jejuno-ileum 
and ileum of rats gavaged with water, low-dose or high-dose rhubarb 
extract (1 mL) for an 8-d trial period. Rats received an intraperitoneal 
injection of saline or 5-FU on day 5. Data were expressed as mean [MPO Units 
(U)/g] ± SEM. Mean values were significantly different (fP < 0.001) vs water + 
5-FU. cP < 0.05 vs water + 5-FU. JI: Jejuno-ileum; LDR: Low-dose RE; HDR: 
high-dose RE; RE: Rhubarb extract.
Figure 6  Combination of villus height and crypt depth as a repre-
sentation of overall mucosal thickness in female Dark Agouti rats. Effects 
of RE and 5-FU on villus height and crypt depth in female Dark Agouti rats. 
Rats received a daily water, HDR or LDR gavage for an 8-d trial period and 
an intraperitoneal injection of 5-FU or saline on Day 5. Mean values were 
significantly different vs water + 5-FU (cP < 0.05, fP < 0.001). aP < 0.05, eP < 
0.001 vs water + saline. JI: Jejuno-ileum; LDR: Low-dose RE; HDR: High-dose 
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intestinal weight and mucosal integrity which was also 
demonstrated in the current study[13,31]. Jejunum and 
ileum weights were significantly decreased in 5-FU 
treated rats, accompanied by increased villus and 
crypt damage when compared to healthy controls. 
Enterocyte apoptosis in 5-FU treated rats was likely 
responsible for the reduced small intestinal weight. 
However, RE administered to 5-FU treated rats had no 
significant effect on intestinal weight, compared to 5-FU 
controls, which suggested that RE did not enhance cell 
regeneration after 5-FU toxicity. 
Administration of 5-FU may result in exposure of 
the submucosa to harsh luminal conditions[6]. As a 
compensatory mechanism, the muscularis externa 
contracts to reduce submucosal contact with the 
luminal environment in an attempt to prevent bacterial 
translocation. In the current study, the length of 
the total jejunum and ileum was reduced by 5-FU 
treatment, as described previously by Mashtoub et 
al
[31]. However, consistent with previous studies, this 
effect was not present in the duodenum and colon as 
5-FU damage was less severe in these regions of the 
intestine[12,13,31].
In the current study, LDR treatment resulted in 
a significant increase in ileal villus height and crypt 
depth; possibly representing LDR promoted crypt 
cell regeneration and hence, increased migration of 
rejuvenated cells to the villus. Alternatively, LDR may 
have exerted an anti-oxidative effect, mediated by 
the water soluble polysaccharides of rhubarb which 
may have protected the intestinal mucosa against 
cell apoptosis; maintaining villus and crypt structure. 
A reduction in ileal MPO activity by LDR in 5-FU 
treated rats indicated a decrease in neutrophil activity 
which further supports the anti-oxidative and anti-
inflammatory properties of RE. These results are 
consistent with previous studies which have exploited 
plant polysaccharides for their anti-inflammatory 
and antioxidant properties[12,40,41]. Cheah et al[12,14] 
examined grape seed extract (GSE), a tannin rich by-
product of the wine and grape juice industries, in the 
setting of chemotherapy-induced intestinal mucositis. 
It was discovered that GSE could partially ameliorate 
small intestinal inflammation and mucosal damage 
caused by 5-FU cytotoxicity. Tannins, an active 
constituent of GSE and possibly RE, possess the ability 
to prevent the overproduction of ROS or decrease the 
production of pro-inflammatory cytokines such as IL-4 
and IFN-γ[12,17]. Further investigations are therefore 
required to understand the protective and anti-
inflammatory mechanism of action of RE in improving 
acute intestinal inflammation and damage to the 
mucosa. 
A significant improvement in ileal mucosal integrity 
and inflammation was observed in 5-FU rats treated 
with LDR, but not HDR. Limited RE studies have been 
Figure 7  A comparison of the histological structure of ileal sections in a healthy rat (A), after administration of 5-FU (B) and rats treated with LDR + 5-FU (C). 
Ileum sections of rats from the LDR + 5-FU treatment group (C) exhibited improved mucosal integrity as demonstrated by more defined villi and crypts in comparison 
to water + 5-FU controls (B). The black line on each diagram represents villus height in each section which was significantly shorter in 5-FU controls. Sections were 
stained with haematoxylin and eosin and mucosal thickness was analysed by quantitative measurements of villus height and crypt depth. Original photographs were 
captured at 4 × magnification. LDR: Low-dose rhubarb extract.
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conducted, therefore the low and high dose range 
of 20 mg/kg and 200 mg/kg were selected in the 
current study to determine the effects of RE across 
a broad dose range. The efficacy of RE in the current 
study may therefore have been dose-dependent. 
Prior to this study, the effects of RE on 5-FU-induced 
mucosal damage and inflammation were unknown 
and accordingly, the RE optimal concentration remains 
undefined. The present study suggested that the 
effectiveness of RE at varying concentrations may 
follow a normally distributed relationship. Potentially, 
at high concentrations (≥ 200 mg/kg BW), no 
significant effects may have been observed due to 
steric involution of bioactive binding sites. Further 
studies are therefore required to determine the optimal 
concentration to attain maximal mucosal protection. 
Chemotherapy recipients experiencing intestinal 
mucositis have altered membrane integrity and 
impaired water absorption and secretion[7]. Any 
molecule of a similar size or shape possesses the 
capability to attach to the pore vestibule and block 
the transport of water through AQP channels. 
Pharmacological blockers of aquaporin fluid fluxes 
are thought to occlude the pore vestibule and impede 
the bi-directional transport of water through the 
channel[42-44]. In the current study, RE present in the 
circulatory system may have targeted AQP 4 channels 
within enterocytes, resulting in a unidirectional blo-
ckade, and thereby decreased water secretion into 
the lumen of the small intestine. This hypothesised 
theory is further explained in Figure 1D. Wang et al[29] 
determined that AQP 4 knockout mice had significantly 
higher stool moisture content in comparison to wild-
type (P < 0.05). This suggested that stool consistency 
was dependent on the functionality of AQP 4 channels. 
This study also established that AQP 4 channels are 
scarce within the large intestine. Furthermore, within 
the large intestine, AQP 4 channels are only present on 
the initial section of the proximal colon[29]. Therefore, it 
is probable that fluid absorption and secretion across 
AQP 4 channels in the small intestine may have been 
partly responsible for the moisture content of the 
faeces in the current study. Further in vivo studies 
should identify the expression levels of AQP 4 and 
other aquaporins to determine morphological and 
potential functional changes after 5-FU exposure. Qin 
et al
[18] demonstrated that aqueous RE improved stool 
consistency in mice with castor oil and magnesium 
sulphate-induced diarrhoea. Furthermore, aqueous 
RE caused constipation when administered to normal 
mice suggesting that RE may have been acting on AQP 
4 channels to alter water absorption in the intestine. 
Consequently, further studies are required to determine 
the moisture content of caecal fluid to confirm or 
refute the hypothesis that RE affects stool consistency. 
This would allow for comparison of water absorption 
and secretion in the small intestine, independent of the 
colon. A reduction in caecal moisture content would 
suggest that RE was preventing fluid secretion across 
small intestinal AQP 4 channels.
In summary, the present study demonstrated that 
the ancient herbal remedy RE in its aqueous form, 
at relatively low dose, offers partial protection to the 
distal intestinal mucosa against tissue damage and 
inflammation associated with 5-FU-induced intestinal 
mucositis. Further studies are warranted to identify the 
anti-inflammatory and antioxidant properties of RE via 
examination of inflammatory cytokines in blood and 
tissue. This provides preliminary information regarding 
the potential use of RE as an adjunct to chemotherapy 
to improve particular histological manifestations 
of intestinal mucositis. Moreover, the reduced ileal 
inflammation and improved mucosal thickness 
suggests further therapeutic potential for other 
gastrointestinal inflammatory disorders that ultimately 
affect the more distal regions of the alimentary tract. 
However, the potential drug-drug interactions of 
RE and chemotherapy drugs, such as 5-FU should 
be thoroughly investigated as recent studies have 
highlighted concern over such interactions[45]. Future 
research should also focus on analysing moisture 
content of caecal fluid to determine whether RE acts as 
a unidirectional blocker of AQP 4 channels in the small 
intestine. Finally, further investigation into the active 
constituents of RE would be beneficial to improve our 
understanding of its potential utility in bowel disease 
and its associated mechanism of action. 
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The need to discover effective treatment approaches for chemotherapy-induced 
intestinal mucositis is growing as cancer incidence continues to increase and 
thus, the incidence of treatment-related side-effects increases. Traditional 
medicines are continually being examined for their therapeutic potential in 
cancer and chemotherapy settings. Accordingly, the aqueous extract of rhubarb 
(Rheum Spp.) was investigated for its potential to improve intestinal integrity 
and acute inflammation in experimentally-induced intestinal mucositis in rats.
Research frontiers
To our knowledge, this is the first study of its kind to identify the therapeutic 
effect of aqueous rhubarb extract (RE) in experimentally-induced intestinal 
mucositis. 
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This is the first study examining the potential for aqueous RE to improve 
intestinal integrity and acute inflammation in a rat model of 5-FU-induced 
intestinal mucositis. 
Applications
The promising findings presented in the current study indicate that a low dose 
of aqueous RE improves selected parameters of 5-fluorouracil (5-FU)-induced 
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intestinal mucositis. Future studies should determine the active factor of the 
compound so that it can be extracted and further examined for clinical efficacy.
Terminology
5-FU is a widely utilised chemotherapy drug used to treat a range of cancer 
types from colon to breast cancer. It may be used independently however, 
is most commonly used in combination with other chemotherapy drugs, 
such as Methotrexate. RE was obtained from the stalks of the traditional 
herbal medicine Rheum spp. The low dose of RE (LDR) was based on the 
estimated dose required to block aquaporin water channel activity in the oocyte 
expression system, and the high dose (HDR) was selected as a 10 fold higher 
concentration for comparison. Aquaporins (AQPs) are integral membrane 
proteins responsible for the regulation of water transport across a membrane 
via an osmotic gradient. Currently, 13 mammalian AQPs have been identified 
(AQP 0-12). AQPs are abundant in tissues reliant on high water permeability 
to maintain correct function and are involved in metabolic processes such as 
kidney, lung, brain and gastrointestinal function. 
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tests are well explained and conducted. Results are fairly discussed, notably 
the question of the need for further experiments investigating an optimal dose.
REFERENCES
1 Wachtel-Galor S, Benzie IF. Herbal Medicine: An Introduction 
to Its History, Usage, Regulation, Current Trends, and Research 
Needs. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: 
Biomolecular and Clinical Aspects. Boca Raton FL: Llc., 2011
2 Ashikaga T, Bosompra K, O’Brien P, Nelson L. Use of 
complimentary and alternative medicine by breast cancer patients: 
prevalence, patterns and communication with physicians. Support 
Care Cancer 2002; 10: 542-548 [PMID: 12324809 DOI: 10.1007/
s00520-002-0356-1]
3 Australian Institute of Health and Welfare & Australasian Association 
of Cancer Registries. Cancer in Australia: An overview of 2012. 
Canberra, 2012
4 Sonis ST. Mucositis as a biological process: a new hypothesis 
for the development of chemotherapy-induced stomatotoxicity. 
Oral Oncol 1998; 34: 39-43 [PMID: 9659518 DOI: 10.1016/
S1368-8375(97)00053-5]
5 Soares PM, Mota JM, Souza EP, Justino PF, Franco AX, Cunha 
FQ, Ribeiro RA, Souza MH. Inflammatory intestinal damage 
induced by 5-fluorouracil requires IL-4. Cytokine 2013; 61: 46-49 
[PMID: 23107827 DOI: 10.1016/j.cyto.2012.10.003]
6 Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-
Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein 
EB. Perspectives on cancer therapy-induced mucosal injury: 
pathogenesis, measurement, epidemiology, and consequences for 
patients. Cancer 2004; 100: 1995-2025 [PMID: 15108222 DOI: 
10.1002/cncr.20162]
7 Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea 
and constipation: mechanisms of damage and prevention strategies. 
Support Care Cancer 2006; 14: 890-900 [PMID: 16604351 DOI: 
10.1007/s00520-006-0040-y]
8 Sakai H, Sagara A, Matsumoto K, Hasegawa S, Sato K, Nishizaki 
M, Shoji T, Horie S, Nakagawa T, Tokuyama S, Narita M. 
5-Fluorouracil induces diarrhea with changes in the expression of 
inflammatory cytokines and aquaporins in mouse intestines. PLoS 
One 2013; 8: e54788 [PMID: 23382968 DOI: 10.1371/journal.
pone.0054788]
9 Lalla RV, Peterson DE. Treatment of mucositis, including new 
medications. Cancer J 2006; 12: 348-354 [PMID: 17034671]
10 Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire 
D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST. Clinical 
practice guidelines for the prevention and treatment of cancer 
therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 
100: 2026-2046 [PMID: 15108223 DOI: 10.1002/cncr.20163]
11 Yazbeck R, Howarth GS. Complementary medicines: emerging 
therapies for intestinal mucositis. Cancer Biol Ther 2009; 8: 
1629-1631 [PMID: 19633432 DOI: 10.4161/cbt.8.17.9452]
12 Cheah KY, Howarth GS, Yazbeck R, Wright TH, Whitford EJ, 
Payne C, Butler RN, Bastian SE. Grape seed extract protects 
IEC-6 cells from chemotherapy-induced cytotoxicity and 
improves parameters of small intestinal mucositis in rats with 
experimentally-induced mucositis. Cancer Biol Ther 2009; 8: 
382-390 [PMID: 19305141 DOI: 10.4161/cbt.8.4.7453]
13 Wright TH, Yazbeck R, Lymn KA, Whitford EJ, Cheah KY, Butler 
RN, Feinle-Bisset C, Pilichiewicz AN, Mashtoub S, Howarth GS. 
The herbal extract, Iberogast, improves jejunal integrity in rats 
with 5-Fluorouracil (5-FU)-induced mucositis. Cancer Biol Ther 
2009; 8: 923-929 [PMID: 19276679 DOI: 10.4161/cbt.8.10.8146]
14 Cheah KY, Howarth GS, Bastian SE. Grape seed extract dose-
responsively decreases disease severity in a rat model of mucositis; 
concomitantly enhancing chemotherapeutic effectiveness in colon 
cancer cells. PLoS One 2014; 9: e85184 [PMID: 24465501 DOI: 
10.1371/journal.pone.0085184]
15 Schepetkin IA, Quinn MT. Botanical polysaccharides: macro-
phage immunomodulation and therapeutic potential. Int Immuno-
pharmacol 2006; 6: 317-333 [PMID: 16428067 DOI: 10.1016/
j.intimp.2005.10.005]
16 Peigen X, Liyi H, Liwei W. Ethnopharmacologic study of Chinese 
rhubarb. J Ethnopharmacol 1984; 10: 275-293 [PMID: 6748707 
DOI: 10.1016/0378-8741(84)90016-3]
17 Liu L, Guo Z, Lv Z, Sun Y, Cao W, Zhang R, Liu Z, Li C, Cao S, 
Mei Q. The beneficial effect of Rheum tanguticum polysaccharide 
on protecting against diarrhea, colonic inflammation and ulceration 
in rats with TNBS-induced colitis: the role of macrophage 
mannose receptor in inflammation and immune response. Int 
Immunopharmacol 2008; 8: 1481-1492 [PMID: 18790466 DOI: 
10.1016/j.intimp.2008.04.013]
18 Qin Y, Wang JB, Kong WJ, Zhao YL, Yang HY, Dai CM, Fang 
F, Zhang L, Li BC, Jin C, Xiao XH. The diarrhoeogenic and 
antidiarrhoeal bidirectional effects of rhubarb and its potential 
mechanism. J Ethnopharmacol 2011; 133: 1096-1102 [PMID: 
21112382 DOI: 10.1016/j.jep.2010.11.041]
19 Carneiro-Filho BA, Lima IP, Araujo DH, Cavalcante MC, 
Carvalho GH, Brito GA, Lima V, Monteiro SM, Santos FN, 
Ribeiro RA, Lima AA. Intestinal barrier function and secretion in 
methotrexate-induced rat intestinal mucositis. Dig Dis Sci 2004; 
49: 65-72 [PMID: 14992437]
20 Agre P, King LS, Yasui M, Guggino WB, Ottersen OP, Fujiyoshi 
Y, Engel A, Nielsen S. Aquaporin water channels--from atomic 
structure to clinical medicine. J Physiol 2002; 542: 3-16 [PMID: 
12096044 DOI: 10.1113/jphysiol.2002.020818]
21 King LS, Kozono D, Agre P. From structure to disease: the 
evolving tale of aquaporin biology. Nat Rev Mol Cell Biol 2004; 5: 
687-698 [PMID: 15340377 DOI: 10.1038/nrm1469]
22 Cui Y, Bastien DA. Water transport in human aquaporin-4: 
molecular dynamics (MD) simulations. Biochem Biophys Res 
Commun 2011; 412: 654-659 [PMID: 21856282 DOI: 10.1016/
j.bbrc.2011.08.019]
23 Ishibashi K. New members of mammalian aquaporins: AQP10-
AQP12. Handb Exp Pharmacol 2009; (190): 251-262 [PMID: 
19096782 DOI: 10.1007/978-3-540-79885-9_13]
24 Nicchia GP, Nico B, Camassa LM, Mola MG, Loh N, Dermietzel 
R, Spray DC, Svelto M, Frigeri A. The role of aquaporin-4 in the 
blood-brain barrier development and integrity: studies in animal 
and cell culture models. Neuroscience 2004; 129: 935-945 [PMID: 
15561409 DOI: 10.1016/j.neuroscience.2004.07.055]
25 Frigeri A, Gropper MA, Turck CW, Verkman AS. Immuno-
localization of the mercurial-insensitive water channel and glycerol 
intrinsic protein in epithelial cell plasma membranes. Proc Natl 
Acad Sci USA 1995; 92: 4328-4331 [PMID: 7538665 DOI: 
10.1073/pnas.92.10.4328]
26 Mobasheri A, Marples D, Young IS, Floyd RV, Moskaluk CA, 
Frigeri A. Distribution of the AQP4 water channel in normal 
human tissues: protein and tissue microarrays reveal expression 
in several new anatomical locations, including the prostate gland 
and seminal vesicles. Channels (Austin) 2007; 1: 29-38 [PMID: 
Bajic JE et al . Rhubarb extract partially improves intestinal mucositis
8333 October 7, 2016|Volume 22|Issue 37|WJG|www.wjgnet.com
19170255 DOI: 10.4161/chan.3735]
27 Ricanek P, Lunde LK, Frye SA, Støen M, Nygård S, Morth JP, 
Rydning A, Vatn MH, Amiry-Moghaddam M, Tønjum T. Reduced 
expression of aquaporins in human intestinal mucosa in early stage 
inflammatory bowel disease. Clin Exp Gastroenterol 2015; 8: 
49-67 [PMID: 25624769 DOI: 10.2147/ceg.s70119]
28 Koyama Y, Yamamoto T, Tani T, Nihei K, Kondo D, Funaki 
H, Yaoita E, Kawasaki K, Sato N, Hatakeyama K, Kihara I. 
Expression and localization of aquaporins in rat gastrointestinal 
tract. Am J Physiol 1999; 276: C621-C627 [PMID: 10069989 DOI: 
10.1165/ajrcmb.24.3.4367]
29 Wang KS, Ma T, Filiz F, Verkman AS, Bastidas JA. Colon water 
transport in transgenic mice lacking aquaporin-4 water channels. 
Am J Physiol Gastrointest Liver Physiol 2000; 279: G463-G470 
[PMID: 10915657]
30 Tomas FM, Murray AJ, Jones LM. Modification of glucocorticoid-
induced changes in myofibrillar protein turnover in rats by protein 
and energy deficiency as assessed by urinary excretion of Ntau-
methylhistidine. Br J Nutr 1984; 51: 323-337 [PMID: 6426502 
DOI: 10.1079/BJN19840039]
31 Mashtoub S, Tran CD, Howarth GS. Emu oil expedites small 
intestinal repair following 5-fluorouracil-induced mucositis in 
rats. Exp Biol Med (Maywood) 2013; 238: 1305-1317 [PMID: 
24047797 DOI: 10.1177/1535370213493718]
32 Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read 
LC. Milk growth factors enriched from cheese whey ameliorate 
intestinal damage by methotrexate when administered orally to 
rats. J Nutr 1996; 126: 2519-2530 [PMID: 8857513]
33 Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran 
DJ. Treatment of dextran sulfate sodium-induced murine colitis by 
intracolonic cyclosporin. Dig Dis Sci 1993; 38: 1722-1734 [PMID: 
8359087 DOI: 10.1007/BF01303184]
34 Beyer AJ, Smalley DM, Shyr YM, Wood JG, Cheung LY. PAF 
and CD18 mediate neutrophil infiltration in upper gastrointestinal 
tract during intra-abdominal sepsis. Am J Physiol 1998; 275: 
G467-G472 [PMID: 9724257]
35 Campbell EM, Birdsell DN, Yool AJ. The activity of human 
aquaporin 1 as a cGMP-gated cation channel is regulated by tyrosine 
phosphorylation in the carboxyl-terminal domain. Mol Pharmacol 
2012; 81: 97-105 [PMID: 22006723 DOI: 10.1124/mol.111.073692]
36 Yool AJ, Morelle J, Cnops Y, Verbavatz JM, Campbell EM, 
Beckett EA, Booker GW, Flynn G, Devuyst O. AqF026 is a 
pharmacologic agonist of the water channel aquaporin-1. J Am Soc 
Nephrol 2013; 24: 1045-1052 [PMID: 23744886 DOI: 10.1681/
ASN.2012080869]
37 Torres DM, Tooley KL, Butler RN, Smith CL, Geier MS, Howarth 
GS. Lyprinol only partially improves indicators of small intestinal 
integrity in a rat model of 5-fluorouracil-induced mucositis. Cancer 
Biol Ther 2008; 7: 295-302 [PMID: 18059190 DOI: 10.4161/
cbt.7.2.5332]
38 Green R, Horn H, Erickson JM. Eating experiences of children 
and adolescents with chemotherapy-related nausea and mucositis. 
J Pediatr Oncol Nurs 2010; 27: 209-216 [PMID: 20562389 DOI: 
10.1177/1043454209360779]
39 Smith JL, Malinauskas BM, Garner KJ, Barber-Heidal K. Factors 
contributing to weight loss, nutrition-related concerns and advice 
received by adults undergoing cancer treatment. Adv Med Sci 2008; 
53: 198-204 [PMID: 18614435 DOI: 10.2478/v10039-008-0019-7]
40 Cheng CL, Koo MW. Effects of Centella asiatica on ethanol 
induced gastric mucosal lesions in rats. Life Sci 2000; 67: 2647-2653 
[PMID: 11104366 DOI: 10.1016/S0024-3205(00)00848-1]
41 Garrido G, González D, Lemus Y, García D, Lodeiro L, Quintero 
G, Delporte C, Núñez-Sellés AJ, Delgado R. In vivo and in 
vitro anti-inflammatory activity of Mangifera indica L. extract 
(VIMANG). Pharmacol Res 2004; 50: 143-149 [PMID: 15177302 
DOI: 10.1016/j.phrs.2003.12.003]
42 Seeliger D, Zapater C, Krenc D, Haddoub R, Flitsch S, Beitz E, 
Cerdà J, de Groot BL. Discovery of novel human aquaporin-1 
blockers. ACS Chem Biol 2013; 8: 249-256 [PMID: 23113556 
DOI: 10.1021/cb300153z]
43 Wacker SJ, Aponte-Santamaría C, Kjellbom P, Nielsen S, de 
Groot BL, Rützler M. The identification of novel, high affinity 
AQP9 inhibitors in an intracellular binding site. Mol Membr Biol 
2013; 30: 246-260 [PMID: 23448163 DOI: 10.3109/09687688.201
3.773095]
44 Migliati E, Meurice N, DuBois P, Fang JS, Somasekharan S, 
Beckett E, Flynn G, Yool AJ. Inhibition of aquaporin-1 and 
aquaporin-4 water permeability by a derivative of the loop diuretic 
bumetanide acting at an internal pore-occluding binding site. Mol 
Pharmacol 2009; 76: 105-112 [PMID: 19403703 DOI: 10.1124/
mol.108.053744]
45 Ma L, Zhao L, Hu H, Qin Y, Bian Y, Jiang H, Zhou H, Yu L, 
Zeng S. Interaction of five anthraquinones from rhubarb with 
human organic anion transporter 1 (SLC22A6) and 3 (SLC22A8) 
and drug-drug interaction in rats. J Ethnopharmacol 2014; 153: 
864-871 [PMID: 24685584 DOI: 10.1016/j.jep.2014.03.055]
P- Reviewer: Liew FY, Touchefeu Y    S- Editor: Gong ZM 
L- Editor: A    E- Editor: Wang CH
Bajic JE et al . Rhubarb extract partially improves intestinal mucositis
